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Lipidomics and Decoding of Antiproliferative and
Anti-Inﬂammatory Activity
Elisabete da Costa 1, Tânia Melo 1, Ana S. P. Moreira 1, Carina Bernardo 2, Luisa Helguero 2,
Isabel Ferreira 3, Maria Teresa Cruz 3, Andreia M. Rego 4, Pedro Domingues 1, Ricardo Calado 5,
Maria H. Abreu 4 and Maria Rosário Domingues 1,*
1 Centro de Espectrometria de Massa, Departamento de Química & QOPNA, Universidade de Aveiro,
Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; elisabetecosta@ua.pt (E.d.C.);
taniamelo@ua.pt (T.M.); ana.moreira@ua.pt (A.S.P.M.); p.domingues@ua.pt (P.D.)
2 Instituto de Biomedicina (IBIMED), Departamento de Ciências Médicas, Universidade de Aveiro,
3810-193 Aveiro, Portugal; carinabernardo@ua.pt (C.B.); luisa.helguero@ua.pt (L.H.)
3 Centro de Neurociências e Biologia Celular (CNC), Universidade de Coimbra, 3004-517 Coimbra &
Faculdade de Farmácia, Universidade de Coimbra, 3000-548 Coimbra, Portugal; isabelcvf@gmail.com (I.F.);
trosete@ff.uc.pt (M.T.C.)
4 ALGAplus-Produção e Comercialização de Algas e seus Derivados, Lda., 3830-196 Ílhavo, Portugal;
amrego@algaplus.pt (A.M.R.); htabreu@algaplus.pt (M.H.A.)
5 Departamento de Biologia & CESAM, Universidade de Aveiro, Campus Universitário de Santiago,
3810-193 Aveiro, Portugal; rjcalado@ua.pt
* Correspondence: mrd@ua.pt
Academic Editor: Peer B. Jacobson
Received: 11 November 2016; Accepted: 13 February 2017; Published: 2 March 2017
Abstract: The lipidome of the red seaweed Gracilaria sp., cultivated on land-based integrated
multitrophic aquaculture (IMTA) system, was assessed for the ﬁrst time using hydrophilic
interaction liquid chromatography-mass spectrometry and tandem mass spectrometry (HILIC–MS
and MS/MS). One hundred and forty-seven molecular species were identiﬁed in the lipidome of the
Gracilaria genus and distributed between the glycolipids classes monogalactosyl diacylglyceride
(MGDG), digalactosyl diacylglyceride (DGDG), sulfoquinovosyl monoacylglyceride (SQMG),
sulfoquinovosyl diacylglyceride (SQDG), the phospholipids phosphatidylcholine (PC), lyso-PC,
phosphatidylglycerol (PG), lyso-PG, phosphatidylinositol (PI), phosphatidylethanolamine (PE),
phosphatic acid (PA), inositolphosphoceramide (IPC), and betaine lipids monoacylglyceryl-
and diacylglyceryl-N,N,N-trimethyl homoserine (MGTS and DGTS). Antiproliferative and
anti-inﬂammatory effects promoted by lipid extract of Gracilaria sp. were evaluated by monitoring
cell viability in human cancer lines and by using murine macrophages, respectively. The lipid
extract decreased cell viability of human T-47D breast cancer cells and of 5637 human bladder
cancer cells (estimated half-maximal inhibitory concentration (IC50) of 12.2 μg/mL and 12.9 μg/mL,
respectively) and inhibited the production of nitric oxide (NO) evoked by the Toll-like receptor
4 agonist lipopolysaccharide (LPS) on the macrophage cell line RAW 264.7 (35% inhibition at a
concentration of 100 μg/mL). These ﬁndings contribute to increase the ranking in the value-chain of
Gracilaria sp. biomass cultivated under controlled conditions on IMTA systems.
Keywords: glycolipids; phospholipids; betaine lipids; seaweeds; bioactivity; mass spectrometry;
hydrophilic interaction liquid chromatography–electrospray ionization–mass spectrometry
HILIC–ESI–MS
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1. Introduction
Red seaweeds within the genus Gracilaria are one of the world’s most cultivated and valuable
marine macrophytes. This group of seaweeds is well adapted to cultivation on land-based integrated
multitrophic aquaculture (IMTA) systems, allowing its sustainable production under controlled and
replicable conditions that provide a secure supply of high-grade seaweed biomass for demanding
markets (e.g., food, pharmaceuticals) [1–3]. Gracilaria sp. is a source of multiple products, among
which lipids, namely polyunsaturated fatty acids (PUFAs) such as arachidonic (20:4(n-6), AA) and
eicosapentaenoic (20:5(n-6), EPA) acids, are emerging as valuable components [4]. Fatty acids (FAs) are
mainly esteriﬁed to polar lipids such as glycolipids, phospholipids, and betaine lipids. Polar lipids are
nowadays recognized as an important reservoir of fatty acids with nutritional value, e.g., n-3 FAs [5,6],
and they are also considered high-value novel lipids with beneficial health effects such as antitumoral [7,8],
antiviral [8,9], antifungal [10], antibacterial [11], and anti-inﬂammatory [11,12], with potential
applications in the nutraceutical and pharmaceutical industries [7,8,11]. However, in spite of their
recognized potential, they are still scarcely studied [12–15]. Some studies reported that polar lipids
isolated from seaweeds can promote growth-inhibiting effects on human hepatocellular carcinoma
cell lines (HepG2) [16] and thus can act as inhibitors of DNA polymerases with capability to inhibit
tumor cell proliferation [17]. Moreover, they have been associated with anti-inﬂammatory properties
through the inhibition of pro-inﬂammatory cytokines interleukin IL-6 and IL-8 production [15] and/or
by the inhibition of nitric oxide (NO) production [18–21]. Lipid-based agents are therefore emerging
molecules in therapeutics aimed to regulate inﬂammatory pathways or even impair downstream
tumorigenic processes [22–24].
To fully explore the bioactive properties of seaweed lipids and thus contribute to seaweed
valorization, it is fundamental to characterize their structure and understand how it modulates
bioactivity [13,14]. Nowadays, the detailed structural characterization of lipids can be accomplished
by using mass spectrometry (MS) coupled with liquid chromatography (LC). This lipidomic approach
has the advantage of providing a detailed analysis of the lipid proﬁle and affording the identiﬁcation
and quantiﬁcation of more than 200 lipid molecular species in one single LC–MS run [25,26]. This
detailed information on the speciﬁcity of molecular species and corresponding classes of polar lipids
cannot be achieved using traditional approaches, typically based on the previous separation of polar
lipid classes by thin-layer chromatography (TLC) and silica gel on column chromatography, followed
by off-line gas chromatography-mass spectrometry (GC–MS) analysis of FAs [27–33]. MS-based
technologies allowed researchers to explore the full lipidomic signature of distinct matrices [34–36].
To date, they allowed for the identiﬁcation of the full lipidome signature of cultivated seaweeds
Ulva lactuca Linnaeus, 1753 [37], Chondrus crispus Stackhouse, 1797 [26], and Codium tomentosum
Stackhouse, 1797 [25]. These novel approaches based on speciﬁc identiﬁcation and quantiﬁcation at
the molecular level using high-throughput analysis are promising tools for bioprospection [3,38,39].
The main goal of the present study was to identify and characterize the polar lipid proﬁle
of Gracilaria sp. cultivated under controlled conditions on a land-based integrated multitrophic
aquaculture (IMTA) system, using hydrophilic interaction liquid chromatography-electrospray
ionization-mass spectrometry (HILIC–ESI–MS). The lipid extract of this red seaweed was also
screened for its growth inhibitory effects in human breast and bladder cancer cell lines, as well
as anti-inﬂammatory effects by inhibiting the production of NO.
2. Results and Discussion
The lipid extract of Gracilaria sp. obtained by chloroform:methanol extraction accounted for about
3000 ± 600 mg/kg dry mass (relative standard deviation (RSD) < 20%). The lipid extract was mainly
composed of glycolipids (1980 ± 148 mg/kg of biomass) and phospholipids (165 ± 53 mg/kg of
biomass), and the remaining lipid extract corresponded to betaine lipids and others (Table 1).
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Table 1. Composition of lipid extract of Gracilaria sp. (mean and SD of triplicate).
Composition Mean SD
Lipids (mg/kg biomass) 3000 600
Glycolipids (mg/kg biomass) 1980 148
Phospholipids (mg/kg biomass) 165 52.7
Betaines and others 1 855 -
1 Betaines and others were determined by the difference of lipid content and the sum of content of glycolipids
and phospholipids.
2.1. Polar Lipidome
The proﬁle of Gracilaria polar lipidome was determined by HILIC–ESI–MS and allowed for the
identiﬁcation of molecular species of glycolipids, phospholipids, and betaine lipids. Overall, the
lipidome of Gracilaria sp. comprised 147 molecular species (Figure 1).
Figure 1. Number of molecular species identiﬁed by HILIC–ESI–MS, distributed by the
classes of glycolipids: monogalactosyl diacylglyceride (MGDG), digalactosyl diacylglyceride
(DGDG), sulfoquinovosyl monoacylglyceride (SQMG), sulfoquinovosyl diacylglyceride (SQDG),
phospholipids: phosphatidylcholine (PC) and lyso-PC (LPC), phosphatidylglycerol (PG) and
lyso-PG (LPG), phosphatidylinositol (PI), phosphatic acid (PA), phosphatidylethanolamine (PE),
inositolphosphoceramide (IPC), and betaine lipids: monoacylglyceryl- and diacylglyceryl-N,N,N-
trimethyl homoserine (MGTS and DGTS).
The glycolipids of the classes monogalactosyl diacylglyceride (MGDG) and digalactosyl
diacylglyceride (DGDG) were identiﬁed in the LC–MS spectra in positive mode as [M + NH4]+ ions [25].
Detailed structure of MGDG and DGDG molecular species was accomplished by LC–MS/MS analysis
of [M + NH4]+ ions and analysis of ESI–MS/MS of the [M + Na]+ ions after solid phase extraction
(SPE) fractionation of lipid extract (fraction 3 rich in glycolipids). Overall, 34 molecular species
were identiﬁed, as described in Table 2. Galactolipids contained nine MGDG molecular species and
10 DGDG molecular species (Table 2, Figure S1a,b). The most abundant MGDG molecular species
were found at m/z 774.3 and 796.3 [M + NH4]+, corresponding to MGDG (18:1/16:0) and to MGDG
(20:4/16:0), with a minor contribution from MGDG (18:2/18:2), respectively. Other MGDG molecular
species identiﬁed contained in their composition 14-, 16-, and 18-carbon saturated fatty acids (SFAs)
and monounsaturated fatty acids (MUFAs) and 18:2, 20:4, and 20:5 polyunsaturated fatty acyl (PUFAs)
moieties (Table 2). Regarding DGDGs, the most abundant molecular species were identiﬁed as
[M + NH4]+ ions at m/z 936.3, corresponding to DGDG (18:1/16:0), followed by DGDG (20:4/16:0)
with minor contribution of DGDG (18:2/18:2) at m/z 958.2. Moreover, other DGDG molecular species
were identiﬁed containing 14-, 16-, 18-, and 20-carbon fatty acids (FAs) such as 20:4 and 20:5 PUFAs.
Concerning sulfolipids, 12 sulfoquinovosyl diacylglycerides (SQDGs) and three sulfoquinovosyl
monoacylglycerides (SQMGs) were identiﬁed as negative [M − H]− ions. The most abundant
species were attributed to SQDG (14:0/16:0), SQDG (16:0/16:0) and SQDG (16:0/20:4), observed
as [M − H]− ions at m/z 765.5, 793.5, and 841.6, respectively. The fatty acyl signature of SQDGs
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included 14-, 16-, 18-carbon SFAs and MUFAs and 18- and 20-carbon PUFAs (Table 2, Figure S1c).
Three SQMGs were identiﬁed as SQMG (14:0), SQMG (16:0), and SQMG (16:1). SQMGs were never
before reported in the lipidome of seaweeds from the genus Gracilaria. Glycolipids have already been
identiﬁed for members of the Rhodophyta (red seaweeds), namely in the genus Gracilaria [21,30,40–42].
However, the majority of published works only identiﬁed a few species of glycolipids, either by using
ofﬂine TLC–MS [30,40,42,43] or selected solvent extraction and MS analysis [15,20,29]. More recently,
a detailed proﬁle of Chondrus crispus was reported using LC–MS and MS/MS [26].
Table 2. Identiﬁcation of MGDG and DGDG molecular species observed by HILIC–ESI–MS,
as [M + NH4]+ ions and SQDG and SQMG molecular species observed as [M − H]− ions 2.
[M + NH4]+ Lipid Species Fatty Acyl Chains
m/z (C:N)
Monogalactosyl diacylglyceride (MGDG)
746.3 MGDG (32:1) 16:1/16:0 and 14:0/18:1
748.3 MGDG (32:0) 16:0/16:0 and 14:0/18:0
774.3 MGDG (34:1) 18:1/16:0
776.3 MGDG (34:0) 18:0/16:0
794.3 MGDG (36:5) 20:5/16:0
796.3 MGDG (36:4) 20:4/16:0 and 18:2/18:2
Digalactosyl diacylglyceride (DGDG)
908.3 DGDG (32:1) 16:1/16:0 and 14:0/18:1
910.3 DGDG (32:0) 16:0/16:0 and 14:0/18:0
934.3 DGDG (34:2) 18:2/16:0 and 18:1/16:1
936.3 DGDG (34:1) 18:1/16:0
956.3 DGDG (36:5) 20:5/16:0
958.3 DGDG (36:4) 20:4/16:0 and 18:2/18:2
[M − H]− Lipid Species Fatty Acyl Chains
Sulfoquinovosyl diacylglyceride (SQDG)
763.6 SQDG (30:1) 14:0/16:1
765.6 SQDG (30:0) 14:0/16:0
791.6 SQDG (32:1) 16:1/16:0 and 14:0/18:2
793.6 SQDG (32:0) 16:0/16:0 and 14:0/18:0
813.6 SQDG (34:4) 18:4/16:0
817.6 SQDG (34:2) 18:2/16:0
819.6 SQDG (34:1) 18:1/16:0
839.6 SQDG (36:5) 20:5/16:0
841.6 SQDG (36:4) 20:4/16:0
857.6 SQDG (36:4-OH) 20:4-OH/16:0
Sulfoquinovosyl monoacylglyceride (SQMG)
527.4 SQMG (14:0)
553.4 SQMG (16:1)
555.4 SQMG (16:0)
2 The assignment of the fatty acyl composition of molecular species was made according to the interpretation
of the corresponding MS/MS spectra. Bold m/z values correspond to the most abundant species detected
in the LC–MS spectrum; C means the number of carbon atoms; N represents double bonds in the fatty acyl
chains; MGDG: monogalactosyl diacylglyceride; DGDG: digalactosyl diacylglyceride; SQMG: sulfoquinovosyl
monoacylglyceride; SQDG: sulfoquinovosyl diacylglyceride; and HILIC–ESI–MS: hydrophilic interaction liquid
chromatography–electrospray ionization–mass spectrometry.
Gracilaria sp. lipidome included 87 molecular species of phospholipids (PLs) within eight
classes, namely phosphatidylglycerol (PG) and lyso-PG (LPG), phosphatidylcholine (PC) and lyso-PC
(LPC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), inositolphosphoceramide (IPC) and
phosphatidic acid (PA). PC is a main component of extraplastidial membranes, while PG is found in
chloroplastic membranes [5].
The PL classes PG, lyso-PG, PA, PI, and IPC were identified as negative [M − H]− ions, while PC
and lyso-PC were identiﬁed as negative [M + CH3COO]− ions. PC, LPC and PE were also identiﬁed
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as positive [M + H]+ ions. The identity of all molecular species identiﬁed (Table 3) was conﬁrmed
by LC–MS/MS, as described in the literature [25,26]. About 39 PCs were identiﬁed by LC–MS
(Figure S2a). The most abundant ions were observed at m/z 760.6 and at m/z 782.6, respectively
attributed to PC (16:0/18:1) and to PC (16:0/20:4) with a minor contribution of PC (18:2/18:2). Other
PC molecular species were identiﬁed and contained 14- to 22-carbon fatty acids. Lyso-PC consisted
of eight molecular species (Table 3, Figure S2b) and the most abundant was LPC (20:4), observed at
m/z 544.4. All molecular species identiﬁed are described in Table 3. Thirteen PGs and four lyso-PGs
species were identiﬁed by LC–MS as [M – H]− ions (Table 3, Figure S2c,d). The most abundant ion was
observed at m/z 769.4, mainly corresponding to PG (16:0/20:4), with a minor contribution from PG
(18:2/18:2). The prominent lyso-PG at m/z 483.3 was LPG (16:0). PI species were observed as [M − H]−
ions at m/z 833.5 and 835.5 and attributed to PI (16:1/18:1) and PI (16:0/18:1), respectively. Eight PAs
were identiﬁed (Table 3, Figure S2e), with the most abundant species identiﬁed as PA (20:4/20:4) at
m/z 743.3, while the other PA molecular species were esteriﬁed to 16:0, 18:1, 18:2, 18:3, 20:3, 20:4, and
20:5 FAs. PEs contained eight molecular species, identiﬁed as [M + H]+ (Table 3, Figure S2f). The
most abundant ion was observed at m/z 716.4 and identiﬁed as PE (16:1/16:1) and PE (16:0/18:2).
The phospholipids from Gracilaria sp. hold PCs and LPCs, PGs, LPGs, PIs, PEs, and PAs, already
reported for the lipidome of other Rhodophyta [20,26,31,32]. Fatty acids esteriﬁed in the PLs included
saturated and unsaturated 16-, 18-, and 20-carbon FAs, and PCs and PAs were the only PLs classes that
included 20:3(n-6) FA. The 20:3(n-6) FA is usually a minor component of the whole pool of FAs in red
seaweeds [31,32] but is an important intermediate compound in the biosynthesis of 20:4(n-6) FA.
Table 3. Identiﬁcation of phospholipid molecular species observed by HILIC–ESI–MS, as [M + H]+
ions for PC, LPC, and PE and as [M − H]− ions for PG, LPG, PI, PA, and IPC 2.
[M + H]+ Lipid Species Fatty Acyls Chain
m/z (C:N)
Phosphatidylcholine (PC)
732.6 PC (32:1) 16:0/16:1 and 14:0/18:1
734.6 PC (32:0) 16:0/16:0 and 14:0/18:0
754.6 PC (34:4) 14:0/20:4 and 16:2/18:2
756.6 PC (34:3) 16:0/18:3 and 14:0/20:3
758.6 PC (34:2) 16:0/18:2 and 16:2/18:1
760.6 PC (34:1) 16:0/18:1
762.6 PC (34:0) 16:0/18:0
780.6 PC (36:5) 16:0/20:5 and 18:2/18:3
782.6 PC (36:4) 16:0/20:4 and 18:2/18:2
784.6 PC (36:3) 16:0/20:3 and 18:1/18:2
786.6 PC (36:2) 18:0/18:2 and 18:1/18:1
788.6 PC (36:1) 18:0/18:1
798.5 PC (37:3) 16:0/21:3 and 18:1/19:2
804.5 PC (38:7) 18:3/20:4 and 18:2/20:5
806.5 PC (38:6) 18:2/20:4 and 18:1/20:5
808.5 PC (38:5) 18:1/20:4 and 18:2/20:3
810.5 PC (38:4) 18:1/20:3 and 16:0/22:4
812.5 PC (38:3) 18:0/20:3 and 18:1/20:2
814.5 PC (38:2) 16:0/22:2 and 18:1/20:1
818.5 PC (38:0) 18:0/20:0 and 16:0/22:0
840.4 PC (40:3) 18:1/22:2
844.4 PC (40:1) 18:1/22:0
Lyso-phosphatidylcholine (LPC)
494.4 LPC (16:1)
496.4 LPC (16:0)
518.4 LPC (18:3)
520.4 LPC (18:2)
522.4 LPC (18:1)
524.4 LPC (18:0)
542.4 LPC (20:5)
544.4 LPC (20:4)
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Table 3. Cont.
[M + H]+ Lipid Species Fatty Acyls Chain
m/z (C:N)
Phosphatidyletanolamine (PE)
716.4 PE (34:2) 16:1/18:1 and 16:0/18:2
718.3 PE (34:1) 16:1/18:0 and 16:0/18:1
740.4 PE (34:0) 16:0/18:0
742.4 PE (36:3) 18:1/18:2
744.4 PE (36:2) 18:1/18:1
746.3 PE (36:1) 18:0/18:1
[M − H]− Lipid Species Fatty Acyl Chains
Phosphatidylglycerol (PG)
717.4 PG (32:2) 16:1/16:1 and 16:0/16:2
719.4 PG (32:1) 16:0/16:1
721.4 PG (32:0) 16:0/16:0
741.4 PG (34:4) 16:0/18:4
743.5 PG (34:3) 16:0/18:3
745.5 PG (34:2) 16:1/18:1
747.5 PG (34:1) 16:0/18:1 and 16:1/18:0
767.5 PG (36:5) 16:0/20:5
769.4 PG (36:4) 16:0/20:4 and 18:2/18:2
773.5 PG (36:2) 18:1/18:1
Lyso-phosphatidylglycerol (LPG)
481.3 LPG (16:1)
483.3 LPG (16:0)
509.3 LPG (18:1)
531.3 LPG (20:4)
Phosphatidylinositol (PI)
833.5 PI (34:2) 16:1/18:1
835.5 PI (34:1) 16:0/18:1
Phosphatidic acid (PA)
693.4 PA (36:5) 16:0/20:5
695.4 PA (36:4) 16:0/20:4
717.4 PA (38:7) 18:3/20:4
719.4 PA (38:6) 18:2/20:4
721.4 PA (38:5) 18:1/20:4
741.3 PA (40:9) 20:4/20:5
743.3 PA (40:8) 20:4/20:4
745.3 PA (40:7) 20:3/20:4
Inositolphosphoceramide (IPC)
810.5 IPC (t35:0) t18:0/17:0
908.6 IPC (d42:0) d18:0/24:0
920.6 IPC (t42:2) t18:1/24:1
922.6 IPC (t42:1) t18:0/24:1
924.6 IPC (t42:0) t18:0/24:0
2 The assignment of the fatty acyl composition of molecular species was made according to the interpretation
of the corresponding MS/MS spectra. Bold m/z values correspond to the most abundant species detected
in the LC–MS spectrum; C means the number of carbon atoms; N represents double bonds in the fatty acyl
chains; PC: phosphatidylcholine; LPC: lyso-PC; PG: phosphatidylglycerol; LPG: lyso-PG; PI: phosphatidylinositol;
PA: phosphatic acid; PE: phosphatidylethanolamine; and IPC: inositolphosphoceramide.
Five molecular species were assigned as IPCs and the most abundant ones were IPC (t18:0/17:0),
observed at m/z 810.5, and IPC (t18:1/24:1), observed at m/z 920.6 (Figure S3a). LC–MS/MS spectrum
of the [M − H]− ions of IPCs, as exempliﬁed for IPC at m/z 920.6 in Figure S3b, showed the typical
fragmentation pathways of IPCs such as the losses of 162 Da and 180 Da, due to the fragmentation
pathways that lead to the elimination of inositol, the product ion at m/z 538.3 resulting from the loss of
fatty acyl chains, and the product ion at m/z 259.0 that corresponded to an inositol monophosphate
anion. IPCs were identiﬁed in lipid extract of Gracilaria sp. and are considered an important biomarker
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of Rhodophyta taxonomy, in accordance with what was already reported for Chondrus crispus using a
lipidomic approach [26]. IPCs are required to maintain membrane properties such as viscosity and
electrical charge and participate in the control of enzymatic activity or act as membrane anchors for
some proteins [44].
Twenty-one DGTS and ﬁve MGTS molecular species were identiﬁed by LC–MS and MS/MS as
[M + H]+ ions (Table 4, Figure S4a,b, respectively). The most abundant DGTS species were found at m/z
710.7, corresponding to DGTS (16:0/16:1), with a minor contribution from DGTS (14:0/18:1) species,
followed by DGTS (18:1/18:1) observed at m/z 764.8. Overall, DGTSs combine distinctive molecular
species bearing different combinations of FAs, ranging between 14- and 20-carbon FAs, as reported on
Table 4. MGTSs comprised MGTS (14:0), MGTS (16:1), MGTS (16:0), MGTS (18:2), and MGTS (18:1)
species, identiﬁed at m/z 446.5, 472.5, 474.5, 498.6, and 500.6, respectively.
Table 4. Identification of DGTS andMGTSmolecular species observed byHILIC–ESI–MS as [M +H]+ ions 2.
[M + H]+ Lipid Species Fatty Acyls Chain
m/z (C:N)
Diacylglyceryl trimethyl homoserine (DGTS)
656.7 DGTS (28:0) 14:0/14:0
682.7 DGTS (30:1) 14:0/16:1
684.8 DGTS (30:0) 14:0/16:0
708.7 DGTS (32:2) 16:1/16:1 and 14:0/18:2
710.7 DGTS (32:1) 16:0/16:1 and 14:0/18:1
712.7 DGTS (32:0) 16:0/16:0 and 14:0/18:0
732.7 DGTS (34:4) 16:2/18:2 and 14:0/20:4
734.7 DGTS (34:3) 16:1/18:2
736.7 DGTS (34:2) 16:0/18:2 and 16:1/18:1
738.7 DGTS (34:1) 16:0/18:1 and 16:1/18:0
740.7 DGTS (34:0) 16:0/18:0 and 14:0/20:0
760.6 DGTS (36:4) 16:0/20:4
764.8 DGTS (36:2) 18:1/18:1
766.8 DGTS (36:1) 18:0/18:1
Monoacylglyceryl trimethyl homoserine (MGTS)
446.5 MGTS (14:0)
472.5 MGTS (16:1)
474.5 MGTS (16:0)
498.6 MGTS (18:2)
500.6 MGTS (18:1)
2 The assignment of the fatty acyl composition of molecular species was made according to the interpretation
of the corresponding MS/MS spectra. Bold m/z values correspond to the most abundant species detected in the
LC–MS spectrum; C means the number of carbon atoms; N represents double bonds in the fatty acyl chains;
MGTS: monoacylglyceryl-N,N,N-trimethyl homoserine; and DGTS: diacylglyceryl-N,N,N-trimethyl homoserine.
Betaine lipids are components of extraplastidial membranes [45]. They are naturally occurring
lipids not found in higher plants, but are widely distributed in algae [45,46]. Betaines are a class of acyl
glycerolipids that have a quaternary amine alcohol ether-linked to a diacylglycerol moiety, lacking
in phosphorous. Interestingly, DGTSs are described herein for the ﬁrst time in the lipidome of genus
Gracilaria and MGTS species were not reported before in the lipidome of red seaweeds. This may be due
to the lack of sensitivity of most reported analytical tools based on TLC and GC–MS approaches, since
the co-elution of betaines and PC by TLC approaches could have prevented their discrimination [47].
Only recently, through the use of MS-based tools, betaine lipids were identiﬁed in the lipidome of red
seaweed Chondrus crispus [26] and green seaweed Codium tomentosum [25].
2.2. Fatty Acid Proﬁle
The fatty acid proﬁle of the lipid extract was characterized by GC–MS analysis of fatty acid methyl
esters (FAMEs). The proﬁle of fatty acids included 14:0, 16:0, 18:0, 18:1(n-9), 18:2(n-6), 20:4(n-6), and
20:5(n-3), among which 16:0 (48.5% ± 1.1%), 18:1(n-9) (14.4% ± 0.38%), and 20:4(n-6) (13.6% ± 0.46%)
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were the most abundant (Figure 2). Overall, SFAs accounted for 57.5% of the total FAs identiﬁed,
followed by MUFAs (18.3%) and PUFAs (18.4%). The fatty acids identiﬁed by GC–MS were also
reported to be esteriﬁed to polar lipids of Gracilaria sp. by LC–MS and MS/MS analysis.
ȱ
Figure 2. Fatty acid proﬁle of lipids from Gracilaria sp. determined by GC–MS analysis of fatty acid
methyl esters (FAMEs). Mean ± SD (%) of triplicate, traces < 0.1% not shown.
The n-6/n-3 ratio determined for ourGracilaria sp. sample was 3.6. TheWorldHealth Organization
(WHO) recommends an optimal balance intake of n-6 PUFAs and n-3 PUFAs to prevent chronic diseases
and that this balance should be maintained with an adequate daily dosage of n-6 PUFAs (5%–8% of
daily energy intake) and n-3 PUFAs (1%–2% of daily energy intake) [48]. With this recommendation
in mind, it is possible to estimate that a suitable n-6/n-3 ratio is less than 5. Also, some authors
reported that a ratio of n-6/n-3 less than 4 is adequate in the prevention of several diseases such
as cardiovascular [49], autoimmune [50], and inﬂammatory diseases [50,51], and cancer [49,50].
These ﬁndings support the use of Gracilaria sp. for human consumption.
2.3. Bioactivity of Lipid Extract of Gracilaria sp.
The bioactivity of Gracilaria sp. lipid extract was assessed, speciﬁcally its antiproliferative effect in
two human cancer cell lines (breast cancer—T-47D and bladder cancer—5637) and its anti-inﬂammatory
effect in a mouse leukemic monocyte macrophage cell line (RAW 264.7) stimulated with LPS.
2.3.1. Activity of Lipid Extract on Human Cancer Cell Viability
The growth inhibitory effect induced by the lipid extract on cancer cells is shown in Figure 3.
A lipid extract of Gracilaria sp. reduced cell viability in both cell lines in a dose-dependent manner
at concentration range of 10 to 20 μg/mL (p < 0.001), with a calculated half-maximal inhibitory
concentration (IC50) of 12.2 μg/mL and 12.9 μg/mL for T-47D (Figure 3A) and 5637 (Figure 3B) cancer
cells, respectively.
The anti-tumor effects of polar lipids were previously reported as affecting angiogenesis and
solid tumor growth via inhibition of replicative DNA polymerase activities [22,52]. Extracts rich in
glycolipids isolated from distinct seaweeds inhibited the growth of a human hepatocellular carcinoma
cell line (HepG2) (IC50 of 126 μg/mL) [16] and were found to induce apoptosis of human colon
carcinoma Caco-2 cells when associated with sodium butyrate [53]. Otherwise, SQDG isolated
from Gigartina tenella Harvey, 1860, accepted as Chondracanthus tenellus (Harvey) Hommersand,
1993, inhibited DNA polymerase α, DNA polymerase β, and HIV-reverse transcriptase type 1 or
downregulated Tie2 gene expression in tumors [17,54]. It has been hypothesized that the biological
properties of glycolipids such as SQDG are closely related to the sugar moiety and the presence of
PUFA chains.
8
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 62
Figure 3. Effect of lipid extracts of Gracilaria sp. on T-47D breast (A) and 5637 bladder (B) cancer cell
lines, after 96 h incubation. Results are shown as mean ± SD of three independent determinations
(*** p < 0.001, compared to control). OD: optical density; a.u.: arbitrary units.
2.3.2. Activity of the Lipid Extract on Nitric Oxide Production
The anti-inﬂammatory activity of the lipid extract of Gracilaria sp. was assessed based on its ability
to inhibit nitric oxide (NO) production in RAW 264.7 macrophages stimulated with LPS. For a range of
concentrations between 25 and 100 μg/mL, the lipid extract did not compromise the cellular viability
of macrophages (Figure 4A). The extract showed a dose-dependent NO inhibition of 35% attained at
the concentration of 100 μg/mL (Figure 4B). Therefore, the concentration exhibiting anti-inﬂammatory
activity also presented a safety proﬁle to macrophages (Figure 4A). Meanwhile, at lower concentrations
(≤ 50 μg/mL), the extract had no signiﬁcant inhibitory effect.
Figure 4. Cell viability and anti-inﬂammatory activity of Gracilaria sp. lipid extract. (A) Assessment
of metabolically active cells was performed using a resazurin bioassay. Results are expressed as a
percentage of resazurin reduction relative to the control (Ctrl); (B) Anti-inﬂammatory activity was
measured as inhibition of NO production, quantiﬁed by the Griess assay. Nitrite concentration was
determined from a sodium nitrite standard curve and the results are expressed as concentration (μM)
of nitrite in a culture medium. Each value represents the mean ± SD from at least three independent
experiments (** p < 0.01 compared to Ctrl; # p < 0.05, ### p < 0.001 compared to ethanol (EtOH, vehicle)
plus lipopolysaccharide (LPS)).
Previousworks have reported that polar lipidmay be beneficial for inflammatory diseases [11,20,55,56].
Accordingly, polar lipids isolated from red algae have demonstrated strong anti-inﬂammatory activity,
even higher when compared with pure 20:5(n-3) FA isolated from the same extracts [43], suggesting that
the polar lipid itself may contribute to the anti-inﬂammatory activity. In the cases of Chondrus crispus
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and Palmaria palmata (Linnaeus) Weber & Mohr, 1805, the polar lipids such as glycolipids and
phospholipids showed NO inhibitory activity through downregulation of inducible nitric oxide
synthase (iNOS) [20,21,57]. Moreover, extracts rich in glycolipids bearing high proportions of PUFA,
isolated from the red seaweeds Palmaria palmata, Porphyra dioica J. Brodie & L. M. Irvine, 1997, and
Chondrus crispus, downregulated LPS-induced pro-inﬂammatory responses in human macrophages
through the inhibition of IL-6 and IL-8 production, thus inferring their potential anti-inﬂammatory
activity [15]. Therefore, as for other red seaweeds, the lipid extract from Gracilaria sp. proved to have
effective anti-inﬂammatory activity.
Lipid extract fromGracilaria sp. showed antiproliferative and anti-inﬂammatory activity. However,
it was not possible to determine exactly which lipid components are responsible for these bioactivities.
Even in the literature, the majority of studies have also addressed biological activities of lipid extracts
rather than pure lipid molecules, which hampers the determination of a relationship between structure
and bioactivity. This is due to the fact that the isolation of a pure lipid molecule is very difﬁcult and
even pure lipid standards are not available for several lipid classes. Some authors have put some effort
into this issue, scarcely addressed for the lipid extracts from seaweed, and isolated enriched extracts in
some classes of lipids to further test their bioactivity. Ohta et al. [17] reported that SQDG (20:5/16:0),
isolated from red seaweed Gigartina tenella, was a potent inhibitor of eukaryotic DNA polymerases [17].
Tsai et al. also reported that enriched extract with SQDG isolated from red seaweeds, with high
levels of PUFAs such as 20:4(n-6) FA and 20:5(n-3) FA, inhibited the growth of human hepatocellular
carcinoma cell line (HepG2), rather than enriched extracts with MGDG or DGDG [16]. This research
group has also showed that the sulfolipids isolated from seaweed exhibited higher inhibitory effect
than sulfolipids isolated from spinach, previously reported as inhibitors of DNA polymerases and
of the proliferation of human cervix carcinoma (HeLa) [22]. The aforementioned SQDG-enriched
extracts displayed strong inhibitory effects and contained SQDG (20:5/16:0) [17] or contained SQDG
assembling PUFAs [16], which are also found in the extract of Gracilaria sp. analyzed within this work.
Thus, SQDG (18:2/16:0), SQDG (18:4/16:0), SQDG (20:4/16:0), and SQDG (20:5/16:0), identiﬁed in the
extract of Gracilaria sp., can contribute to the observed antiproliferative effects.
In what concern anti-inﬂammatory activities, Banskota et al. reported that the extracts rich in
MGDG and DGDG isolated from red seaweed Chondrus crispus inhibited NO production through
downregulation of iNOS [21]. The enriched extract contained MGDG (20:5/20:5), MGDG (20:5/20:4),
MGDG (18:4/16:0), MGDG (20:4/16:0), and MGDG (20:5/16:0) and the respective DGDG analogues.
Interestingly, the majority of these molecular species were also found in the extract of Gracilaria sp.
analyzed in the present work. Moreover, the same group of researchers isolated MGDG, DGDG,
SQDG, PC, and PG molecular species from the lipid extract of Palmaria palmata and all the polar lipids
showed NO inhibitory activity [20]. The isolated polar lipids identiﬁed were MGDG (20:5/20:5),
MGDG (20:5/16:0), DGDG (20:5/20:5), DGDG (20:5/14:0), DGDG (20:5/16:0), SQDG (20:5/14:0), PG
(20:5/16:0), PG (20:5/16:1) and PC (20:5/20:5). All the molecular species contained 20:5(n-3) FA, and
showed higher activity than the free FA 20:5(n-3), suggesting that the entire polar lipid structure
(e.g., sulfolipid, phospholipid, or galactolipids) is essential for the extension of NO inhibition. Aside
from the PC, the reported glycolipids and PG were also found in the lipidome of Gracilaria sp. Thus,
the presence of these glycolipids and PGs in the lipid extract of Gracilaria sp. can contribute to the
observed anti-inﬂammatory properties.
The presence of several polar lipids with recognized bioactive polar lipids in Gracilaria sp. can be
related to the bioactivity observed in this work. However, more studies are needed to understand the
structural/bioactivity relation of seaweed polar lipids, which deserve to be explored.
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3. Experimental Section
3.1. Biomass
Dried samples (25 ◦C, up to 12% moisture content) of Gracilaria sp. (G. vermiculophylla or G. gracilis,
pending conﬁrmation by DNA barcode analysis) (harvested in August 2014) were provided by
ALGAplus Ltd. (production site located at Ria de Aveiro, mainland Portugal, 40◦36’43” N, 8◦40’43” W).
The biomass is continuously produced by clonal propagation (asexual reproduction strategy) and thus
has lower variability than would be expected from wild harvested biomass.
3.2. Reagents
HPLC grade chloroform and methanol were purchased from Fisher Scientiﬁc Ltd. (Loughborough,
UK). All other reagents were purchased from major commercial sources. Milli-Q water (Synergy,
Millipore Corporation, Billerica, MA, USA), RPMI 1640 media from PAA (Pasching, Austria),
Phenol-red-free RPMI 1640 medium, penicillin–streptomycin, TrypLE express, fetal bovine serum
(FBS), and Presto Blue from Gibco Technologies (Invitrogen Life Sciences, Paisley, UK) were used.
3.3. Lipid Extraction Procedure
A mixture of chloroform/methanol (1:2, v/v) was added to 250 mg of dry weight seaweed.
The mixture was transferred to a glass tube with a Teﬂon-lined screw cap and, after the addition of
3.75 mL of solvent mixture, it was homogenized by vortexing for 2 min and then incubated in ice on
an orbital shaker for 2 h 30 min. The mixture was centrifuged at 2000 rpm for 10 min and the organic
phase collected. The biomass residue was re-extracted twice with 1.5 mL of solvent mixture and
2.3 mL of water was added to the total collected organic phase to induce phase separation. Following
this procedure, samples were centrifuged for 10 min at 1500 rpm, and the organic (lower) phase was
collected in a new tube. Three biological replicates were performed, with extractions and analyses
taking place on different days. Lipid extracts were dried under a stream of nitrogen gas and the lipid
content was estimated as (%) of dry weight. Lipid extracts were stored at −20 ◦C prior to analysis
by LC–MS.
3.4. Quantiﬁcation of Glycolipids and Phospholipids
Glycolipid quantiﬁcation was achieved by calculating the hexose content (% glucose) through the
orcinol colorimetric method (CyberLipids, [58]). The amount of sugar was read from a calibration curve
prepared by performing the reaction on known amounts of glucose (up to 40 μg, from an aqueous
solution containing 5 mg/mL of sugar). Phospholipids were quantiﬁed by a molybdovanadate method
for the simultaneous assay of orthophosphate and some organic phosphates, as described by Bartlett
and Lewis, and routinely performed in the authors’ laboratory [26,59,60]. Absorbance of standards and
samples was measured on a microplate UV-Vis spectrophotometer (Multiskan GO, Thermo Scientiﬁc,
Hudson, NH, USA).
3.5. Fractionation of Lipid Extract
Isolation of polar lipids from pigments was performed using a modiﬁcation of Pacetti’s
method [61]. A sample of lipid extract (1 mg) was dissolved in 300 μL of chloroform and transferred to
a Supelclean™ LC–Si SPE Tube (bed wt. 500 mg, volume 3 mL cartridges; SUPELCO, Sigma–Aldrich,
St. Louis, MO, USA), followed by sequential elution with 4 mL of chloroform, 3 mL of ether diethyl
ether:acetic acid (98:2), 5 mL of acetone:methanol (9:1 v/v), and 4 mL of methanol. Fractions 1 and 2,
corresponding to neutral lipids and pigments, were discarded. Fractions 3 and 4, rich in glycolipids
and in phospholipids plus betaines, respectively, were recovered, separated, dried under nitrogen, and
stored at −20 ◦C prior to analysis by ESI–MS.
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3.6. Hydrophilic Interaction Liquid Chromatography–Electrospray Ionization–Mass
Spectrometry (HILIC–ESI–MS)
Lipid extracts were analyzed by hydrophilic interaction liquid chromatography (HILIC) on a
Waters Alliance 2690 HPLC system (Waters Corp., Milford, MA, USA) coupled to a Finnigan LXQ
electrospray linear ion trap mass spectrometer (Thermo Fisher, San Jose, CA, USA). Mobile phase
A consisted of 25% water, 50% acetonitrile, and 25% methanol, with 1 mM ammonium acetate, and
mobile phase B consisted of 60% acetonitrile and 40% methanol with 1 mM ammonium acetate.
Lipid extracts (12.5 μg) were diluted in mobile phase B (100 μL) and 10 μL of the reaction mixture were
introduced into an Ascentis Si HPLC Pore column (15 cm × 1.0 mm, 3 μm; Sigma–Aldrich, St. Louis,
MO, USA). The solvent gradient, ﬂow rate through column and conditions used for acquisition of full
scan LC–MS spectra and LC–MS/MS spectra in both positive and negative ion modes were the same
as previously described [25,26]. The identiﬁcation of molecular species of polar lipids was based on
the assignment of the molecular ions observed in LC–MS spectra. Only ions observed in the LC–MS
spectra with a relative abundance >2% were considered for identiﬁcation. All analyses were performed
in analytical triplicate.
3.7. Electrospray–Mass Spectrometry (ESI–MS) Conditions
Fractions 3 and 4 recovered from lipid extract were analyzed by ESI–MS on a Q-Tof 2 quadrupole
time of ﬂight mass spectrometer (Micromass, Manchester, UK) operating in positive mode.
Each sample, diluted in 195 μL of methanol, was introduced through direct infusion with the following
electrospray conditions: ﬂow rate of 10 mL/min, voltage applied to the needle at 3 kV, a cone voltage
at 30 V, source temperature of 80 ◦C, and solvation temperature of 150 ◦C [62]. The resolution was set
to about 9000 FWHM (full width at half maximum). Tandem mass spectra (MS/MS) were acquired
by collision induced dissociation (CID), using argon as the collision gas (pressure measured as the
setting in the collision cell 3.0 × 105 Torr). The collision energy was between 30 and 60 eV. Both MS
and MS/MS spectra were recorded for 1 min. Data acquisition was carried out with a MassLynx
4.0 data system.
3.8. Fatty Acid Analysis by Gas Chromatography-Mass Spectrometry (GC–MS)
Fatty acid methyl esters (FAMEs) were prepared from lipid extracts using a methanolic solution
of potassium hydroxide (2.0 M) according to the methodology previously described [26]. Volumes
of 2.0 μL of the hexane solution containing FAMEs were analyzed by gas chromatography-mass
spectrometry (GC–MS) on an Agilent Technologies 6890 N Network (Santa Clara, CA, USA) equipped
with a DB-FFAP column with the following speciﬁcations: 60 m long, 0.25 mm internal diameter,
and 0.25 μm ﬁlm thickness (J & W Scientiﬁc, Folsom, CA, USA). The GC equipment was connected to
an Agilent 5973 Network Mass Selective Detector operating with an electron impact mode at 70 eV and
scanning the range m/z 40–500 in a 1 s cycle in a full scan mode acquisition. The oven temperature was
programmed from an initial temperature of 80 ◦C, a linear increase to 155 ◦C at 15 ◦C/min, followed
by linear increase at 8 ◦C/min to 210 ◦C, then at 30 ◦C/min to 250 ◦C, standing at 250 ◦C for 18 min.
The injector and detector temperatures were 220 and 280 ◦C, respectively. Helium was used as the
carrier gas at a ﬂow rate of 0.5 mL/min. The identiﬁcation of each FA was performed by mass spectrum
comparison with those in the Wiley 275 library and conﬁrmed by its interpretation and comparison
with the literature. The relative amounts of FAs were calculated by the percent area method with
proper normalization, considering the sum of all areas of the identiﬁed FAs.
3.9. Cell Viability Assay on T-47D and 5637 Tumor Cell Lines
The antiproliferative activity of lipid extracts was examined by the effect of Gracilaria sp. lipid
extracts on the T-47D human breast cancer and urinary bladder cancer cell lines’ metabolism using
the Prestoblue colorimetric assay (Invitrogen Life Sciences, Paisley, UK). Tumor cells were cultivated
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in Dulbecco’s Modiﬁed Eagle Medium (DMEM-F12, Invitrogen Life Technologies, Paisley, UK) with
10% fetal bovine serum (FBS; Gold, PAA) and 5 mg/L 1% penicillin/steptomicin (Invitrogen) in a
humidiﬁed incubator at 37 ◦C under an atmosphere of 5% CO2. Cell were plated on 96-well plates
and allowed to attach for 24 h, 100 μL of cell suspension (1–2 × 104 cell/mL in complete medium)
were used. Following this step, 200 μL of the treatment solution in a range of 25–100 μg/mL were
applied to the culture. The lipid extract was dissolved in DMSO and diluted to a ﬁnal concentration
of 0.1% DMSO in a phenol-red free RPMI 1640 medium supplemented with 2% charcoal treated
FBS (DCC), 1% glutamate, and 1% PEST. The same concentration of DMSO was used in untreated
controls [63]. The treatment medium was changed 48 h later, and was removed from each cell after
48 h for viability assay using PrestoBlue Absorbance measured at 570 nm and 600 nm at 1, 2, 3, 4,
and 5 h on a plate reader, which gave a linear absorbance range. Experiments were carried out in
quadruplicate and three independent experiments were carried out for each cell line.
3.10. Anti-Inﬂammatory Activity on Nitrite Production in RAW 264.7 Cells
Test solutions of Gracilaria sp. lipid extracts (25 mg/mL) were prepared in ethanol and stored
at –20 ◦C until used. Serial dilutions of tested solutions with culture medium were prepared and
sterilized by ﬁltration immediately before in vitro assays. Ethanol concentrations ranged from 0.1% to
0.8% (v/v).
RAW 264.7, a mouse leukemic monocyte macrophage cell line from American Type Culture
Collection (ATCC TIB-71), was supplied by Otília Vieira (Centro de Neurociências e Biologia Celular,
Universidade de Coimbra, Coimbra, Portugal) and cultured in Dulbecco’s Modiﬁed Eagle Medium
(Invitrogen Life Technologies, Paisley, UK) supplemented with 10% non-inactivated fetal bovine serum,
100 U/mL penicillin, and 100 μg/mL streptomycin at 37 ◦C in a humidiﬁed atmosphere of 95% air
and 5% CO2. During the experiments, cells were monitored through microscope observation to detect
any morphological change. Assessment of metabolically active cells was performed using a resazurin
bioassay [64]. Brieﬂy, cell duplicates were plated at a density of 0.1 × 106/well, in a 96-well plate
and allowed to stabilize overnight. Following this period, cells were either maintained in a culture
medium (control) or pre-incubated with various concentrations of Gracilaria sp. lipid extracts or its
vehicle for 1 h, and later activated with 50 ng/mL LPS for 24 h. After the treatments, resazurin solution
(50 μM in culture medium) was added to each well and incubated at 37 ◦C for 1 h, in a humidiﬁed
atmosphere of 95% air and 5% CO2. As viable cells are able to reduce resazurin (a non-ﬂuorescent blue
dye) into resoruﬁn (pink and ﬂuorescent), their number correlates with the magnitude of dye reduction.
Quantiﬁcation of resofurin was performed on a Biotek Synergy HT (BioTek Instruments, Winooski, VT,
USA) plate reader at 570 nm, with a reference wavelength of 620 nm. The production of nitric oxide
was measured by the accumulation of nitrite in the culture supernatants, using a colorimetric reaction
with the Griess reagent [65]. Brieﬂy, 170 μL of culture supernatants were diluted with equal volumes
of the Griess reagent [0.1% (w/v) N-(1-naphthyl)-ethylenediamine dihydrochloride and 1% (w/v)
sulphanilamide containing 5% (w/v) H3PO4] and maintained for 30 min in the dark. The absorbance
at 550 nm was measured on a Biotek Synergy HT plate reader. Culture medium was used as a blank
and nitrite concentration (μM) was determined from a regression analysis using serial dilutions of
sodium nitrite as standard. Experiments were carried out at least three times.
3.11. Statistical Analysis
Antiproliferative and anti-inﬂammatory bioassays were measured in quadruplicate and in three
different and independent experiments. Results were expressed as mean ± SD. One-way analysis
of variance (ANOVA) followed by Dunnett’s multiple comparison tests was used to compare the
treatment group to a single control group, after checking for assumptions. Statistical differences were
calculated and represented with the following symbols of signiﬁcance level ** p < 0.01, *** p < 0.001,
# p < 0.05, ### p < 0.001. Statistical analysis was performed using GraphPad Prism 5.0 for Windows
(GraphPad Software, San Diego, CA, USA).
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4. Conclusions
The comprehensive elucidation of the Gracilaria sp. lipidome has been successfully accomplished
for the first time. Liquid chromatography–mass spectrometry–based approach afforded the identification of
147 molecular species of polar lipids, distributed between the glycolipids, phospholipids, and betaine
lipids classes. It was possible to identify novel sulfolipids (SQMG) and betaine lipids, among which
DGTS were identiﬁed for the ﬁrst time on the genus Gracilaria and MGTS within the Rhodophyta.
Lipid extracts (~80% polar lipids) from Gracilaria sp. cultivated on land-based IMTA were screened for
bioactivity and collectively shown to be a natural source of bioactive lipids with antiproliferative and
anti-inﬂammatory activities. The presence of these bioactive polar lipids in Gracilaria sp. promotes
its consumption as a functional food for the prevention of various diseases. Seaweeds’ land-based
culture using IMTA is a sustainable solution towards the production of large volumes of biomass
displaying replicable bioactive properties. The higher degree of production conditions control enabled
by land-based IMTA, versus open-water large-scale culture, allows for the production of higher value
products with better positioning in value-chains supplying high-end markets.
Supplementary Materials: LC–MS spectra information are available online at www.mdpi.com/1660-3397/15/3/62/s1.
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Abstract: Background: Parenteral nutrition is often a mandatory therapeutic strategy for cases
of septicemia. Likewise, therapeutic application of anti-oxidants, anti-inﬂammatory therapy, and
endotoxin lowering, by removal or inactivation, might be beneﬁcial to ameliorate the systemic
inﬂammatory response during the acute phases of critical illness. Concerning anti-inﬂammatory
properties in this setting, omega-3 fatty acids of marine origin have been frequently described.
This study investigated the anti-inﬂammatory and LPS-inactivating properties of krill oil
(KO)-in-water emulsion in human macrophages in vitro. Materials and Methods: Differentiated
THP-1 macrophages were activated using speciﬁc ultrapure-LPS that binds only on the toll-like
receptor 4 (TLR4) in order to determine the inhibitory properties of the KO emulsion on the
LPS-binding capacity, and the subsequent release of TNF-α. Results: KO emulsion inhibited the
macrophage binding of LPS to the TLR4 by 50% (at 12.5 μg/mL) and 75% (at 25 μg/mL), whereas,
at 50 μg/mL, completely abolished the LPS binding. Moreover, KO (12.5 μg/mL, 25 μg/mL,
or 50 μg/mL) also inhibited (30%, 40%, or 75%, respectively) the TNF-α release after activation
with 0.01 μg/mL LPS in comparison with LPS treatment alone. Conclusion: KO emulsion inﬂuences
the LPS-induced pro-inﬂammatory activation of macrophages, possibly due to inactivation of the
LPS binding capacity.
Keywords: krill oil-in-water emulsion; omega-3 fatty acids; phospholipids; LPS; cytokines;
septic shock
1. Introduction
Sepsis and septic shock due to Gram-negative pathogens are responsible for signiﬁcant morbidity
and mortality in human populations [1]. LPS binding to phagocytic cells stimulates the synthesis and
release of cytokines, such as TNF-α, IL-1β, and IL-6 [2]. Cytokine secretion is an important component
of host defense, but when overstimulation occurs, excessive cytokine secretion may lead to the systemic
signs and symptoms of sepsis [3]. Exogenous or endogenous stimulation of biological factors that
modulate the extent of binding of LPS to monocytes and macrophages may play a pivotal role in
determining the outcome of endotoxin exposure [1]. In this context, serum factors that bind LPS may
prevent macrophage activation [4]. In vitro and in vivo, HDL binds LPS and neutralizes it and the
LPS-induced cytokine response is attenuated [5,6]. However, the phospholipid (PL) content, rather than
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the cholesterol content, correlates with the effectiveness of LPS neutralization [7]. Additionally,
circulating levels of HDL are reduced in sepsis/septic shock, and this reduction is positively correlated
with the severity of the illness [8], and decreased LDL levels (≤70 mg/dL) were associated with
increased risks of sepsis [9]. In an optimal way, the substance used to neutralize the endotoxin effect
during sepsis should be anti-oxidative, anti-inﬂammatory, and with endotoxin-binding capacity. In this
context, omega-3 fatty acids (n-3 fatty acids) decrease the production of inﬂammatory eicosanoids,
cytokines, reactive oxygen species (ROS) and adhesion molecules [10]. The key link between PUFAs
and inﬂammation is that eicosanoids, which are among the primary mediators and regulators of
inﬂammation during acute metabolic stress, are generated from 20-carbon PUFAs [10]. The three
types of omega-3 fatty acids involved in human physiology are α-eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), both of which are usually found in marine ﬁsh oils and linolenic acid
(ALA), commonly found in plant oils. With respect to the precursor fatty acid ALA, in human it has
poor bioconversion to the essential omega-3 fatty acids EPA and DHA and, therefore, it is an unreliable
source for these bioactive fatty acids [11]. In this context, ﬁsh oil dietary supplements play a role of
increasing the strategic importance in meeting daily requirements of essential nutrients [12].
Applications of intravenous lipid emulsions containing ﬁsh oil reduce the length of stay in
hospital [13], as well as antibiotic use and mortality [14]. Moreover, ﬁsh oil with parenteral nutrition
provided to septic intensive care patients increases plasma EPA, modiﬁes inﬂammatory cytokine,
improves gas exchange [15], and may exert profound inﬂuence on the status of immunocompetence
and inﬂammation [16,17] The anti-inﬂammatory properties of marine omega-3 fatty acids have already
been described [18,19]. In addition to triglycerides, marine n-3 fatty acids are also available in other
forms, such as in crude krill oil (KO), which provides EPA and DHA, mainly in the form of PLs, and
as ethyl esters of pharmaceutical grade, highly-concentrated preparations [18]. In this context, most
recently, KO, which contains a signiﬁcant portion of its n-3 LC-PUFA in PLs, is also increasingly found
on the market, and is promoted as being of “higher efﬁcacy” [12,20]. Additionally, most recently a new
product category, derived from Antarctic krill (Euphausia superba Dana), has been brought onto the
omega-3 market, characterized by a greater ease of absorption due to higher PL content [12,20].
KO comes from sustainable ﬁsheries and is nearly at the beginning of a food chain, compared with
ﬁsh sources that are more affected by environmental pollutants [12,20]. In addition, a higher fraction
of omega-3 LC-PUFA is associated with PLs in KO, compared to triacylglycerol in ﬁsh oils, and this
property may improve gastrointestinal absorption and bioavailability of omega-3 LC-PUFA [21]. KO
contains PUFAs, including the bioactive EPA and DHA, (up to 35% w/w of the fatty acids proﬁle),
with up to 95% w/w PLs and up to 45% triglycerides [22]. According to these characteristics, we
hypothesize that an injectable KO emulsion might in vitro exert anti-inﬂammatory properties from
the presence of omega-3 fatty acids, and also bind endotoxin, thereby inhibiting LPS mediated effects,
i.e., LPS is less able to stimulate and activate macrophages to release pro-inﬂammatory cytokines.
2. Results
2.1. Effect of KO Emulsion or LPS on the Viability of Differentiated Human THP-1 Macrophages
As shown in Figure 1A, we found that, after 24 h, treatment with 5–250 μg/mL KO did not
display any cytotoxicity. Glycerol used as the vehicle was not cytotoxic (Figure 1A). Incubation of
differentiated human THP-1 macrophages for 4 h with LPS did not show cytotoxicity (Figure 1B).
2.2. Effect of KO Emulsion on the LPS Binding
We used two binding assays to evaluate the interaction of LPS with macrophage-TLR4 and the
inhibitory effect of KO. As shown in Figure 2, macrophages incubated 24 h with 1 μg or 5 μg/mL
LPS-EB-biotin displays positive binding, detected by ﬂuorescence (Figure 2), compared with controls
without LPS.
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Figure 1. (A) Effects of 24 h treatment with KO emulsion or the glycerol vehicle (numbers in brackets
indicate the volume of glycerol used in the corresponding KO concentration), on the viability of
THP-1 macrophages. Values (in % viability of cells without treatment (control = 100%)) are given
as the mean + SEM; ANOVA test, signiﬁcance vs. negative control, ** p ≤ 0.01, *** p ≤ 0.001; n = 7
independent experiments; and (B) the effects of 4 h treatment with ultrapure LPS-EB-biotin on the
viability of differentiated human THP-1 macrophages. Values (in % viability of cells without treatment
(control = 100%)) are given as the mean + SEM; n = 4 independent experiments.
Figure 2. Effect of the KO emulsion on the LPS binding by differentiated human THP-1 macrophages.
Photographs of the inhibitory effect of KO on the binding of ultrapure LPS-EB-biotin after 24 h
incubation, was detected with streptavidin-Cy3-conjugated as ﬂuorochrome. White arrows: nuclei.
Magniﬁcation: 200×.
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LPS (1 μg/mL) pre-incubated with KO (100 μg/mL) inhibited the binding, but not when using
LPS at a concentration of 5 μg/mL (Figure 2). The LPS binding was increased at 0.1 μg/mL (6.5%),
1 μg/mL (20.3%, p ≤ 0.05), and 5 μg/mL (100%, p ≤ 0.05) when compared with the negative control
(Figure 3).
ȱ
Figure 3. Effect of the KO emulsion on the LPS binding on macrophage-TLR4. Ultrapure LPS-EB-biotin
binding assay was performed by using PMA-differentiated THP-1 macrophages after 3 h incubation,
including streptavidin-HRP-OPD system for detection and colorimetric quantiﬁcation. Values
(binding relative to negative control (value = 1) without LPS-EB-biotin) are given as the mean + SEM;
ANOVA test, signiﬁcance vs. negative control without LPS, * p ≤ 0.05; n = 4 independent experiments.
After co-incubation of 0.1 μg/mL LPS-EB with KO, the macrophages were treated for 3 h with
different concentrations of LPS + KO: at 12.5 μg/mL LPS + KO, LPS-binding decreased by 50%
(not signiﬁcant); at 25 μg/mL LPS + KO LPS binding signiﬁcantly decreased by 75% (p ≤ 0.05) and,
at 50 μg/mL LPS + KO, it was abolished (p ≤ 0.01), as shown in Figure 4.
ȱ
Figure 4. Ultrapure LPS-EB-biotin binding assay on macrophage-TLR4. LPS-EB-biotin (0.1 μg/mL) was
co-incubated overnight with different concentrations of KO emulsion or LPS antagonist (LPS-RS AN),
added to differentiated THP-1 macrophages (3 h). LPS binding was spectrophotometrically quantiﬁed
using streptavidin-HRP-OPD system. Values (in % binding relative to positive control (100% binding)
with LPS-EB-biotin) are given as the mean + SEM; ANOVA test, signiﬁcance vs. positive control
(=LPS-EB-Biotin), * p ≤ 0.05, ** p ≤ 0.01; n = 6 independent experiments.
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As the LPS-binding control, 25 μg/mL nLDL showed a similar effect as KO at 12.5 μg/mL,
however, this was not signiﬁcant. LPS-RS-AN antagonist signiﬁcantly (p ≤ 0.01) prevented the binding
of LPS-biotin and, thus, mimicked the effect of KO (Figure 4). A total and signiﬁcant inhibition of
the binding was obtained when 1 μg/mL LPS-EB was co-incubated with 6.25, 12.5 μg/mL (p ≤ 0.01),
25 μg/mL (p ≤ 0.01), or 50 μg/mL (p ≤ 0.001) KO when compared with the control. Furthermore, LDL
showed a similar inhibition pattern as KO. Additionally, the LPS-RS antagonist completely inhibited
the LPS binding on the TLR4 (Figure 5). Moreover, we have performed this experiment using 5 μg/mL
LPS-EB-biotin, however, without a statistically signiﬁcant difference between LPS/KO co-incubation
and LPS alone (data not shown).
ȱ
Figure 5. Ultrapure LPS-EB-biotin binding assay on macrophage-TLR4. LPS-EB-biotin (1 μg/mL)
was co-incubated overnight together with different concentrations of KO emulsion or 100 μg/mL
LPS antagonist (LPS-RS AN) added to differentiated human THP-1 macrophages (3 h). LPS binding
was spectrophotometrically quantiﬁed using streptavidin-HRP-OPD system. Values (in % binding
relative to positive control (100% binding) with LPS-EB-biotin) are given as the mean + SEM; ANOVA
test, signiﬁcance vs. positive control (=LPS-EB-Biotin), * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; n = 6
independent experiments using four wells per treatment and experiment.
2.3. Effect of KO Emulsion on TNF-α Release of Differentiated Human THP-1 Macrophages Stimulated
with LPS-EB
The TNF-α release in cell supernatants of differentiated human THP-1 macrophages treated with
LPS-EB (pre-incubated with KO) was markedly reduced when 0.01 μg/mL or 0.1 μg/mL LPS was
used. A signiﬁcant inhibition of the TNF-α release was obtained after incubation of 0.01 μg/mL LPS
with 12.5 μg/mL (−30%, p ≤ 0.01), 25 μg/mL (−40%, p ≤ 0.001) or 50 μg/mL (−75%, p ≤ 0.001) KO
in comparison with the control LPS (Figure 6A).
Treatment with 0.1 μg/mL LPS pre-incubated with 25 μg/mL or 50 μg/mL KO showed a 50%
(p ≤ 0.05) or 60% (p ≤ 0.01) inhibition in comparison with control LPS (Figure 6B). Treatment with KO
alone had no effect on the TNF-α production (Figure 6B). Incubation with antagonist LPS-RS abolished
the TNF-α release (Figure 6B).
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Figure 6. Analyses (by ELISA) of the inhibitory effect of KO emulsion on the TNF-α release by LPS-EB
differentiated human THP-1 macrophages. (A) LPS-EB 0.01 μg/mL, or (B) 0.1 μg/mL was co-incubated
overnight together with different concentrations of KO or 10 μg/mL LPS antagonist (LPS-RS-AN) and
afterwards for 3 h with the differentiated THP-1 macrophages. Values (in %TNF-α release relative to
positive (LPS-EB) control (=100% release)) are given as the mean + SEM; ANOVA test, signiﬁcance vs.
positive control (=LPS-EB), * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; n = 3–5 independent experiments.
3. Discussion
Sepsis has been deﬁned as a systemic immune activation in patients with infection, characterized
by low rates of survival [23]. Bacterial endotoxemia is considered one of the major causes of sepsis,
resulting from the release of LPS by microorganisms, e.g., within the colon, that translocate across
a compromised intestinal wall [17,24]. In this context, we performed in vitro experiments to test the
efﬁcacy of a KO emulsion against endotoxin-triggered pro-inﬂammatory effects.
Death rates in patients caused by sepsis reach about 30%–80% [25], especially in oncologic
patients [26]. Sepsis-associated organ failure and death result from an overwhelming inﬂammatory
immune response that culminates in a generalized autodestructive process [27] and development of
multi-organ dysfunction syndrome, or MODS [28]. Under normal physiological conditions, in which
ROS levels are controlled by endogenous anti-oxidant systems, sepsis induces an imbalance between
pro- and antioxidant systems, which leads to oxidative stress [29]. Moreover, long-chain n-3 PUFAs
decrease the production of inﬂammatory mediators (eicosanoids, cytokines, and ROS) [22,30]. Once
incorporated into cell membranes, a key step to exert cytoprotection, n-3-FAs dramatically modulate
the body’s response to inﬂammation, oxidative stress, ischemia, and immune function through
several downstream bioactive mediators, (e.g., cytokines, prostaglandins, thromboxanes, leukotrienes,
resolvins, protectins, etc.) [22]. The combination of “cytoprotective excipients” [31], together with
nutritional, anti-oxidant, and anti-inﬂammatory properties, make the omega-3 therapy a successful
candidate for the management of sepsis in patients under intensive care. By using EPA or ﬁsh oil,
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inhibition of endotoxin-induced TNF-α production by monocytes [32], may exert effects on both,
the generation of inﬂammatory mediators, and on the resolution of inﬂammatory processes [15].
These observations suggest direct effects of long-chain n-3 PUFA on inﬂammatory gene expression
via inhibition of activation of the transcription factor NF-κB [33]. Several studies in healthy human
volunteers involving supplementation of the diet with ﬁsh oil have demonstrated decreased production
of TNF-α, IL-1β, and IL-6 after endotoxin-stimulation of monocytes or mononuclear cells [34,35].
The beneﬁts of ﬁsh oil in animal models of experimental endotoxemia have been clearly demonstrated
when dietary ﬁsh oil or ﬁsh oil infused intravenously enhances the survival of guinea pigs after
intraperitoneal endotoxin injection [36]. In this context, strategies to attenuate the immune response
and prevent organ failure could help patients with sepsis or septic shock. Given that ultrapure LPS-EB
speciﬁcally binds to TLR4 and the LPS antagonist LPS-RS, leading to an almost complete suppression
of the TNF-α release, conﬁrms the speciﬁc binding of LPS-EB to TLR4. The same effect observed with
KO, can be explained by an inactivation of LPS during the co-incubation with KO or an inhibition
of the binding to TLR4. Nevertheless, the present study clearly demonstrates that KO inhibited the
production of TNF-α after stimulation with LPS. Available data have conﬁrmed an effective reduction
in the LPS level in the patients’ blood after this procedure [37], and could effectively eliminate a wide
range of the factors as LPS, cytokines, etc., from peripheral blood.
Our ﬁndings suggest that KO has properties to inactivate and bind LPS, leading to the inhibition
of activation of macrophages. In this context, we found a reduction of LPS binding capacity on
differentiated human THP-1 macrophages after 3 h treatment with LPS that has been co-incubated
(24 h) with 100 μg/mL KO (Figure 2), by reduction of the ﬂuorescence intensity at a concentration of
1 μg/mL LPS (Figure 2). These data support studies showing less LPS internalization into murine
macrophages after 24 h treatment, when LPS was pre-exposed to high-density lipoprotein (HDL) [4].
In agreement with these studies, we used human LDL as binding control and we found that LDL
reduced the binding of LPS on macrophages (Figures 4 and 5). Moreover, KO signiﬁcantly reduced
the LPS-binding on macrophages over a range of LPS concentrations when both had been previously
co-incubated and, afterwards, were applied to the macrophages. Human serum or LDL inactivate
endotoxins and inhibit the IL-1β release in LPS-activated monocytes [38]. Consequently, this observed
KO characteristic may be a sign of a possible LPS adsorption, inactivation, or hiding of the binding
sites. Using the LPS antagonist Rhodobacter sphaeroides, which binds to the TLR4 but does not induce
TLR4 signaling, we can conﬁrm the speciﬁcity of the activation (Figures 4 and 5). After co-incubation
(24 h) of LPS and KO (12.5, 25 or 50 μg/mL), LPS lost its pro-inﬂammatory capacity and inhibited the
TNF-α release. KO alone or LPS antagonist did not affect the TNF-α production, and conﬁrmed that
KO has beneﬁcial, and not detrimental, effects. Therefore, our results impressively indicate that KO
can efﬁciently prevent macrophages from being activated by LPS, including suppression of negative
consequences. like the release of pro-inﬂammatory cytokines, such as TNF-α.
The effects we have observed with a KO emulsion are likely the result of two main mechanisms
of action. First, the phopsholipids present in KO bind and neutralize LPS endotoxin. This effect
has been shown previously in a study of normal human volunteers receiving an intravenous
dose of Escherichia coli endotoxin during a 6-h PL infusion, and attenuation of the clinical and
laboratory responses were directly related to PL levels in the bloodstream [39]. However, when
this formulation was tested in the critical care setting in patients with severe Gram-negative sepsis, the
high dose arm (1350 mg/kg by continuous infusion) had to be stopped because of the increased
incidence of life-threatening signiﬁcant adverse events and obvious futilty to show a survival
advantage [40]. The PL emulsion used in this investigation consisted of 92.5% soy-based, PL, and 7.5%
soy triglycerides. Although this formulation contained PLs capable of binding endotoxin, the dosing
was probably excessive. Additionally, the fatty acid proﬁle of soybean oil-derived triacylglycerols and
phosphoglycerides mainly contain pro-inﬂammatory omega-6 fatty acids (i.e., linoleic acid). In contrast,
the KO-based PL emulsion in the present study contained both the necessary PL to bind the endotoxin,
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plus the anti-inﬂammatory omega-3 fatty acids to modulate eicosanoid metabolism, and they clearly
exhibit positive synergistic effects.
Finally, the KO emulsion used in this study was a crude formulation made from an unreﬁned
natural source that is widely found in oral supplements and, thus, would be unsuitable for
intravenous administration. Therefore, our study provided an indication of a proof-of-concept with
this phospholipid-omega-3 combination in a cell culture model. We clearly recognize that for such a
product to be a potentially viable injectable emulsion in the clinical setting, the crude KO would need
to undergo reﬁnement steps (similar to that applied to ﬁsh oil) [41] to concentrate the PL in amounts
and levels of purity similar to currently available and widely used egg PL which, for example, contain
at least 80% phosphatides (versus ~40%, and about equal amounts of triglycerides). In addition,
since the triglycerides present in crude KO are essentially devoid of omega-3 fatty acids, the ideal
injectable product would also include ﬁsh oil triglcyerides enriched with omega-3 fatty acids for
maximal therapeutic efﬁcacy.
We conclude that KO emulsion inhibits the LPS-binding on macrophage-TLR4 and, thus, the
TNF-α release induced by LPS in vitro. The addition of omega-3 fatty acids potentiates the therapeutic
actions by reducing the intensity of the systemic inﬂammatory response. These properties may be
beneﬁcial for patients under intensive care with septicemia.
4. Materials and Methods
4.1. Krill Oil-In-Water Emulsion
Three separate batches of a 5% KO-in-water emulsion were aseptically prepared in the laboratory
and sterilized prior to use. This was done to be sure the emulsions could be successfully made using
a crude source of KO, since a pharmaceutical-quality grade, suitable for parenteral administration,
does not exist. The mean droplet size of all the emulsions was approximately 190 nm and, thus,
they were considered pharmaceutically equivalent. The composition of the ﬁnal emulsions are shown
in Table 1.
Table 1. Krill oil-in-water emulsion.
Ingredient Amount/1000 mL
Glycerol 25.0 g
Krill Oil * 50.0 g
Sterile Water for Injection 1000 mL
pH 6.89 ± 0.06
* Virgin Krill Oil, LLC, Braintree, MA, USA, Lot #1107091, Key Ingredient Totals (w/w): n-3-FAs = 26%; PLs = 41.2%.
4.2. Cells and Culture Conditions
The in vitro experiments were performed using the THP-1 (human acute monocytic leukemia)
cell line (DSMZ GmbH, Braunschweig, Germany), cultured in 90% RPMI-1640 (PAA GmbH,
Cölbe, Germany), 10% FBS (PAA GmbH); 100 U/mL penicillin; and 0.1 mg/mL streptomycin (PAA
GmbH). All experiments were carried out in medium with 10% FBS.
4.3. Determination of LPS and KO Emulsion Cytotoxicity
THP-1 (5 × 104) cells were seeded in 96-well plates (BD Falcon™, Becton Dickinson GmbH,
Heidelberg, Germany). After differentiation with 0.1 μg/mL phorbol-12-myristate-13-acetate (PMA)
Sigma-Aldrich, St. Louis, MO, USA), the medium was changed and the macrophages treated with
0.05 μg/mL-10 μg/mL ultrapure biotinylated lipopolysaccharide (LPS-EB) from E. coli O111:B4
(Cayla-InvivoGen Europe, Toulouse, France), which is recognized only by toll-like receptor-4 (TLR4);
KO 5 μg/mL to 250 μg/mL, or glycerol. After 24 h KO or 4 h LPS treatment, viability was assessed
using PrestoBlue™ reagent (Invitrogen-Life Technologies GmbH, Darmstadt, Germany). After 1 h the
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optical density (OD) was measured at 570 nm/600 nm with a SUNRISE ELISA-reader (Tecan Salzburg,
Austria). Results are expressed as the % of viability/survival (OD570 nm/600 nm of samples ×
100/OD570 nm/600 nm of control without substances).
4.4. Determination of the LPS Binding on Differentiated THP-1 Macrophages, Effect of the Treatment with KO
Emulsion, Detected by Fluorescence Microscopy
THP-1 (5 × 104) cells were seeded in 100 μL medium/well in 96-well plates (BD Falcon™).
After eight days of differentiation into macrophages using 0.1 μg/mL PMA, the medium was changed
and the macrophages were treated with 1 μg/mL or 5 μg/mL ultrapure LPS-EB-biotin alone or
with KO. After 3 h the cells were ﬁxed with 1% paraformaldehyde (PFA/PBS) for 20 min and
incubated afterwards with streptavidin-Cy3 (Dianova, Hamburg, Germany). Digitalized images
were obtained using an inverted microscope Eclipse-TS100 (Nikon GmbH, Düsseldorf, Germany) and
an AxioCamMRc/AxioVision digital imaging system (Carl Zeiss GmbH, Jena, Germany).
4.5. Determination of the LPS Binding on Differentiated THP-1 Macrophages Detected by Spectrophotometry
THP-1 (5 × 104) cells were seeded as described above and treated with 0.1 μg/mL,
1 μg/mL, or 5 μg/mL ultrapure LPS-EB-biotin. After 3 h the macrophages were ﬁxed with
1% PFA/PBS for 20 min, then incubated with streptavidin-biotinylated horseradish peroxidase
(HRP-streptavidin-biotin) complex Amersham (GE Healthcare Europe GmbH, Freiburg, Germany).
Subsequently, the macrophages were incubated with 50 μL peroxidase substrate Sigma Fast™ (OPD)
(Sigma-Aldrich, St. Louis, MO, USA) for 30 min at RT. The reaction was stopped with 25 μL 3N
HCl, and the absorbance was measured at 490 nm/655 nm. Afterwards, the cells were stained with
crystal violet solution (0.04% paraformaldehyde crystal violet in 4% (v/v)). The OPD absorbance was
normalized against the crystal violet absorbance measured at 595 nm/660 nm.
4.6. Inhibitory Effects of the KO Emulsion on the LPS Binding Capacity
PMA-differentiated THP-1 macrophages were treated for 3 h with the LPS-EB-biotin and KO
mixture (both previously incubated together at 4 ◦C overnight), afterwards the cells were ﬁxed
with 1% PFA-PBS for 20 min, washed with PBS, incubated with streptavidin-biotin-complex-HRP
(Amersham, GE Healthcare), afterwards with OPD and measured as described above. The positive
control was performed by incubation of macrophages with ultrapure LPS-EB-biotin alone and the
negative controls incubated only with medium or with KO. In humans, low-density lipoproteins (LDLs)
may bind LPS and inactivate it; we used native LDL (nLDL, HoelzelDiagnostika GmbH, Cologne,
Germany) as a control to compare the adsorption properties of KO [38]. The antagonist LPS from
Rhodobactersphaeroides (LPS-RS) was used as control of the TLR4 speciﬁc binding by competitive
inhibition at 100-fold excess of the agonist LPS-EB.
4.7. Effects of the KO Emulsion on TNF-α Release
The release of TNF-α was determined using ELISA. Therefore, 5 × 105 THP-1 cells were
seeded in 24-well plates (BD Falcon™). After ﬁve days of PMA-induced differentiation (0.1 μg/mL),
the macrophages were treated 3 h with LPS-EB and KO (previously incubated as described). After the
treatment, the culture medium was harvested and centrifuged at 500× g (5 min). The cells were
homogenized in RIPA buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) for protein
quantiﬁcation using the bicinchoninic acid assay (Thermo Fisher Scientiﬁc, Bonn, Germany). Human
TNF-α was determined in the supernatant using the DuoSet-ELISA kit (R&D Systems Europe,
Ltd., Abingdon, UK) according to the manufacturer’s instructions; 96-well NUNC MaxiSorp™
(Thermo Fisher Scientiﬁc) were used. The amount of TNF-α was normalized with the protein content.
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4.8. Statistical Analyses
The SigmaPlot®-12 software (Systat Software GmbH, Erkrath, Germany) was used to carry out
statistical analyses by one-way analysis of variance test (ANOVA) using Dunnett’s method appropriate
for multiple comparisons versus the control group. Data are shown as mean + SEM.
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Abstract: Polyunsaturated fatty acids (PUFAs) have been acknowledged as essential nutrients
for cephalopods but the speciﬁc PUFAs that satisfy the physiological requirements are unknown.
To expand our previous investigations on characterisation of desaturases and elongases involved
in the biosynthesis of PUFAs and hence determine the dietary PUFA requirements in cephalopods,
this study aimed to investigate the roles that a stearoyl-CoA desaturase (Scd) and an elongation
of very long-chain fatty acid 4 (Elovl4) protein play in the biosynthesis of essential fatty acids
(FAs). Our results conﬁrmed the Octopus vulgaris Scd is a Δ9 desaturase with relatively high afﬁnity
towards saturated FAs with ≥ C18 chain lengths. Scd was unable to desaturate 20:1n-15 (Δ520:1)
suggesting that its role in the biosynthesis of non-methylene interrupted FAs (NMI FAs) is limited to
the introduction of the ﬁrst unsaturation at Δ9 position. Interestingly, the previously characterised Δ5
fatty acyl desaturase was indeed able to convert 20:1n-9 (Δ1120:1) to Δ5,1120:2, an NMI FA previously
detected in octopus nephridium. Additionally, Elovl4 was able to mediate the production of 24:5n-3
and thus can contribute to docosahexaenoic acid (DHA) biosynthesis through the Sprecher pathway.
Moreover, the octopus Elovl4 was conﬁrmed to play a key role in the biosynthesis of very long-chain
(>C24) PUFAs.
Keywords: biosynthesis; elongation of very long-chain fatty acids 4 protein; non-methylene-
interrupted fatty acids; polyunsaturated fatty acids; Octopus vulgaris; stearoyl-CoA desaturase
1. Introduction
Cephalopods have been regarded as promising candidates for the diversiﬁcation of marine
aquaculture due to their great commercial interest [1]. Despite signiﬁcant progress made over the
last decade, culture of cephalopod species with pelagic paralarval stages like the common octopus
Octopus vulgaris is still challenging due to the massive mortalities occurring upon the settlement
phase [2]. The speciﬁc factors causing such mortalities of paralarvae remain unclear, although it has
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become increasingly obvious that nutritional issues associated with inadequate supply of essential
nutrients such as lipids are crucial to ensure normal growth and development of O. vulgaris paralarvae
and ultimately improve their viability [3].
Previous investigations postulated that polyunsaturated fatty acids (PUFAs) are essential nutrients
for the common octopus [4,5]. However, the speciﬁc PUFAs that satisfy the physiological requirements
were not determined, partly due to the difﬁculties in running nutritional trials on octopus paralarvae.
In order to provide insights to the endogenous capability for PUFA biosynthesis in O. vulgaris,
we have recently conducted a series of studies aiming to identify and characterise the function
of genes encoding enzymes that mediate the conversions in the PUFA biosynthetic pathways.
First, we identiﬁed a fatty acyl desaturase (Fad) cDNA sequence with homology to the vertebrate
Fads family [6], enzymes that participate in long-chain (C20–24) PUFA (LC-PUFA) biosynthetic
pathways [7–9]. The expression of the common octopus Fad in yeast demonstrated that the enzyme
was a Δ5 desaturase (Δ5 Fad) with high efﬁciency towards both saturated and polyunsaturated fatty
acid (FA) substrates [6]. Thus, the O. vulgaris Δ5 Fad was able to desaturate the yeast endogenous
saturated FAs 16:0 and 18:0 to the corresponding monoenes 16:1n-11 (Δ516:1) and 18:1n-13 (Δ518:1),
respectively. Furthermore, the O. vulgaris Δ5 Fad efﬁciently desaturated the PUFA 20:4n-3 and 20:3n-6
to the Δ5 desaturation products eicosapentaenoic acid (EPA, 20:5n-3) and arachidonic acid (ARA,
20:4n-6), respectively (Figure 1).
A second study provided further evidence of the existence of an active PUFA biosynthetic system
in the common octopus [10]. Thus, a cDNA encoding a protein with high homology to an elongation
of very long-chain fatty acids (Elovl) protein was isolated [10]. Phylogenetic analysis comparing the
amino acid (aa) sequence of the O. vulgaris Elovl with other elongases from molluscs and vertebrates
clearly showed that the common octopus Elovl, as well as other putative elongases from molluscs,
was grouped as a basal cluster of the vertebrate Elovl2 and Elovl5 families [10]. Consequently,
such an elongase has been termed “Elovl5/2” [11] or “Elovl2/5” [12,13]. Regarding its function,
the common octopus Elovl2/5 exhibited substrate speciﬁcities resembling those of vertebrate Elovl5
but not Elovl2, as it efﬁciently elongated C18–20 PUFAs [10] but had no activity towards C22 substrates.
This was hypothesised as one of the reasons accounting for the inability of cephalopods to biosynthesise
docosahexaenoic acid (DHA; 22:6n-3) (Figure 1) [10,11] through the so-called “Sprecher pathway”
requiring the production of 24:5n-3 as an intermediate in the pathway [14]. Among alternative
Elovl-like enzymes with a role in the biosynthesis of LC-PUFAs such as DHA in the common octopus,
the Elovl4 elongase is an interesting candidate, as studies on teleost orthologues have shown that
Elovl4 can efﬁciently catalyse the elongation of 22:5n-3 to 24:5n-3 [15–19], and recent studies have
further demonstrated a similar elongation ability in molluscs [12].
The above studies on O. vulgaris [6,10], as well as those on homologous genes from the common
cuttleﬁsh Sepia ofﬁcinalis [20], have enabled us to predict the biosynthetic pathways of PUFAs in
cephalopods (Figure 1). Beyond the biosynthesis of standard PUFAs, i.e., FAs whose double bonds are
always separated by a methylene group (-CH2-) [9], one can predict that some pathways involving
the Δ5 Fad and Elovl2/5 lead to the production of so-called “non-methylene-interrupted FAs”
(NMI FAs), a particular type of PUFA that had been previously reported in other molluscan classes
(bivalves, gastropods), as well in sponges, echinoderms and other phyla [21–23]. Analyses performed
in wild-caught specimens of O. vulgaris conﬁrmed that the polar lipid fractions of nephridium,
male gonad, eye and caecum contained NMI FAs identiﬁed as Δ5,1120:2, Δ7,1320:2, Δ5,11,1420:3 and
Δ7,1322:2 [10]. From the unsaturation pattern of these compounds, it became clear that, in addition to
Δ5 Fad, a further desaturase with Δ9 activity was likely involved in the NMI FA biosynthetic pathways
accounting for the Δ5,9 unsaturation patterns typically found among these compounds [22,23].
The stearoyl-CoA desaturase (Scd), an enzyme that is expressed in virtually all living organisms [24],
has Δ9 desaturation capability and thus appears to play a role in NMI FA biosynthesis [7].
Our overall aim is to characterise the biosynthetic pathways of PUFAs including NMI FAs in
cephalopods. Using the common octopus O. vulgaris as model species, we herein isolated two cDNAs,
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namely Scd and Elovl4 sequences, and characterised their functions by heterologous expression in
yeast. In order to establish the mechanisms accounting for biosynthesis of Δ5,9 dienes (NMI FA) we
further investigated the roles that the herein characterised Scd and the previously reported Δ5 Fad [6]
play within these pathways.
Figure 1. Model of biosynthetic pathways of polyunsaturated fatty acids in cephalopods.
Enzymatic activities shown in the diagram are predicted from heterologous expression in yeast
(Saccharomyces cerevisiae) of fatty acyl desaturases (red arrows) and elongation of very long-chain
fatty acid (Elovl) proteins (green arrows) from Octopus vulgaris [6,10] and Sepia ofﬁcinalis [20].
Dotted arrows indicate reactions that have not yet been demonstrated prior to the present study.
β-ox, partial β-oxidation.
2. Results
2.1. Octopus vulgaris Scd Sequence
TheO. vulgaris Scd-like cDNA consisted of a 981-bp open reading frame (ORF) encoding a putative
protein of 326 amino acids (aa) with a predicted molecular weight of 37.9 kDa. Its sequence was
deposited in the GenBank database with the accession number JX310655. In common with other Scd
proteins, the O. vulgaris putative Scd possessed three histidine boxes (HXXXH, HXXHH and HXXHH),
four membrane-spanning regions rich in hydrophobic aa, and lacked the cytochrome b5 domain
characteristic of Fads (Figure 2).
The deduced aa sequence from the common octopus Scd was 50.8%–53.4% identical to Scd
sequences from vertebrates including Homo sapiens (NP_005054.3), Gallus gallus (NP_990221.1)
and Xenopus laevis (NP_001087809.1), and 40.7% and 43.9% identical to Scd from the nematode
Caenorhabditis elegans FAT-5 (NP_507482.1) and FAT-6 (NP_001255595.1), respectively. When compared
to mollusc Scd-like protein sequences, the O. vulgaris Scd showed relatively high identity scores
with orthologues from Octopus bimaculoides (99.0%) (XP_014788510.1), Crassostrea gigas (63.0%)
(XP_011452904.1) and Lottia gigantea (60.7%). Importantly, identities between the newly cloned Scd and
several Fads desaturases including the Δ5-like desaturase identiﬁed in O. vulgaris [6] were below 16.0%.
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Figure 2. ClustalW amino acid alignment comparing the Octopus vulgaris stearoyl-CoA
desaturase (Scd) with homologous sequences from the Octopus bimaculoides (XP_014788514.1),
the Caenorabditis elegans FAT-5 (NP_507482.1) and the C. elegans FAT-6 (NP_001255595.1), and a portion
of the Saccharomyces cerevisiae Ole1p sequence. Identical residues are shaded black and similar residues
(using ClustalW2 default parameters) are shaded grey. The three histidine boxes (HXXXH, HXXHH and
QXXHH) are highlighted with grey squares. Four (I–IV) trans-membrane domains predicted by Watts
and Browse [25] are underlined with dashed lines.
2.2. Octopus Elovl4-Like Sequence
The Elovl4-like cDNA consisted of an ORF of 930 bp whose deduced protein had 309 aa
with a predicted molecular weight of 37.9 kDa (deposited in GenBank database with accession
number KJ590963). From analogy to vertebrate orthologues [15–18], ﬁve putative transmembrane
domains containing hydrophobic aa stretches can be predicted (Figure 3). The common octopus
putative Elovl4 contained the histidine dideoxy-binding motif HXXHH, and the putative endoplasmic
reticulum (ER) retrieval signal with a histidine (H) and lysine (K) residues at the carboxyl terminus,
HXKXX (Figure 3) [26].
Comparison of the deduced aa sequence of the O. vulgaris Elovl4 with other orthologues revealed
high identity with the O. bimaculoides Elovl4 (93.5%) (XP_014784234.1), with remarkable lower identity
scores obtained when compared with Elovl4 sequences from L. gigantea (57.9%) (XP_009051096.1),
C. gigas (41.6%) (XP_011450778.1), the sea squirt Ciona intestinalis (48.9%) (AAV67802.1) [27],
H. sapiens (50.8%) (NP_073563.1), G. gallus (49.1%) (NP_001184238.1) and Anolis carolinensis (47.6%)
(XP_003215742.1). Identity scores of 36.6% and 36.2% were obtained by comparing the O. vulgaris
Elovl4 with the previously characterised Elovl2/5 from O. vulgaris (AFM93779.1) [10] and S. ofﬁcinalis
(AKE92956.1) [20], respectively.
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Figure 3. ClustalW amino acid alignment of the Octopus vulgaris Elovl4 with homologous sequences
from Octopus bimaculoides (XP_014784234.1), Lottia gigantea (XP_009051096.1), Ciona intestinalis
(AAV67802.1) and Homo sapiens (NP_073563.1). Identical residues are shaded black and similar residues
(using ClustalW default parameters) are shaded grey. Indicated are the conserved histidine box motif
HXXHH, ﬁve (I–V) putative membrane-spanning domains, and the putative endoplasmic reticulum
(ER) retrieval signal.
2.3. Functional Characterisation of the Octopus Scd
Yeast Saccharomyces cerevisiae cells lacking the OLE1 gene are unable to synthesise
Δ9-monounsaturated FAs including palmitoleic acid (16:1n-7) and oleic acid (18:1n-9), which are
essential for growth [28]. To address whether the O. vulgaris Scd was able to complement yeast OLE1
function, an S. cerevisiae ole1Δ mutant strain (L8-14C) was transformed with a plasmid expressing
the octopus Scd (p416OLE1-Scd) under the control of yeast OLE1 promoter. The ole1Δmutant yeast
were also transformed with a plasmid expressing the S. cerevisiae OLE1 (Δ9 desaturase) under the
control of its own promoter (p416OLE1-OLE1) as a positive control, and with empty vector (pRS416)
as a negative control. All three yeast transformants were able to grow in media supplemented with at
least one supplemented FA (16:1n-7 and/or 18:1n-9) (Figure 4a–c). However, only yeast cells expressing
either the S. cerevisiae OLE1 or the O. vulgaris Scd grew on medium that was not supplemented with
monounsaturated FAs (Figure 4d). These results indicated that the common octopus Scd complemented
the function of the yeast OLE1 desaturase.
Figure 4. Complementation of the Saccharomyces cerevisiae ole1Δ mutant strain L8-14C with the
Octopus vulgaris stearoyl-CoA desaturase (Scd) coding region. Yeast were transformed with the pRS416
empty vector (negative control), p416OLE1-OLE1 (expressing the S. cerevisiae OLE1 under the control
of its own promoter) and p416OLE1-Scd (expressing the O. vulgaris Scd under the control of S. cerevisiae
OLE1 promoter) and grown in SC medium lacking uracil (SC-ura) supplemented with 16:1n-7 and
18:1n-9 (a), 16:1n-7 (b) or 18:1n-9 (c), or in the absence of these fatty acids (d).
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To analyse in more detail the complemention of yeast ole1Δ mutants by the O. vulgaris Scd,
we determined the FA composition of ole1Δ yeast cells transformed with either p416OLE1-OLE1 (i.e.,
expressing the S. cerevisiae OLE1) or p416OLE1-Scd (i.e., expressing the O. vulgaris Scd), and grown in
liquid medium with no exogenously supplemented FAs. Yeast expressing the O. vulgaris Scd grew
notably slower compared to controls and formed clumps as previously described [29]. Moreover,
the p416OLE1-Scd yeast contained signiﬁcantly (p ≤ 0.05) less 16:1n-7 and more 16:0 than control yeast
expressing the S. cerevisiae OLE1, suggesting a low afﬁnity of the O. vulgaris Scd towards 16:0. On the
contrary, contents of 18:1n-9 showed no statistical differences between yeast cells expressing Scd or
OLE1, indicative of the octopus Scd participating in the biosynthesis of 18:1n-9 similar to S. cerevisiae
Ole1p. The distinctive substrate speciﬁcities of the O. vulgaris Scd were further emphasised by the
higher 18:1n-9/16:1n-7 ratio of yeast complemented with the O. vulgaris Scd compared to that of OLE1
control yeast (Table 1).
The substrate speciﬁcities of the O. vulgaris Scd were further investigated through
an overexpression assay using the S. cerevisiae strain InvSc1 (Invitrogen, Paisley, UK), possessing the
endogenous Ole1p. Comparison of the FA proﬁles between the control yeast (i.e., transformed with the
empty pYES2) and yeast expressing the O. vulgaris Scd (i.e., transformed with pYES2-Scd) conﬁrmed
a role of the common octopus Scd in the biosynthesis of monounsaturated FAs (Table 2). Thus,
signiﬁcant (p ≤ 0.05) increases in the contents of 18:1n-9 (oleic acid) in pYES2-Scd yeast compared to
control yeast were observed. Parallel decreased levels of the saturated FA precursor 18:0 were detected
in pYES2-Scd yeast (p ≤ 0.05). Additionally, other monoenes corresponding to 20:1n-11 and 22:1n-13
were detected in total lipids of InvSc1 yeast expressing the O. vulgaris Scd. These results conﬁrmed that
the O. vulgaris Scd is a Δ9 desaturase with activity towards saturated FAs with chain-lengths ≥ C18.
In contrast, shorter FAs (≤C16) did not appear to be adequate substrates for the octopus Scd and,
for instance, the content of 16:1n-7 in yeast expressing the common octopus Scd was signiﬁcantly lower
than that of control yeast (p ≤ 0.05) (Table 2).
Table 1. Fatty acid (FA) composition of the S. cerevisiae strain L8-14C transformed with the
yeast-endogenous OLE1 (SC OLE1) or stearoyl-CoA desaturase from O. vulgaris (OV Scd). Results are
expressed as an area percentage of total fatty acids (FAs) found in transformed yeast. Different letters
for each FA or ratio indicate signiﬁcant differences among treatments (t-test, p ≤ 0.05).
Fatty Acid SC OLE1 OV Scd
16:0 23.5 ± 3.6 b 59.3 ± 4.9 a
16:1n-9 0.5 ± 0.4 0.7 ± 0.7
16:1n-7 35.0 ± 2.2 a 4.5 ± 1.0 b
18:0 8.0 ± 1.7 5.6 ± 1.3
18:1n-9 31.8 ± 2.5 29.8 ± 6.0
18:1n-7 1.1 ± 0.2 a 0.0 ± 0.0 b
18:1n-9/16:1n-7 0.9 ± 0.1 b 6.8 ± 2.0 a
Table 2. Fatty acid (FA) composition of the S. cerevisiae InvSc1 transformed with either empty pYES2
vector (Control) or the common octopus Scd open reading frame (ORF). Different letters for each FA
indicate signiﬁcant differences among treatments (t-test, p ≤ 0.05).
Fatty Acid Control OV Scd
14:0 1.6 ± 0.2 a 1.0 ± 0.1 b
14:1n-5 0.5 ± 0.1 0.7 ± 0.1
16:0 25.9 ± 0.3 a 22.2 ± 1.2 b
16:1n-7 37.7 ± 0.8 a 28.6 ± 3.3 b
18:0 8.5 ± 0.3 a 4.4 ± 0.9 b
18:1n-9 24.1 ± 0.7 b 40.9 ± 3.6 a
18:1n-7 1.1 ± 0.1 1.1 ± 0.2
20:0 0.1 ± 0.0 0.1 ± 0.0
20:1n-11 N.D. b 0.4 ± 0.2 a
22:0 0.1 ± 0.0 0.1 ± 0.0
22:1n-13 N.D. b 0.1 ± 0.0 a
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In order to establish the biosynthetic pathways of NMI FAs with Δ5,9 unsaturation patterns
(or their derivatives such as Δ5,11) found in the common octopus lipids [10], InvSc1 yeast transformed
with pYES2-Scd were grown in the presence of the monoene 20:1n-15 (Δ520:1), while InvSc1 yeast
expressing the Δ5 Fad (i.e., transformed with pYES2-Fad) [6] were grown in the presence of 20:1n-9
(Δ1120:1) (Figure 5). Our results showed that the O. vulgaris Scd was unable to desaturate the substrate
Δ520:1 (20:1n-15) to Δ5,920:2 (Figure 5a), although yeast transformed with pYES2-Fad were able to
produce Δ5,1120:2 (2.7% ± 0.2% conversion), thus conﬁrming activity as Δ5 desaturase on Δ1120:1)
(Figure 5b).
(a)ȱ (b)
Figure 5. Biosynthesis of non-methylene interrupted fatty acids (FAs) in cephalopods: (a) Gas
chromatography (GC) trace of yeast Saccharomyces cerevisiae expressing the Octopus vulgaris Scd and
grown in the presence of 20:1n-15 (Δ520:1); (b) GC trace of yeast S. cerevisiae expressing the previously
characterised O. vulgaris Δ5 Fad [6] and grown in the presence of 20:1n-9 (Δ1120:1). Peaks 1-5 represent
S. cerevisiae endogenous FAs, namely 16:0 (1), 16:1 isomers (2), 18:0 (3), 18:1n-9 (4) and 18:1n-7 (5).
Peaks derived from exogenously added substrates (*) and the desaturation product Δ5,1120:2 (b) are
indicated accordingly.
2.4. Functional Characterisation of the Octopus Elovl4
The role of theO. vulgaris Elovl4 in the biosynthesis of very long-chain (>C24) PUFAs (VLC-PUFAs)
was investigated in yeast S. cerevisiae (strain InvSc1) expressing the Elovl4 and grown in the presence of
one of either C18 (18:3n-3, 18:2n-6, 18:4n-3 and 18:3n-6), C20 (20:5n-3 and 20:4n-6), C22 (22:5n-3, 22:4n-6,
22:6n-3) or C24 (24:5n-3) PUFA substrates (Table 3). Gas Chromatography-Mass Spectrometry (GC–MS)
analyses conﬁrmed that the control yeast did not have the ability to elongate PUFAs, consistent with the
previously reported lack of a PUFA elongase in S. cerevisiae strain InvSc1 [30]. However, the common
octopus Elovl4 conferred the yeast the ability to elongate PUFAs to the corresponding elongated
polyenoic products of both n-3 and n-6 series (Table 3). With the exception of DHA (22:6n-3),
the addition of C22 and C24 PUFA substrates resulted in the production of polyenes of C32 products or
even C34 when 24:5n-3 was used as substrate (Table 3). Indeed, the endogenous production of PUFAs
with chain lengths ≥ C26 in yeast supplemented with exogenously supplemented C22 and C24 PUFAs
allowed us to estimate the Elovl4 efﬁciency (as % conversion) towards potential VLC-PUFA substrates
that are not commercially available. The results showed that the highest % conversions (often over
88.0%) were consistently detected on C28, C30 and C32 substrates (Table 3). It is noteworthy that the
octopus Elovl4 was able to convert the exogenously added 20:5n-3 and 22:5n-3 to 24:5n-3, the substrate
for DHA biosynthesis via the Sprecher pathway [14], although it showed relative low elongase activity
towards DHA itself, which was marginally elongated (0.7%) to 24:6n-3.
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Table 3. Role of the Octopus vulgaris Elovl4 in the biosynthesis of very long-chain (>C24)
polyunsaturated fatty acids (FAs). Conversions were calculated for each stepwise elongation
according to the formula (areas of ﬁrst product and longer chain products/(areas of all products
with longer chain than substrate + substrate area)) × 100. The substrate FA varies as indicated in each
step-wise elongation.
FA Substrate Product % Conversion Elongation
18:3n-3
20:3n-3 2.8 C18→22
22:3n-3 3.0 C20→22
18:2n-6
20:2n-6 1.1 C18→22
22:2n-6 26.2 C20→22
18:4n-3 20:4n-3 1.0 C18→20
18:3n-6 20:3n-6 0.8 C18→20
20:5n-3
22:5n-3 1.9 C20→24
24:5n-3 8.1 C22→24
20:4n-6
22:4n-6 1.0 C20→24
24:4n-6 6.2 C22→24
22:5n-3
24:5n-3 4.8 C22→32
26:5n-3 37.9 C24→32
28:5n-3 95.0 C26→32
30:5n-3 93.5 C28→32
32:5n-3 51.9 C30→32
22:4n-6
24:4n-6 3.6 C22→32
26:4n-6 44.5 C24→32
28:4n-6 94.1 C26→32
30:4n-6 91.5 C28→32
32:4n-6 46.3 C30→32
22:6n-3 24:6n-3 0.7 C22→24
24:5n-3
26:5n-3 1.4 C24→34
28:5n-3 88.8 C26→34
30:5n-3 88.6 C28→34
32:5n-3 63.2 C30→34
34:5n-3 17.3 C32→34
3. Discussion
Fish and seafood are the primary sources of omega-3 long-chain (C20–24) PUFAs for humans [31]
and this partly explains the considerable interest in elucidating the PUFA biosynthetic pathways in
aquatic and marine species, particularly in farmed ﬁsh for which current trends in feed formulation
are impacting the nutritional quality for human consumers [32]. Previous investigations on
O. vulgaris [6,10,33] and S. ofﬁcinalis [20] revealed that cephalopods possess active desaturase and
elongase enzymes involved in the biosynthesis of PUFAs including NMI FAs. Using the common
octopus O. vulgaris as model species, the present study aimed to expand our knowledge of roles that
further desaturases and elongases could have on PUFA biosynthesis in cephalopods. Consequently,
we characterised a stearoyl-CoA desaturase (Scd) with a putative role in the biosynthesis of NMI FAs,
and an Elovl4 elongase that, in addition to its participation in the biosynthesis of VLC-PUFAs [15–19,34],
could potentially catalyse the elongation of 22:5n-3 to 24:5n-3 required for DHA biosynthesis through
the Sprecher pathway [14].
The Scd, present in virtually all living organisms [24], is an enzyme with Δ9 desaturase activity.
Consistently, the newly-cloned O. vulgaris Scd cDNA was conﬁrmed to encode a Δ9 desaturase that was
able to operate on a range of saturated FA substrates with different chain lengths, particularly ≥ C18.
These functions are similar to those described for two homologous sequences found in the nematode
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C. elegans, namely FAT-6 and FAT-7, which can efﬁciently desaturate 18:0 to 18:1n-9 but have lower
activity towards 16:0 [25]. Interestingly, FAT-5, another Scd-like sequence existing in C. elegans,
efﬁciently desaturated 16:0 to 16:1n-7 but had nearly undetectable activity on 18:0, and it is thus
regarded as a palmitoyl-CoA-speciﬁc desaturase [25]. The functional characterisation of the O. vulgaris
Scd and its particularly high substrate afﬁnity towards 18:0 is consistent with 18:1n-9 typically
appearing several folds above the levels of shorter monoenes such as 16:1n-7 in lipids across the
Mollusca phylum [21]. Beyond its role in biosynthesis of monounsaturated FA, occurrence of NMI FAs
with Δ5,9 unsaturation patterns in lipids from molluscs [22] suggested a role of Scd in the biosynthesis
of this particular type of PUFA. Our results revealed that the O. vulgaris Scd was not able to introduce
a second double bond on a Δ5 monoene such as 20:1n-15 (Δ520:1). While the possibility that cephalopod
Scd can introduce Δ9 desaturations on other monoenes cannot be ruled out, these results strongly
suggest that the role of Scd in the biosynthesis of NMI FAs with Δ5,9 unsaturation patterns is limited
to the insertion of the ﬁrst unsaturation at Δ9 position on saturated FAs. Indeed, the O. vulgaris Δ5
Fad, previously characterised as Δ5 desaturase [6], was able to introduce a Δ5 unsaturation on 20:1n-9
(Δ1120:1) producing the NMI FA Δ5,1120:2. Overall, these results allow us to hypothesise that the
insertion of double bonds required for NMI FA biosynthesis is initiated with a Δ9 desaturation by
Scd and a subsequent Δ5 desaturation catalysed by Δ5 Fad. Compared to other molluscan classes,
the occurrence of NMI FAs in cephalopods appears to be rather limited and hence the contribution
of endogenous production of NMI FAs vs. dietary input is difﬁcult to establish. Nevertheless,
the mechanism of Δ5,1120:2 biosynthesis postulated herein aligns well with the occurrence of Δ5,1120:2
in the polar lipids of nephridia of adult O. vulgaris [10], suggesting that NMI FA biosynthesis is possible
in cephalopods and likely other molluscs.
In addition to desaturases, certain Elovl enzymes play crucial roles in the biosynthesis of essential
PUFAs such as EPA, ARA and DHA [9,11,26]. Whereas the previously characterised cephalopod
Elovl2/5 demonstrated an ability to efﬁciently elongate C18 and C20 PUFA substrates [6,20], lack of
elongase capability towards 22:5n-3 was hypothesised as a major limiting factor for DHA biosynthesis
through the Sprecher pathway [6,20]. Functional characterisation of theO. vulgaris Elovl4 demonstrated
the ability of this enzyme to contribute potentially to DHA biosynthesis by producing 24:5n-3,
which is the substrate for Δ6 desaturation and chain-shortening to produce DHA in the Sprecher
pathway [14]. Such an ability of Elovl4 has been reported in ﬁsh orthologues [15–19]. Despite the
elongation capability of O. vulgaris herein revealed, our overall observations on gene repertoire and
function [6,10,20,33] strongly suggest that DHA is still an essential FA for cephalopods. The limited
ability to biosynthesise DHA is related, rather than to an issue with elongase activity, to the apparent
absence of key desaturation abilities (Δ6 or Δ4) required for DHA biosynthesis according to the two
aerobic pathways known in vertebrates (Figure 1). In addition to the abovementioned Δ6 desaturation
required in the Sprecher pathway [14], an alternative pathway described in some teleost ﬁsh involves
a Δ4 desaturation from 22:5n-3 to produce DHA directly (Figure 1) [9]. Molecular evidence provided
by the recently published Octopus bimaculoides genome project [35] suggests that cephalopods possess
one single Fad-like desaturase in their genome and this is likely to be a Δ5 desaturase since all the
Fad-like desaturase functionally characterised not only from cephalopods such as O. vulgaris and
S. ofﬁcinalis [6,10] but also from bivalves [36] and gastropods [37], have Δ5 desaturase activities.
In non-cephalopod molluscs, further Fad-like desaturases exist [38] but, with the exception of the Δ8
desaturase found in the scallop Chlamys nobilis [39], their functions have not been determined and
therefore it is yet not possible to predict whether Δ6 and/or Δ4 desaturase activities exist to enable
DHA biosynthesis in those species.
The O. vulgaris Elovl4 is also involved in the biosynthesis of VLC-PUFAs as it was able to elongate
exogenously supplemented PUFAs ranging from C18–24 to PUFA products with chain lengths of ≥C26.
Such conversions are largely consistent with those previously exhibited by human [34] and ﬁsh [15–19]
Elovl4 proteins. Surprisingly, no elongation products beyond C24 were reported in the functional
characterisation of the bivalve C. nobilis Elovl4 [39]. The elongation activities of the O. vulgaris Elovl4
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estimated in the yeast expression system strongly suggested that this enzyme is particularly efﬁcient
towards C26–30 substrates, for which the highest % conversions were observed. Similarly, the human
ELOVL4 had PUFAs of ≥C26 as preferred substrates for elongation, although the human ELOVL4
was able to produce up to C38 PUFA elongation products in mammalian cell lines [34]. Due to
technical challenges in their analysis and relatively low abundance, the functions of VLC-PUFAs
are not fully understood [40]. Nevertheless, the structural features of VLC-PUFAs combining those
from saturated FAs at one end and those from PUFAs at the other allow unique membrane lipid
conformations in photoreceptors and spermatozoa, thus suggesting important roles of VLC-PUFAs
in vision and reproduction of vertebrates [40–43]. Investigations of VLC-PUFAs in cephalopods
and, therefore, the herein reported activities of the O. vulgaris Elovl4 cannot be correlated with the
presence of VLC-PUFAs in vivo. Interestingly, some very long-chain NMI FAs have been reported
in nudibranchs [44,45] but, unfortunately, the potential role of Elovl4 in the biosynthesis of such
compounds was not determined. Interestingly, unpublished data on tissue distribution analysis of the
common octopus Elovl4 mRNA indicated that gonads and, to a lesser extent eye, were also major sites
for VLC-PUFA biosynthesis in cephalopods.
In conclusion, the present study demonstrated that the common octopus O. vulgaris possesses
an Scd with high afﬁnity for saturated FA substrates with chain lengths of 18 carbons or longer.
Its inability to introduce a double bond into Δ5 monoene strongly suggested that the role of the
Scd in NMI FA biosynthesis was restricted to the introduction of the ﬁrst double bond at the Δ9
position, whereas the O. vulgaris Δ5 Fad can introduce the second unsaturation at the Δ5 position
according to the herein conﬁrmed ability to convert 20:1n-9 to Δ5,1120:2, an NMI FA previously reported
in nephridia of O. vulgaris adult specimens. Beyond desaturases, we could also demonstrate that
O. vulgaris possesses an Elovl4 responsible for the biosynthesis of VLC-PUFAs.
4. Materials and Methods
4.1. Tissue Samples
Tissue samples including brain, nerve, muscle, heart, hepatopancreas, gill, caecum, eye,
nephridium and gonads were obtained from the dissection of two (male and female) common octopus
adult specimens as previously described [6,10]. Brieﬂy, two (male and female) wild O. vulgaris adults
(~1.5 kg) were maintained in seawater tanks at the facilities of the Instituto de Acuicultura Torre
de la Sal; before they were cold, they were anesthetised and sacriﬁced by direct brain puncture.
After collection, samples were immediately frozen at −80 ◦C until further analysis. Total RNA was
extracted from octopus tissues using TriReagent® (Sigma-Aldrich, Alcobendas, Spain) according
to manufacturer’s instructions. Two μg of total RNA tissue samples were used for synthesis of
ﬁrst strand cDNA using M-MLV reverse transcriptase (Promega, Southampton, UK) primed with
random hexamers.
4.2. Molecular Cloning of the Scd and Elovl4 cDNA Sequences
The full-length sequences of the Scd and Elovl4 cDNA were obtained as follows. The deduced
aa sequences of Scd proteins from Homo sapiens (NP_005054.3), Gallus gallus (NP_990221.1),
Anolis carolinensis (XP_003226591.1), Caenorhabditis elegans (FAT-7) (NP_504814.1), Acheta domesticus
(AAK25796.1) and Pediculus humanus (XP_002424386.1) were aligned using BioEdit v5.0.6 (Tom Hall,
Department of Microbiology, North Carolina State University, Raleigh, NC, USA). Conserved regions
were used for in silico searches of mollusc expressed sequence tags (EST) using The National Center for
Biotechnology Information (NCBI) tblastn tool (http://www.ncbi.nlm.nih.gov/). Processed Scd-like
Expressed Sequence Tags (ESTs) from the molluscs Lottia gigantea (FC767047.1 and FC644199.1),
Aplysia californica (FF074235.1, FF076278.1, EB307164.1, EB253812.1 and EB281044.1), Limnaea stagnalis
(ES580199.1 and ES579822.1), Crassostrea gigas (CU997931.1 and FP006991.1), Euprymna scolopes
(DW280836.1, DW269578.1 and DW273589.1) and Ruditapes decussatus (AM870139.1), were aligned
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(Bioedit) and conserved regions used for the design of the degenerate primers UNID9F
(5′-ATCACAGCTGGWGCTCAYCG-3′) and UNID9R (5′-TGGCATTGTGWGGGTCWGCATC-3′).
To clone the ﬁrst fragment of the octopus Elovl4, blastn searches of mollusc ESTs were
performed using the so-called “transcript 2” from L. gigantea that was previously identiﬁed
by [6] (gi|Lotgi1|178149|) as query. Thus, additional Elovl4-like consensus sequences derived
from ESTs from A. californica (EB285681.1, GD233360.1, EB316848.1, GD212825.1, EB325217.1,
EB345626.1, EB345430.1), Saccostrea kagaki (AB375033.1) and C. gigas (HS215834.1, AM866458.1)
were obtained and aligned with L. gigantea Elovl4-like to design the degenerate primers UNIE4F
(5′-GCCAAGGCATTRTGGTGGTT-3′) and UNIE4R (5′-GTSAGRTATCKYTTCCACCA-3′).
Polymerase chain reactions (PCR) were performed with the GoTaq® Green Master Mix (Promega)
and using a mixture of cDNAs from brain, nerve and hepatopancreas as template. The PCR consisted
of an initial denaturing step at 95 ◦C for 2 min, followed by 35 cycles of denaturation at 95 ◦C for
30 s, annealing at 50 ◦C for 30 s, extension at 72 ◦C for 40 s, followed by a ﬁnal extension at 72 ◦C for
5 min. PCR products of approximately 180 bp (Scd) and 290 bp (Elovl4) were obtained and thereafter
conﬁrmed as positive by sequencing (DNA Sequencing Service, IBMCP-UPV, Valencia, Spain).
Full-length cDNA of the octopus Scd and Elovl4 were completed by 5′ and 3′ rapid ampliﬁcation of
cDNA ends (RACE) PCR (FirstChoice RLM-RACE kit, Ambion, Applied Biosystems, Warrington, UK)
with gene-speciﬁc primers shown in Table S1.
4.3. Sequence Analysis
The deduced aa sequences of the O. vulgaris Scd and Elovl4 ORF were compared to corresponding
orthologues from other invertebrate and vertebrate species and sequence identity scores were
calculated using the EMBOSS Needle Pairwise Sequence Alignment tool (http://www.ebi.ac.uk/
Tools/psa/emboss_needle/). Deduced aa sequence alignments were carried out using the built-in
ClustalW tool (BioEdit v7.0.9, Tom Hall, Department of Microbiology, North Carolina State University,
Raleigh, NC, USA).
4.4. Functional Characterisation of Octopus Scd: Complementation Assay of the S. cerevisiae ole1ΔMutant
Strain L8-14C
The open reading frame (ORF) of the common octopus Scd was ampliﬁed from a mixture
of cDNAs (brain, nerve and hepatopancreas) using the high ﬁdelity Pfu Turbo DNA polymerase
(Promega) and the primers OVD9VF and OVD9VR, containing restriction sites HindIII and XhoI,
respectively (underlined in Table S1). PCR conditions consisted of an initial denaturing step at 95 ◦C
for 2 min, followed by 32 cycles of denaturation at 95 ◦C for 30 s, annealing at 58 ◦C for 30 s, extension at
72 ◦C for 2.5 min, followed by a ﬁnal extension at 72 ◦C for 5 min. After restriction of the PCR product,
the O. vulgaris Scd ORF was cloned into the yeast expression vector p416TEF (a centromeric plasmid
with a URA3 selectable marker) to produce the construct p416TEF-Scd, in which octopus Scd was under
the control of the yeast TEF1 promoter. Subsequently, the promoter region of the S. cerevisiae OLE1
Δ9-fatty acid desaturase gene ampliﬁed from yeast genomic DNA with the primers SCPromOLE1F and
SCPromOLE1R containing SacI and HindIII sites, respectively, was cloned upstream of the O. vulgaris
Scd, replacing the TEF1 promoter and producing the construct p416OLE1-Scd, in which octopus
Scd is expressed under the control of the yeast OLE1 promoter. As a positive control, the promoter
and ORF of S. cerevisiae OLE1 were ampliﬁed by PCR from yeast genomic DNA using the primers
SCPromOLE1F and SCOLE1R that contained restriction sites for SacI and XhoI, respectively (Table S1).
To obtain the p416OLE1-OLE1 plasmid, the OLE1 PCR fragment was cloned into p416TEF SacI and
XhoI restriction sites, allowing TEF1 promoter replacement by OLE1 promoter and ORF.
To address the common octopus Scd function we used S. cerevisiae L8-14C (MATa ole1Δ::LEU2,
leu2-3,112, trp1-1, ura3-52, his4; kindly donated by Dr. Charles E. Martin), a strain whose OLE1 gene has
been deleted. Therefore, L8-14C cells lack the only yeast Δ9-fatty acid desaturase and require the supply
of monounsaturated FAs including 0.5 mM palmitoleic (16:1n-7) and 0.5 mM oleic (18:1n-9) acids in the
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medium for growth. To address whether the octopus Scd complemented the growth defect displayed
by L8-14C cells in media lacking FAs, yeast mutants transformed with pRS416 (empty vector as
negative control), p416OLE1-OLE1 (positive control) or p416OLE1-Scd plasmids were grown in liquid
SC medium lacking uracil (SC-ura) with supplemented FAs until exponential phase, and then assayed
for growth on plates in 10-fold serial dilution drops starting at OD600 = 0.1. Plates were incubated for
3 days at 30 ◦C and photographed. To determine FA composition, four L8-14C colonies from yeast
transformed with either p416OLE1-OLE1 or p416OLE1-Scd were grown in 10 mL of yeast extract
peptone dextrose (YPD) broth lacking 18:1n-9 and 16:1n-7. After incubation at 30 ◦C for 48 h, a 5 mL
aliquot of yeast culture was pelleted (1000 g for 2 min), washed twice with ddH2O, homogenised in
chloroform/methanol (2:1, v/v) containing 0.01% butylated hydroxy toluene (BHT) [30,46], and kept
at −20 ◦C until further analysis.
4.5. Functional Characterisation of Octopus Scd: Overexpression in the S. cerevisiae Strain InvSc1
Primers containing HindIII (forward) and XhoI (reverse) restriction sites (underlined in Table S1)
OVD9VF and OVD9VR (Scd) were used to amplify the ORF of the O. vulgaris Scd, using the high
ﬁdelity Pfu Turbo DNA polymerase (Promega). Further cloning into the yeast expression vector pYES2
(Invitrogen), which contains a GAL1 promoter that is inducible by galactose and has URA3 as selective
marker, was achieved after ligation of restricted ORF amplicons and plasmid pYES2 to produce the
construct pYES2-Scd. The recombinant plasmids pYES2-Scd or pYES2 empty (negative control) were
transformed into S. cerevisiae competent cells InvSc1 (S.c. EasyComp Transformation Kit, Invitrogen).
Yeast were grown in SC-ura for 3 days.
One single yeast colony containing the pYES2-Scd or pYES2 was grown overnight at 30 ◦C in
5 mL of liquid SC-ura. Cell cultures were then used to inoculate 10 mL of fresh SC-ura for a ﬁnal
OD600 of 0.4. Four replicates for each construct (pYES2-Scd or pYES2) were run. Cells were grown
at 30 ◦C for 5 h before the expression of the transgene was induced by the addition of galactose
to 2% (w/v) [46]. After 48 h of galactose induction, yeast samples were collected, washed and
homogenised in chloroform/methanol (2:1, v/v) containing 0.01% BHT. Samples were kept at −20 ◦C
until further analysis.
4.6. Role of the Octopus Scd and Δ5 Fad in the Biosynthesis of Non-Methylene-Interrupted FAs
In order to establish the role of Scd and the previously characterised Δ5 Fad [6] in the biosynthetic
pathways of Δ5,9 (or Δ5,11) non-methylene interrupted FAs (NMI FAs) we conducted the following
experiment. First, yeast InvSc1 transformed with pYES2-Scd, i.e., expressing the octopus Scd,
were grown in the presence of exogenously added 5-eicosenoic acid (20:1n-15 or Δ520:1). Second,
yeast InvSc1 transformed with pYES2-Fad, i.e., expressing the octopus Fads that was previously
reported to exhibit Δ5-desaturase [6], were grown in the presence of 11-eicosenoic acid (20:1n-9
or Δ1120:1). Final concentration of exogenously-added substrates (Δ520:1 or Δ1120:1) was 0.75 mM.
Culture conditions and yeast sample collection were performed as described above. Yeast transformed
with empty pYES2 were also grown in presence of Δ520:1 and Δ1120:1 as control treatments.
4.7. Functional Characterisation of Octopus Elovl4: Expression in the S. cerevisiae Strain InvSc1
The octopus Elovl4 was functionally characterised by heterologous expression in yeast S. cerevisiae
(strain InvSc1, Invitrogen). Similarly, as described above for the Scd overexpression experiment,
the octopus Elovl4 ORF was ampliﬁed with primers OVE4VF and OVE4VR containing restriction
sites for HindIII and XhoI, respectively (Table S1) which allowed its cloning into pYES2 to produce the
construct pYES2-Elovl4. Yeast InvSc1 transformed with pYES2-Elovl4 were grown in SC-ura plates.
One colony was subsequently grown in SC-ura broth to produce a bulk culture that allowed us to
establish subcultures of OD600 0.4 in Erlenmeyer ﬂasks that contained 5 mL of SC-ura broth and were
in some cases supplemented with potential PUFA substrates for fatty acyl elongases. In order to assess
the ability of the octopus Elovl4 to elongate PUFA substrates, yeast transformed with pYES2-Elovl4
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were grown in the presence of one of the following PUFA substrates: 18:3n-3, 18:2n-6, 18:4n-3, 18:3n-6,
20:5n-3, 20:4n-6, 22:5n-3, 22:4n-6, 22:6n-3 and 24:5n-3. The FA substrates were added to the yeast
cultures at ﬁnal concentrations of 0.5 (C18), 0.75 (C20), 1.0 (C22) and 1.2 (C24) mM to compensate for
decreased efﬁciency of uptake with increased chain length [47].
To test the ability of the octopus Elovl4 to elongate saturated FAs, yeast transformed with
pYES2-Elovl4 or pYES2 (negative control) were grown in the absence of exogenously added substrates
and the capability of the Elovl4 to elongate saturated FAs was estimated by comparing the saturated
FA proﬁles of both transformants. Three different replicates for each treatment were established.
4.8. Fatty Acid Analysis by GC-MS
Lipid extracts [48] from the transgenic yeast were utilised for preparing fatty acid methyl esters
(FAME) as previously described [6,10]. Brieﬂy, FAME were identiﬁed and quantiﬁed using an Agilent
6850 Gas Chromatograph coupled to a 5975 series Mass Selective Detector (MSD, Agilent Technologies,
Santa Clara, CA, USA). The activity of the newly cloned octopus Scd was estimated by comparing
the FA proﬁles (expressed as % of total FAs) of control yeast with those from yeast transformed
with p416OLE1-Scd (complementation experiment) or pYES2-Scd (overexpression experiment).
The efﬁciency of the O. vulgaris Δ5 Fad to desaturate Δ1120:1 into the NMI FAs Δ5,1120:2 was calculated
as % conversion according to the formula: (area of product/(area of product + area of substrate)) × 100.
The double bond positions in FA products derived from conversion by transgenic yeast towards Δ520:1
and Δ1120:1 was conﬁrmed by preparing FA picolinyl ester derivatives according to the methodology
described by [49] and modiﬁed according to [10]. Finally, the ability of the O. vulgaris Elovl4 to elongate
the exogenously-added PUFA substrates (18:3n-3, 18:2n-6, 18:4n-3, 18:3n-6, 20:5n-3, 20:4n-6, 22:5n-3,
22:4n-6, 22:6n-3 and 24:5n-3) was calculated by the step-wise proportion of substrate FAs converted
to elongated product as (areas of ﬁrst product and longer chain products/(areas of all products with
longer chain than substrate + substrate area)) × 100 [50].
4.9. Statistical Analyses
For the functional characterisation experiments (complementation and overexpression) of the
octopus Scd, FA analyses from yeast samples were expressed as mean values ± standard deviation
(n = 4). Similarly, the assay aiming to determine the ability of the octopus Elovl4 for elongation
saturated FA was run in replicates (n = 3) and FA contents expressed as mean values ± standard
deviation. Homogeneity of variances was checked by Barlett’s test. Comparison of FA proﬁles from
control and yeast expressing the O. vulgaris Scd (complementation and overexpression experiments) or
Elovl4 were compared with a Student’s t-test. Comparisons of the means with p values less or equal
than 0.05 were considered signiﬁcantly different. All the statistical analyses were carried out using the
SPSS statistical package (SPSS Inc., Chicago, IL, USA).
4.10. Materials
All PUFA substrateswere purchased fromNu-Chek Prep, Inc. (Elysian,MN,USA), except stearidonic
acid (18:4n-3) from Sigma-Aldrich (Alcobendas, Spain) and tetracosapentaenoic acid (24:5n-3) from
Larodan (Larodan Fine Chemicals AB, Malmö, Sweden). All chemicals used to prepare the S. cerevisiae
media were from Sigma-Aldrich, except for the bacteriological agar obtained from Oxoid Ltd.
(Hants, UK).
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Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/3/82/s1,
Table S1: Primer sequences used in the present study.
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Abstract: Increased evidence suggests that marine unsaturated fatty acids (FAs) can protect
neurons from amyloid-β (Aβ)-induced neurodegeneration. Nuclear magnetic resonance (NMR),
high performance liquid chromatography (HPLC) and gas chromatography (GC) assays showed
that the acetone extract 4-2A obtained from shrimp Pandalus borealis industry processing wastes
contained 67.19% monounsaturated FAs and 16.84% polyunsaturated FAs. The present study
evaluated the anti-oxidative and anti-inﬂammatory effects of 4-2A in Aβ25–35-insulted differentiated
SH-SY5Y cells. Cell viability and cytotoxicity were measured by using 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays. Quantitative PCR and
Western blotting were used to study the expression of neurotrophins, pro-inﬂammatory cytokines
and apoptosis-related genes. Administration of 20 μM Aβ25–35 signiﬁcantly reduced SH-SY5Y cell
viability, the expression of nerve growth factor (NGF) and its tyrosine kinase TrkA receptor, as
well as the level of glutathione, while increased reactive oxygen species (ROS), nitric oxide, tumor
necrosis factor (TNF)-α, brain derived neurotrophic factor (BDNF) and its TrkB receptor. Aβ25–35 also
increased the Bax/Bcl-2 ratio and Caspase-3 expression. Treatment with 4-2A signiﬁcantly attenuated
the Aβ25–35-induced changes in cell viability, ROS, GSH, NGF, TrkA, TNF-α, the Bax/Bcl-2 ratio and
Caspase-3, except for nitric oxide, BDNF and TrKB. In conclusion, 4-2A effectively protected SH-SY5Y
cells against Aβ-induced neuronal apoptosis/death by suppressing inﬂammation and oxidative
stress and up-regulating NGF and TrKA expression.
Keywords: Acetone extract from shrimp processing by-product (4-2A); polyunsaturated fatty acids;
Aβ25–35; human neuroblastoma cell (SH-SY5Y); neuroprotection; Alzheimer’s disease (AD)
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1. Introduction
The neurodegenerative process in Alzheimer’s disease (AD) is associated with progressive
accumulation of intracellular and extracellular neurotoxic amyloid-β (Aβ) oligomers in the
brain [1–3]. Excessive Aβ-deposition may induce AD through oxidative stress and neuroinﬂammation.
Amyloid-beta oligomers can activate microglia in vitro and in vivo [4], resulting in the production and
release of reactive oxygen species (ROS) and pro-inﬂammatory cytokines such as tumor necrosis factor
(TNF)-α, both of which can cause neural degeneration. Elevated levels of ROS interfere with the actions
of many key molecules including enzymes, membrane lipids and DNA, which leads to cell apoptosis or
death [5,6]. Increased pro-inﬂammatory cytokine release may stimulate neurons to produce increased
amounts of Aβ oligomers and cause neuronal dysfunction and apoptosis [7,8]. Another hallmark
of AD is decreased neurogenesis due to the dysfunction in neurotrophic signaling mechanisms [9].
In particular, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) and their
receptors in the brain are disrupted. Reduced BDNF expression in the brain is a common feature
of AD and cognitive dysfunction [10]. In addition, Aβ peptides are able to interfere with BDNF
signal transduction pathways involved in neuronal survival and synaptic plasticity, hampering the
transmission of neurotrophic responses [11].
Because the etiology of AD remain unknown, treatments that target AD are ineffective and often
cause severe side-effects [12]. Most neurodegenerative diseases, including AD, are irreversible because
the failure of neurogenesis and the increase in neuron death occurs before the clinical symptoms
appear [13]. Thus, much effort is directed towards the discovery of neural pathways and their
molecular mechanism that can be targeted by novel therapeutics to prevent AD. Natural substances
with anti-oxidative and/or anti-inﬂammatory activity could provide effective treatments for the
prevention of AD.
In the past decade, many studies have demonstrated that unsaturated fatty acids of marine
origin, such as omega (n)-3 and n-9 fatty acids, could play a beneﬁcial role in brain functions. Our
previous studies have highlighted the effectiveness of dietary n-3 polyunsaturated fatty acids (PUFAs)
as a potential treatment strategy for affective diseases [14,15]. Recent studies have demonstrated that
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) possess neuroprotective properties
because of their anti-oxidant and anti-inﬂammatory functions [14–16]. There are also data showing
neuroprotective potential of monounsaturated fatty acids (MUFAs). For example, oleic acid, which
belongs to n-9 MUFAs, has been found to modulate mitochondrial dysfunction, insulin resistance and
inﬂammatory signaling [17–19] and act as neurotrophic factors for neurons [20]. Palmitoleic acid, a
naturally occurring 16-carbon n-7 MUFA, and one of the most abundant fatty acids in the serum and
tissues, was considered to be a lipokine and has been found to beneﬁt some physiological function,
such as regulating cell proliferation, and decreasing the expression of pro-inﬂammatory mediators and
adipokines [21–23].
Tchoukanova and Benoit [24] developed a method to recover organic solids and oils from
marine by-products. Using this method, shrimp oil was produced and found to be rich in long-chain
unsaturated fatty acids [25]. The solid residue may also contain nutritional and bioactive ingredients
that can be exploited. In the present study, an acetone extract 4-2A obtained from the solid phase was
found to be rich in n-3 and n-9 unsaturated fatty acids. Because of the above mentioned neuroprotective
function of unsaturated fatty acids, the present study aimed to determine whether the 4-2A extract
from shrimp by-products would protect neurons from Aβ-induced neurotoxicity via its regulation of
neurotrophic function, anti-inﬂammatory and anti-oxidative effects. To carry out this experiment, a
cellular model of AD was set up using Aβ25–35-insulted differentiated SH-SY5Y cells. Following this,
the effects of 4-2A on Aβ25–35-induced changes in cell viability, oxidative stress (ROS, NO, and GSH)
and neurotrophins (NGF, BDNF and their TrkA and TrkB receptors) were measured. Since TNF-α is a
key “pro-neuropathic” cytokine [26] and can activate a pro-apoptotic factor JNK pathway and trigger
cellular death signaling [27], TNF-α expression was measured to test 4-2A anti-inﬂammatory effect in
the present study. Then, the ability of 4-2A to regulate the expression of apoptosis-related genes (Bcl-2,
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Bax and Caspase-3) in the model was explored. The experimental design and content is presented in
Figure 1.
Figure 1. Experimental design and contents. NMR: Nuclear Magnetic Resonance; HPLC: High
Performance Liquid Chromatography; GC: Gas Chromatograph. “+”: strengthening; “−”: weakening.
2. Results
2.1. Characterization of Shrimp Extract 4-2A
Reddish and oily sample 4-2A was extracted from the solid residue of shrimp processing waste
using acetone and yielded 2.55% of original dry mass. Both 1H-NMR and 13C-NMR spectra indicated
that this shrimp extract was rich in lipids. The detailed assignments of the most common proton and
carbon signals are shown in Figure 2. They have been compiled in the online resources of AOCS Lipid
Library by a wide range of fatty compounds [28]. The spectra ranging from 0 to 6 ppm in the 1H-NMR
spectrum covered the proton chemical shifts of most lipids (Figure 2A). To be noted, the signals around
2.8 ppm indicated the presence of methylenes between two double bonds –CH=CH-CH2-CH=CH-, a
typical feature of polyunsaturated fatty acids. The shifts at 0.93–1.01 ppm suggested the protons of
ω-3 terminal methyl groups. The intensity of these signals indicated that 4-2A contained relatively
high level of ω-3 PUFAs. The chemical shifts between 3.5 and 4.0 ppm showed the presence of small
amount of monoglycerides.
In the 13C-NMR spectrum (Figure 2B), the chemical shifts at 180.3 ppm indicated the carbons of
C=O groups. The shifts around 130 ppm showed the two oleﬁnic carbon atoms of double bonds.
The carbons of the terminal methyl groups of lipids were identiﬁed by the chemical shifts at
15.3–15.6 ppm. Collectively, the major components of 4-2A were identiﬁed by NMR as lipids containing
large amount of unsaturated fatty acids.
Lipid standards were subjected on HPLC to qualify the separations. As indicated in Figure 3, the
major components of 4-2A are free fatty acids and monoglycerides with elution window from 16 min
to 36 min by charged aerosol detector (CAD). Based on the chromatogram, this extract does not contain
much triglycerides and phospholipids. This is consistent with the result obtained from NMR analyses.
In order to understand the fatty acids proﬁles in this shrimp extract, the total fatty acids were
released from 4-2A and analyzed on GC instrument. As a result shown in Table 1, the major FAME
proﬁles of 4-2A was 18:1n-9 (20.65%), 16:1n-7 (14.75%), 22:1n-7 (11.04%), 20:5n-3 (8.45%), 20:1n-9
(7.97%), 18:1n-7 (7.07%), 16:0 (6.56%) and 22:6n-3 (6.54%). Most fatty acids (over 93%) are unsaturated,
including 67.19% of monounsaturated fatty acids (MUFAs) and 16.84% of polyunsaturated fatty acids
(PUFAs). To be mentioned, 4-2A contains 14.99% of omega-3 fatty acids (20:5n-3, Eicosapentaenoic
acid, EPA and 22:6n-3, Docosahexaenoic acid, DHA).
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ȱ
Figure 2. Characterization of 4-2A byNMR: (A) 1H-NMR spectrum (n≥ 1); and (B) 13C-NMR spectrum.
ȱ
Figure 3. Characterization of 4-2A by HPLC with CAD detector.
Table 1. Major fatty acid methylated esters (FAME) proﬁles of 4-2A by GC analysis.
FAME Intensity (%) Stdev (n = 4, %)
14:0 2.10 0.25
16:0 6.56 0.58
18:0 0.70 0.08
16:1n-7 14.75 0.21
18:1n-5 0.77 0.16
18:1n-7 7.07 0.31
18:1n-9 20.65 2.62
20:1n-7 1.08 0.03
20:1n-9 7.97 0.97
20:1n-11 1.95 0.01
22:1n-7 11.04 0.24
22:1n-9 1.91 0.78
18:2n-6 0.86 0.10
20:4n-6 0.99 0.12
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Table 1. Cont.
FAME Intensity (%) Stdev (n = 4, %)
20:5n-3 8.45 0.83
22:6n-3 6.54 1.02
Total 93.39
Saturated 9.36
Monounsaturated 67.19
Polyunsaturated 16.84
Omega-3 14.99
Omega-6 1.85
Omega-7 33.94
Omega-9 30.53
In brief, the acetone extract 4-2A obtained from shrimp processing wastes was identiﬁed by
NMR, HPLC and GC to contain mainly unsaturated free fatty acids and monoglycerides, including
ω-3 PUFAs.
2.2. Aβ25–35-Induced Decrease in Neuronal Cell Viability Was Ameliorated by 4-2A
The cell morphology of differentiated SH-SY5Y cells is more like the classic neuron-like cells with
long synapse compared to undifferentiated cells (Figure 4). As detected by 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) method, Aβ25–35 signiﬁcantly decreased cell viability of
differentiated SH-SY5Y cells in a time- and dose-dependent manner, such as at 15 μM for 12 h (p > 0.05),
24 h (p < 0.05) and 48 h (p < 0.01); and at 10 μM (p > 0.05), 15 μM (p < 0.05) and 20 μM (p < 0.01) for
24 h (Figure 5A). 4-2A treatment (1–20 μg/mL) alone did not exert any signiﬁcant inﬂuence on the
survival rate of SH-SY5Y cells, though 40 μg/mL of 4-2A slightly decreased the cell viability (p > 0.05)
(Figure 5B). However, pretreated with different concentrations of 4-2A markedly attenuated the
reduction of cell viability caused by Aβ25–35 in a dose-dependent manner at 1 (p > 0.05), 5 (p < 0.05),
and 10–20 μg/mL (all p < 0.01) (Figure 5C). The protective role of 4-2A against Aβ25–35-induced insults
in SH-SY5Y cells was further conﬁrmed by lactate dehydrogenase (LDH) release assay (Figure 5D),
which is an index of cell death. Combining the results from above assays, we could safely draw the
conclusion that 4-2A could effectively protect the differentiated SH-SY5Y cells from Aβ25–35-induced
cellular damage.
(A)ȱ
(C)ȱ
ȱ
(B)ȱ
ȱ
(D)ȱ
Figure 4. Cell morphology of undifferentiated SH-SY5Y cells (A); differentiated SH-SY5Y cells (B);
differentiated SH-SY5Y cells insulted by Aβ25–35 (C); and differentiated SH-SY5Y cells treated with
4-2A and Aβ25–35 (D). Scale bar = 50 μm.
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Figure 5. Cell viability and Cytotoxicity: (A) Treatment of Aβ25–35 at various doses for 12 h, 24 h and
48 h; (B) cells treated with 4-2A at indicated doses for 24 h; (C) changes in cell survival rate after the
treatment with 20 μM Aβ25–35 for 24 h in the absence or presence of 4-2A at indicated doses; and (D)
changes in lactate dehydrogenase (LDH) release after the treatment with 20 μM Aβ25–35 for 24 h in
the absence or presence of 4-2A at indicated doses. Data represent mean ± SEM of three separate
experiments (n = 4 in each experiment) and three mean values from independent experiment were
used for statistics. * p < 0.05, ** p < 0.01 vs. control group; # p < 0.05, ## p < 0.01 vs. Aβ25–35 group.
2.3. Treatment with 4-2A Attenuated the Changes in ROS, Nitric Oxide (NO) and Glutathione (GSH) Level
Induced by Aβ25–35
Figure 6A illustrated that Aβ25–35 markedly increased ROS ﬂuorescence when compared to
control group (p < 0.01). However, cells pretreated with 4-2A (10 μg/mL) showed a partial decrease
in mean ﬂuorescence intensities by about 23% when compared to Aβ25–35-insulted group (p < 0.05).
As shown in Figure 6C, a signiﬁcant increase of about 44.42% in the level of nitrate was observed
when the cells were treated with Aβ25–35 alone (p < 0.05), while 4-2A pre-treatment could not attenuate
the Aβ25–35-induced change in NO concentration. The results shown in Figure 6C indicate a marked
reduction in the GSH content of the Aβ25–35 insulted cells (p < 0.05), and 4-2A pre-treatment could
completely restore this reduction (p < 0.01).
2.4. Treatment with 4-2A Attenuated the Aβ25–35-Inducued Increased Expression of Pro-Inﬂammatory
Cytokine TNF-α
TNF-α mRNA expression was signiﬁcantly increased by Aβ25–35 administration as early as 4 h of
incubation (p < 0.05), but the increase in protein expression could not be found until 12 h of incubation
with Aβ25–35 (p < 0.01). Pretreatment with 4-2A alone did not signiﬁcantly affect TNF-α expression
either in mRNA or in protein levels, but it could partially but signiﬁcantly decrease the effect of Aβ25–35
(mRNA expression: p < 0.05 and protein expression p < 0.01, Figure 7).
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Figure 6. The effect of 4-2A on the changes of oxidative and anti-oxidative response induced by Aβ25–35.
(A) ROS production in fully differentiated SH-SY5Y cells treated with Aβ25–35 20 μM and/or 4-2A
10 μM for 24 h. Data represent mean ± SEM percentage of control. (B) NO production and (C) GSH
content in fully differentiated SH-SY5Y cells treated with Aβ25–35 20 μM and/or 4-2A 10 μM for 24 h.
Data represent mean ± SEM of concentration (μM per mL). The statistics were based on data from
six separate experiments, n = 6 in each experiment. * p < 0.05, ** p < 0.01 vs. control group; # p < 0.05,
## p < 0.01 vs. Aβ25–35 group.
(A)ȱ
ȱ
(B)ȱ
Figure 7. The expression of pro-inﬂammatory cytokine tumor necrosis factor-alpha (TNF-α). mRNA
expression level (A); and protein expression level (B) of TNF-α, normalized to the corresponding level
expression of housekeeping gene β-Actin, in differentiated SH-SY5Y cells treated with Aβ25–35 (20 μM)
and/or 4-2A (10 μg/mL) for indicated times. The data of both mRNA and protein expression from six
independent experiments (n = 1 in each experiment) were analyzed and expressed as mean ± SEM.
* p < 0.05, ** p < 0.01 vs. control group; # p < 0.05 vs. Aβ25–35 group.
2.5. Effect of 4-2A on the Expression of Neurotrophins: NGF and BDNF and Their TrkA and TrkB Receptors
Similar to TNF-α gene, the obvious change of NGF gene expression appeared at 4 h of
Aβ25–35 treatment. Compared to control group, NGF mRNA expression in Aβ25–35-insulted cells
was signiﬁcantly down-regulated (p < 0.01, Figure 8A). Meanwhile, BDNF gene mRNA expression
in Aβ25–35-insulted cells was also down-regulated at both 4 and 8 h (p < 0.01, Figure 8B). Compared
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to the control, a signiﬁcantly decreased protein expression of NGF was found until 12 h incubation
(p < 0.01, Figure 8C), whereas BDNF protein was signiﬁcantly increased in Aβ25–35-insulted cells
(p < 0.01, Figure 8D). However, in cells treated with 4-2A only, either NGF or BDNF gene was not
affected at both mRNA and protein level compared to the control (p > 0.05). 4-2A pre-treatment could
partially but signiﬁcantly attenuate the Aβ25–35-induced change in NGF mRNA (p < 0.05) and protein
(p < 0.01) expression (Figure 8A,C) and BDNF mRNA expression (both p < 0.01, Figure 8D), but not in
BDNF protein expression (p > 0.05, Figure 8D).
ȱ
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Figure 8. The effect of 4-2A on the expression of neurotrophin genes: NGF and BDNF. NGF mRNA
expression (A); and protein expression (C); and BDNF mRNA expression (B); and protein expression
(D), normalized to the expression of housekeeping gene β-Actin, in differentiated SH-SY5Y cells treated
with Aβ25–35 (20 μM) and/or 4-2A (10 μg/mL) for 4, 8, 12, 24 h. The data of both mRNA and protein
expression from six independent experiments (n = 1 in each experiment) were analyzed and expressed
as mean ± SEM. ** p < 0.01 vs. control group; # p < 0.05, ## p < 0.01 vs. Aβ25–35 group.
Unlike previously discussed genes, TrkA and TrkB were only affected at 24 h following Aβ25–35
administration. Aβ25–35 signiﬁcantly decreased TrkA protein expression (p < 0.01). Pretreatment with
4-2A only had no effect on TrkA protein expression, but it could signiﬁcantly attenuate the effect of
Aβ25–35 on the receptor (p < 0.01, Figure 9A). In contrast to TrkA changes, TrkB protein in the cells
treated with 4-2A only was signiﬁcantly increased (p < 0.01) compared to the control. In the cells
administrated with Aβ25–35 alone, a less but signiﬁcantly increased protein of TrkB was also found
(p < 0.05). 4-2A pretreatment did not reverse Aβ25–35-induced change, but further increased in TrkB
expression (p < 0.05, Figure 9B).
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Figure 9. The effect of 4-2A on the expression of neurotrophin receptors: TrkA and TrkB. TrkA (A); and
TrkB (B) protein expression, normalized to the protein expression of housekeeping gene β-Actin, in
differentiated SH-SY5Y cells treated with Aβ25–35 (20 μM) and/or 4-2A (10 μg/mL) for 24 h. The data
of protein expression from six independent experiments (n = 1 in each experiment) were analyzed
and expressed as mean ± SEM. * p < 0.05, ** p < 0.01 vs. control group; # p < 0.05, ## p < 0.01 vs.
Aβ25–35 group.
2.6. Treatment with 4-2A Regulated the Expression of Apoptosis Related Genes: Bax, Bcl-2 and Caspase-3
The genes Bax, Bcl-2 and Caspase-3 protein expression were tested at different incubation times
with Aβ25–35 (4, 8, 12 and 24 h). The expression of Bcl-2 was strongly decreased by Aβ25–35 at 24 h of
incubation with Aβ25–35, which was signiﬁcantly increased (p < 0.01) by 4-2A. 4-2A by itself had no
effect on Bcl-2. With regard to Bax, no obvious change was found after 4–24 h incubation. The Bax:
Bcl-2 ratio was signiﬁcantly increased in cells administrated with Aβ25–35 alone (p < 0.01). Pretreatment
with 4-2A signiﬁcantly reversed the ratio of Bax: Bcl-2 to the control level (p < 0.01, Figure 10A).
For Caspase-3, Aβ25–35 signiﬁcantly increased its protein expression (p < 0.01), whereas pretreatment
with 4-2A only did not affect the expression, but it could partially attenuate the effect of Aβ25–35
(p < 0.05, Figure 10B).
 
(A) 
 
(B) 
Figure 10. 4-2A regulated the expression of apoptosis related genes: Bcl-2, Bax and Caspase-3. Bax:Bcl-2
ratio (A); and Caspase-3 (B) protein expression (normalized to the protein expression of housekeeping
gene β-Actin) in differentiated SH-SY5Y cells treated with Aβ25–35 20 μM and/or 4-2A 10 μg/mL for
24 h. The data of both mRNA and protein expression from six independent experiments (n = 1 in each
experiment) were analyzed and expressed as mean ± SEM. ** p < 0.01 vs. control group; # p < 0.05,
## p < 0.01 vs. Aβ25–35 group.
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3. Discussion
Aβ25–35, an active fragment corresponding to amino acids 25–35 in full-length Aβ, possesses
the same β-sheet structure and retains full toxicity of full-length Aβ1–42 [29]. Many experiments
have demonstrated that Aβ25–35 can induce neurotoxicity and AD-like pathology, such as activating
glial cells, increasing cholinesterase expression [30] and oxidative stress [31], as well as impairing
spatial learning and memory [32,33]. Our previous study also showed that Aβ25–35 could result in
neuroinﬂammatory response and dysfunction of neurotrophin system [34]. As such, Aβ25–35 has
been popularly utilized to induce in vitro or in vivo AD models [32,33,35,36]. The present study
demonstrates that 4-2A protects the SH-SY5Y cells from Aβ25–35-induced reduction in cell viability
by suppressing oxygen stress and inﬂammation, regulating neurotrophin levels, hence attenuating
neuron apoptosis.
Even though the exact pathophysiology of AD is unclear, oxidative stress has been found to play
a fatal role in the pathogenic process of AD. Previous studies demonstrated that toxicity of Aβ25–35 in
models of neurodegenerative diseases in vitro and in vivowas associatedwith the enhancement of ROS
and NO liberation and oxidative damage [37–41], which up-regulated redox-sensitive transcription
factors such as NF-κB, an important factor responsible for oxidative and inﬂammatory reactions
in AD [42]. In agreement with these studies, Aβ25–35 increased the ROS and NO production from
SH-SY5Y cells in the present study. ROS and NO are oxidants in the Alzheimer’s brain. However, NO
is also a neurotransmitter, which may protect synapses by increasing neuronal excitability [43,44]. Thus,
whether the Aβ-induced increase in NO acts as a compensatory and neuroprotective or neurotoxic role
is unclear. The administration of 4-2A into Aβ25–35-treated cells partially but signiﬁcantly decreased
ROS production, which means 4-2A may partially protect neurons against free radicals or may improve
mitochondrial dysfunction which is the major source of ROS. Furthermore, the decrease in GSH content
caused by Aβ25–35 was signiﬁcantly attenuated by 4-2A treatment. These ﬁndings indicated that 4-2A
could restore the imbalance between oxidative stress factors and antioxidant systems. However, 4-2A
could not affect the Aβ25–35-induced NO change, which may be related to a hypothesis that 4-2A may
contribute to the self-protective ability of Aβ-insulted cells if this increase in NO is neuroprotective.
Inﬂammation is another important contributor to neurodegenerative diseases. Experimental and
clinical ﬁndings provide evidence for the hypothesis that the neuronal degeneration in AD is not simply
due to the Aβ deposition, but to neuroinﬂammation [45,46]. Consistent with the above studies, an
increased expression of TNF-α gene was found in the present AD cellular model. Increased TNF-α can
activate a pro-apoptotic factor JNK pathway that is involved in cell differentiation and proliferation [47]
and trigger cellular death signaling [27]. In the present study, 4-2A showed anti-inﬂammatory property
since it partially down-regulated the expression of TNF-α either in the mRNA or in protein level.
In our previous study, we showed that neuroinﬂammation could reduce the levels of neurotrophic
factors, such as NGF [48] and BDNF [49]. In the present study, Aβ25–35 differently regulated the
expression of the two neurotrophic factor genes. The decreased expression of NGF and its receptor
TrkA seems to be reasonable for the low neuronal viability induced by Aβ. However, a signiﬁcant
increase in the expression of BDNF and its receptor TrkB protein in SH-SY5Y cells exposed to Aβ25–35
was unexpected, which was unparalleled by the decreased mRNA level in BDNF. The present data are
partially in agreement with a previous in vitro study showing that the exposure of SH-SY5Y cells to
Aβ25–35 induced a signiﬁcant increase of BDNF [50]. We speculate that the increase of BDNF levels
might act as a compensatory response against amyloid toxicity, while Aβ25–35 may trigger distinct
effects on BDNF expression in different systems, conditions and incubation time.
Over-production of pro-inﬂammatory cytokines, oxidative stress and neurotrophin dysfunction
may reduce neurogenesis and induce apoptosis [51,52], which result in neuronal death and
memory loss in AD [53–56]. In the present study, Aβ25–35 treatment increased the pro-apoptotic
Bax/anti-apoptotic Bcl-2 ratio and Caspase-3 expression, which were attenuated by pretreatment of
4-2A, suggesting 4-2A can regulate the imbalance between pro- and anti-apoptotic gene expression.
The mechanism by which 4-2A attenuated Aβ-induced neuron damage may be through its
unique components.
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The acetone extract 4-2A from the shrimp by-products consists of lipids containing large amount of
unsaturated fatty acids, especially monounsaturated fatty acid (MUFAs, 67.19%), including n-9 MUFAs
and n-7 MUFAs. Oleic acid (18:1n-9) and palmitoleic acid (16:1n-7) are the most common MUFAs,
which represent n-9 and n-7 MUFAs, respectively. The total fatty acids analysis proﬁles that 18:1n-9
(oleic acid, 20.65%) is the most abundant fatty acid in 4-2A. As the major n-9 MUFAs, oleic acid is high
in olive oil which is the main characteristic of the Mediterranean Style Diet (MSD). Recent data from
large epidemiological studies suggest a relationship between MSD adherence and signiﬁcant reduction
in incidence of Parkinson’s disease and AD and mild cognitive decline or risk of dementia [57].
Moreover, the protective effect of oleate against palmitate-induced mitochondrial dysfunction, insulin
resistance and inﬂammatory signaling has been evaluated in several cell models [17,58]. Interestingly,
in neuronal cells, Kwon et al. demonstrated that oleate preconditioning was superior to DHA or
linoleate (18:2n-6) in the protection from the above palmitate-induced insults [58]. These effects may
be associated with the neuroprotective ability of 4-2A to exert anti-inﬂammatory effects and restore the
imbalance between oxidative stress factors and antioxidant systems. In addition, oleic acid may behave
as a neurotrophic factor for neurons via up-regulation of molecular markers of axonal and dendritic
growth, such as GAP-43 and MAP-2 [20]. This may be an important factor related to the ability of 4-2A
to modulate Aβ25–35-induced abnormality in neurotrophic systems. These results strongly suggest that
the ability of 4-2A to prevent SH-SY5Y cells from neurotoxicity induced by Aβ25–35 may be associated
with its high content of oleic acid.
In recent years, n-7 palmitoleic acid (16:1n-7, 14.75%) has drawn increasing attention since its
characterization as a bioactive lipid that coordinates metabolic crosstalk between the liver and adipose
tissue [59]. Studies in cultured hepatocytes and mouse models of diet-induced obesity suggest that
palmitoleic acid has anti-inﬂammatory and insulin-sensitizing effects [60]. Moreover, both in vitro and
in vivo studies have demonstrated that palmitoleic acid can decrease the level of pro-inﬂammatory
mediators and reduce the level of C-reactive protein in mice [21,23]. These anti-inﬂammatory effects
may also contribute to the neuro-protective effect of 4-2A in the present study. However, because of
rare reports about the effect of other MUFAs in health, the role of other two n-9 MUFAs (20:1n-9 and
22:1n-9) and three n-7 MUFAs (18:1n-7, 20:1n-7 and 22:1n-7) of longer chain length (≥C18) in 4-2A
is unclear.
It is not surprising that 4-2A could protect SH-SY5Y neurons-like cells against Aβ25–35-induced
apoptosis and death since 4-2A is rich in polyunsaturated n-3 fatty acids, such as EPA and DHA.
Our previous studies have conﬁrmed that n-3 fatty acids possess broad spectrum of neuroprotective
activities in both in vitro and in vivo experiments because of their anti-oxidant and anti-inﬂammatory
properties [61–66]. Additionally, Wu et al. [67] showed that n-3 PUFAs signiﬁcantly attenuated the
gene expression of pro-inﬂammatory cytokines, including IL-1β, IL-6, and TNF-α, and the protein
levels of NF-κB and iNOS in brain tissues of rats with doxorubicin-induced depressive-like behaviors
and neurotoxicity. In another in vivo study, Taepavarapruk and Song [48] revealed that n-3 PUFAs
improved memory through IL-1-glucocorticoid-ACh release and IL-1-NGF-ACh release pathways.
Moreover, there is evidence that dietary supplementation with DHA reduced the intraneuronal
accumulation of not only amyloid-beta, but also tau, another important pathology marker for AD, in
the 3xTg-AD mouse model via decreasing steady-state levels of presenilin 1 [68,69]. Based on these
ﬁndings, there is no doubt that the neuroprotective effect of 4-2A was related to the rich n-3 PUFAs
component. As the concentration of n-6 PUFAs are very low (1.85%), their effect in 4-2A can be ignored.
Finally, the saturated fatty acid in 4-2A may have no effect or only serve as an energy component
in the cell cultural system because no biological activity was reported.
Taken together, shrimp processing by-product acetone extract 4-2A was prepared and
characterized as lipids consisting of large amount of unsaturated fatty acids by NMR, HPLC-CAD
and GC analyses. As a multifunctional agent, 4-2A showed potent inhibition against Aβ25–35
cytotoxicity, which conﬁrms our hypothesis that 4-2A may exert neuroprotective effect via anti-oxidant,
anti-inﬂammation and increasing neurotrophins. These effects of 4-2A may result from its various FAs
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components targeting various molecular pathways. The limitations of the present study are ﬁrstly
that the treatment of 4-2A should be studied in the animal model of AD. Secondly, the effect of each
FA component and their combination in different ratios should be determined, which can reveal the
exact role of each FA and potential synergistic action of their combination in inﬂammatory, oxidant
and neurotrophic functions in the brain. Thirdly, as the main components of neuronal membranes, the
effect of FAs in 4-2A on the function of cell membrane and other mechanisms involved should also
be investigated.
4. Materials and Methods
4.1. Preparation of the Shrimp Extract 4-2A
Fatty acids from the solid residue of shrimp Pandalus borealis processing waste were extracted
with hexane (15 mL/g, v/w dry weight) at room temperature for 30 min, followed by 10 min of
sonication, ﬁltered, and then extracted with acetone under the same conditions. The liquid acetone
extracts were combined, concentrated using rotary evaporator at reduced pressure, and then dried
under N2. The resulting extract was named 4-2A.
4.2. Characterization of Shrimp Extract 4-2A
4.2.1. Characterization of 4-2A by NMR
Both 1H-NMR and 13C-NMR spectra of 4-2A (1 mg, dissolved in 700 μL of 99.8% CDCl3) were
recorded at 4 ◦C on a Bruker AV-III 700 MHz spectrometer (Bruker BioSpin Canada, Milton, ON,
Canada), equipped with a 5 mm TCI cryoprobe. The data were processed using the standard TopSpin
V 2.1 (Bruker BioSpin Canada, Milton, ON, Canada) software.
4.2.2. Characterization of 4-2A by HPLC
HPLC analysis was carried out on an 1100 series instrument (Agilent Technologies, Santa Clara,
CA, USA) with a Thermo Scientiﬁc™ Dionex™ Corona™ Charged Aerosol Detector (Burlington,
ON, Canada). The method was adopted from dionex.com [70] with modiﬁcations. Samples were
prepared by diluting 1 mg of analyte in 1 mL of methanol/chloroform (1:1, v/v). Ten microliter of each
sample solution was injected on a HALO C8 column (2.1 mm × 100 mm, 2.7 μm, Advanced Materials
Technology Inc., Wilmington, DE, USA) with a 0.45 mL/min ﬂow rate at 40 ◦C. A 5 × 2.1 mm C8
cartridge (2.7 μm, Advanced Materials Technology Inc.) was used as a pre-column. Mobile phase A
methanol/water/acetic acid (750:250:4) and phase B acetonitrile/methanol/tetrahydrofuran/acetic
acid (500:375:125:4) were proceeded from 100% A at the beginning at 0.8 mL/min to 30% A and 70% B
at 40 min at 1.0 mL/min, then reached to 20% A and 80% B in 10 min at 1.0 mL/min and ﬁnally to
100% B in 10 min at 1.0 mL/min, held for 10 min, and then back to 100% A in 10 min at 0.8 mL/min.
The column temperature was at 40 ◦C.
Free fatty acids (myristic acid, cis-palmitoleic acid, cis-vaccenic acid, trans-vaccenic acid, oleic acid,
elaidic acid, pentadecanoic acid, palmitic acid, heptadecanoic acid, cis-10-heptadecenoic acid, stearic acid,
9-cis,12-cis-linoleic acid, cis,cis,cis-9,12,15-octadecatrienoic acid, cis,cis,cis-6,9,12-octadecatrienoic acid, cis-11-
eicosenoic acid, arachidonic acid, cis-5,8,11,14,17-eicosapentaenoic acid, cis-4,7,10,13,16,19-docosahexaenoic
acid and tricosanoic acid), monoglycerides (DL-α-palmitin, 1-monopalmitoleoyl-rac-glycerol and
1-Oleoyl-rac-glycerol), diglycerides (1,2-distearoyl-rac-glycerol and 1,3-distearoylglycerol), triglycerides
(olive oil), and phospholipids mixer (L-α-lysophosphatidylcholine, L-α-phosphatidylcholine,
L-α-phosphatidylethanolamine and L-α-phosphatidy- linositol sodium salt) purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA) were applied on the column under the same conditions.
4.2.3. GC Analysis of 4-2A
GC analysis was performed as described by Jiao et al. [25]. Total fatty acids were released
from 4-2A by hydrolyzing with 1.5 N NaOH methanol solution under N2 at 100 ◦C for 5 min, then
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methylated with 14% of BF3 methanol solution at 100 ◦C for 30 min. Distilled water was then added
to stop the reaction. The methylated fatty acids were extracted with hexane and subjected on an
Agilent Technologies 7890A GC spectrometer (Agilent Technologies, Santa Clara, CA, USA) using an
Omegawax 250 fused silica capillary column (30 m× 0.25 mm× 0.25 μm ﬁlm thickness, Sigma-Aldrich,
St. Louis, MO, USA). Supelco® 37 component fatty acid methylated esters (FAME) mix and PUFA-3
(Supelco, Bellefonte, PA, USA) were used as FAME standards.
4.3. SH-SY5Y Culture and Differentiation
SH-SY5Y cells were obtained from ATCC (CRL-2266, Lot. 61983120) and were maintained in
DMEM/F12 medium (Gibco®, Burlington, ON, Canada) supplemented with 10% fetal bovine serum
(FBS, Gibco®, Burlington, ON, Canada) and 1% penicillin–streptomycin in a humid atmosphere of
5% CO2 at 37 ◦C. SH-SY5Y cells were differentiated into fully human neuron-like cells with treatment
all-trans-retinoic acid (RA, Sigma Aldrich, Oakville, ON, Canada), at a ﬁnal concentration of 10 μM in
DMEM/F12 with 3% FBS (media changed every 2 days), for 7–8 days.
4.4. Experimental Design
Once the SH-SY5Y cells were differentiated into classic neuron-like cells with long axons compared
to undifferentiated cells, they were used in the experiments. Aβ25–35 (synthetic, ≥97% HPLC, Sigma
Aldrich, Oakville, ON, Canada, A4559) was dissolved in sterile double-distilledwater at a concentration
of 1 mmol/L stock solution, was aged at 37 ◦C for 4 day, and then stored at −20 ◦C before use
(This aging procedure was proved to produce birefringent ﬁbril-like structures, globular amorphous
aggregates and induce cognitive impairment in rats [34,71]). The 4-2A was dissolved in ethanol at a
stock concentration of 100 mg/mL, and then added to DMEM/F12 (ﬁnal ethanol concentration 0.1%).
The effects of Aβ25–35 at 5, 10, 15, 20 and 25 μM at 12, 24 and 48 h and the effects of 4-2A at 1, 5, 10, 20
and 40 μg/mL on Aβ25–35-induced SH-SY5Y cell injury were then determined separately. The optimal
dose and culture duration of Aβ25–35 (20 μM, 24 h) and 4-2A (10 μg/mL, pretreated for 12 h before
addition of 20 μM Aβ25–35) were selected based on when the signiﬁcant decrease in cell viability or
attenuation of this effect appeared respectively. In the present study, four groups of SH-SY5Y cells
were used: (i) control (cells in culture media which contained 0.1% v/v ethanol); (ii) 4-2A (cells in
culture media with 10 μg/mL 4-2A; (iii) Aβ25–35 (cells in culture media with 20 μM Aβ25–35); and (iv)
4-2A and Aβ25–35 (cells pretreated with 10 μg/mL 4-2A for 12 h before addition of 20 μM Aβ25–35).
After the addition of Aβ25–35, the SH-SY5Y cells were incubated for 24 h, after which cell viability,
oxidative stress, inﬂammatory cytokine TNF-a, neurotrophins and apoptosis were measured.
4.5. Measurement of Cell Viability by MTT Assay
Cell viability was measured using MTT assay which measures the cell proliferation rate and the
reduction in cell viability. Cells were seeded in 96-well plates and 90 μL of cell suspension added to
each well. Following experimental treatment, 10 μL MTT (ATCC) was added to each well and the
plate was incubated for additional 4 h at 37 ◦C. The optical density was measured at 570 nm using a
microplate reader (BioTek, Winooski, VT, USA). The absorbance of the control group was considered
as 100% of the cell viability.
4.6. Cytotoxicity Assay by LDH Assay
As MTT assay was sensitive to cell numbers which was affected by both cell proliferation and cell
viability, it was essential to use another assay to conﬁrm the result. The CytoTox-96 assay kit (Promega,
Madison, WI, USA) was employed to evaluate the total release of cytoplasmic lactate dehydrogenase
(LDH) into the medium, which is a consequence of cellular integrity damage. The assay is based upon
a coupled enzymatic conversion from 2-p-(iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride
(INT, a tetrazolium salt) into a formazan product, and the enzymatic reaction is catalyzed by LDH
released from cells and diaphorase in the assay substrate mixture. Absorbance was read at 490 nm by
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the microplate reader. The mean absorbance of each group was normalized to the percentage of the
control value.
4.7. Measurement of Oxidative Stress and Antioxidant Response
The intracellular level of ROS was measured with a ﬂuorometric intracellular ROS kit
(Sigma Aldrich) according to manufacturer’s instructions. The ﬂuorescence intensity was detected
at lex = 650/lem = 675 nm using a ﬂuorescence microplate reader (Reader Synergy HT, BioTek).
The intracellular level of NO production was determined by the Griess Reagent System (Promega)
according to manufacturer’s instructions. The absorbance was measured at 540 nm using a
microplate reader.
The level of GSH was determined with a glutathione assay kit (Sigma Aldrich) according to
manufacturer’s instructions. The ﬂuorescence intensity was measured by a ﬂuorimeter plate reader set
at an excitation wavelength of 390 nm and emission wavelength of 478 nm.
4.8. Determination of Gene Expression with Quantitative PCR
SH-SY5Y cells treated as described above were harvested. The total RNA was extracted as
recommended by the manufacturer (RNeasy® Lipid Tissue Handbook, Qiagen, Germantown, MD,
USA). Complementary DNA (cDNA) was synthesized from 2 μg RNA using the GoScript™ Reverse
Transcriptase (Promega, Madison, WI, USA). Primer sequences (Table 2) were obtained from
Invitrogen Corporation. PCR reactions were prepared using Quantitect SYBR Green master mix
(Qiagen, Germantown, MD, USA) and carried out using a Real-Time PCR Detection Systems (Bio-Rad,
Hercules, CA, USA) CFX96™ Real-Time System. The real-time PCR was optimized to run with
conditions of the initial incubation at 95 ◦C for 5 min, denaturation at 94 ◦C for 15 s, annealing at 59 ◦C
for 30 s, and extension at 72 ◦C for 30 s with a single ﬂuorescence measurement and up to 38 cycles.
Expression levels of target mRNAs were normalized to beta actin (relative quantiﬁcation) with the
ΔΔCT correction.
Table 2. Primer names and sequences.
Primer Names Sequences
hActin F GATGAGATTGGCATGGCTTT
hActin R CACCTTCACCGTTCCAGTTT
hBAX F GGGGACGAACTGGACAGTAA
hBAX R CAGTTGAAGTTGCCGTCAGA
hBCL 2 F TCTAGGGGAGGTGGTAGGCT
hBCL 2 R CTGAGCAAGTCAGAGACCCC
hCaspase 3 F GACTCTAGACGGCATCCAGC
hCaspase 3 R TGACAGCCAGTGAGACTTGG
hNGF F ACCTTTCTCAGTAGCGGCAA
hNGF R TGTGTCACCTTGTCAGGGAA
hTNF-α F AGGTTTGGCCTCACAAGGAC
hTNF-α R GCGGTAGGGACAGTTCACAG
hBDNF F GGAGACACATCCAGCAAT
hBDNF R ACAAGAACGAACACAACAG
hTrkB F CTATGCTGTGGTGGTGATT
hTrkB R CCGAAGAAGATGGAGTGTTA
hTrkA F TACAGCACCGACTATTACC
hTrkA R ATGATGGCGTAGACCTCT
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4.9. Analysis of Protein Expression by Western Blotting
SH-SY5Y cells treated as described above were collected and centrifuged at 10,000× g for 10 min.
The cell pellet was lysed with a RIPA buffer (RIPA, Thermo Fisher Scientiﬁc, Hudson, NH, USA) aided
by sonication, and then spun down at 10,000× g for 10 min at 4 ◦C. The supernatant was collected and
aliquots containing 20–40 μg of protein were loaded after boiling and separated on 10% SDS PAGE
gels at 100 V for 60 min in electrophoresis buffer. After running the gels, the proteins were transferred
to Polyvinylidene diﬂuoride (PVDF) membranes (Millipore, Bellerica, MA, USA). The membranes
were blocked with 5% non-fat milk in Tris buffer saline for 1 h at 20 ◦C. Following blocking, blots
were washed with TBST for 5 min and incubated with primary antibodies, including the rabbit origin
polyclonal antibodies for Actin (Abcam, Cambridge, MA, USA; ab8227, 42 kDa, 1:4000), NGF (Abcam,
ab52918, 27 kDa, 1:500), BDNF (Abcam, ab6201, 28kDa, matured form, 1:200), TrkA (Abcam, ab59272,
85 kDa, 1:800), TrkB (Thermo Fisher Science, Hudson, NH, USA; MA5-14903, 90-140 kDa, 1:1000),
TNF-α (Abcam, ab9739, 17 kDa, 1:2500), Bcl-2 (Abcam, ab136285, 26 kDa, 1:5000), Bax (Abcam, ab32503,
21 kDa, 1:2000) and Caspase-3 (Abcam, ab44976, 32 kDa, activated forms, 1:500), overnight at 4 ◦C,
followed by the secondary antibody, peroxidase (HRP)-conjugated anti-rabbit IgG (Abcam, ab6721,
1:5000), for 1 h at 20 ◦C. The blots were washed in TBS three times. Immunoreactive bands were
detected by Clarity™ Western ECL Substrate Kit (Bio-Rad, Hercules, CA, USA) on a ChemiDoc™ MP
System with Image Lab™ Software (Bio-Rad, Hercules, CA, USA). All target proteins were quantiﬁed
by normalizing them to β-Actin re-probed on the same membrane and then calculated as a percentage
of the control group.
4.10. Statistics
Results were expressed as mean ± SEM. Statistical evaluation was performed with IBM SPSS
Statistics 22. For the dose–response test of 4-2A/Aβ25–35, results were analyzed by one-way ANOVA,
followed by Dunnett post-hoc test in case of signiﬁcant main effects (p < 0.05). The possible interaction
between Aβ25–35 and 4-2A was measured by two-way ANOVA with Tukey’s post-hoc tests. A value of
p < 0.05 was considered statistically signiﬁcant.
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Abstract: Different biological sources of n-3 polyunsaturated fatty acids (n-3 PUFA) in mainstream
commercial products include algae and ﬁsh. Lipid oxidation in n-3 PUFA-rich oil is the most important
cause of its deterioration. We investigated the kinetic parameters of n-3 PUFA-rich oil during
oxidation via Rancimat (at a temperature range of 70~100 ◦C). This was done on the basis of the
Arrhenius equation, which indicates that the activation energies (Ea) for oxidative stability are
82.84–96.98 KJ/mol. The chemical substrates of different oxidative levels resulting from oxidation via
Rancimat at 80 ◦C were evaluated. At the initiation of oxidation, the tocopherols in the oil degraded
very quickly, resulting in diminished protection against further oxidation. Then, the degradation of
the fatty acids with n-3 PUFA-rich oil was evident because of decreased levels of PUFA along with
increased levels of saturated fatty acids (SFA). The quality deterioration from n-3 PUFA-rich oil at
the various oxidative levels was analyzed chemometrically. The anisidine value (p-AV, r: 0.92) and
total oxidation value (TOTOX, r: 0.91) exhibited a good linear relationship in a principal component
analysis (PCA), while oxidative change and a signiﬁcant quality change to the induction period (IP)
were detected through an agglomerative hierarchical cluster (AHC) analysis.
Keywords: n-3 PUFA; oxidative stability index; Rancimat test; kinetic parameter
1. Introduction
Fish oil accounts for less than 1% of all the global edible oil produced, but it is the main source
of n-3 PUFA, speciﬁcally, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [1]. These
oils are becoming increasingly popular with consumers in view of the clear evidence of the health
beneﬁts of n-3 PUFA for individuals with cardiovascular conditions, including their beneﬁcial role as
antithrombotic, anti-inﬂammatory, and hypolipidemic fatty acids [2,3]. The n-6/n-3 ratio in a person’s
dietary intake is also an important consideration due to its inﬂuences on cardiovascular health and
inﬂammation, with high intake of n-6 PUFA potentially attenuating the known proﬁtable effects of n-3
PUFA. Due to the nutritional changes described above in the Western diet, the n-6/n-3 ratio has now
increased to falls between 10 and 20. The dietary recommendations regarding n-3 PUFA intake are,
thus, of increasing importance [4].
In Europe, the recommended daily intake of EPA and DHA is 450 mg per day, that is, around 3 g
per week, while the WHO/FAO recommends daily consumption of 250 mg (for primary prevention) to
2 g (for secondary prevention) of EPA and DHA to prevent cardiovascular conditions [5]. In contrast,
the FDA and American Dietetic Association suggest a minimum intake of close to 500 mg/day to
prevent coronary health diseases [6]. In recent years, consumers have identiﬁed n-3 PUFA supplements
as options for reducing the probability of illness and avoiding expensive medical bills, so that the
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rate of sales growth for such supplements is currently around 15% per annum. The calculated market
value of packaged products containing n-3 PUFA, which primarily consist of infant formula, has been
estimated to reach $34.7 billion by 2016, and to grow at a CAGR of 9.1% from 2015 to 2022 [7].
Worldwide ﬁsh stocks peaked some years ago, but in recent years there has been a shortage in
the supply of ﬁsh oils. In the future, as the global population continues to grow, in turn increasing
the need for products allowing consumers to meet the suggested intake of EPA and DHA, sustainable
sources of n-3 PUFA-containing products will be needed to meet the growing demand [8,9]. With that
in mind, the use of other forms of marine life, including Antarctic krill and algae, to provide n-3 PUFA
continues to be developed, with these sources already having been commercialized. These sources
may provide some high value and highly concentrated products for human consumption, including
contaminant-free products with good sensory qualities that are also safe and environmentally friendly.
In particular, the fermentation of algae can be used to shorten the growth process of algae and produce
highly concentrated oil [10,11].
The drawback of using n-3 PUFA-rich oils for functional foods is that they are readily oxidized
in the presence of oxygen, heat, light, and metal ions, and the secondary products of lipid oxidation
can impair the sensory qualities and acceptability of products among consumers [12]. In addition,
previous studies involving animal research have conﬁrmed that oxidative products contain genotoxic
and cytotoxic compounds [13]. Moreover, these oxidative compounds, when present in diets, have
been considered as the possible causative agents of several diseases, such as chronic inﬂammation,
neurodegenerative diseases, atherogenesis, diabetes, and certain types of cancer. Among these
oxidative products, the oxygenated aldehydes are the most broadly studied, and their adsorption
capacity and functional group proﬁles are most closely related to toxicity [13,14].
The Global Organization for EPA and DHA (GOED) voluntary monograph is the quality standard
for EPA- and DHA-rich oils, and is used to help ensure that consumers have access to high-quality
products; it is applicable to the EPA and DHA fatty acids obtained from ﬁsh, plant, or microbial
sources [15]. Numerous analytical methods of lipid oxidation are used to measure food quality.
However, there is no common and standard method for detecting all oxidative variations in multiple
food systems. Therefore, it is necessary to select a proper and adequate method for the analysis of any
fatty acid composition and its substrates.
Lipid oxidation occurs very slowly at room temperature and, hence, accelerated methods should
be applied in order to estimate the oxidative stability of a product or the induction time of the
autoxidation reaction in a more rapid manner, especially as the temperature and the rate of said
reaction are exponentially related [16]. Well-established accelerated aging testing methods include
the active oxygen method, Schaal Oven test, and Rancimat test. For the determination of IP, which is
the time needed for oil deterioration to commence, the Rancimat test observes the changes to the
conductivity of samples while the other two methods look at peroxide value (POV). So the Rancimat
test is easy to use and has good reproducibility [17]. The Rancimat method has been widely used to
evaluate the shelf lives of various products, including the kinetic parameters of antioxidants in oil
samples, as well as the inhibition of lipid peroxidation in such antioxidants [16–18].
The Rancimat test promotes the oxidation process by exposing oil samples to a high temperature
or temperatures and a sufﬁcient amount of oxygen. In the current study, we collected oils with different
oxidation levels during the induction period. This study discusses the evolution of substrate changes
and the formation of primary and secondary oxidation products, which were characterized in terms
of oxidative stability through the use of agglomerative hierarchical cluster AHC analysis and PCA.
These parameters were used to evaluate the oxidative properties of n-3 PUFA-rich oil, and the resulting
information can further be used to control the stability and shelf lives of PUFA-containing products.
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2. Results and Discussion
2.1. Kinetic Analysis
Given the uncertainty regarding the best temperature conditions for accelerated methods, the
oxidative stability of n-3 PUFA-rich oils was studied using the Rancimat test with temperatures ranging
from 70 ◦C to 100 ◦C. The IP for the lipid oxidation of n-3 PUFA-rich oils at different temperatures are
presented in Figure 1. For use of the Rancimat test at temperatures of 70 ◦C, 80 ◦C, 90 ◦C, and 100 ◦C,
the induction times were 15.4, 6.8, 3.4, and 0.92 h, respectively, for the VA; 15.9, 7.6, 3.6, and 0.97 h,
respectively, for the SuF; and 4.8, 2.3, 1.01, and 0.47 h, respectively, for the SiF. The temperature used
affects the degree of oxygen solubility in a given oil sample, with the oxygen solubility decreasing by
almost 25% for each 10 ◦C rise in temperature [19]. Generally, the induction time was halved with
each 10 ◦C increase in temperature. Previous research has shown that the PIs (at 50~80 ◦C) of ﬁsh oils
without antioxidants ranged from 24.3~0.6 h, and that the IP of the same oils ranged from 52.3~2.4 h
when 400 ppm of α-tocopherol were added [20].
Many studies have shown that the Rancimat test can be used to determine and evaluate the
kinetic parameters of oils. The determination of such kinetic parameters is valuable for the purpose of
distinguishing the origins of various oils, for characterizing the differences or similarities in the oils,
and for predicting the oxidative stability of oils under various storage conditions [17,19]. In this study,
there was semi-logarithmic relationship with Equation (1) for all the oil samples, including a linear
dependency with good correlation of determination, with R2 being 0.979 for the VA, 0.977 for the SuF,
and 0.998 for the SiF (Figure 1).
Temperature (K)
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Figure 1. Semi-logarithmic relationship between k and temperature values for lipid oxidation of the
n-3 PUFA-rich oils.
The Ea value is of interest for the properties of oils, which demonstrates the delay of the initial
oxidation reaction due to the bond scission that takes place to form primary oxidation products [21].
Table 1 shows Ea values of the assayed oils were 96.98 kJ/mol for the VA, 96.97 kJ/mol for the SuF,
and 82.84 kJ/mol for the SiF (Table 1). The Ea is inﬂuenced by unsaturated number of oil samples, as
the Ea seems to be lower for oils with higher PUFA levels. According to the reference, the Ea values
of DHA and EPA ethyl esters (of 95–97% purity), which were in the range of 52.1~62.4 kJ/mol [22].
However, this is contradicted by the example of the VA assayed in this study. Speciﬁcally, while the
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PUFA content of the VA was higher than those of the other tested oils, because the process of molecular
distillation can increase the IP of VA, it had a higher Ea value than the other oils [23].
Table 1. Regression parameters for Arrhenius relationships between the reaction rate constant and the
temperature for the n-3 PUFA-rich oils.
Groups VA SuF SiF
ln(k) = a(1/T) + b
a −11.66 −11.66 −9.96
b 31.16 31.1 27.44
R2 0.973 0.971 0.998
Ea (kJ/mol) 96.98 96.97 82.84
2.2. Monitoring Substrate Variants
As shown in Table 2, we identiﬁed eight types of fatty acids as presented under the VA column,
12 types of fatty acids as presented under the SuF column, and 14 types of fatty acids as presented
under the SiF column. We observed that the constituents of 100 g of VA consisted of 34.4 g of SFA,
34.5 g of MUFA, and 30.3 g of PUFA, while 100 g of SuF contained 44.5 g of SFA, 20.2 g of MUFA,
and 17.6 g of PUFA. One hundred grams of SiF consisted of 43.9 g of SFA, 28.0 g of MUFA, and 24.0 g
of PUFA. The concentration (g/100 g) of n-3 PUFA was 26.8 for VA, 16.4 for SuF, and 16.3 for SiF.
The literature on this topic indicated that DHA could be efﬁciently synthesized in microalgae via
an anaerobic pathway involving polyketide synthases [11].
Table 2. The fatty acid composition and tocopherol levels of the n-3 PUFA-rich oils.
Groups VA SuF SiF
Fatty Acid (g/100 g)
SFA a 34.4 44.5 43.9
C14:0 2.6 8.6 15.6
C16:0 30.2 29.8 25.6
C18:0 1.6 6.1 2.7
MUFA b 34.5 20.2 24.0
C14:1 1.3 1.9 1.1
C16:1 N.D d 4.8 18.0
C18:1 33.2 11.7 7.1
C20:1 N.D 1.8 1.8
PUFA c 30.3 17.6 24.0
C18:2 3.5 1.2 3.5
C20:2 N.D N.D 3.3
C20:3 N.D 1.9 0.6
AA N.D N.D 0.9
EPA N.D 4.6 9.9
DPA 3.5 1.0 1.1
DHA 23.3 8.9 4.7
Tocopherol (mg/kg)
δ- 219.3 252.9 167.3
γ- 529.4 445.3 N.D
α- 106.6 124.4 N.D
a SFA, Saturated fatty acid; b MUFA, monounsaturated fatty acid; c PUFA, polyunsaturated fatty acid; d N.D,
not detected.
The combination of fatty acids in edible oil is the most important factor in determining the oil’s
oxidation stability. Processing sophistication and antioxidants can improve the oxidation stability of
commercial products. The levels of fatty acids change at 80 ◦C under the Rancimat test (Figure 2),
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with the difference in the PUFA amounts of the VA, SuF, and SiF blends being −16.60%, −13.11%, and
−2.76% at the 100% oxidation level, and −29.43%, −24.08%, and −16.61% at the 125% oxidation level,
mainly as a result of DHA degradation. The difference in the SFA amounts of the VA, SuF, and SiF
blends were 1.01%, 4.11%, and 2.29% at the 100% oxidation level, and −0.67%, 4.34%, and 12.36% at the
125% oxidation level. It is known that the thermal treatment of oils and fats generates hydroperoxide
breakdown of any fatty acids with a chain shorter than ten carbon atoms, such that such breakdown
can be considered a chemical indicator of the fat degradation grade [24]. This study was similar to
such results, as SFA formation appeared to be correlated with PUFA loss, and with monounsaturated
fatty acid (MUFA) increases and decreases.
Figure 2. Percentage variations (g/100 g oil) of the (A) SFA, (B) MUFA, (C) PUFAs, and (D) total
tocopherol measured in the n-3 PUFA-rich oils.
Tocopherols are the most abundant antioxidants in n-3 PUFA concentrates, because of their
capacity to inhibit hydroperoxides and C-3 aldehydes [25]. In commercial products, tocopherol can
be used independently or in combination with other compounds, such as ascorbic acid palmitate,
lecithin, and catechin, and has shown signiﬁcantly in ﬁsh oil stabilization. On the other hand,
the structure conformation also affects the physical property of tocopherol, as γ- and δ-tocopherol
have thermal resistance. Hydroperoxyl radical-scavenging activity occurs in the order of α- > β- > γ-
> δ-tocopherol [26]. As shown in Figure 2, half of the total tocopherols of the tested n-3 PUFA-rich
oils was lost at the 50% oxidation level under the Rancimat test, while 90% of the total was lost at
the 100% oxidation level under the Rancimat test. The fact that the tocopherol content dropped very
quickly under the Rancimat test conditions could be due mainly to the very high susceptibility of this
molecule to oxidation to tocopherol quinones at high temperatures, which diminishes the protection of
unsaturated fatty acids against oxidation [27].
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2.3. Monitoring Oxidation Products
Lipid oxidation products have negative impacts on the ﬂavor and odor of sensory parameters,
which can, in turn, have harmful effects on human health. The progress of lipid oxidation can be
evaluated by the monitoring of a diverse series of primary, secondary, and tertiary oxidation products
over time. The quality standards of GOED require speciﬁc levels of acid value (AV, ≤3 mg KOH/g),
POV (≤5 meq/kg), p-AV (≤20), and TOTOX (≤26) throughout the stated lifetime of a product [15].
We found that the VA and SuF tested in this study met their stated label claims for GOED (Table 3).
POV and AV are used in the industry’s on-line quality control index. POV has a signiﬁcant correlation
to the off-ﬂavour compounds created during the initial oxidation. AV represents the content of free
fatty acids which are easily oxidized to hydro-peroxides [28].
The EC regulations suggest that absorbances at 234 nm (K234), 270 nm (K270), and 280 nm
(K280) be used to measure oils according to their oxidated products such as ethylenic diketones,
conjugated ketodienes, and the dienal formation of conjugated dienes and trienes. K234 is a primary
oxidation index that has been found to be closely related to hydroperoxide content [29]. In addition,
the measurement of UV absorbance at 270 and 280 nm has been used previously in analyzing edible
oils. Absorption at these wavelengths is mainly due to secondary oxidation. In a spectral analysis
conducted for this study (Table 3), we found that the absorbances of 10 mg/mL of VA, SuF, and SiF
were 3.33, 14.79, and 7.58, respectively, at K234; 1.12, 0.66, and 1.78, respectively, at K270; and 1.08,
0.51 and 1.48, respectively, at K280. Most of them increased as the oxidation levels increased. The K234
of SuF had high values at the beginning, a ﬁnding which can be attributed to the residual oxidated
products or fat-soluble compounds that were produced from the simpliﬁed reﬁning process.
Table 3. Initial quality characteristics of the n-3 PUFA-rich oils.
Groups VA SuF SiF
Quality Indicators
AV (mg KOH/g) 0.48 ± 0.02 0.49 ± 0.01 0.65 ± 0.01
CVD (%) 0.22 ± 0.05 1.18 ± 0.17 0.58 ± 0.03
POV (meq/kg) 1.98 ± 0.27 4.12 ± 0.34 13.62 ± 0.42
p-AV (meq/kg) 6.33 ± 0.71 15.12 ± 0.64 29.23 ± 1.84
TOTOX (meq/kg) 10.30 ± 0.92 23.26 ± 1.24 56.46 ± 2.11
Visible Spectra (10 mg/mL)
K234 a 3.33 ± 0.07 14.79 ± 0.14 7.58 ± 0.17
K270 1.12 ± 0.01 0.66 ± 0.02 1.78 ± 0.04
K280 1.08 ± 0.02 0.51 ± 0.01 1.48 ± 0.07
a K234, K270, and K280, speciﬁc absorption at 234, 270, and 280 nm.
In the literatures, hierarchical cluster was showed that could apply to grouping basis on quality,
sensory attributes and reﬁned level [30,31]. The AHC analysis was applied to identify clusters of
samples with similar oxidation properties. Three main clusters were extracted (Figure 3). Cluster 1
contained the 0–100% oxidation levels of the VA, the 0–75% oxidation levels of the SuF, and the 0–75%
oxidation levels of the SiF. Cluster 2 contained the 100% oxidation levels of the SuF and SiF. Cluster 3
contained the 125% oxidation levels of the VA, SuF, and SiF. These results showed that there are
signiﬁcant changes of quality in the IP of a given oil when it is subjected to the Rancimat test. These
results were similar to those of a previous study reported by our team, which oxidized volatiles of n-3
PUFA [32].
With regard to the quality standard change at 80 ◦C under the Rancimat test, according to the
PCA analysis, two dimensions were extracted and together account for approximately 91.51% of
the variability from the original data (Figure 3). In our results, we observed p-AV (r: 0.92), TOTOX
(r: 0.91), K270 (r: 0.88), and POV (r: 0.87) with PAC1; and K234 (r: 0.83) and conjugated dienes (CVD,
r: 0.81) with PCA2. The POV and p-AV are measures of primary oxidation and secondary oxidation,
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respectively. The TOTOX value gives an overall indication of the complete oxidation status of oil,
and consists of the combination of the POV and the p-AV values to determine the oxidation level
of the oil. Correlations between the quality parameters and spectral analysis is that K234, with AV,
POV, p-AV, and TOTOX is low (R < 0.5), while K270 and K280 with acid value (AV), POV, p-AV, and
TOTOX is high (R > 0.7). These results were based on measuring the formation of secondary oxidation
products; for example, p-AV and K270 are available to support the AV evaluation of frying oil quality,
and aldehyde molecules were a common marker for K270, K280, and p-AV [28,33].
ȱ
Figure 3. PCA plots of quality changes for the different oxidation levels of the n-3 PUFA-rich oils under
the Rancimat method; the circles represent the clusters detected with AHC analysis; the solid ﬁll type
highlights the values with PCA.
3. Materials and Methods
3.1. Materials
Conventional algae oils (VA) were provided by VEDAN Enterprise Corporation (Taichung,
Taiwan), and conventional ﬁsh oils from mackerel (SuF) were provided by SUN AGRICULTURE
(Ilan, Taiwan). Additional ﬁsh oils (SiF) were provided by Sigma (Sigma-Aldrich, Taufkirchen,
Germany). A fatty acid methyl ester standard (FAME) mixture, Supelco 37 Component FAME
Mix, was purchased from Supelco (Sigma-Aldrich, Taufkirchen, Germany). Standards of α-, γ-,
and δ- tocopherol were purchased from Merck (Darmstadt, Germany).
3.2. Rancimat Test
The oxidative stability index of the n-3 PUFA-rich oil was previously determined at four different
temperatures (70 ◦C, 80 ◦C, 90 ◦C, and 100 ◦C) as the induction period (hours) that was recorded using
a Rancimat 743 apparatus and a 5 ± 0.05 g sample of oil with an air ﬂow of 10 L/h. Then, oil samples
were oxidized at 80 ◦C for periods of time that corresponded to 25%, 50%, 75%, 100%, and 125% of
their respective induction periods. The oil samples that were used to determine the oxidative stability
were also analyzed for their volatile oxidation compounds. The IP of the n-3 PUFA-rich oils were
automatically recorded and taken as the break point of the plotted curves (the intersection point of the
two extrapolated parts of the curve).
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3.3. Kinetic Data Analysis
The kinetic parameters were determined according to the method previously utilized as reported
in [17]. The IP of the oil samples were automatically recorded and taken as the break point of the
plotted curves (the intersection point of the two extrapolated parts of the curve). A kinetic rate constant
was taken as the inverse of the IP (k, h−1).
Temperature coefﬁcients (T Coeff, K−1) were determined from the slopes of the lines generated
by regressing ln(k) vs. the absolute temperature (T, K):
ln(k) = a(T) + b (1)
where a and b are the equation parameters.
Activation energies (Ea, kJ/mol) and pre-exponential or frequency factors (A, h−1) were
determined from the slopes and intercepts, respectively, of the lines generated by regressing ln(k) vs.
1/T using the Arrhenius equation:
ln(k) = ln(A) − (Ea/RT) (2)
where k is the reaction rate constant or reciprocal IP (h−1), and R is the molar gas constant
(8.3143 J/mol K).
3.4. Analysis of Tocopherol
Each oil sample (0.1 g) was diluted with 2-propanol to a volume of 10 mL and ﬁltered through
an MS nylon syringe ﬁlter with a 0.45 μm pore size directly to vials and then immediately analyzed
using an HPLC system. Aliquots of 10 μL of the ﬁltrate were injected into the injection port and
analyzed with HPLC (Hitachi L-2130 pump, Hitachi, Tokyo, Japan). The remaining procedures were
carried out as previously reported [34] using an HPLC attached to a detector L-2400 UV and a Hitachi
L-2130 pump. An RP-18GP250 Mightysil column (l = 250 mm; i.d. = 4.6 mm; thickness = 0.32 μm;
Kanto Chemical Co., Inc., Tokyo, Japan) was used for separation. The same mobile phase and elution
conditions were adopted. The calibration curves were, respectively, established for tocopherol by
plotting the peak area vs. each corresponding concentration, from which quantitations of the standards
were achieved.
3.5. Fatty Acid Analysis
The n-3 PUFA-rich oil was analyzed for its fatty acid composition via GC/FID. The triacylglycerols
were converted to methyl esters using the AOCS Ofﬁcial Method Ce 2–66 [35]. The methyl esters were
separated using a column that was coated with DB-23 (30 m × 0.25 mm × 0.25 μm, Agilent, Palo Alto,
CA, USA), and helium was used as the carrier gas at a ﬂow rate of 1.0 mL/min. The oven temperature
was initially held for 8 min at 200 ◦C, and then increased at 10 ◦C/min to 220 ◦C and then held there
for 40 min. The FID was maintained at 270 ◦C, and the injector (split mode 1:40, 4 mm liner) was
maintained at 250 ◦C. The contents of the fatty acids were determined using the normalization method,
with heneicosanoic methyl ester used as an internal standard to quantitation.
3.6. Quality Analytical Determination
The POV and UV spectrophotometric were measured using the analytical methods described
in European Regulation EEC 2568/91 [36]. The CDA measures the formed from PUFA during lipid
oxidation according to the AOCS method Ti la-64 [35]. The p-AV measures secondary oxidation
products, such as 2-alkenal and 2,4-alkadienal. The p-AV of each sample was determined according
to the AOCS method Cd 18–90 [35]. The AV was determined using a titration with 0.1 N potassium
hydroxide alcoholic solution.
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3.7. Statistical Analysis
The data reported were obtained from triplicate measurements of each sample and were expressed
as means. The data were subjected to an AHC analysis with squared Euclidean distances. Subsequently,
the data were analyzed using PCA combined with VARIMAX rotation. For the AHC and PCA analysis,
XLSTAT software (version 2010.2.01, Addinsoft Deutschland, Andernach, Germany) was used.
4. Conclusions
In this work, the Rancimat test was applied to the analysis of the oxidation properties of n-3
PUFA-rich oil. The results of the present study indicated: (1) the degree of unsaturation in fatty acids
is not the only parameter for assessing oil quality, which is mainly inﬂuenced by commercialization.
The oxidation stability of n-3 PUFA-rich oils is improved by commercialization, especially with respect
to antioxidant protection; and (2) chemometric applications have also clariﬁed the nature of the
differences in correlation among oxidative and chemical parameters. The IP of primary and secondary
oxidation product formations represented the quality changes as detected via AHC analysis. Not
all quality parameters increased linearly through PCA analysis, which can allow for the selection of
a proper and adequate method for a particular application. It is recommended for p-AV, TOTOX, K270,
and POV to be used when carrying out quality control for n-3 PUFA- rich oils.
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AHC Agglomerative hierarchical cluster
References
1. Pike, I.H. Fish oil: Supply and demand as a source of long-chain n-3 polyunsaturated fatty acids in the
human diet. Eur. J. Lipid Sci. Technol. 2015, 117, 747–750. [CrossRef]
2. Nichols, P.D.; McManus, A.; Krail, K.; Sinclair, A.J.; Miller, M. Recent advances in omega-3: Health beneﬁts,
Sources, Products and bioavailability. Nutrients 2014, 9, 3727–3733. [CrossRef] [PubMed]
3. Kris-Etherton, P.M.; Harris, W.S.; Appel, L.J.; Committee, N. Fish consumption, ﬁsh oil, omega-3 fatty acids,
and cardiovascular disease. Circulation 2002, 106, 2747–2757. [CrossRef] [PubMed]
73
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 97
4. Watanabe, N.; Onuma, K.; Fujimoto, K.; Miyake, S.; Nakamura, T. Long-term effect of an enteral diet with
a different n-6/n-3 ratio on fatty acid composition and blood parameters in rats. J. Oleo Sci. 2011, 60, 109–115.
[CrossRef] [PubMed]
5. Lim, D.K.; Garg, S.; Timmins, M.; Zhang, E.S.; Thomas-Hall, S.R.; Schuhmann, H.; Li, Y.; Schenk, P.M.
Isolation and evaluation of oil-producing microalgae from subtropical coastal and brackish waters. PLoS ONE
2012, 7, e40751. [CrossRef] [PubMed]
6. Opperman, M.; Marais, D.W.; Benadé, A.S. Analysis of omega-3 fatty acid content of South African ﬁsh oil
supplements. Cardiovasc. J. Afr. 2011, 22, 324–329. [CrossRef] [PubMed]
7. Facts, P. Global Market for EPA/DHA Omega-3 Products; Packaged Facts: Rockville, MD, USA, 2012.
8. Adarme-Vega, T.C.; Thomas-Hall, S.R.; Schenk, P.M. Towards sustainable sources for omega-3 fatty acids
production. Curr. Opin. Biotechnol. 2014, 26, 14–18. [CrossRef] [PubMed]
9. Adarme-Vega, T.C.; Lim, D.K.; Timmins, M.; Vernen, F.; Li, Y.; Schenk, P.M. Microalgal biofactories:
A promising approach towards sustainable omega-3 fatty acid production. Microb. Cell Fact. 2012, 11, 96.
[CrossRef] [PubMed]
10. Kuratko, C.N.; Norman, S. Docosahexaenoic acid from algal oil. Eur. J. Lipid Sci. Technol. 2013, 115, 965–976.
[CrossRef]
11. Martins, D.A.; Custódio, L.; Barreira, L.; Pereira, H.; Ben-Hamadou, R.; Varela, J.; Abu-Salah, K.M.
Alternative sources of n-3 long-chain polyunsaturated fatty acids in marine microalgae. Mar. Drugs 2013, 11,
2259–2281. [CrossRef] [PubMed]
12. Drusch, S.; Groß, N.; Schwarz, K. Efﬁcient stabilization of bulk ﬁsh oil rich in long-chain polyunsaturated
fatty acids. Eur. J. Lipid Sci. Technol. 2008, 110, 351–359. [CrossRef]
13. Guillén, M.D.; Goicoechea, E. Toxic oxygenated α, β-unsaturated aldehydes and their study in foods:
A review. Crit. Rev. Food Sci. Nutr. 2008, 48, 119–136. [CrossRef] [PubMed]
14. Guillén, M.D.; Cabo, N.; Ibargoitia, M.L.; Ruiz, A. Study of both sunﬂower oil and its headspace throughout
the oxidation process. Occurrence in the headspace of toxic oxygenated aldehydes. J. Agric. Food Chem. 2005,
53, 1093–1101. [CrossRef] [PubMed]
15. GOED. Available online: http://www.goedomega3.com/healthcare (accessed on 10 January 2016).
16. Tan, C.; Man, Y.C.; Selamat, J.; Yusoff, M. Application of Arrhenius kinetics to evaluate oxidative stability
in vegetable oils by isothermal differential scanning calorimetry. J. Am. Oil Chem. Soc. 2001, 78, 1133–1138.
[CrossRef]
17. Farhoosh, R.; Niazmand, R.; Rezaei, M.; Sarabi, M. Kinetic parameter determination of vegetable oil oxidation
under Rancimat test conditions. Eur. J. Lipid Sci. Technol. 2008, 110, 587–592. [CrossRef]
18. Chen, M.H.; Huang, T.C. Volatile and Nonvolatile Constituents and Antioxidant Capacity of Oleoresins
in Three Taiwan Citrus Varieties as Determined by Supercritical Fluid Extraction. Molecules 2016, 21, 1735.
[CrossRef] [PubMed]
19. Robertson, G.L. Shelf life of packaged foods, its measurements and prediction. In Developing New Food
Products for a Changing Marketplace; CRC Press: Boca Raton, FL, USA, 2000; pp. 329–353.
20. Rupasinghe, H.V.; Erkan, N.; Yasmin, A. Antioxidant protection of eicosapentaenoic acid and ﬁsh oil
oxidation by polyphenolic-enriched apple skin extract. J. Agric. Food Chem. 2009, 58, 1233–1239. [CrossRef]
[PubMed]
21. Adhvaryu, A.; Erhan, S.; Liu, Z.; Perez, J. Oxidation kinetic studies of oils derived from unmodiﬁed and
genetically modiﬁed vegetables using pressurized differential scanning calorimetry and nuclear magnetic
resonance spectroscopy. Thermochim. Acta 2000, 364, 87–97. [CrossRef]
22. Yoshii, H.; Furuta, T.; Siga, H.; Moriyama, S.; Baba, T.; Maruyama, K.; Misawa, Y.; Hata, N.; Linko, P.
Autoxidation kinetic analysis of docosahexaenoic acid ethyl ester and docosahexaenoic triglyceride with
oxygen sensor. Biosci. Biotechnol. Biochem. 2002, 66, 749–753. [CrossRef] [PubMed]
23. Wang, W.; Li, T.; Ning, Z.; Wang, Y.; Yang, B.; Ma, Y.; Yang, X. A process for the synthesis of PUFA-enriched
triglycerides from high-acid crude ﬁsh oil. J. Food Eng. 2012, 109, 366–371. [CrossRef]
24. De Leonardis, A.; Macciola, V. Heat-oxidation stability of palm oil blended with extra virgin olive oil.
Food Chem. 2012, 135, 1769–1776. [CrossRef] [PubMed]
25. Kulås, E.; Ackman, R.G. Properties of α-, γ-, and δ-tocopherol in puriﬁed ﬁsh oil triacylglycerols. J. Am. Oil
Chem. Soc. 2001, 78, 361–367. [CrossRef]
74
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 97
26. Fujisawa, S.; Kadoma, Y. Kinetic study of the radical-scavenging activity of vitamin E and ubiquinone.
In Vivo 2005, 19, 1005–1011. [PubMed]
27. Verleyen, T.; Kamal-Eldin, A.; Dobarganes, C.; Verhé, R.; Dewettinck, K.; Huyghebaert, A. Modeling of
α-tocopherol loss and oxidation products formed during thermoxidation in triolein and tripalmitin mixtures.
Lipids 2001, 36, 719–726. [CrossRef] [PubMed]
28. Navas, J.A.; Tres, A.; Codony, R.; Guardiola, F. Optimization of analytical methods for the assessment of the
quality of fats and oils used in continuous deep fat frying. Grasas Aceites 2007, 58, 154–162.
29. Shahid Chatha, S.A.; Anwar, F.; Manzoor, M.; Rehman Bajwa, J.U. Evaluation of the antioxidant activity of
rice bran extracts using different antioxidant assays. Grasas Aceites 2006, 57, 328–335.
30. Navarro, T.; de Lorenzo, C.; Pérez, R. SPME analysis of volatile compounds from unfermented olives
subjected to thermal treatment. Anal. Bioanal. Chem. 2004, 379, 812–817. [CrossRef] [PubMed]
31. Tu, D.; Li, H.; Wu, Z.; Zhao, B.; Li, Y. Application of headspace solid-phase microextraction and multivariate
analysis for the differentiation between edible oils and waste cooking oil. Anal. Bioanal. Chem. 2014, 7,
1263–1270. [CrossRef]
32. Yang, K.M.; Cheng, M.C.; Chen, C.W.; Tseng, C.Y.; Lin, L.Y.; Chiang, P.Y. Characterization of Volatile
Compounds with HS-SPME from Oxidized n-3 PUFA Rich Oils via Rancimat tests. J. Oleo Sci. 2017, 66,
113–122. [CrossRef] [PubMed]
33. Grau, A.; Guardiola, F.; Boatella, J.; Baucells, M.D.; Codony, R. Evaluation of lipid ultraviolet absorption
as a parameter to measure lipid oxidation in dark chicken meat. J. Agric. Food Chem. 2000, 48, 4128–4135.
[CrossRef] [PubMed]
34. Shehata, A.B.; Rizk, M.S.; Farag, A.M.; Tahoun, I.F. Development of two reference materials for all
trans-retinol, retinyl palmitate, α- and γ-tocopherol in milk powder and infant formula. J. Food Drug Anal.
2015, 23, 82–92. [CrossRef]
35. American Oil Chemists’ Society (AOCS). Ofﬁcial Methods and Recommended Practices of the American Oil
Chemists’ Society; Firestone, D., Ed.; AOCS Press: Champaign, IL, USA, 1998.
36. Regulation, H. Commission Regulation (EEC) No. 2568/91 of 11 July 1991 on the characteristics of olive
oil and olive-residue oil and on the relevant methods of analysis Ofﬁcial Journal L 248, 5 September 1991.
Off. J. L 1991, 248, 1–83.
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
75
Bo
ok
s
M
DP
I
marine drugs 
Review
Marine Lipids on Cardiovascular Diseases and
Other Chronic Diseases Induced by Diet: An Insight
Provided by Proteomics and Lipidomics
Lucía Méndez 1,*, Gabriel Dasilva 1, Nùria Taltavull 2, Marta Romeu 2 and Isabel Medina 1
1 Instituto de Investigaciones Marinas (IIM-CSIC), Eduardo Cabello 6, E-36208 Vigo, Spain;
gabrielsilva@iim.csic.es (G.D.); medina@iim.csic.es (I.M.)
2 Unitat de Farmacologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili,
Sant Llorenç 21, E-43201 Reus, Spain; nuria.taltavull@urv.cat (N.T.); marta.romeu@urv.cat (M.R.)
* Correspondence: luciamendez@iim.csic.es; Tel.: +34-986-231930; Fax: +34-986-292762
Received: 16 May 2017; Accepted: 15 August 2017; Published: 18 August 2017
Abstract: Marine lipids, especially ω-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), have largely been linked to prevention of diet-induced
diseases. The anti-inﬂammatory and hypolipidemic properties of EPA and DHA supplementation
have been well-described. However, there is still a signiﬁcant lack of information about their
particular mechanism of action. Furthermore, repeated meta-analyses have not shown conclusive
results in support of their beneﬁcial health effects. Modern “omics” approaches, namely proteomics
and lipidomics, have made it possible to identify some of the mechanisms behind the beneﬁts of
marine lipids in the metabolic syndrome and related diseases, i.e., cardiovascular diseases and type 2
diabetes. Although until now their use has been scarce, these “omics” have brought new insights
in this area of nutrition research. The purpose of the present review is to comprehensively show
the research articles currently available in the literature which have speciﬁcally applied proteomics,
lipidomics or both approaches to investigate the role of marine lipids intake in the prevention or
palliation of these chronic pathologies related to diet. The methodology adopted, the class of marine
lipids examined, the diet-related disease studied, and the main ﬁndings obtained in each investigation
will be reviewed.
Keywords: marine lipids; EPA; DHA; proteomics; lipidomics; metabolic syndrome; cardiovascular
disease; type 2 diabetes
1. Introduction
1.1. Chronic Diseases Induced by Diet: A World Health Problem
The intake of westernized diets, which are rich in reﬁned carbohydrates, cholesterol, saturated
and trans fats, and have an increased ratio of ω-6/ω-3 PUFAs, along with a sedentary lifestyle can
quickly lead to the development of different pathologies and metabolic disorders [1]. These chronic
diseases related to diet, such as cardiovascular diseases (CVD), obesity, overweight, hypertension,
type 2 diabetes, hyperlipidemia, hyperinsulinemia, osteoporosis, osteopenia or cancer, are considered
the epidemic of modern societies. It is estimated that 20–30% of the adult population in these countries
suffers Metabolic Syndrome (MetS) [2]. The MetS is a compilation of risk factors associated with CVD
and type 2 diabetes. These factors include dyslipidemia (decreased high-density lipoprotein (HDL)
cholesterol levels and increased low-density lipoprotein (LDL) cholesterol and triglycerides levels),
hyperglycemia, hypertension, insulin resistance and obesity. Inﬂammation and oxidative stress have
also been closely related to MetS and derived diseases [3].
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According to the Eurostat report of May 2016, the ﬁrst two leading causes of death in Europe
were CVD and cancer, well above respiratory diseases, which were the third most common cause
of death [4]. The average in Europe was 132 deaths/100,000 inhabitants due to CVD in 2013, being
350/100,000 in countries like Hungary or Slovakia, and less than 100/100,000 in Spain, Portugal or
Greece. Data from the World Health Organization (WHO) in 2015 also showed that the leading causes
of death in high-income countries were CVD and cancer, while infectious diseases were the leading
cause of death in low-income countries [5].
Therefore, the study of diet components and their relation to the progression of chronic diseases
and metabolic disorders has arisen as a ﬁeld of great interest for the scientiﬁc community. Accordingly,
the number of publications found in the Scopus database (www.scopus.com) which are focused on this
topic has exponentially grown, especially since 1990. Considering the search criteria: TITLE-ABS-KEY
(nutrition OR diet) AND TITLE-ABS-KEY (“metabolic disorder” OR “metabolic alteration” OR obesity
OR “metabolic syndrome” OR diabetes OR “cardiovascular disease” OR cholesterol OR insulin OR
atherosclerosis OR inﬂammation OR “oxidative stress”), around 272,000 were found. From these, 75%
are research articles and 14% are reviews. The rest of the published work consists of book chapters,
notes, conferences, etc. In relation to the ﬁeld of study, 76% of the publications belong to the ﬁeld
of medicine, 27% to biochemistry, and the rest of them are framed in the ﬁelds of agricultural and
biological sciences, nursing, pharmacology, toxicology and pharmaceutics, neuroscience, chemistry,
immunology and microbiology, etc.
As a consequence of these investigations, huge quantities of bioactive compounds have been
found to exert beneﬁcial effects on human health. Among that, ω-3 PUFAs from marine origin have
quickly gained more attention. Currently, there is considerable evidence that the intake of marine-origin
polyunsaturated fatty acids (PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), can help in the prevention/palliation of inﬂammatory processes and metabolic diseases,
although their mechanisms of action are not entirely understood yet.
1.2. Marine Lipids as Bioactive Compounds against MetS and Chronic Diseases Induced by Diet
Marine lipids, especially EPA and DHA, have largely demonstrated their bioactivity in human
health. The interest in their intake arose from a series of pioneering studies in the Inuit Eskimo
population during the 1960s and 1970s. These studies reported a lower incidence of cardiovascular
pathologies in that population associated with a high intake of ﬁsh in their diet. Later, similar
relationships were discovered in human populations from other regions, particularly in Iceland and
Alaska Natives [6].
In addition to these investigations, marine ω-3 PUFAs have been shown to alleviate metabolic
disorder symptoms, such as heart disease, diabetes, obesity and insulin resistance. Since the late 1950s,
the number of publications found in the Scopus database (TITLE-ABS-KEY (“omega 3” OR “PUFA” OR
“eicosapentaenoic” OR “docosahexaenoic” OR “marine fatty acids” OR “marine lipid” OR “marine oil”
OR “fish oil” OR “fish lipid”) AND TITE-ABS-KEY (nutrition OR diet) AND TITLE-ABS-KEY (“metabolic
disorder” OR “metabolic alteration” OR “metabolic disease” OR obesity OR “metabolic syndrome” OR
diabetes OR “cardiovascular disease” OR cholesterol OR insulin OR atherosclerosis OR inflammation
OR “oxidative stress”)), which have related the consumption of marine fatty acids or lipids to these
metabolic disorders, has increased exponentially, mainly since the late 1970s. On the whole, more than
13,100 publications can currently be found in the Scopus database. Sixty-five percent of these publications
are research articles, 23% are reviews and the rest of them are book chapters, notes, conferences, etc.
These research articles have used a plethora of different approaches (from chemistry or
biochemistry to phycology) and a huge variety of methodologies to address this topic. As a consequence,
the publications are categorized in very diverse fields of study, medicine (74%), biochemistry (30%),
agricultural and biological sciences (20%), nursing (19%) and the rest of the articles are framed in the
ﬁelds of pharmacology, toxicology and pharmaceutics, chemistry, neuroscience, immunology and
microbiology, phycology, social sciences, mathematics, computer science, etc.
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The aim of the present review is to comprehensively show those research articles currently
available in the literature which have speciﬁcally used proteomics, lipidomics or both approaches to
investigate the role of marine lipids intake in the prevention/palliation of chronic pathologies induced
by the consumption of westernized diets, namely MetS, CVD and type 2 diabetes. Our ultimate
objective is to highlight the usefulness of the application of these approaches to nutrition research,
in order to discover the underlying mechanisms of the beneﬁcial effects of marine lipids in human
metabolic health, since its translation to practice via nutritional interventions is still in its infancy.
2. Omics for Unrevealing Mechanisms: Proteomics and Lipidomics
Almost all cellular processes, from gene expression to synthesis, degradation and protein activity,
can be affected by diet and lifestyle. Therefore, nutrients and other food components (including
marine lipids) may alter metabolic functions in cells in a quite complex way. This complex relationship
between nutrition and health makes nutrition research an ideal ﬁeld for the application of systems
biology approaches [7], as being holistic and integrated. Systems biology encompasses a broad
range of functional areas called “omics” These areas include genomics, transcriptomics, proteomics,
metabolomics, lipidomics and bioinformatics [8]. This new outlook started as a result of the human
genome project in the early 2000s [9].
The number of publications found in the literature which incorporates the most novel omics
approaches (proteomics and lipidomics) to the study of the beneﬁcial effects of marine lipids against
MetS and their associated chronic diseases is still scarce. Proteomics and lipidomics studies applied
to nutrition research have to cope with a variety of difﬁculties ranging from experimental design,
sample processing and optimization strategies to data analysis and identiﬁcation. The need for
high-sensitivity modern mass spectrometers combined with bioinformatics resources increases costs
and requires highly qualiﬁed staff. In spite of these difﬁculties, the interest of the scientiﬁc community
in these approaches has been progressively growing, in parallel with analytical advancements in liquid
chromatography, mass spectrometry and bioinformatics.
In the following subsections, we review the research articles currently available in the literature
which have used proteomics (Section 2.1), lipidomics (Section 2.2) or both (Section 2.3) to analyze the
effects of the consumption of marine lipids on the development and progression of human MetS as
well as their associated chronic diseases (CVD and type 2 diabetes).
2.1. Beneﬁcial Effects of Marine Lipids Intake Assayed by Proteomics
Proteins are important mediators of biological activities in all living cellular units. Proteomics is
the large-scale study of proteins and therefore comprises the methodologies used for the study of a
proteome [10]. The “proteome” a term ﬁrstly coined by Wilkins et al. in the early 2000s, is comprised
of all expressed proteins encoded by the genome of a cellular system, including all cellular proteins
and all protein species (isoforms and protein modiﬁcations) [11,12].
The study of how ω-3 PUFAs regulate proteins and metabolic pathways may signiﬁcantly
contribute to understanding the putative mechanisms by which marine lipids elicit their beneﬁcial
health effects. In fact, nutrition research has lately adopted the proteomics tools to measure changes
in the protein complement of a biological system. This adoption has enabled modeling of biological
processes in response to dietary marine lipids, as well as the elucidation of novel biomarkers for health
or disease which are sensitive to such lipids [13]. There are limited studies which have addressed
the inﬂuence of marine lipids on proteome with the aim to investigate their effects against human
metabolic disorders. These studies have mainly used classical two-dimensional gel electrophoresis
(2-DE) combined with mass spectrometry (MS) to elucidate changes in metabolic pathways and target
proteins which may explain a certain beneﬁcial effect on human health. This traditional methodology
has made it possible to identify changes in several metabolic pathways, such as glucose and fatty acid
metabolism, oxidative stress, antioxidant defense mechanisms and redox status. The study of minor
abundant proteins such as those participating in inﬂammatory pathways requires the introduction in
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nutrition research of more quantitative and sensitive methods, like multiple reaction monitoring (MRM)
and multiplexed immunoassays. Both strategies might be useful for the evaluation and validation of
newly discovered candidate biomarkers in human bioﬂuids.
By using Scopus database, 53 publications have been found following the search criteria:
TITLE-ABS-KEY (“omega 3” OR “PUFA” OR “eicosapentaenoic” OR “docosahexaenoic” OR “marine
fatty acids” OR “marine lipid” OR “marine oil” OR “ﬁsh oil” OR “ﬁsh lipid”) AND TITE-ABS-KEY
(nutrition OR diet) AND TITLE-ABS-KEY (“metabolic disorder” OR “metabolic alteration” OR
“metabolic disease” OR obesity OR “metabolic syndrome” OR diabetes OR “cardiovascular disease”
OR cholesterol OR insulin OR atherosclerosis OR inﬂammation OR “oxidative stress”) AND
TITE-ABS-KEY (proteomic OR proteomics OR proteome). These publications, mainly research articles
(56%) and reviews (30%), belong, in descending order of abundance, to the ﬁelds of biochemistry,
genetics and molecular biology (63%) and medicine (58%), and to a lesser extent nursing, agricultural
and biological sciences, pharmacology, toxicology and pharmaceutics, immunology and microbiology,
neuroscience, chemistry, etc.
In this review, only research articles focusing on proteomics are presented. The studies which
have used ω-3 PUFAs from a vegetal origin, i.e., α-linolenic acid (ALA), have been excluded. Only
articles which have assayed the effect of marine lipids on human metabolic disorders related to diet
(i.e., features of MeS, cardiovascular diseases and type 2 diabetes) and those that have used animal or
cellular models to mimic these alterations are presented. Moreover, articles which have combined both
lipidomics and proteomics tools in the same research are shown jointly in Section 2.3.
According to these ﬁlters, 14 research articles have been found. All of them investigated the effect of
EPA or DHA or both on metabolic health. Most of these studies used bottom-up proteomics approaches,
based on 2-DE coupled with MS protein identification. Novel gel-free proteomics techniques based on
MS, such as shotgun proteomics, have scarcely been used yet, as noted in Table 1.
2.1.1. Proteomics in Clinical Trials
Two studies analyzed the effect of the supplementation of a mix of EPA and DHA on the
modulation of the peripheral blood mononuclear cells (PBMCs) proteome after acute intake [14]
or after 12 weeks of dietary intervention [15] in patients with MetS. In the ﬁrst case, proteomics
analysis identiﬁed ﬁve proteins related to cell signaling and interaction, DNA repair, cellular assembly
and organization, and cell morphology which were regulated by acute consumption of marine PUFAs.
In the second study, the prolonged intake of EPA and DHA regulated 17 proteins of PBMCs
proteome involved in immunological diseases and inﬂammatory response, down-regulating proteins
directly related to oxidative stress, inﬂammation, endoplasmic reticulum stress andDNA repair. A third
study, which was carried out with the same dietary intervention and proteomics tools, evaluated the
changes induced in subcutaneous white adipose tissue (WAT) proteome after 12 weeks of EPA and
DHA intake [16]. Three proteins of glucose metabolism were found down-regulated by marine PUFAs
supplementation. These proteins were correlated with lower systemic insulin resistance and improved
insulin signaling in subcutaneous WAT of the MetS patients.
Also in humans, De Roos et al. [17] studied mechanisms involved in preventing the early onset
of coronary heart disease (CHD) through ﬁsh oil intake. Authors identiﬁed ten serum proteins that
were down-regulated in healthy volunteers after the consumption of a daily dose of 3.5 g of ﬁsh
oil for 6 weeks. These altered serum proteins, metabolically related to lipoprotein metabolism and
inﬂammation, led to a signiﬁcant shift towards the larger, more cholesterol-rich HDL2 particle which
might imply that ﬁsh oil activated anti-inﬂammatory and lipid modulating mechanisms believed to
impede the early onset of CHD. This speciﬁc effect of ﬁsh oil on HDL metabolism has later been
investigated by Burillo et al. [18]. They compared the proteome of HDL before and after ω-3
PUFAs intake for 5 weeks. Healthy smoker volunteers ingested a commercial mixture of marine
and non-marine ω-3 fatty acids. The consumption of marine ω-3 PUFAs up-regulated seven proteins
related to the antioxidant, anti-inﬂammatory and anti-atherosclerotic properties of HDL. Likewise,
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marine lipids down-regulated six proteins involved in the regulation of complement activation and
acute phase response. Moreover, the modiﬁcation of lipoprotein containing apoAI (LpAI) proteome
suggested that the protein changes found might have improved the functionality of the particle.
2.1.2. Proteomics in Animal Models and Cell Cultures
Besides clinical trials, several studies have used animal or cell models to investigate the role of
marine ω-3 PUFAs in regulating cellular proteomes which are rather difﬁcult to analyze in humans,
such as the liver proteome. In a study carried out in C57BL/6 mice, Ahmed et al. [19] investigated the
regulation of the liver proteome by a dietary intervention with 10% ω-3 PUFAs from menhaden oil
for 4 months. Proteomics data showed that ﬁsh oil up-regulated eight proteins related to lipid,
carbohydrate, protein and one-carbon metabolism and the citric acid cycle, which involved an
integrated regulation of metabolic pathways by ﬁsh oil. This proteome modulation was correlated
with a signiﬁcant reduction of plasma triglycerides and free fatty acid (FFA) levels.
Likewise, other studies investigated the effect of ﬁsh oil when it was added to high fat, cholesterol
and sucrose diets. The ﬁrst study [20] evaluated changes in the liver mitochondrial subproteome,
an organelle which plays a critical role in cell metabolism and the development of metabolic alterations,
induced in rats by the supplementation with 10% ﬁsh oil of a high fat diet for 50 weeks as compared to
rats fed low fat diet. As a result, Wrzesinski et al. identiﬁed 54 mitochondrial proteins regulated by
ﬁsh oil. These proteins were involved in fatty acid oxidation and amino acid metabolism as well as in
the increase of oxidative phosphorylation.
In a second research, De Roos et al. [21] studied the modulation of the liver proteome by ﬁsh oil
supplementation of a diet high in saturated fat and cholesterol (HFC) for 3 weeks in APOE*3 Leiden
transgenic mice, a model for lipid metabolism and atherosclerosis. These authors identiﬁed up to
44 proteins altered by ﬁsh oil as compared to HFC, which were mainly involved in glucose and lipid
metabolism, as well as oxidation and aging processes. These changes were correlated with lower
plasma and liver cholesterol and triglycerides levels as well as minor plasma FFA and glucose but
higher plasma insulin levels, revealing new insights into mechanisms by which these ﬁsh oils can
regulate lipid metabolism and related pathways.
A third research [22] reported the physiological modulation of rat liver proteome induced by
24-week supplementation with ﬁsh oil considering two different background diets: standard or high
in fat and sucrose (HFHS). Méndez et al. demonstrated a different capacity of ﬁsh oil for regulating
liver proteins depending on the background diet (6 proteins into standard diet and 31 into HFHS diet).
Proteome changes induced by ﬁsh oil, especially under HFHS diet, consisted of decreasing the level of
enzymes from lipogenesis and glycolysis, enhancing fatty acid beta-oxidation and insulin signaling
and ameliorating endoplasmic reticulum stress. Moreover, the consumption of ﬁsh oil decreased
protein oxidation and improved several biochemical parameters.
Other authors have used cell culture experiments to evaluate EPA and DHA effects on the
proteome. Kalupahana et al. [23] investigated the effects of EPA on proteins from 3T3-L1 adipocytes
treated with either EPA or arachidonic acid (ARA). EPA-treated cells presented higher levels of
19 proteins involved in carbohydrate and fatty acid metabolism and several other proteins related to
cellular metabolism including response to stress. Likewise, EPA treatment resulted in lower levels
of eight proteins belong to lipogenesis and other cellular metabolic processes such as cytoskeleton
organization and biogenesis.
Proteomics has also been employed to evaluate the differential effect of the main marine ω-3
PUFAs. Mavrommantis et al. [24] analyzed the potentially different effects on the liver proteome
regulation exerted by the dietary supplementation either with ﬁsh oil (EPA and DHA) or DHA alone
in apoE knockout mice (model of atherosclerosis) fed HFC diet for 2 weeks. Both DHA and ﬁsh
oil regulated 35 liver proteins, mainly involved in the metabolism of lipoproteins and oxidative
stress. However, their effects on the proteome were not the same, since four of these proteins were
differentially modulated by DHA or ﬁsh oil. As a consequence, although both ﬁsh oil and DHA
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could beneﬁcially affect lipoprotein metabolism and oxidative stress, intervention with ﬁsh oil but
not with DHA resulted in signiﬁcantly lower levels of hepatic soluble epoxide hydrolase, an enzyme
closely related to cardiovascular disease, as compared to control oil. This different behavior between
EPA and DHA was also highlighted by Johnson et al. [25]. These authors evaluated the potentially
independent protective/reversal effect of dietary EPA or DHA against mitochondrial dysfunction in
aging skeletal muscle, after diet supplementation of young or older C57BL/6 mice. Authors found that
10-weeks of dietary supplementation with EPA but not with DHA partially attenuated the age-related
decay in mitochondrial function. Thirty-nine mitochondrial proteins changed between old control
and old EPA-treated mice. Thirty-two mitochondrial proteins changed between old control and old
DHA-treated mice. However, only three proteins for EPA supplementation and seven for DHA were
coincident with those proteins which were found to differ in young and old control mice. Authors
concluded that neither EPA nor DHA attenuated the age-related drop in mitochondrial protein content,
although these changes demonstrated that both EPA and DHA exerted some common biological effects
(anticoagulation, anti-inﬂammatory, reduced FXR/RXR activation). Additionally, proteomics data
showed that EPA improved muscle protein quality, speciﬁcally by decreasing mitochondrial protein
carbamylation, a post-translational protein modiﬁcation (PTM) that is driven by inﬂammation.
2.1.3. Proteomics for Studying Post-Translational Protein Modiﬁcations (PTMs)
Abundant evidence has shown that ω-3 PUFAs inﬂuence redox homeostasis [26] and several
researchers have described both antioxidant and pro-oxidant properties for these fatty acids.
Since diet-induced metabolic diseases are often associated with increased oxidative stress, the
characterization of oxidative PTMs seems to be critical for understanding the mechanisms underlying
the action of marine ω-3 PUFAs in theses pathologies. However, studies focused on the effects
of EPA and DHA in modulating protein quality, besides protein quantity, are scarce likely due to
methodological limitations.
Among the oxidative PTMs, protein carbonyl moieties formed in proteins (protein carbonylation),
which are the more common oxidative PTMs, are considered as a major hallmark of oxidative protein
damage. Metabolic alterations have strongly been correlated with high levels of protein carbonylation.
However, only a very few studies have used proteomics tools to identify protein carbonylation targets
in metabolic diseases and evaluate the potential effects that marine lipids exerted on them. A study
addressed the effect of various dietary EPA and DHA ratios (1:1, 2:1, and 1:2, respectively) on protein
carbonylation from plasma, kidney, skeletal muscle, and liver [27] in rats after 13 weeks of dietary
intervention. Rats fed soybean (rich inω-6 linoleic acid (LA)) or linseed oil (rich inω-3 ALA) were used
as controls. Authors identiﬁed targets of protein carbonylation in all the analyzed tissues. The three ﬁsh
oil ratios, especially the 1:1 EPA:DHA, exerted a selective-protective effect against carbonylation of six
proteins from plasma and liver, which was correlated with the improvement of biochemical features.
Jourmard-Cubizolles et al. [28] studied a speciﬁc oxidative PTM, namely 4-hydroxynonenal
(4-HNE) protein adducts derived from PUFA peroxidation. These authors investigated the
modulation of the aortic proteome in atherosclerotic prone (LDLR−/−) mice fed an atherogenic diet
supplemented with DHA for 20 weeks. Nineteen proteins were differentially regulated in the aorta of
DHA-supplemented group. Most of them were related to glucose or lipid metabolism, including the
up-regulation of superoxide dismutase by DHA which suggested an impact on vascular antioxidant
defenses. This up-regulation was in agreement with data from the quantiﬁcation of proteins with
4-HNE adducts. None of the twelve different identiﬁed proteins with 4-HNE adducts enhanced their
oxidation in response to DHA supplementation. The articles cited in this section of the review are
summarized in Table 1.
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2.2. Beneﬁcial Effects of Marine Lipids Intake Assayed by Lipidomics
In the era of genomics, transcriptomics and proteomics, metabolomics is becoming a critical
component of the omics revolution and systems biology [9]. Among the four types of biological
molecules that compose the human body, i.e., nucleic acids, amino acids, carbohydrates and lipids, the
study of lipid homeostasis has been attracting increasing interest, especially during the last decade.
As a subﬁeld of metabolomics, lipidomics addresses the large-scale study of lipids, including the
detailed characterization of lipid metabolites, their interactions and inﬂuence on biological systems.
Lipidomics comprises the methodologies used for the study of a lipidome, which can be deﬁned as the
comprehensive and quantitative description of a set of lipid species present in an organism [29].
In spite of a lack of a commonly accepted deﬁnition, lipids are hydrophobic or amphipathic
compounds of relatively small molecular weight. They include a vast plethora of different structures
which play a critical role in cell physiology. Based on their chemical structure, lipids are divided
into eight main classes: (a) fatty acyls, such as polyunsaturated fatty acids (PUFAs); (b) glycerolipids
(GLs), such as triglycerides (TGs); (c) glycerophospholipids (GPs), also referred to as phospholipids
(PLs), such as phosphatidylcholine; (d) sphingolipids (SPs), such as ceramides; (e) sterol lipids (STs)
such as cholesterol; (f) prenol lipids (PRs); (g) saccharolipids (SLs); (h) polyketides (PKs). Some of the
biological functions of these lipids are energy storage and structural components of cellular membranes,
cell signaling, endocrine actions and essential role in signal transduction, membrane trafﬁcking and
morphogenesis [30].
Lipids are potent signaling molecules which can act as biosynthetic precursors of lipid mediators.
In this review, the lipid mediators derived from ω-6 and ω-3 PUFAs, such as ARA, EPA, and DHA,
are particularly noteworthy. These lipid mediators, which are generally known as eicosanoids
(derivatives from the oxidation of C20 PUFAs, i.e., ARA, EPA, and dihomo-γ-linolenic acid (DGLA))
and docosanoids (derivatives from the oxidation of C22 PUFAs, i.e., DHA and docosapentaenoic acid
(DPA)), are bioactive compounds related to inﬂammatory processes [31]. While most of them are
formed by the action of lipoxygenases (LOX), cyclooxygenases (COX), cytochrome P450 (CyP450),
and several subsequent enzymes on PUFAs, several compounds, for instance, isoprostanes, are the
consequence of non-enzymatic process [32]. The main lipid mediators originated from ARA, EPA, and
DHA are shown in Table 2.
The enormous complexity of lipidomes implies that lipidomics must consider the characterization
of thousands of pathways and networks which involve cellular lipids species and their interactions
with other molecules. Lipidomics is a valuable tool to investigate the inﬂuence of marine lipids on
health. However, its use is still limited due to its novelty but also to several difﬁculties associated with
data interpretation, among other limitations [33]. In consequence, only a few studies have addressed
the effect of marine lipids on the lipidome in the context of human metabolic disorders. Some of them
used lipidomics to characterize total lipid classes, mainly by using gas chromatography (GC)-MS or
LC-MS, and others were focused on lipid mediators, mainly by using solid phase extraction (SPE)
coupled to identiﬁcation and quantiﬁcation by LC-MS/MS.
By using Scopus database, 53 publications were found following these search criteria:
TITLE-ABS-KEY (“omega 3” OR “PUFA” OR “eicosapentaenoic” OR “docosahexaenoic” OR “marine
fatty acids” OR “marine lipid” OR “marine oil” OR “ﬁsh oil” OR “ﬁsh lipid” ) AND TITLE-ABS-KEY
(nutrition OR diet) AND TITLE-ABS-KEY (“metabolic disorder” OR “metabolic alteration” OR
“metabolic disease” OR obesity OR “metabolic syndrome” OR diabetes OR “cardiovascular disease”
OR cholesterol OR insulin OR atherosclerosis OR inﬂammation OR “oxidative stress”) AND
TITLE-ABS-KEY (lipidomic OR lipidomics OR lipidome). These publications, mainly research articles
(69%) and reviews (19%), belong, in descending order of abundance, to the ﬁelds of medicine (65%)
and biochemistry, genetics and molecular biology (61%), and to a lesser extent nursing, agricultural
and biological sciences, pharmacology, toxicology and pharmaceutics, chemistry, immunology and
microbiology, neuroscience, etc.
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In this section, the same inclusion criteria exposed above (Section 2.1) for proteomics articles is
followed (i.e., only research articles focusing on lipidomics, which have assayed the effect of marine
lipids on features of MetS, cardiovascular diseases and type 2 diabetes, excluding the studies which
have used ω-3 PUFAs from vegetal origin, i.e., ALA). Likewise, works which have combined both
proteomics and lipidomics approaches will be presented in Section 2.3.
According to these ﬁlters, 35 research articles have been found and are summarized below.
2.2.1. Lipidomics in Clinical Trials
Several researches have used lipidomics tools in human clinical trials to gain insights of physiological
mechanisms behind the evidence of the multiple beneﬁcial health effects of ﬁsh consumption.
Some of them have investigated the modulation of plasma/serum lipidome by ﬁsh oil in
healthy subjects. Ottestad et al. [34] studied the plasma lipidomic proﬁle in healthy subjects which
received either 8 g/day of ﬁsh oil from cod liver or high oleic sunﬂower oil for 7 weeks. Authors
identiﬁed and quantiﬁed 260 different lipids in plasma, being 23 lipids signiﬁcantly decreased and
51 signiﬁcantly increased by ﬁsh oils. Data analysis demonstrated that ﬁsh oil supplementation altered
lipid metabolism and increased the plasma proportion of PLs and TGs containing long-chain PUFAs.
Therefore, the beneﬁcial effects of ﬁsh oil supplementation could be explained in part by a remodeling
of the plasma lipids. Rudkowska et al. [35] combined transcriptomics and metabolomics technologies
to investigate molecular and metabolic changes in healthy subjects underwent 6-week supplementation
with EPA and DHA. Authors measured 107 lipids in plasma, which were further subdivided into three
different classes: 15 sphingomyelins (SMs) and SM derivatives, 15 lysophosphatidylcholines (lysoPCs)
and 77 glycerophosphatidylcholines (glyPCs). Results showed some gender differences in lipidomic
proﬁles between pre- and post- ω-3 supplementation, although the main differences were found as a
result of ﬁsh oil supplementation. These differences were principally due to changes in glyPCs, and
overall, results demonstrated that there was an increase in unsaturated fatty acids after the ω-3 PUFAs
supplementation period. These and others data given by authors supported the cardioprotective
effects of the ω-3 PUFAs supplementation, although some of their mechanisms can be dependent on
gender. The high variability in lipid proﬁles and lipidome responses to PUFAs supplementation was
addressed in a third study performed by Nording et al. in healthy subjects. These authors used a
multi-platform lipidomics approach to investigate both the consistent and inconsistent responses to
a deﬁned ω-3 intervention for 6 weeks [36]. Thus, Nording et al. evaluated the changes induced by
ω-3 intervention in total lipidomic plasma proﬁle (including fatty acids, lipid classes and lipoprotein
distribution) but also the effects of ω-3 on lipid mediators. Authors measured 7 lipid classes, and
a total of 87 lipid mediators. Results showed signiﬁcant changes in both total lipidomic and lipid
mediator proﬁles after ω-3 supplementation, as well as a strong correlation between lipid mediator
proﬁles and EPA and DHA incorporated into different lipid classes. However, authors found that
both ω-3 and ω-6 fatty acid metabolites displayed a large degree of variation among the subjects;
for instance, only the 50% of the subjects presented signiﬁcantly decreased levels of PGE2, TXB2
and 12-HETE whereas the other 50% did not show any change or even increased levels. Speciﬁcally,
12-HEPE showed high heterogeneity, decreasing up to 82% in some subjects and increasing up to 5%
in others. This work pointed out the highly variable response to ω-3 fatty acids supplementation
and the need for an in-depth lipidomic phenotype characterization in order to properly assess their
effectiveness against diseases.
Since lipidomic characterization requires an accurate determination of the huge range of lipidmediators
and fatty acid derivatives, some authors have tried to shed light on this matter. Mas et al. [37] published
the development of a SPE-LC-MS/MS assay to measure resolvins and protectins families generated
from the ω-3 EPA and DHA in human blood after ﬁsh oil supplementation (4 g ﬁsh oil containing
35% EPA and 25% DHA/day for 3 weeks). It was the ﬁrst time that 17R/SHDHA RvD1 and RvD2
were detected in plasma/serum after oral ω-3 fatty acid supplementation. Authors found that those
RvD1 and RvD2 were within the biological range of anti-inﬂammatory and pro-resolving activities
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detected in isolated human leukocytes and in vivo studies in mice. This methodology was further
employed to examine the effect of short-term (5 days) ω-3 fatty acid supplementation. As compared to
baseline, ω-3 intake signiﬁcantly increased plasma levels of RvE1, 18R/S-HEPE, 17R/S-HDHA, and
14R/S-HDHA up to concentrations biologically active in healthy humans. Therefore, ω-3 PUFAs were
able to exhibit their anti-inﬂammatory action even after short interventions [38].
Furthermore, Keelan et al. [39] determined if the supplementation with EPA and DHA during
pregnancy could modify placental PUFAs composition and the accumulation of lipid mediators.
In this case, only resolvins (RvD1, 17R-RvD1 and RvD2) and protectins from the D-series (PD1 and
10S, 17SdiHDHA) and upstream precursors (18-HEPE and 17-HDHA) were measured. Authors
found that the ω-3 PUFAs supplementation increased placental DHA levels, as well as the levels
of precursors 18-HEPE and 17-HDHA, but the concentration of EPA was not signiﬁcantly increased
neither concentrations of RvD1, 17R-RvD1, RvD2 and PD1. Placental pro-resolving lipid mediator
levels seemed to be modulated by maternal dietary PUFAs, although their biological signiﬁcance in
the placenta remains unknown.
Besides healthy subjects, other authors have used lipidomics tools to evaluate changes in
lipid homeostasis induced by ω-3 in patients suffering metabolic disorders. The modulation of
lipid mediators by EPA and DHA was analyzed in plasma of humans with MetS [40]. Dietary
intervention consisted in a daily supplementation with EPA and DHA in the form of TGs for
3 weeks. Plasma lipid mediators (i.e., 18-HEPE, E-series resolvins, 17-HDHA, D-series resolvins,
14-HDHA, and maresin-1) from MetS volunteers and their healthy controls (at baseline and after
dietary intervention) were measured. Results showed that ω-3 PUFAs supplementation increased
E-series resolvins to a similar extent in MetS subjects and controls. However, only the healthy controls
presented increased concentrations of E- and D-series resolvin precursors and 14-HDHA in response
to ω-3 PUFAs supplementation. The action of EPA and DHA supplementation was also investigated
in hyperlipidemic men (cholesterol >200 mg/dL; triglyceride >150 mg/mL) after 12-weeks daily
intake [41]. Schuchardt et al. measured serum levels of 44 free hydroxy, epoxy and dihydroxy
fatty acids and found that after supplementation, all subjects (including healthy controls) showed
considerably elevated levels of EPA-derived lipid mediators and a less pronounced increment of
DHA-derived ones. However, the supplementation with higher amounts of DHA than EPA (DHA:EPA
5:1) for 3 months induced a signiﬁcant increase of pro-resolving DHA derivatives in plasma of obese
women [42]. All these different results in the level of EPA and DHA derivatives seemed to be correlated
with the EPA and DHA supplement content.
In another study, Lankinen et al. [43] investigated how fatty ﬁsh or lean ﬁsh in a diet affect
serum lipidomic proﬁles in subjects with coronary heart disease after their consumption for 8 weeks.
Lipidomic changes among groups were detected in at less 59 bioactive lipid plasma species, including
ceramides, lysoPCs and diacylglycerols (DGs), which were found signiﬁcantly diminished in the fatty
ﬁsh group, whereas in the lean ﬁsh group cholesterol esters and speciﬁc long-chain TGs increased
signiﬁcantly. Therefore, fatty ﬁsh intake reduced lipid species which are potential mediators of
lipid-induced insulin resistance and inﬂammation, and these results might be associated with the
protective effects of fatty ﬁsh on the progression of atherosclerotic vascular diseases or insulin
resistance. However, Midtbø et al. [44] demonstrated in mice fed western diets that the consumption
of farmed salmon, which had previously fed ﬁsh feed with a reduced ratio of ω-3/ω-6 PUFAs, led
to a selectively increased abundance of ARA in the liver PLs pool of the mice. This increment was
accompanied by higher levels of hepatic ceramides and ARA-derived pro-inﬂammatory mediators
and a reduced abundance of lipid mediators derived from EPA and DHA. Therefore, the studies
made after ﬁsh consumption rather than ﬁsh oil have to consider the PUFA composition of ﬁsh to get
proper conclusions.
Two articles have used enriched ω-3 PUFAs dairy products to test their effects on lipidome.
In the ﬁrst one, mildly hypertriacylglycerolemic subjects consumed yogurt supplemented with 3 g
of EPA and DHA per day for 10 weeks [45]. Results showed that a daily intake of supplemented
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yogurt signiﬁcantly increased plasma EPA-derived mediators (PGE3, 12-, 15-, 18-HEPE), as well as
EPA and DHA levels in plasma and red blood cells, and improved some cardiovascular risk factors.
In the second one, overweight and moderately hypercholesterolemic subjects consumed 250 mL of
enriched milk with EPA and DHA for 28 days [46]. In this case, the changes induced on LDL-lipidome
composition were primarily addressed. Enriched milk signiﬁcantly reduced TGs and very low-density
lipoprotein (VLDL) cholesterol and caused signiﬁcant changes in the LDL lipid metabolite pattern,
increasing the long-chain polyunsaturated cholesteryl esters and the ratio PC36:5/lysoPC16:0. All these
modiﬁcations were associated with its reduced inﬂammatory activity.
2.2.2. Lipidomics in Animal Models
In animal models, several authors have investigated the inﬂuence of dietary EPA and DHA on
lipid homeostasis in the context of metabolic alterations through lipidomics approaches. Some of
them have used healthy models to look into the potentially different effects of EPA and DHA to ﬁnd
their optimal proportions in the diet. Dasilva et al. [47] tested whether the intake of three proportions
of EPA/DHA (1:1, 2:1 or 1:2) for 22 weeks provoked a different modulation of the formation of
lipid mediators. Then, authors examined their inﬂuence on various indexes of inﬂammation and
oxidative stress in Wistar Kyoto rats. A total of nine compounds derived from PUFA oxidative
metabolism (namely ﬁve EPA eicosanoids -12HEPE, 15HEPE, 12HpHEPE, 15HpHEPE, TXB3-, two
DHA docosanoids -17HDoHE, 17HpDoHE-, and two ARA eicosanoids -11HETE, PGE2) were identiﬁed
and quantiﬁed in plasma. Results evidenced that the ratios 1:1 and 2:1 EPA:DHA exerted a remarkable
healthy effect generating a less oxidative environment and modulating LOX and COX activities
towards a decrease in the production of pro-inﬂammatory ARA eicosanoids and oxidative stress
biomarkers from EPA and DHA. On the other hand, the higher DHA amount in the diet (i.e., 1:2 ratio)
reduced the health beneﬁts described in terms of inﬂammation and oxidative stress. The beneﬁcial
effect of the ratios with higher EPA amount was further evaluated in a rat model of MetS (SHROB
rats), in which the 1:1 and 2:1 ratios exerted the highest health beneﬁts. In this other work, EPA
and DHA supplementation also decreased the level of pro-inﬂammatory ARA eicosanoids produced,
in agreement with the results found in the healthy model [48]. Other authors [49] reported that
the beneﬁt of ω-3 PUFA-rich diets could be attributed to the generation of electrophilic oxygenated
metabolites that transduce anti-inﬂammatory actions rather than the suppression of pro-inﬂammatory
ARA metabolites. This work was focused on the endogenous production of ω-3 PUFAs electrophilic
ketone derivatives and their hydroxy precursors in human neutrophils. Authors evaluated in vitro
endogenous generation of these lipid mediators from DHA and DPA in neutrophils isolated from
healthy subjects, both at baseline and upon stimulation with calcium ionophore. Additionally, their
potential modulation by diet was assessed through a randomized clinical trial carried out with
healthy adults receiving daily oil capsule supplements, which contained either 1.4 g of EPA and
DHA or soybean oil, for 4 months. Results reported the 5-LOX-dependent endogenous generation of
7-oxo-DHA, 7-oxo-DPA and 5-oxo-EPA and their hydroxy precursors stimulated in human neutrophils,
whereas the dietary supplementation with EPA and DHA increased the formation of 7-oxo-DHA and
5-oxo-EPA, without signiﬁcant modulation of ARA metabolite levels.
In C57BL/6 mice fed a diet containing 10% ω-3 PUFAs from menhaden oil for 4 months,
Balogun et al. [50] analyzed the effect of ﬁsh oil on the fatty acid composition of various bioactive lipids
in plasma and liver by using lipidomics. Results demonstrated a signiﬁcantly higher concentration of
EPA containing phosphatidylcholine (PCs), lysophosphatidylcholine (LPCs), and cholesteryl esters
(CEs) after ﬁsh oil intake in plasma and liver, as well as a higher concentration of free ω-3 PUFAs.
In healthy rats, lipidomics was also used to determine if LOX-generated lipid mediators were
presented in bone marrow and if so, their modulation by dietary EPA and DHA supplementation [51].
Data analysis revealed the presence of LOX-pathway lipid mediators derived from ARA, EPA and
DHA, including lipoxins, resolving D1, resolvin E1, and protectin D1 in bone marrow. Moreover, the
daily supplementation with DHA or with EPA ethyl ester for 4 months increased the percentage of
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DHA and EPA in bone marrow, and the proportion of LOX mediators biosynthesized from DHA or
EPA, respectively. Given the potent bioactivities of the lipoxins, resolvins and protectins, their presence
and changes in their proﬁle found after EPA and DHA ethyl ester supplementation may be of interest
in bone marrow function and as a potential source of these mediators in vivo.
Several articles have used lipidomics to assay the protective effects of EPA and DHA against
metabolic alterations induced by unhealthy diets. In rats, Taltavull et al. [52] investigated how
supplementation of a high fat and sucrose diet with both EPA and DHA modified the hepatic ceramide
profile triggered by the unhealthy diet in a dietary intervention of 24 weeks. Authors found that ω-3
PUFAs reduced total liver ceramide content and altered ceramide profiles in pre-diabetic rats. They also
observed a significant positive linear correlation between long chain ceramide 18:1/18:0 and the HOMA
index, and negative between very long chain ceramides 18:1/24:0 and 18:1/20:0 and plasma insulin
levels and the HOMA index. Overall, these data may help explain the protective action of ω-3 PUFAs
against liver insulin resistance induced by diet. Caesar et al. [53] used lipidomics tools to evaluate the
regulation of lipid composition in mice liver and serum by dietary ﬁsh oil as compared to lard oil, but
considering their interaction with gut microbiota. After 11 weeks, menhaden ﬁsh oil supplementation
induced signiﬁcant changes in abundance of most lipid classes. The gut microbiota affected lipid
composition by increasing hepatic levels of cholesterol and cholesteryl esters in mice fed high-fat lard
diet but not in mice fed high-fat ﬁsh oil diet. These results highlighted that the regulation of hepatic
cholesterol metabolism induced by gut microbiota was dependent on dietary lipid composition.
Animal models of obesity have also been used to investigate the modulation of lipid metabolism
in the adipose tissue. Kuda et al. [54] identified cells producing lipid mediators in epididymal
WAT of mice fed for 5 weeks obesogenic high-fat diet, which was supplemented or not with EPA
and DHA. Results demonstrated selectively increased levels of anti-inflammatory lipid mediators in
WAT in response to ω-3, reflecting either their association with adipocytes (endocannabinoid-related
Ndocosahexaenoylethanolamine) or with stromal vascular cells (pro-resolving lipid mediator protectin
D1). In parallel, tissue levels of obesity-associated pro-inflammatory endocannabinoidswere suppressed.
Moreover, they found that adipose tissue macrophages (ATMs) were not the main producers of
protectin D1 and that ω-3 PUFAs lowered lipid load in ATMs while promoting their less-inflammatory
phenotype. Besides these specific roles of various cell types in WAT, the kind of fat depots seemed
to be also critical. In the abdominal (epididymal) fat but not in other fat depots, Flachs et al. [55]
found a synergistic induction of the mitochondrial oxidative capacity and lipid catabolism after
combining ω-3 PUFAs intake and caloric restriction in high-fat fed mice. This combination resulted in
an increased oxidation of metabolic fuels in the absence of mitochondrial uncoupling, while low-grade
inﬂammation was suppressed, reﬂecting changes in tissue levels of anti-inﬂammatory lipid mediators,
namely 15-deoxy-Δ(12,15)-prostaglandin J2 and protectin D1.
Lipidomics analysis [56] also revealed that ω-3 PUFAs supplementation could alleviate hepatic
steatosis in ob/ob mice, an obesity model of insulin resistance and fatty liver disease. ω-3 PUFAs
inhibited the formation of ω-6 PUFAs derived eicosanoids while triggering the formation of ω-3
PUFAs derived resolvins and protectins. Moreover, representative members of these lipid mediators,
namely resolvin E1 and protectin D1, mimicked the insulin sensitizing and anti-steatotic effects of ω-3
PUFAs and induced adiponectin expression to a similar extent that the antidiabetic drug rosiglitazone.
These ﬁndings uncovered beneﬁcial actions of ω-3 PUFAs and their bioactive lipid derivatives in
preventing obesity-induced insulin resistance and hepatic steatosis. Similar conclusions were obtained
by Kalish et al. [57] who demonstrated in a mouse model of steatosis that parental nutrition with ﬁsh
oil-based lipid emulsions was associated with the production of anti-inﬂammatory and pro-resolving
lipid mediators. The preventive effect of EPA and DHA against necroinﬂammatory injury in liver was
also investigated in mice fed high saturated fat diets containing either DHA or both EPA and DHA
for 5 weeks [58]. Both marine ω-3-rich diets induced an increased hepatic formation of DHA-derived
lipid mediators (i.e., 17S-hydroxy-DHA (17S-HDHA) and protectin D1), which was correlated with
signiﬁcant protection of liver injury. This work reported a potential role for DHA-derived products,
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speciﬁcally 17SHDHA and protectin D1, in mediating the protective effects of dietary DHA against
necroinﬂammatory liver injury.
The potential role of ﬁsh oil to prevent glomerulosclerosis in a rat model of MetS (JCR:LA-cp rats)
via renal eicosanoidmetabolism and lipidomics analysis was addressed byAukema et al. [59]. MetS rats
were supplemented with 5% or 10% ﬁsh oil for 16 weeks. Dietary ﬁsh oil reduced glomerulosclerosis
and albuminuria and the 11- and 12-HETE levels, as well as other (5-, 9- and 15-) HETE. Also, ﬁsh oil
reduced endogenous renal levels of 6-keto PGF1α (PGI2 metabolite), thromboxane B2 (TXB2), PGF2α,
and PGD2 by approximately 60% in rats fed 10% ﬁsh oil as compared to untreated MetS rats. Whereas
in rats fed 5% ﬁsh oil, TXB2 decreased in 250% and PGF2a in 241%. These results suggested that dietary
ﬁsh oil might improve dysfunctional renal eicosanoid metabolism associated with kidney damage
during conditions of the MetS.
The impact of DHA supplementation on the proﬁles of PUFA oxygenated metabolites and their
contribution to atherosclerosis prevention were investigated by Gladine et al. [60]. The study was
conducted with atherosclerosis prone mice which received increasing doses of DHA (0%, 0.1%, 1%
or 2% of energy) during 20 weeks. Targeted lipidomics analysis determined a signiﬁcant modulation
of EPA and DHA and their respective oxygenated metabolites in plasma and liver. Remarkably,
hepatic F4-neuroprostanes were strongly correlated with the hepatic DHA level. The hepatic
level of F4-neuroprostanes was the variable most negatively correlated with the plaque extent and
plasma EPA-derived diols. Thus, oxygenated ω-3 PUFAs derivatives, particularly F4-neuroprostanes,
were revealed as potential biomarkers of DHA-associated_atherosclerosis prevention which might
contribute to the anti-atherogenic effects of DHA.
It is well known that oils from marine organisms have a different fatty acid composition and
differ in their molecular composition. Fish oil has a high content of EPA and DHA mostly esteriﬁed to
TGs, while in krill oil these fatty acids are mainly esteriﬁed to PLs. Considering that, Skorve et al. [61]
studied the effects of these oils on the lipid content and fatty acid distribution in the various lipid
classes in liver and brain of mice. After 6 weeks of feeding a high-fat diet supplemented with ﬁsh oil
or with krill oil, shotgun lipidomics showed that in both ﬁsh and krill oil fed mice, the TGs content in
the liver was more than doubled compared to control mice. The fatty acid distribution was affected by
the oils in both liver and brain with a decrease in the abundance of LA and ARA, and an increase in
EPA and DHA in both study groups. LA decreased in all lipid classes in the ﬁsh oil group but with
only minor changes in the krill oil one. Differences were especially evident in some of the minor lipid
classes associated with inﬂammation and insulin resistance. Ceramides and DGs were decreased, and
cholesteryl esters increased in the liver of the krill oil group, while plasmalogens were diminished in
the ﬁsh oil group. In the brain, DGs were decreased, more by krill than ﬁsh oil, while ceramides and
lactosylceramides were increased, more by ﬁsh than krill oil. Changes in hepatic sphingolipids and
ARA fatty acid levels were higher in the krill oil group than in the ﬁsh oil one. These changes were
consistent with a hypothesis that krill oil may have a stronger anti-inﬂammatory action and enhance
insulin sensitivity more potently than ﬁsh oil.
2.2.3. Lipidomics in Cell Cultures
Finally, some authors have applied lipidomics approaches in cell cultures and in vitro assays to
deeply analyze the metabolic effect of dietary marine ω-3 PUFAs. Polus et al. demonstrated that the
addition of EPA during differentiation of human subcutaneous adipose tissue stromal vascular fraction
cells induced the formation of small lipid droplets and reduced the production of pro-inﬂammatory
mediators in adipose tissue in comparison to ARA addition. These changes were the consequence of
the production of anti-inﬂammatory eicosanoids derived from EPA [62].
The preventive effect of DHA at physiological doses against insulin resistance was investigated in
C2C12 myotubes exposed to palmitate. DHA decreased protein kinase C activation, restored cellular
acylcarnitine proﬁle, insulin-dependent AKT phosphorylation and glucose uptake. Results showed that
DHA participated in the regulation of muscle lipid and glucose metabolism by preventing lipotoxicity,
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inﬂammation and insulin resistance in skeletal muscle [63]. Likewise, in in vitro experiments,
Ting et al. [64] investigated structural changes in cardiolipins after DHA or EPA supplementation
and compared them to ARA treatment, using H9c2 cardiac myoblast as a cell model. Among the
116 cardiolipin species with 36 distinct mass identiﬁed, the three PUFAs treatments differentially
perturbed the fatty acyl chain compositions in the mitochondrial of the H9c2 cardiac myoblast,
suggesting that bothmitochondrial membrane composition and functionwere susceptible to exogenous
lipids. Additionally, DHA supplementation correlated with an elevation of less unsaturated and ω-3
cardiolipin species, which appeared to be a minor effect on EPA but not on ARA.
2.2.4. Marine Lipids and Other Bioactive Compounds Assayed by Lipidomics
Several articles have also used lipidomics to study the combined action of ω-3 PUFAs
with other bioactive compounds which have shown potential beneﬁts in subjects susceptible to
cardiovascular diseases.
The protective effects of fatty ﬁsh consumption on the progression of insulin resistance were
tested in combination with other products with recognized effect on glucose metabolism (whole grain
and low postprandial insulin response grain products, and bilberries) in a clinical trial [65]. Plasma
lipidomic proﬁles of people with impaired glucose metabolism and with at least two other features of
the MetS were evaluated after 12 weeks of dietary intervention. Among the 364 characterized lipids in
plasma, 25 changed signiﬁcantly in the treated group, including multiple TGs incorporating the long
chain ω-3 PUFAs. These results were supported by biochemical data and suggested an improvement
of glucose metabolism and a beneﬁcial effect in preventing type 2 diabetes in population groups at
considerably higher risk of suffering it.
Other three articles found in literature have employed lipidomics tools to study the combined
action of ω-3 PUFAs with other bioactive compounds which have shown potential beneﬁts in
subjects suffering CVD or at considerably high risk. The ﬁrst one [66] was designed to assay the
combined effect of L-alanyl-L-glutamine and ﬁsh oil supplementation for 3 months on skeletal muscle
function and metabolism in patients with chronic heart failure. Patients were randomized to either
L-alanyl-L-glutamine and PUFAs or placebo (safﬂower oil and milk powder). Regular uptake of the
bioactive compounds led to the expected increase in unsaturated fatty acids. Moreover, the lipidomic
analysis revealed a decrease in circulating levels in total ceramides and two ceramide subspecies (C22:1
and C20:1) induced by supplements at 4 weeks, which was not detectable in samples at 3 months.
In another study, the combined effect of ω-3 fatty acids with Coenzyme Q10 was evaluated on plasma
lipid mediators proﬁle in patients with chronic kidney disease (CKD), which are highly predisposed
to suffer CVD, partially due to their chronic inﬂammation [67]. Patients received a daily dose of
ω-3 PUFAs, Coenzyme Q10 (CoQ), or both supplements for 8 weeks. Compounds as 18-HEPE,
17-HDHA, RvD1, 17R-RvD1, and RvD2 were measured in plasma before and after the intervention.
Results showed that ω-3 PUFAs but not CoQ signiﬁcantly increased plasma levels of the upstream
precursors of the E and D-series resolvins (18-HEPE and 17-HDHA, respectively) as well as RvD1.
This ﬁnding may have important implications for limiting ongoing low-grade inﬂammation in CKD.
Finally, Bondía-Pons et al. [68] investigated the effects of ω-3 PUFAs and polyphenol rich diets on
plasma and HDL fraction lipidomic proﬁles in MetS patients. Authors compared the effects of diets
contained low or high ω-3 PUFAs (EPA and DHA) in combination with low or high of polyphenols,
resulting in 4 isoenergetic diets, differing in their naturalω-3 PUFAs and polyphenols amount. Authors
successfully identiﬁed 350 and 293 lipid species in total plasma and HDL fraction samples respectively.
Results showed that the two diets high in ω-3 PUFAs highly increased unsaturated long-chain TGs
and EPA and DHA-containing PLs levels and decreased levels in total plasma of low unsaturated
PLs, and PCes, LysoPCs, and PCps with ARA in their structure. With regards to HDL, PCs and TGs
with DHA or EPA in their structure increased after the consumption of high ω-3 PUFAs diets, while
PCes and PCps with ARA in their structure, and medium-chain PCs decreased. The diet high in
both ω-3 and polyphenols signiﬁcantly reduced PCs and PEs levels, especially of those alkyl and
90
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 258
alkenyl ether lipids with 16:0 in their structure as well as saturated and low-unsaturated PCs and PEs.
The study found a relevant association among lipidomics data, dietary and clinical/anthropometric
variables. The most remarkable and complex association among variables was observed after the
intervention with the diet high in both ω-3 PUFAs and polyphenols. Different types of TGs were
positively or negatively associated with waist circumference, which was positively associated with
insulin levels. Glucose was positively associated with body weight, which was negatively associated
with EPA. This latter association was only detected after feeding the combined diet, which may mean
that dietary polyphenols interacted with ω-3 PUFAs in the regulation of body weight in MetS subjects.
Overall, data reﬂected different lipid rearrangements after a nutritional intervention with diets rich in
ω-3 PUFAs and polyphenols in these patients at a high CVD risk.
The promising cooperative effect between ﬁsh oil and polyphenols was further analyzed
considering the ability of polyphenols as antioxidants to potentially ameliorate oxidative damage of
ω-3 PUFAs when they are consumed together and to enhance their individual potential effects on
metabolic health through the modulation of fatty acids proﬁling and the formation of lipid mediators.
Dasilva et al. [69] evaluated the effect of diet supplementation with EPA and DHA, grape polyphenols
or both in rats fed either standard or high fat and sucrose diets (a total of eight diets), on the
inﬂammatory response and redox unbalance triggered by these unhealthy diets. Authors analyzed
total fatty acid composition in the liver, plasma, adipose tissue, erythrocytes as well as circulating
FFA in plasma across experimental groups and calculated fatty acid desaturases (FADs) indexes
(stearoyl-CoA desaturases SCD-16 and SCD-18 as well as desaturases Δ4, Δ5, and Δ6). Likewise, a
total of nine compounds derived from PUFA oxidative metabolism (namely ﬁve EPA eicosanoids, two
DHA docosanoids and two ARA eicosanoids) were identiﬁed and quantiﬁed in plasma. Data analysis
reﬂected that the supplementation with ﬁsh oil led to an anti-inﬂammatory situation associated with a
lower ω-6/ω-3 index in plasma and membranes, a lower production of ARA pro-inﬂammatory lipid
mediators, an up-regulation of desaturases related to EPA and DHA synthesis and a down-regulation
of these desaturases to synthesize ARA. However, polyphenols bioactivity was inﬂuenced by the
background diet. In a standard diet, they seemed to modulate enzymes towards an anti-inﬂammatory
and antioxidant response, and the combination with ﬁsh oil down-regulated Δ5D related with ARA
synthesis, decreased COX activity on ARA, enhanced the antioxidant enzymes and decreased total FFA
in plasma. Similarly, the combination of both supplements also produced a signiﬁcant improvement in
the antioxidant balance and oxidative stress in unhealthy diets. However, the efﬁcacy of polyphenols to
reduce inﬂammation was lower when were added to the unhealthy diet, and some pro-inﬂammatory
pathways were found even up-regulated. Therefore, ﬁsh oil seemed to be the main responsible for the
anti-inﬂammatory effects observed in the combined group in the unhealthy diet. The combination
of both bioactive supplements may improve the metabolic health in both background diets by acting
on inﬂammation and oxidative stress pathways. A summary of the articles cited in this section of the
review is shown in Table 3.
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2.3. Beneﬁcial Effects of Marine Lipids Intake Assayed by Both Proteomics and Lipidomics
The number of research articles which have combined both proteomics and lipidomics approaches
to address the beneﬁcial effects of marine lipids in metabolic alterations induced by unhealthy diet
intake is scant yet. More articles have used genomics or transcriptomics tools, but gene expression or
transcription is not always correlated with protein levels or activities. The application of proteomics
and lipidomics approaches can help overcome this drawback and identify molecular pathways actually
affected by marine lipids. The integration of different omics seems essential to have a complete picture
of how marine lipids affect health. In spite of this observation, only three research articles which have
combined both proteomics and lipidomics are currently available.
The ﬁrst study was carried out in healthy overweight men with mildly elevated plasma C-reactive
protein concentrations. Bakker et al. [70] performed a dietary intervention with a mix of several
products selected for their evidence-based anti-inﬂammatory properties. That “anti-inﬂammatory
dietary mix” consisted of ﬁsh oil, green tea extract, resveratrol, vitamin E, vitamin C, and tomato
extract. Regarding ﬁsh oil, subjects consumed 1200 mg cold water ﬁsh oil/day, composed of 380 mg
EPA and 260 mg DHA, and 60 mg other ω-3 PUFAs. Authors measured inﬂammatory and oxidative
stress defense markers in plasma and urine. Furthermore, 120 plasma proteins, 274 plasma metabolites
(lipids, FFA, and polar compounds) and the transcriptomes of peripheral blood mononuclear cells and
adipose tissue were also quantiﬁed. Therefore, this study combined proteomics, metabolipidomics
and transcriptomics tools. Plasma adiponectin concentrations increased by 7%, whereas C-reactive
protein (principal inﬂammation marker) was unchanged. However, a multitude of subtle changes
was detected by an integrated analysis of the omics data, which indicated modulated inﬂammation
of adipose tissue, improved endothelial function and oxidative stress, and increased liver fatty acid
oxidation. Using the same subjects, Pellis et al. [71] determined their postprandial response to the
consumption of a standardized 500 mL high-fat dairy shake by using metabolomics and proteomics
tools. During a 6 h time course after Postprandial Challenge Test (PCT), authors quantiﬁed several
plasma metabolites, 79 plasma proteins and 7 clinical biochemistry parameters (glucose, insulin,
total FFA, total TGs, hsCRP, IL6, and TNFa). Among these, 31 had different responses over time
between treated and control groups, revealing differences in amino acid metabolism, oxidative stress,
inﬂammation, and endocrine metabolism. Results showed different short-term metabolic responses to
the PCT in subjects previously supplemented with the anti-inﬂammatory mix compared to the controls.
Additional metabolic changes related to the dietary intervention were also detected as compared to
non-perturbed conditions.
In the third research [72] the obesogenic effect of diets heavily enriched in ω-6 PUFAs and poor
in ω-3 PUFAs was assayed by combined proteomics and lipidomics. The study was carried out
in aging mice, which had previously suffered a myocardial infarction, after 5 months of feeding
a ω-6 enriched diet (ω-6:ω-3 442:1 ratio). Plasma proteomic proﬁling revealed higher VCAM-1,
macrophage inﬂammatory protein-1 andD40 andmyeloperoxidase in theω-6 PUFAs group. Lipidomic
analysis showed higher levels of ARA and 12(S)-HETE and altered levels of inﬂammation-resolving
enzymes 5-LOX, COX-2, and heme oxygenase-1, which reﬂected that excess ofω-6 stimulate prolonged
neutrophil trafﬁcking and pro-inﬂammatory lipid mediators after myocardial infarction. Table 4
summarizes the articles cited in this section of the review.
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3. Mechanisms behind the Beneﬁcial Effects of Marine Lipids Assayed by Proteomics
and Lipidomics
The information obtained from both proteomics and lipidomics approaches has conﬁrmed
mechanisms proposed by genomics and transcriptomics data on the role of marine lipids in
diet-induced metabolic diseases. But interestingly, these techniques have also provided new insights
suggesting the modulation of new molecular pathways and proteins.
Lipidomics tools have revealed the potential mechanisms related to the inﬂuence exerted on the
regulation of lipid proﬁles in plasma/blood, tissues and membranes and lipid mediator synthesis by
marine lipids in human, animal and cell-model experiments. These lipid proﬁles and their derivative
metabolites from fatty acids have closely been associated with inﬂammation, oxidative stress and the
endogenous antioxidant system [73,74].
Besides their known effects in decreasing plasma TGs and cholesterol levels, some of the
lipidomics studies reported in this review have found a remodeling of the plasma/membrane/tissue
lipids into PLs, TGs, lipoproteins and other lipid species of long chain PUFAs, including plasma FFA
proﬁles [34–36,39,43–48,50–53,60,61,63–66,68,69]. In general, the consumption of marine ω-3 led to a
replacement of ARA with EPA and DHA in cell membranes and lipid species presented in plasma,
erythrocytes and liver and adipose tissue, but also kidney and muscle. Such replacement provoked
the consequent enrichment on ω-3 long chain PUFAs accompanied by modulation of LOX and COX
activities, which was attributed to a competence mechanism, especially between ARA and EPA. As
a result, the production of lipid mediators was affected. Additionally, the uptake of ω-3 PUFAs
modulated the synthesis de novo of ARA through elongases and desaturases. In fact, lipidomics
data from the liver, which is in charge of the de novo fatty acids synthesis, conﬁrmed the preferential
substrate competition of Δ5D, which controls de novo synthesis of EPA and ARA, for ω-3 PUFAs
over ω-6 PUFAs [44,50,53,60,61,69]. Marine lipids also regulated the formation of bioactive lipids such
as ceramides. The level of long chain ceramides associated with insulin resistance was found to be
reduced in plasma [43,66] and liver [52,61] together to an increment of the concentration of very long
chain ceramides which seemed to be IR protective.
The fatty acids modulation in the liver due to the consumption of marine lipids was reﬂected in the
total fatty acids proﬁle of plasma and adipose tissue [34–36,43,45–48,50,53,65,68,69]. Such modulation
was also observed in circulating plasma FFA and the incorporation of fatty acids into erythrocyte
membranes [47,48,69]. Fatty acids released from the adipose tissue, which become circulating FFA in
plasma revealed the inﬂuence of the diet and synthesis de novo in the accumulation of fat in adipocytes.
In consequence, the ω6/ω3 ratio in plasma, circulating FFA, membranes and tissues was lower after
feeding marine lipids. The ω6/ω3 ratio is an excellent clinical marker for cellular inﬂammation [75]
and higher values are correlated with increased prevalence of chronic inﬂammatory diseases [76].
In agreement with these effects, lipidomics studies focused on the formation of lipid mediators
from marine PUFAs demonstrated that the intake of these lipids promoted the generation
of anti-inﬂammatory and pro-resolving lipid mediators derived from EPA and DHA while
decreasing pro-inﬂammatory mediators derived from ARA [37–42,44,45,47–49,51,54–58,60,62,64,67,69].
This anti-inﬂammatory response can be further due to the fact that ω-3 PUFAs, especially EPA, and
ω-6 PUFAs can compete for the same enzymes, including phospholipases, desaturases, lipoxygenases
and cyclooxygenases, resulting in a higher production of derived metabolites from EPA and DHA than
derived from ARA.
By using genomics and transcriptomics tools, some authors had previously reported that
PUFAs inhibited the nuclear factor kb (NF-κB) and reduced cytokine production because EPA and
DHA can inhibit the binding between saturated fats and toll-like receptors of membranes by direct
competition. The binding to saturated fats would activate NF-κB gene transcription factor, which
induces inﬂammatory responses through COX and cytokine synthesis [77]. Moreover, although it
is not fully known, marine ω-3 PUFAs may also control gene expression by direct interaction with
at least another 4 metabolic nuclear receptors: PPAR (peroxisome proliferator activated receptor),
97
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 258
LXR (liver X receptor), HNF-4α (hepatic nuclear factor 4) and farnesol X receptor (FXR). Likewise,
marine PUFAs can reduce the levels of sterol regulatory element binding proteins (SREBPs) and the
carbohydrate response element binding protein (ChREBP) [78]. Therefore, the modulation of EPA
and DHA levels and their outcomes revealed by lipidomics approaches may explain their actions
in regulating gene expression. In addition to these ﬁndings, the use of proteomics approaches has
conﬁrmed the inﬂuence of EPA and DHA on several pathways modulated by these transcriptional
factors. Interestingly, proteomics data identiﬁed speciﬁc proteins with a pivotal role in these pathways
which were altered by marine lipids. In this regard, it is necessary to highlight that a direct correlation
between the level of gene expression and the cellular content of proteins cannot always be found [79].
Consequently, proteomics becomes a critical tool for understanding marine lipid actions on cellular
metabolism and for identifying biomarkers of modulation. Proteomics has speciﬁcally revealed that
the inﬂuence of marine lipids intake is not limited to regulating cellular protein quantity but also
protein quality by controlling the formation of oxidative PTMs on proteins, mainly carbonyl moieties.
The control of these oxidative PTMs plays a key role in understanding the mechanism behind the
beneﬁcial effect of marine lipids in decreasing the risk of CVD and type 2 diabetes [80].
In the adipose tissue, aorta and especially liver, proteomics analysis revealed that ω-3 PUFAs
from ﬁsh oil produced an improvement of lipid proﬁles and lower accumulation of fat through a
mechanism that involved the down-regulation of proteins participating in lipogenesis and glycolysis
while causing the up-regulation of proteins involved in fatty acid beta-oxidation. Fish oil also showed
an important action on proteins implicated in the urea cycle and protein metabolism. Additionally,
EPA and DHA demonstrated to act on insulin signaling by modulating proteins such as proteasome
system [16,19–24,27,28].
Proteomics also found a substantial up-regulation of the antioxidant system in blood/plasma and
the rest of tissue analyzed. In fact, ﬁsh oil induced higher levels of antioxidant enzymes, ameliorating of
endoplasmic oxidative stress and stimulating protein and DNA cellular system repair [14–23,25,27,28].
Moreover, EPA and DHA altered protein carbonylation levels of speciﬁc liver proteins, demonstrating
an additional mechanism of protein regulation by marine lipids, which is particularly interesting in the
investigation of diseases induced by diet. It is important to point out that the impairment of normal
redox homeostasis, and the consequent accumulation of oxidized biomolecules, has been linked to
the onset and/or development of a great variety of diet-induced diseases [81,82]. Fish oil reduced
carbonylation of proteins related to the antioxidant system such as albumin or 3-α-hydroxysteroid
dehydrogenase in plasma and liver, respectively. Proteomics ﬁndings in liver demonstrated that EPA
and DHA improved ammonia detoxiﬁcation by decreasing carbonylation level of argininosuccinate
synthetase while increasing oxidation of aspartate aminotransferase. Finally, in skeletal muscle, ﬁsh oil
intake exerted a protection from cellular dysfunction by ameliorating actin carbonylation level [27].
Therefore, proteomics and lipidomics can largely help understand some of the mechanisms
behind the beneﬁcial effect of marine lipids against chronic disease induced by diet. These mechanisms
are mainly related to competence from enzymes involved in lipid de novo synthesis and oxidation,
modulation of anti-inﬂammatory and antioxidant pathways as well as protein homeostasis. Data also
reﬂected that the effect of dietary marine lipids is closely dependent on their doses, the EPA and
DHA ratio, diet components or health status of patients, among others. A schematic representation of
mechanisms and beneﬁcial effects of EPA and DHA intake found by proteomics and lipidomics tools
is shown in Figure 1.
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Figure 1. Schematic representation of mechanisms and beneﬁcial effects of EPA and DHA intake found
by proteomics and lipidomics tools.
4. Concluding Remarks and Final Considerations
Proteomics and lipidomics approaches constitute valuable tools for studying the effects of marine
lipids on metabolic health and disease. In spite of their recent application to nutrition research, these
omics have already allowed the identiﬁcation of numerous metabolic molecules and pathways, tissues
and physiological processes which are modulated by the consumption of marine lipids. These ﬁndings
conﬁrm some of the mechanisms previously suggested by genomics and transcriptomics tools, but they
also provide new insights revealing the existence of novel mechanisms and target molecules of great
interest for the growing ﬁeld of food bioactives and personalized nutrition. Proteomics and lipidomics
contribute to the discovering of new biomarkers of disease and support the optimal design of both
preventive and palliative nutritional strategies against the pathologies in which marine lipids have
previously demonstrated their beneﬁcial effects. The progress on the characterization of mechanisms
of action of marine lipids at proteomics and lipidomics levels might further identify other diseases in
which marine lipids can exert a positive inﬂuence. Therefore, although the combination of proteomics
and lipidomics approaches is still scarce, it could be the key to understanding the mechanisms involved
in the beneﬁcial effects of marine lipids. Such combination will offer a complete overview of cellular
process contributing to clarify several controversial facts regarding the in vivo role of marine lipids.
Finally, it should be noted that the enormous complexity of proteomes and lipidomes together
with the scant knowledge available have limited the use of omics in the ﬁeld of marine lipids.
This inconvenience is especially signiﬁcant for lipidomics due to the lack of information for predicting
the number of individual lipid molecules present in an organism. Additionally, it is necessary to
mention the high variability of results derived from in vivo experiments as well as other caveats related
to high instrumental costs or the need for highly qualiﬁed staff. The achievements on higher sensitivity
and speciﬁcity of the modern MS developments, such as imaging MS or top-down approaches,
constitute promising tools which can help solve these problems.
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Abstract: Polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA; C20:5n-3), are attracting
interest as possible new topical antibacterial agents, particularly due to their potency and perceived
safety. However, relatively little is known of the underlying mechanism of antibacterial action
of EPA or whether bacteria can develop resistance quickly against this or similar compounds.
Therefore, the aim of this present study was to determine the mechanism of antibacterial action
of EPA and investigate whether bacteria could develop reduced susceptibility to this fatty acid
upon repeated exposure. Against two common Gram-positive human pathogens, Bacillus cereus and
Staphylococcus aureus, EPA inhibited bacterial growth with a minimum inhibitory concentration of
64 mg/L, while minimum bactericidal concentrations were 64 mg/L and 128 mg/L for B. cereus and
S. aureus, respectively. Both species were killed completely in EPA at 128 mg/L within 15 min at
37 ◦C, while reduced bacterial viability was associated with increased release of 260-nm-absorbing
material from the bacterial cells. Taken together, these observations suggest that EPA likely kills
B. cereus and S. aureus by disrupting the cell membrane, ultimately leading to cell lysis. Serial passage
of the strains in the presence of sub-inhibitory concentrations of EPA did not lead to the emergence
or selection of strains with reduced susceptibility to EPA during 13 passages. This present study
provides data that may support the development of EPA and other fatty acids as antibacterial agents
for cosmetic and pharmaceutical applications.
Keywords: antibiotic resistance; antimicrobial; ﬁsh oil; free fatty acid; omega-3; wound infections
1. Introduction
The marine-derived polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA; C20:5 n-3) has
antimicrobial properties and there is increasing interest in developing fatty acids as new antibacterial
agents, especially given the rise of bacterial pathogens with resistance against existing antibiotics [1–4].
Similar to many other PUFAs, EPA exerts potent effects against Gram-positive species, including
human pathogens Bacillus cereus and Staphylococcus aureus [3]. S. aureus causes a multitude of
clinical problems from mild skin complaints, such as impetigo, to more serious soft tissue infections,
osteomyelitis, and systemic bacteraemia [5]. Meanwhile, B. cereus is a well-known foodborne pathogen
that causes infections of the gastrointestinal tract, but this bacterium is also responsible for severe
infections of the eyes, lungs, cutaneous tissues, and central nervous system [6]. Importantly, both
pathogens can cause serious infections of wounds and surgical sites [5,6] and new effective treatment
options are highly desirable.
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In clinical and cosmetic applications, free fatty acids such as EPA could be applied topically
to bolster the free fatty acids present naturally on the skin and mucosal surfaces as part of innate
immunity to protect against microbial infection [3,4,7–10]. In addition to antimicrobial activities,
EPA exerts beneﬁcial anti-inﬂammatory actions [11] and has other positive attributes that would
support its development as a new topical antibacterial agent, including wound healing properties [12],
potency and perceived safety [1,4,13], and a suspected lack of acquired bacterial resistance mechanisms
against this and other fatty acids [14]. However, little is known of whether or not bacteria can develop
resistance quickly against this compound, or the underlying mechanisms of antibacterial action of
EPA [3]. Addressing these knowledge gaps may hasten the development of EPA and other fatty acids
as new topical antibacterial agents [1].
The aim of the present study was to characterize the antibacterial activity of EPA against two
Gram-positive pathogens, B. cereus and S. aureus, and investigate whether the bacteria could develop
reduced susceptibility to this fatty acid upon repeated exposure and determine the possible mechanism
of action.
2. Results
The susceptibility of B. cereus NCIMB 9373 and S. aureus Newman to EPA was assessed by
broth micro-dilution according to Clinical and Laboratory Standards Institute protocols [15,16].
EPA demonstrated both growth inhibitory and bactericidal activities against B. cereus and S. aureus.
The minimum inhibitory concentration (MIC) was 64 mg/L for EPA against both B. cereus and S. aureus,
while the minimum bactericidal concentration (MBC) for B. cereus and S. aureus was 64 and 128 mg/L,
respectively. In trials to determine kill kinetics at 128 mg/L EPA, no colonies formed by surviving
cells were detected after plating 5 × 105 colony forming units (CFU)/mL suspensions of B. cereus and
S. aureus in Mueller-Hinton (MH) broth at 15 min or at subsequent sample times (Figure 1). As expected,
some cell division occurred in the control suspensions in MH broth during the 4-h incubation (Figure 1).
This experiment was repeated for cell suspensions prepared in phosphate-buffered saline (PBS) to
determine whether active bacterial growth was necessary for the killing activity of EPA, but again no
colonies formed by surviving cells were detected within 15 min and there was little change in CFU/mL
during the 4-h incubation in the control suspensions (Figure 1).
 
(a) (b)
Figure 1. Enumeration of colonies from cell suspensions of (a) Bacillus cereus NCIMB 9373 and
(b) Staphylococcus aureus Newman in MH broth () or PBS ( ) exposed to eicosapentaenoic acid
(EPA) at 128 mg/L compared to cells suspended in MH broth () or PBS () lacking EPA during 4 h
at 37 ◦C, showing that no viable bacterial cells were detected in suspensions exposed to EPA within
15 min. The detection limit was 2 log10 CFU/mL (dashed line). Data are geometric mean ± standard
error (not all error bars are visible); n = 4.
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Next, to investigate the possibility to select experimentally for strains with reduced susceptibility
to EPA quickly, B. cereus and S. aureus were serially passaged 13 times in the presence of sub-inhibitory
concentrations of this fatty acid in the wells of a 96-well microtitre plate. At each sub-passage,
the contents of the wells used to inoculate the subsequent cultures were stored at −70 ◦C in a cryogenic
tube with 15% glycerol (v/v), so that the susceptibility of each passage isolate to EPA could be
determined by MIC and compared to the parent strains. After passage of the B. cereus strain in
sub-inhibitory concentrations of EPA, the isolates from each of 13 passages and the parent strain
showed no change in susceptibility to EPA as all isolates had identical MIC and MBC values, indicating
the lack of selection of B. cereus cells with reduced susceptibility to EPA (Figure 2). Similarly, the MIC
values of the corresponding S. aureus passage isolates were the same as the parent strain, though the
MBC value of each passaged isolate (except for the ﬁnal passage isolate) was lower than the MBC of
the parent strain (Figure 2). Still, there was no evidence for the selection of S. aureus cells with reduced
susceptibility during repeated exposure to sub-inhibitory concentrations of EPA.
(a) (b)
Figure 2. Minimum inhibitory (solid lines) and bactericidal concentration (dashed lines) values of
the parent (a) Bacillus cereus NCIMB 9373 and (b) Staphylococcus aureus Newman isolates and isolates
collected from each of 13 serial passages in sub-inhibitory concentrations of eicosapentaenoic acid
(EPA), showing that susceptibility of the bacteria to EPA did not reduce during serial passage.
Finally, to determine the mechanism of antibacterial action of EPA, leakage of 260-nm
(A260)-absorbing material from the bacterial cells in suspension was quantiﬁed after exposure to
increasing concentrations of EPA for 30 min, according to a protocol modiﬁed from Carson et al. [17].
The detection of A260-absorbing material can indicate membrane perturbation and an increase in
membrane permeability, and these measurements were taken concomitant with bacterial viability
assessments by plating of the cell suspensions on agar. The bacterial inoculums at the start of incubation
were 1.51 × 109 ± 0.41 × 109 CFU/mL (mean ± standard error) and 1.57 × 109 ± 0.15 × 109 CFU/mL
for B. cereus and S. aureus, respectively, and thus were considerably greater than used in the killing
kinetics experiment above. The carrier solvent (ethanol) had little effect on bacterial viability
and at the greatest concentration of ethanol (2.56%, v/v) the bacteria recovered at 30 min was
1.31 × 109 ± 0.10 × 109 CFU/mL and 2.79 × 109 ± 0.05 × 109 for B. cereus and S. aureus, respectively
(data not shown). Control incubations in the presence of carrier solvent (ethanol) showed that negligible
quantities of A260-absorbing material were detected in cell-free ﬁltrates (data not shown). However,
leakage of A260-absorbing material was detected from B. cereus and S. aureus cell suspensions that
had been incubated in the presence of ≥64 mg/L EPA for 30 min, and greater concentrations of EPA
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led to the detection of greater quantities of A260-absorbing material released from both species of
bacteria (Figure 3). Importantly, the increasing quantities of A260-absorbing material coincided with
reductions in viable CFU/mL in the suspensions (Figure 3). Taken together, these observations suggest
membrane disruption and probable cell lysis of the bacterial cells by EPA.
(a) (b)
Figure 3. Enumeration of colonies from cell suspensions of (a) Bacillus cereus NCIMB 9373 and
(b) Staphylococcus aureus Newman in PBS () and detection of 260-nm (A260)-absorbing material in
cell-free ﬁltrates ( ) after exposure to increasing concentrations of eicosapentaenoic acid (EPA) during
30 min at 37 ◦C, showing that the number of viable cells in suspension reduced concomitant to the
amount of A260-absorbing material in cell-free ﬁltrates, indicating likely cell membrane perturbation
and cell lysis. The bacterial inoculums at the start of incubation were 1.51 × 109 ± 0.41 × 109 CFU/mL
(mean ± standard error) and 1.57 × 109 ± 0.15 × 109 CFU/mL for B. cereus and S. aureus, respectively.
The carrier solvent (ethanol) had little effect on bacterial viability and at the greatest concentration
of ethanol (2.56%, v/v) the bacteria recovered at 30 min was 1.31 × 109 ± 0.10 × 109 CFU/mL
and 2.79 × 109 ± 0.05 × 109 for B. cereus and S. aureus, respectively (data not shown). Meanwhile,
control incubations in the presence of carrier solvent (ethanol) showed that negligible quantities of
A260-absorbing material were detected in cell-free ﬁltrates (data not shown). Data are mean (geometric
mean for CFU values) ± standard error (not all error bars are visible); n = 3 for A260 values, n = 2 for
CFU/mL determinations (detection limit was 2 log10 CFU/mL); note that the secondary y-axis (A260)
scales differ for (a,b).
3. Discussion
EPA is antimicrobial and this property is being exploited in the development of new topical
cosmetics and pharmaceuticals [1–3]; however, relatively little is known for its antibacterial
mechanisms or the ease with which it is possible to select for strains with reduced susceptibility.
In this present study, EPA was observed to kill rapidly two species of Gram-positive pathogen,
probably by causing cell lysis, and there was little evidence for the selection of strains with reduced
susceptibility after 13 passages.
In this present study, EPA inhibited the growth and killed both B. cereus and S. aureus at
concentrations similar to previous reports for these and other Gram-positive species [2,3,18,19].
For B. cereus, MIC and MBC values were the same (64 mg/L) and killing was observed in PBS and
culture medium within 15 min, indicating that actively dividing cells were not essential for bactericidal
action. In conjunction with evidence of leakage of A260-absorbing material from cells at growth
inhibitory and bactericidal concentrations, these data support the likely catastrophic loss of bacterial
cell membrane integrity once a concentration threshold of EPA is reached. Meanwhile, for S. aureus,
there was a two-fold difference between MIC and MBC values of EPA (64 and 128 mg/L, respectively)
and EPA killed cells within 15 min, which is consistent with previous reports [2,18]. Similar to B. cereus,
there was no evidence of the need for actively dividing cells to exert antibacterial action, as EPA killed
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S. aureus equally as effectively in PBS and MH broth. Notably, the leakage experiment showed that
2.10 × 104 CFU/mL of S. aureus survived even at the greatest concentration of EPA (i.e., 512 mg/L)
despite the release of A260-absorbing material being four times greater at this concentration than
observed for B. cereus when no surviving cells were detected. This observation may derive from
differences in the physiology of the cell membranes of these species, and it could be that EPA causes
differential effects on membrane permeability of the two bacteria. Moreover, S. aureus may tolerate
greater membrane perturbation but remain viable (for longer at least), whereas similar disruption of the
B. cereus membrane may be lethal. Indeed, the species-speciﬁc variations in the action of EPA observed
in this present study are worthy of further investigation. In addition, the composition and quantity
of A260-absorbing material (typically nucleic acids [17]) in the cytoplasmic components could differ
between the species and this also would need to be determined. Taken together, these observations
suggest possible concentration-dependent inhibitory and bactericidal mechanisms of action [4],
and EPA probably affects cell membrane-associated metabolic systems or increases permeability,
ultimately leading to cell lysis. This suggestion is consistent with other studies that have proposed the
cell membrane to be the main site of action for antibacterial free fatty acids, with detrimental effects
caused through disruption of vital metabolic processes including cellular respiration [8,20–23] and
nutrient uptake [24], or physical disturbance leading to increased permeability, leakage of cellular
components [8,23,25–28], and cell lysis (reviewed by Desbois and Smith [14]).
Certain bacteria intrinsically resist the actions of fatty acids and the cell wall of Gram-positive
species can confer protection against free fatty acids [25]. Some bacteria increase cell wall synthesis
or decrease cell surface hydrophobicity on exposure to free fatty acids [29–31]. The presence of
cell-membrane-stabilizing carotenoids that decrease ﬂuidity may also reduce susceptibility to free
unsaturated fatty acids [32,33]. Still, there have been few studies on the selection of bacterial strains
with reduced susceptibility to antibacterial free fatty acids, particularly for Gram-positive species,
and, to our knowledge, this present study is the ﬁrst to perform serial passage to select for any strains
with reduced susceptibility to EPA. Previously, strains of Escherichia coli with reduced susceptibility to
caprylic acid (C8:0) or capric acid (C10:0) were selected successfully after 10 serial transfers on agar
containing the fatty acids at sub-inhibitory concentrations [34], though the mechanisms underlying
this phenomenon were not investigated further. Moreover, Petschow et al. [35] reported the isolation
of Helicobacter pylori mutants on agar containing 10× MIC of the medium-chain length saturated
fatty acid lauric acid (C12:0) at a rate of 10−8, but the susceptibility of individual colonies was
not subsequently conﬁrmed. Additionally, Obonyo et al. [36] isolated H. pylori cells that resisted
a previously bactericidal concentration of linolenic acid (C18:3 n-3) after just three sub-cultures in
a sub-bactericidal concentration of this fatty acid. In contrast, Sun et al. [37] reported no change in
susceptibility to lauric acid of H. pylori in response to serial passage six times in sub-inhibitory
concentrations. Meanwhile, Lacey and Lord [38] were unable to select stable S. aureus strains
with reduced susceptibility to linolenic acid including mutants generated by chemical mutagenesis,
and, elsewhere, no S. aureus strains resistant to linoleic acid (C18:2 n-6) were detected in a 5000 clone
transposon insertion library [30]. The opportunity for B. cereus to develop resistance to EPA may be
reduced by MIC and MBC values being the same as the concentration inhibiting growth is close to
the concentration having a lethal effect. However, for S. aureus, culturable cells were detected after
30 min exposure to EPA at 512 mg/L and there exists a difference between MIC and MBC values,
meaning cells are inhibited but not killed at concentrations in this window, thus potentially permitting
the opportunity to select for spontaneous resistant mutants in the surviving population; nevertheless,
this was not borne out in practice and serial passage of both bacteria in the presence of sub-inhibitory
concentrations of EPA did not lead to the emergence or selection of strains with reduced susceptibility.
These observations are consistent with the suggestion that it is more difﬁcult to select for resistance
against compounds that exert their antibacterial action by acting on multiple cellular targets and the
cell membrane. This present study provides some indication of the difﬁculty in rapidly selecting
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for resistance against EPA, but future investigations will use further bacterial species and strains,
undertake more passages, and employ more incremental sub-inhibitory PUFA concentrations.
To conclude, the data in this present study provide support for the development of EPA as
a possible new antibacterial agent due to its favorable potency against Gram-positive pathogens,
lack of rapid selection of bacterial strains with reduced susceptibility or resistance, and bactericidal
mechanism of action.
4. Materials and Methods
4.1. Reagents and Bacteria
EPA (>99% purity) and culture media were purchased from Sigma-Aldrich Ltd. (Poole, Dorset,
UK). An EPA stock was made in ethanol (≥99.5%) to 20 mg/mL and stored at −20 ◦C. All other
solutions and media were made with ultrapure deionized water (Option 3; Elga, High Wycombe,
Bucks, UK) and were sterilized by autoclaving at 121 ◦C for 15 min or by ﬁltration (polyethersulphone,
0.22 μm; Millipore, Watford, UK). S. aureus Newman (gifted by Dr. Angelika Gründling, Imperial
College London, UK) and B. cereus NCIMB 9373 were resuscitated on MH agar at 37 ◦C from 15%
glycerol (v/v) stocks kept at −70 ◦C, and maintained thereafter at 4 ◦C.
4.2. Preparation of Bacterial Suspensions
Typically, bacterial suspensions were prepared from cultures that were inoculated with
3–5 colonies into 5 mL MH broth in universal bottles and incubated (37 ◦C, 150 rpm) until late
exponential phase (determined by measuring the absorbance at 600 nm of the culture and comparing
to growth curves constructed for each species; approximately 12 h). Next, bacterial cells were harvested
by centrifugation (2000× g, 10 min, 4 ◦C), washed twice with PBS (for 1 L: 8 g of NaCl, 0.2 g of KCl,
1.78 g of Na2HPO4·2H2O, 0.24 g of KH2PO4; pH 7.4), and re-suspended to the desired CFU/mL in
MH broth or PBS. The CFU/mL of the suspensions were checked by serially diluting 10 μL in PBS
(in duplicate), plating on MH agar, incubating overnight (37 ◦C, 24 h), and performing CFU counts.
4.3. Assessing Antibacterial Potency
MIC values were determined by broth micro-dilution according to Clinical and Laboratory
Standards Institute protocol [15]. Brieﬂy, EPA in MH broth was serially diluted in ﬂat-bottomed
96-well microtitre plates to ﬁnal well concentrations of 4, 8, 16, 32, 64, 128, 256, and 512 mg/L (100 μL
per well). Five microliters of bacterial suspension at 1 × 107 CFU/mL (prepared in PBS as described in
Section 4.2) was used to inoculate each well. Plates were sealed with Paraﬁlm, incubated (37 ◦C, 24 h),
and the lowest concentration that prevented bacterial growth visible to the naked eye was determined
to be the MIC. Control wells containing either MH broth only or the volume of ethanol equal to the
greatest volume in a test well were also inoculated; a non-inoculated MH broth well was also included.
MBC was determined according to Clinical and Laboratory Standards Institute protocol [16] by plating
20 μL from each well showing no visible growth at 24 h on to MH agar and incubating these plates for
colonies to form (37 ◦C, 24 h). Contents from individual wells were spread across a quarter of an agar
plate and, as no attempt was made to wash away residual EPA, the effect of carryover preventing
the formation of colonies cannot be dismissed. The lowest concentration of EPA that killed ≥99.9%
of the initial inoculum was determined to be the MBC. MIC and MBC values were determined from
duplicated series of wells.
4.4. Killing Kinetics
The times required for EPA at 128 mg/L to kill 5 × 105 CFU/mL from exponential phase cultures
of B. cereus and S. aureus were determined. Brieﬂy, 200 μL of EPA at 128 mg/L in MH was prepared
and dispensed into an Eppendorf tube, while control wells received an equal volume of carrier solvent
(2.56 μL ethanol). Then, 10 μL of a cell suspension (at 1 × 107 CFU/mL and prepared as described in
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Section 4.2) was added to each tube, before the contents were mixed by inversion and then incubated
statically at 37 ◦C. At 15 min, 30 min, 1 h, 2 h, and 4 h, the CFU/mL in each tube was determined
by serial dilution and plating of 10 μL of suspension as described in Section 4.2. Geometric means
and standard errors of these values were calculated from quadruplicate trials. The experiment was
repeated in PBS to determine whether active bacterial growth was necessary for the killing activity
of EPA.
4.5. Selection of Bacterial Strains with Reduced Susceptibility to EPA
To investigate the possibility to select experimentally for strains with reduced susceptibility to
EPA quickly, bacteria were serially passaged in the presence of sub-inhibitory concentrations of this
fatty acid. Brieﬂy, an MIC plate for each bacterium was prepared as described in Section 4.3, except that
the ﬁnal well concentrations of EPA were 16, 32, 64, and 128 mg/L. After 24–48 h incubation, 5 μL from
the well showing growth at the greatest concentration of EPA was used to inoculate the wells of a new
MIC plate set up such that the greatest EPA concentration was double that of the concentration in the
well from which the inoculum was taken. Meanwhile, the remainder of the well contents were stored
at −70 ◦C in a cryogenic tube with 15% glycerol (v/v). This process was continued for 13 passages
for each species of bacterium. Finally, the MICs against EPA of each passage isolate and the original
parent strain were determined as described in Section 4.3, once the cultures had been recovered from
cryogenic stocks by culturing on MH agar (37 ◦C, 24 h) as described in Section 4.1.
4.6. Leakage of A260-Absorbing Material from Bacterial Cells
To assess bacterial membrane perturbation and increasing membrane permeability, leakage of
260-nm absorbing material was quantiﬁed from B. cereus and S. aureus cells in suspension after exposure
to increasing concentrations of EPA for 30 min, according to a protocol modiﬁed from Carson et al. [17].
These measurements were performed concomitant with bacterial viability assessments by plating cell
suspensions on agar. For this, EPA (solubilized in ethanol) was added to PBS and made up to 90 μL
to give 16, 32, 64, 128, 256, and 512 mg/L (ﬁnal volume concentrations after addition of inoculum
below), while control tubes contained 90 μL PBS with ethanol concentrations corresponding to each
of the respective EPA-containing tubes. Two negative control tubes contained PBS only (no EPA or
ethanol). For 10 μL from each tube, A260 was determined on a NanoDrop 1000 spectrophotometer
(ThermoScientiﬁc, Wilmington, DE, USA) and each of these values for the tube solutions served as
the ‘blank’ when readings were to be taken again from each tube at 30 min. After this, to each tube
was added 10 μL of bacterial suspension at 1.5 × 1010 CFU/mL, which had been prepared in PBS as
described in Section 4.2, except that the cells were derived from a 500-mL shake ﬂask culture (37 ◦C,
150 rpm, 24 h). Immediately, one of the negative control tubes was sampled to determine CFU/mL
and the A260 of sterile-ﬁltered supernatant. CFU/mL was determined by serial dilution and plating
of 10 μL of suspension as described in Section 4.2, while the remaining 80 μL of the suspension was
centrifuged (2000× g, 10 min). Then the supernatant was collected and passed through a 0.22-μm
syringe ﬁlter (4 mm; Sterlitech, Washington, DC, USA), before the A260 of this ﬁltrate was measured
on the NanoDrop against its respective ‘blank’. Meanwhile, all other tubes were incubated (37 ◦C,
30 min). After incubation, the CFU/mL of unﬁltered suspension and A260 of ﬁltered suspension were
determined for each tube as described above, however CFU/mL counts were performed only for the
remaining negative control, each EPA-containing tube, and the tube containing the greatest volume of
carrier solvent. Note that as the control incubations in the presence of carrier solvent (ethanol) showed
the presence of only negligible quantities of A260-absorbing material in cell-free ﬁltrates (data not
shown), these A260 values were not subtracted from the A260 value of each respective EPA treatment
reading. This experiment was repeated twice more, though CFU/mL was determined for only one of
these further trials.
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Abstract: Macroalgae have been seen as an alternative source of molecules with promising
bioactivities to use in the prevention and treatment of current lifestyle diseases. In this vein,
the lipophilic fraction of short-term (three weeks) cultivated Bifurcaria bifurcata was characterized
in detail by gas chromatography–mass spectrometry (GC-MS). B. bifurcata dichloromethane extract
was composed mainly by diterpenes (1892.78 ± 133.97 mg kg−1 dry weight (DW)), followed by fatty
acids, both saturated (550.35 ± 15.67 mg kg−1 DW) and unsaturated (397.06 ± 18.44 mg kg−1 DW).
Considerable amounts of sterols, namely fucosterol (317.68 ± 26.11 mg kg−1 DW) were also found.
In vitro tests demonstrated that the B. bifurcata lipophilic extract show antioxidant, anti-inﬂammatory
and antibacterial activities (against both Gram-positive and Gram-negative bacteria), using low
extract concentrations (in the order of μg mL−1). Enhancement of antibiotic activity of drug families
of major clinical importance was observed by the use of B. bifurcata extract. This enhancement of
antibiotic activity depends on the microbial strain and on the antibiotic. This work represents the ﬁrst
detailed phytochemical study of the lipophilic extract of B. bifurcata and is, therefore, an important
contribution for the valorization of B. bifurcata macroalgae, with promising applications in functional
foods, nutraceutical, cosmetic and biomedical ﬁelds.
Keywords: Bifurcaria bifurcata; macroalgae; lipids; lipophilic compounds; diterpenes;
antioxidant activity; anti-inﬂammatory activity; antibacterial activity
1. Introduction
Currently there is a remarkable demand for new bioactive molecules to treat diseases, caused by
the modern lifestyle and the growing exposure to industrial pollutants and environmental toxins.
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Antioxidant compounds have been widely researched, due to their protective action against damage
induced by oxidative stress, which is the major cause of diseases like cancer, diabetes, asthma,
cardiovascular, or neurodegenerative problems [1], and of skin damage. Current lifestyle diseases have
been also associated with inﬂammatory processes [2], which have also encouraged the scientiﬁc
community to search for new molecules with anti-inﬂammatory capacity. At the same time,
the emergence and spread of antibiotic-resistant bacteria strains is a growing public health problem [3],
which has led the scientiﬁc community to search for new antibacterial substitutes or combination of
drugs that might overcome this resistance [4].
Nature has always been an important source of molecules with biological properties as such,
or after chemical modiﬁcation [5]. In recent years, marine resources have become alternative sources
of several value-added compounds [6,7]. Macroalgae, due to their high biological and chemical
diversity and fast-growing properties, are one of the most explored marine resources [8,9]. In fact,
approximately 28.5 million tons of macroalgae (brown, red or green) were produced worldwide in
2014, from both capture and aquaculture [10], with an estimated increase of 15%/year. This resource
has been mainly explored for food consumption or for the production of specialty products, such
as alginic acid, carrageenan, agar, or colorants [7]. In this context, the exploitation of macroalgae
has been gaining increasing attention from several research groups around the world [11–13] and
notably in Portugal [14–18]. In fact, the exploitation of marine resources is also one of the critical
sectors for Portuguese development, given the extent and richness of its Exclusive Economic Zone
(EEZ), being included in the Portuguese Research and Innovation Strategy for Smart Specialization
for 2014–2020 [19].
Amongst the macroalgae species (close to 10,000), only a limited number have been the object of
extensive studies due to their unique composition and consequent diversity of biological activities
or health beneﬁts [20]. Species belonging to the brown Dictyotaceae and Sargassaceae families have
been studied in detail due to the presence of diterpenes, which have a wide range of biological
properties, such as antimicrobial or antitumoral [21]. Among those families, Bifurcaria bifurcata,
which can only be found in the northeastern Atlantic coasts, from Morocco to northwestern Ireland,
is known to biosynthesize components rarely found in other macroalgae species, namely linear
diterpenes [22]. In fact, the presence of these components in B. bifurcata has been widely reported [23–27].
In addition, several in vitro effects of B. bifurcata extracts, such as antimicrobial [28], antimitotic [29],
or antiproliferative activity [30], have been attributed to the presence of diterpenes, although this
assumption has never been adequately complemented by a detailed study of the composition of the
tested extracts. In fact, the relationship between the chemical composition (limited to the fatty acids
proﬁle) and the biological properties (namely, antimicrobial and antioxidant activity) of B. bifurcata
extracts has been addressed in only one study [31].
It has been suggested that the diterpenic composition of B. bifurcata is largely dependent on
abiotic factors and especially on its geographic origin [32]. Furthermore, there are no studies regarding
the lipophilic composition (and the diterpenic fraction in particular) of B. bifurcata cultivated in
nutrient-rich waters (Integrated Multi-Trophic Aquaculture systems (IMTA)) (or even from the
Portuguese coast), where, due to the totally different biotic and abiotic growth conditions, substantial
differences in composition might be anticipated.
In addition, most of the published studies using wild B. bifurcata have neglected the abundance
of diterpenic components, and the few studies that reported their quantiﬁcation have focused on
speciﬁc fractions, not considering the lipophilic fraction as a whole [29,33,34]. The abundance of other
important classes of lipophilic compounds are also unknown, namely sterols, long-chain aliphatic
alcohols and even fatty acids, for which only a single study can be found [31]. The limited number
of compounds identiﬁed in these studies can be overcome using gas chromatography coupled with
mass spectrometry (GC-MS), which allows the detailed identiﬁcation and quantiﬁcation of complex
mixtures of compounds found in the lipophilic extracts [35,36].
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In this study the lipophilic fraction of B. bifurcata cultivated for a short period (three weeks)
in a land-based IMTA system was detailed characterized by GC-MS analysis. In addition, in vitro
assays were performed to evaluate the antioxidant, antibacterial and anti-inﬂammatory activities of
this fraction. Experiments were also conducted aiming to access the synergistic antibiotic–B. bifurcata
lipophilic extract bacterial growth inhibition by determining the minimum inhibitory concentration
(MIC—the lowest concentration where no bacterial growth was detected).
2. Results and Discussion
2.1. Lipophilic Composition
The dichloromethane extraction yield of B. bifurcata accounted for 3.92 ± 0.09% (w/w), which is
quite similar to the n-hexane extraction yield obtained for B. bifurcata from both aquaculture and wild
collected in Portuguese coast [37]. Additionally, the dichloromethane extraction yield was considerably
higher than those observed previously for other Phaeophyta species [15] or for Chlorophyta or
Rhodophyta macroalgae [14].
The chemical composition of the B. bifurcata dichloromethane extract was studied in detail
by GC-MS analysis. With the exception of the diterpenes family, all the lipophilic components
were identiﬁed as their trimethylsilyl derivatives, after derivatization of the dichloromethane
extract. The identiﬁcation of the main lipophilic extractives and the corresponding quantiﬁcation is
summarized in Table 1. In general, the extract was mainly composed of diterpenes, free fatty acids
(C14–C22), long-chain aliphatic alcohols (C14–C28), and sterols, among other components. To the best
of our knowledge this is the ﬁrst study reporting the analysis of the lipophilic fraction of B. bifurcata
by GC-MS. Recently, Alves et al. [31] analyzed the dichloromethane extract of B. bifurcata by GC with
ﬂame ionization detector; however, only the presence of fatty acids was reported.
Table 1. Compounds identiﬁed in B. bifurcata dichloromethane extract expressed in mg g−1 of extract
and in mg kg−1 of dry macroalgae 1.
Rt (min) Compound mg g−1 of Extract mg kg−1 of Dry Macroalgae
Fatty acids 2 24.18 ± 0.56 947.88 ± 21.94
Saturated 14.04 ± 0.40 550.35 ± 15.67
31.0 Tetradecanoic acid 1.94 ± 0.04 76.23 ± 1.69
33.5 Pentadecanoic acid 0.24 ± 0.02 9.45 ± 0.60
36.0 Hexadecanoic acid 10.11 ± 0.43 396.43 ± 17.01
38.2 Heptadecanoic acid 0.30 ± 0.02 11.81 ± 0.78
40.5 Octadecanoic acid 1.05 ± 0.09 41.01 ± 3.49
44.7 Docosanoic acid 0.24 ± 0.01 9.28 ± 0.48
48.5 Tetracosanoic acid 0.16 ± 0.01 6.15 ± 0.20
Unsaturated 10.13 ± 0.47 397.06 ± 18.44
35.3 Hexadec-9-enoic acid 1.08 ± 0.07 42.24 ± 2.79
39.5 Octadeca-9,12-dienoic acid 1.04 ± 0.05 40.74 ± 2.08
39.6 Octadeca-9,12,15-trienoic acid 1.47 ± 0.07 57.81 ± 2.70
39.9 Octadec-9-enoic acid 5.13 ± 0.26 200.95 ± 10.32
42.9 Eicosa-5,8,11,14,17-pentaenoic acid 0.91 ± 0.07 35.86 ± 2.57
43.3 Eicosa-5,8,11-trienoic acid 0.02 ± 0.00 0.75 ± 0.03
43.4 Eicosa-11,14-dienoic acid 0.07 ± 0.01 2.86 ± 0.05
ω-hydroxyacids 0.01 ± 0.00 0.47 ± 0.02
55.3 22-Hydroxydocosanoic acid 0.01 ± 0.00 0.47 ± 0.02
Long-chain aliphatic alcohols 2 0.43 ± 0.03 17.03 ± 1.29
29.0 Tetradecan-1-ol 0.10 ± 0.00 3.78 ± 0.02
34.1 Hexadecan-1-ol 0.15 ± 0.01 5.89 ± 0.38
38.7 Octadecan-1-ol 0.09 ± 0.00 3.41 ± 0.19
58.9 Octacosan-1-ol 0.12 ± 0.00 4.78 ± 0.17
Sterols 2 10.37 ± 0.67 406.45 ± 26.19
58.6 Cholesterol 0.19 ± 0.01 7.29 ± 0.24
62.0 Desmosterol 1.11 ± 0.03 43.56 ± 1.10
63.1 Fucosterol 8.10 ± 0.67 317.68 ± 26.11
63.4 Campesterol 0.97 ± 0.04 37.92 ± 1.61
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Table 1. Cont.
Rt (min) Compound mg g−1 of Extract mg kg−1 of Dry Macroalgae
Monoglycerides 2 0.89 ± 0.03 34.99 ± 1.10
47.8 1-Monohexadecanoin 0.66 ± 0.03 25.82 ± 1.01
50.9 1-Monooctadecenoin 0.13 ± 0.00 5.17 ± 0.17
51.5 1-Monoeicosa-tetraenoin 0.10 ± 0.01 4.00 ± 0.31
Diterpenes 3 48.29 ± 3.42 1892.78 ± 133.97
26.8 Neophytadiene 1.53 ± 0.08 59.86 ± 3.29
32.4 Phytol 0.87 ± 0.07 34.02 ± 3.25
34.0 Trans-geranylgeraniol 1.70 ± 0.16 66.53 ± 2.93
34.5 6,7,9,10,11,12,14,15-Tetradehydrophytol 2.41 ± 0.88 94.35 ± 6.29
36.5 6-Hydroxy-13-oxo-7,7′,10,11-didehydrophytol 16.27 ± 2.41 637.84 ± 34.41
40.7 1-Acetyl-10,13-dioxo-6,7,11,11′,14,15-tridehydrophytol 25.51 ± 4.04 1000.17 ± 94.47
Other terpenic compounds 3 0.28 ± 0.00 10.79 ± 0.18
26.6 6,10,14-Trimethyl-2-pentadecanone 0.28 ± 0.00 10.79 ± 0.18
Total 84.44 ± 4.14 3309.93 ± 162.25
1 Results are the average of the concordant values obtained from the triplicated extracts each injected twice
(less than 5% variation between injections of the same aliquot and between triplicated dichloromethane extracts);
2 Compounds identiﬁed as trimethylsilyl derivatives; 3 Compounds identiﬁed in the method without derivatization.
2.1.1. Diterpenes and Other Terpenoids
Several diterpenes (Figure 1) and other terpenoids were identiﬁed in B. bifurcata dichloromethane
extract, namely neophytadiene, phytol, trans-geranylgeraniol, 6,7,9,10,11,12,14,15-tetradehydrophytol,
6-hydroxy-13-oxo-7,7′,10,11-didehydrophytol, 1-acetyl-10,13-dioxo-6,7,11,11′,14,15-tridehydrophytol
and 6,10,14-trimethyl-2-pentadecanone.
Figure 1. Diterpenes and othermajor lipophilic compounds detected inB. bifurcatadichloromethane extract.
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The fragmentation patterns of these components depend on the number and position of the
double bonds, and on the nature of the substituent groups [23,25,26]. As an example, the mass spectra
of neophytadiene and trans-geranylgeraniol are presented in Figure 2.
Figure 2. Mass spectra of (a) neophytadiene and (b) trans-geranylgeraniol.
The mass spectrum of neophytadiene presents a molecular ion [M]+ at m/z 278 and major
product ions at m/z 43 ([C3H7]+), 57 ([C4H9]+), 68, 82, 95 ([C7H11]+), 109 and 123 ([C9H15]+).
Similarly, trans-geranylgeraniol presents a molecular ion [M]+ at m/z 290, and characteristic product
ions at m/z 69 ([C5H9]+), 81 ([C6H9]+), 121 ([C11H19]+) and 272 (M-H2O]+).
Diterpenes, accounting for 1892.78 ± 133.97 mg kg−1 DW, correspond to about 57% of
the total amount of lipophilic compounds detected in B. bifurcata extract, with 1-acetyl-10,13-
dioxo-6,7,11,11′,14,15-tridehydrophytol and 6-hydroxy-13-oxo-7,7′,10,11-didehydrophytol as the major
components of this family, accounting for 1000.17 ± 94.47 and 637.84 ± 34.41 mg kg−1 DW, respectively.
1-acetyl-10,13-dioxo-6,7,11,11′,14,15-tridehydrophytol and 6-hydroxy-13-oxo-7,7′,10,11-didehydrophytol
were already described as constituent of B. bifurcata collected in Brittany (France) [25,26], but no
information was reported regarding its quantiﬁcation. Considerable amounts of 6,7,9,10,11,12,14,15-
tetradehydrophytol, trans-geranylgeraniol and neophytadiene were also found, and minor amounts
of phytol were also detected. 6,7,9,10,11,12,14,15-Tetradehydrophytol was previously identiﬁed
in B. bifurcata collected in Morocco [23], though no information has been provided concerning its
abundance, while, to the best of our knowledge, phytol and neophytadiene are reported, for the ﬁrst
time, as constituents of B. bifurcata. In opposition, geranylgeraniol has been one of the most reported
constituents of this macroalga species [26,29,38]. Additionally, the abundance of this component in the
B. bifurcata dichloromethane extract is in the range of those (0.0–1.5 mg g−1 DW) reported in a seasonal
variation study of the same species collected in Brittany (France) [39]. Notwithstanding, only traces of
this diterpene were found in a geographical variation study of the diterpene composition of B. bifurcata
collected in Spain [33].
Despite the high abundance verified for all the detected diterpenes, these were not reported in some
of the studies regarding the seasonal and geographical variation of diterpenes in B. bifurcata [29,33,34].
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Diterpenes have been associated with a wide number of health beneﬁts [40]. In particular,
those from macroalgae have been reported to have antioxidant, antimicrobial [41], antifungal [42],
anti-viral [43], or antitumoral activities [44].
Minor amounts (10.79 ± 0.18 mg kg−1 DW) of 6,10,14-trimethyl-2-pentadecanone were found
in B. bifurcata dichloromethane extract. This terpenoid and its derivatives have been described to be
produced by macroalgae from Cystoseiraceae family, namely Cystophora moniliformis [45,46].
2.1.2. Fatty Acids
Fatty acids were the second most abundant family of compounds detected in the lipophilic
fraction of B. bifurcata, corresponding to 947.88 ± 21.94 mg kg−1 DW. Hexadecanoic acid (Figure 1)
was the most abundant fatty acid (396.43 ± 17.01 mg kg−1 DW), followed by tetradecanoic
(76.23 ± 1.69 mg kg−1 DW) and octadecanoic (41.01 ± 3.49 mg kg−1 DW) acids. The high abundance of
hexadecanoic and tetradecanoic acid in B. bifurcata was already reported [31], however, in considerably
higher amounts than those found in this study.
Considerable amounts of unsaturated fatty acidswere found inB. bifurcata (397.06± 18.44mgkg−1 DW),
representing about 42% of the total fatty acids. Octadec-9-enoic acid (Figure 1) was the most
abundant unsaturated fatty acid, accounting for 200.95 ± 10.32 mg kg−1 DW, followed by the
ω-3 octadeca-9,12,15-trienoic acid (57.81 ± 2.70 mg kg−1 DW) and the hexadec-9-enoic acid
(42.24 ± 2.79 mg kg−1 DW). Signiﬁcant amounts of the ω-3 fatty acid eicosa-5,8,11,14,17-pentaenoic
acid were also found (35.86 ± 2.57 mg kg−1 DW), despite being 10 times lower than those reported
previously by Alves et al. [31] for B. bifurcata collected in Peniche coast, Portugal. Notwithstanding,
the high abundance of this component contributes to the low ω-6/ω-3 ratio veriﬁed for this macroalga
(~0.46), which is considerably lower than themaximum (4:1) recommended for a diet in order to prevent
the development of inﬂammatory processes [47]. Additionally, this ratio is signiﬁcantly lower than
those veriﬁed for othermacroalgae species [15,48], whichwere considered promising to be incorporated
in healthy diets. The high abundance of such components, widely associated with the prevention or
delay of chronic diseases, such as cancer, cardiovascular, or coronary problems [49], highlights the
potential of valorization of B. bifurcata also in food and/or nutraceutical industry. However, such
exploitation requires that more detailed studies should be performed, namely evaluating their side
effects and toxicity.
2.1.3. Long-Chain Aliphatic Alcohols
Minor amounts of long-chain aliphatic alcohols (LCAA) were found in B. bifurcata dichloromethane
extract, accounting for 17.03 ± 1.29 mg kg−1 DW. To the best of our knowledge this is the ﬁrst study
reporting the presence of these components in B. bifurcata. Hexadecan-1-ol was the most abundant
LCAA detected, followed by octadecan-1-ol and tetradecan-1-ol.
2.1.4. Sterols
Signiﬁcant amounts of sterols were found in the dichloromethane extract of B. bifurcata
(406.45 ± 26.19 mg kg−1 DW). Other studies reported the total sterols content in this macroalga
collected in different countries [33,39]; however, only fucosterol has been described, with no further
detailed characterization. In fact, fucosterol (Figure 1) was the major sterol detected in B. bifurcata
dichloromethane extract, accounting for 317.68 ± 26.11 mg kg−1 DW. Notwithstanding, this value
was lower than the previous reported contents (1400–5900 mg kg−1 DW) [33,39]. The bioactivities
assigned to this phytosterol have been widely described in literature, such as its capacity to
modulate cholesterol levels [50], its anti-inﬂammatory potential [51], or its dermo-protective
effect [52]. Considerable amounts of desmosterol (43.56 ± 1.10 mg kg−1 DW) and campesterol
(37.92 ± 1.61 mg kg−1 DW) were also found, which is in accordance with results observed for other
Phaeophyta macroalgae [15]. Minor amounts of cholesterol were also detected.
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2.1.5. Monoglycerides
Monoglycerides were also detected in B. bifurcata dichloromethane extract, representing
only a small fraction of the total lipophilic compounds identiﬁed (34.99 ± 1.10 mg kg−1 DW).
To our knowledge, this is also the ﬁrst study reporting the monoglycerides proﬁle of B. bifurcata.
1-Monohexadecanoin was the most abundant compound detected from this family, representing almost
74% of the total monoglycerides. Minor amounts of 1-monooctadecenoin (5.17 ± 0.17 mg kg−1 DW)
and 1-monoeicosa-tetraenoin (4.00 ± 0.31 mg kg−1 DW) were also found.
2.2. Antioxidant Activity
The antioxidant activity of B. bifurcata dichloromethane extract was evaluated by both DPPH
and ABTS in vitro assays. Table 2 presents the obtained results, expressed as the amount of extract
needed to decrease the DPPH• and ABTS+• concentrations by 50% (IC50), as well as in mg of ascorbic
acid (AAE) and trolox (TE) equivalents per g of dry weight. The IC50 values for ascorbic acid and
BHT (for DPPH assay) and for trolox (for ABTS assay) were also estimated and are reported in Table 2
for comparative purposes. B. bifurcata lipophilic extract showed antioxidant activity against both
radicals, although a higher activity was observed against ABTS+•, with the respective IC50 accounting
for 116.25 ± 2.54 μg mL−1, representing 23.10 ± 0.51 mg of trolox equivalents g−1 DW.
Table 2. Antioxidant activity of B. bifurcata dichloromethane extract expressed as IC50 values (μg mL−1)
and in mg of ascorbic acid (AAE)/trolox equivalents (TE) g−1 of dry weight.
Heading DPPH Assay ABTS Assay
IC50 mg AAE g−1 DW IC50 mg TE g−1 DW
B. bifurcata 365.57 ± 10.04 11.18 ± 0.30 116.25 ± 2.54 23.10 ± 0.51
Ascorbic acid 4.08 ± 0.05
BHT 14.32 ± 0.69
Trolox 2.68 ± 0.07
To our knowledge, this is the ﬁrst study reporting the antioxidant activity of a B. bifurcata extract
against ABTS+•. In addition, the IC50 value determined for DPPH assay (365.57 ± 10.04 μg mL−1) was
quite similar to that described before for a dichloromethane extract of B. bifurcata collected from rock
pools in Portuguese coast [31]. Notwithstanding, B. bifurcata lipophilic extracts showed IC50 values
against both radicals signiﬁcantly lower than those determined for ascorbic acid or trolox (Table 2).
2.3. Anti-Inﬂammatory Activity
In order to study the capacity of B. bifurcata dichloromethane extract to modulate nitric oxide
production, an in vitro model of inﬂammation consisting of macrophages stimulated with LPS was
performed. Concomitantly, cell viability was evaluated by the resazurin-based assay (Figure 3) in
order to select concentrations with bioactivity and without cytotoxicity. B. bifurcata lipophilic extract
showed a slightly but statistically signiﬁcant cytotoxic effect at 100 μg mL−1, when compared to
LPS-treated cells.
The effect of B. bifurcata extract on NO production was analyzed by measuring the accumulation
of nitrites in the culture medium, using the Griess assay. RAW 264.7 cells were stimulated with LPS
in the presence or absence of B. bifurcata extract for 24 h. B. bifurcata extract inhibited LPS-induced
NO production in a concentration-dependent manner (Figure 4). This extract markedly inhibited
LPS-induced NO production to 6% and 40% at 50 and 25 μg mL−1, respectively.
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Figure 3. Effect of B. bifurcata dichloromethane extract at 6.25, 12.5, 25, 50, and 100 μg mL−1 on RAW
264.7 cell viability. Evaluation of statistical signiﬁcance was performed using one-way ANOVA with
Dunnett’s multiple comparison test; ## p < 0.01 compared to control (Ctrl).
Figure 4. Inhibitory effect of B. bifurcata dichloromethane extract on nitric oxide production evoked by
LPS in RAW 264.7 cells. B. bifurcata dichloromethane extract was used in the concentration range of
6.25–100 μg mL−1, **** p < 0.0001 compared to LPS.
The decrease in LPS-induced NO production at 50 μg mL−1 to levels similar to those observed
in untreated cells reveals the remarkable anti-inﬂammatory potential of this extract. In fact, the
anti-inﬂammatory activity of the extract is considerable higher than reported for other macroalgae
extracts, namely from Saccharina japonica [53] or Undaria pinnatiﬁda [54]. To our knowledge, this is the
ﬁrst study reporting the anti-inﬂammatory activity of B. bifurcata.
2.4. Antibacterial Activity
The antibacterial activity of B. bifurcata lipophilic extract against Staphylococcus aureus, Escherichiacoli,
Pseudomonas aeruginosa, and Staphylococcus epidermidis were evaluated. Therapeutic strategies to
counteract infections caused by these bacterial strains have been one of the main concerns, particularly
in health care settings. In fact, S. aureus, E. coli, and P. aeruginosa present the higher rates of antibiotic
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resistance, while S. epidermidis has been considered an opportunistic pathogen, being the most common
source of infections on indwelling medical devices [55]. Thus, in this study, the antimicrobial efﬁcacy
of four antibiotics representing drug families of major clinical importance, such as aminoglycosides
(Gent: Gentamicin), tetracyclines (Tetra: Tetracycline), macrocyclics (Rif: Rifampicin), and β-lactams
antibiotics, such as aminopenicillins, (Amp: Ampicillin) were evaluated in combination with the
B. bifurcata lipophilic extract.
Results regarding the antibacterial activity of the B. bifurcata dichloromethane extract are
presented in Table 3. Activity against S. aureus ATCC®6538 (MIC = 1024 μg mL−1), S. aureus
ATCC®43300 (MIC = 2048 μg mL−1) and E. coli (MIC = 2048 μg mL−1) was observed. No growth
inhibition of S. epidermidis and P. aeruginosa PAO1 was veriﬁed in the range of concentrations tested
(MIC > 2048 μg mL−1). B. bifurcata extract showed inhibition against both Gram-negative and
Gram-positive bacteria, in opposition to that observed by Alves et al. [31], which only veriﬁed activity
of a B. bifurcata dichloromethane extract against Gram-negative bacteria. Additionally, these authors
have not reported growth inhibition against the same E. coli strain. Notwithstanding the fact that the
extraction conditions in both studies were not the same, the macroalgae origins are distinct, which may
alter the metabolite composition and therefore their bioactivities, highlighting the importance of
controlling the growth conditions of macroalgae in order to maximize their valorization.
Table 3. Antibacterial activity of B. bifurcata dichloromethane extract and synergistic effects with
different antibiotics expressed in MIC (μg mL−1).
Bacteria Ext Rif Rif+ Ext Gent Gent+ Ext Amp Amp+ Ext Tetra Tetra + Ext
MIC (μg mL−1)
E. coli ATCC®25922 2048 32 16 >256 <2 32 128 18 <2
Staphylococcus aureus ATCC®43300 2048 16 <2 >256 16 128 256 >256 <2
Staphylococcus aureus ATCC®6538 1024 64 64 32 16 256 512 16 8
Pseudomonas aeruginosa PAO1 >2048 32 - 2 - 16 - 16 -
Staphylococcus epidermidis >2048 32 - 512 - >2048 - 32 -
Key: Ext: Extract; Rif: Rifampicin; Gent: Gentamicin; Amp: Ampicillin; Tetra: Tetracycline.
The synergism of B. bifurcata dichloromethane extract with antibiotics was also evaluated against
the same bacterial panel. This approach has been suggested as a promising tool to overcome the
bacterial resistance that has been developed to most of the antibiotic classes recommended for their
treatment [3,4,56]; to our knowledge, no similar study has previously been reported for this macroalga.
The synergetic activity (antibiotic + extract) screening was performed against the bacterial strains
for which a new antibiotic MIC was possible to determine, namely for E. coli ATCC®25922, S. aureus
ATCC®43300 and S. aureus ATCC®6538 (Table 3). Interestingly, the combination of the extract with
gentamicin or tetracycline drastically decreased the antibiotic MIC against the three strains under study,
enabling it to be effective at considerably lower concentrations. Similar behavior was observed for
both E. coli ATCC®25922 and S. aureus ATCC®43300 when the extract was combined with rifampicin.
These observations suggest that the use of B. bifurcata lipophilic fraction may be considered within
a coadjutant/synergistic approach to conventional antibiotherapy, enabling a superior therapeutic
potential against the above-mentioned bacteria.
Concerning the interaction between B. bifurcata dichloromethane extract and ampicillin,
an antagonism effect was observed, with MIC values increasing considerably. This may be linked to
alterations in the antibiotic structure induced by the presence of the extract in solution, leading to its
partial inactivation.
3. Material and Methods
3.1. Sample
Bifurcaria bifurcata R. Ross was cultivated in the land-based aquaculture system of ALGAplus, Lda,
at Ria de Aveiro (Portugal, 40◦36′43” N, 8◦40′43” W). The company operates under the IMTA concept,
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using solely ﬁltered nutrient-rich water from a ﬁshpond to produce seaweed biomass. The culture
starting material was obtained at Aguda beach (Portugal, 41◦2′38” N, 8◦39′10” W) in May 2014 and
grown by vegetative propagation during three weeks at constant conditions. The biomass was washed
with seawater to remove salts, epiphytes, and/or microorganisms and dried at 25 ◦C until it reached a
total moisture content of 12%. The samples were transformed into ﬂakes (1–2 mm), packed, and stored
in hermetic bags in the company’s storage room.
3.2. Lipophilic Compounds Extraction
Three aliquots (20 g) of lyophilized macroalgae samples were Soxhlet extracted with
dichloromethane (Sigma Chemical Co., Madrid, Spain) for 9 h. Solvent was evaporated to dryness,
lipophilic extracts weighted and the results were expressed in percent of dry weight material (% DW).
Dichloromethane was selected as a fairly speciﬁc solvent for lipophilic extractives isolation for
analytical purposes only.
3.3. GC-MS Analysis
The analysis of the lipophilic extracts followed two distinct methodologies: the ﬁrst suitable
for trimethylsilyl (TMS) derivatizable compounds and the second for diterpenic compounds,
as described below.
3.3.1. Analysis of Trimethylsilyl Derivatizable Compounds
Before GC-MS analysis, two aliquots of each dried extract (20 mg each) and an accurate amount
of internal standard (tetracosane, 0.25–0.50 mg, Sigma Chemical Co., Madrid, Spain) were dissolved in
250 μL of pyridine (Sigma Chemical Co.).
The compounds containing hydroxyl and carboxyl groups were converted into TMS ethers and
esters, respectively, by adding 250 μL of N,O-bis(trimethylsilyl)triﬂuoroacetamide (Sigma Chemical
Co.) and 50 μL of trimethylchlorosilane (Sigma Chemical Co.), standing the mixture at 70 ◦C for
30 min [57]. The derivatized extracts were analyzed by GC-MS following previously described
methodologies [15,35] on a GCMS-QP2010 Ultra (Shimadzu, Kyoto, Japan), equipped with a DB–1
J&W capillary column (30 m × 0.32 mm inner diameter, 0.25 μm ﬁlm thickness). The chromatographic
conditions were as follows: initial temperature, 80 ◦C for 5 min; temperature gradient, 4 ◦C min−1;
ﬁnal temperature, 260 ◦C; temperature gradient, 2 ◦C min−1; ﬁnal temperature, 285 ◦C for 8 min;
injector temperature, 250 ◦C; transfer-line temperature, 290 ◦C; split ratio, 1:33.
Compounds were identiﬁed as TMS derivatives by comparing their mass spectra with
two commercial GC-MS spectral libraries (Wiley 275 and U.S. National Institute of Science and
Technology (NIST14) ), their characteristic retention times obtained under the described experimental
conditions [15,35], and by comparing their mass spectra fragmentation proﬁles with published data or
by injection of standards.
For semi-quantitative analysis, GC-MS was calibrated with pure reference compounds,
representative of the major lipophilic extractive families (cholesterol, hexadecanoic acid and
nonadecan-1-ol (Sigma Chemical Co.)) relative to tetracosane. The respective response factors were
calculated as an average of six GC-MS runs. Each one of the three extracts prepared from macroalgae
was injected in duplicate (n = 6). The presented results are the average of the concordant values
obtained (less than 5% variation between injections of the same aliquot and between triplicated
extracts of the same macroalgae).
3.3.2. Analysis of diterpenes
Diterpenes were identiﬁed and quantiﬁed by the analysis of the B. bifurcata extract without
derivatization. About 10 mg of extract were dissolved in 1100 μL of dichloromethane with 0.8 mg of
internal standard (n-hexadecane (Supelco, Bellefonte, PA, USA)).
124
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 340
The extracts were injected in the same GC-MS equipment as described above and the
chromatographic conditions were as follows: initial temperature, 80 ◦C for 5 min; temperature gradient,
5 ◦C min−1, ﬁnal temperature 200 ◦C, temperature gradient, 2 ◦C min−1, ﬁnal temperature 240 ◦C;
temperature gradient, 5 ◦C min−1, ﬁnal temperature 285 ◦C for 8 min; injector temperature, 250 ◦C;
transfer-line temperature, 290 ◦C; split ratio, 1:40. All other conditions were the same as described
above. Diterpenes were identiﬁed by comparing their mass spectra fragmentation proﬁle with library
(Wiley 275 and U.S. National Institute of Science and Technology (NIST14)) and with the characteristic
fragmentation pathway described in literature for these components [23,25,26].
Semi-quantitative analysis was carried out determining the response factor (an average of
six GC-MS runs) of a representative standard, namely phytol (Sigma Chemical Co.), relative to
n-hexadecane. Each one of the three aliquots were injected in duplicate (n = 6).
3.4. Antioxidant Activity
3.4.1. DPPH Assay
The antioxidant activity of the B. bifurcata lipophilic extract wasmeasured by their hydrogen-donating
or radical scavenging ability using the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH•)
(Sigma Chemical Co.), following a previously described procedure [35]: 0.25 mL of DPPH• (0.8 mM
in methanol (Fluka Chemie, Madrid, Spain)) were added to 1.00 mL of the aqueous solution
of the B. bifurcata dichloromethane extract and 2.75 mL of methanol. The extract concentration
ranged between 61.9 and 556.9 μg mL−1. After 30 min of incubation in the dark, at room
temperature, the absorbance was determined at 517 nm, using a Shimadzu UV-1800 spectrophotometer
(Kyoto, Japan). Standards of ascorbic acid (Fluka Chemie) and 3,5-di-tert-4-butylhydroxytoluene (BHT)
(Sigma Chemical Co. were used with concentrations ranging from 0.7 to 5.6 μg mL−1 and 5.0 to
75.8 μg mL−1. Duplicate measurements of three extracts were carried out (n = 6). The antioxidant
activity was expressed in IC50 values, deﬁned as the inhibitory concentration of the extract required to
decrease the initial DPPH radical concentration by 50%, as well as in g of ascorbic acid equivalents per
kg of dry weight (g AAE kg−1 DW).
3.4.2. ABTS Assay
TheABTS assay is based on the scavenging of the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid) radical cation, ABTS+• (Sigma Chemical Co.) converting it into a colorless product. In this
test, ABTS+• cation was generated by reacting 50 mL of ABTS 7 mM solution with 25 mL of
potassium persulfate (Fluka Chemie) 2.45 mM, following a methodology described before with minor
modiﬁcations [35]. This mixture was then incubated in the dark, at room temperature, for 16 h.
Before usage, the ABTS+• solution was diluted with methanol to obtain an absorbance of 0.700 ± 0.02
at 734 nm. 30 μL of B. bifurcata dichloromethane extract or trolox (Aldrich Chemical Co., Madrid,
Spain), used as reference, were mixed with 3 mL of ABTS+• solution, obtaining ﬁnal concentrations of
47.9–239.5 μg mL−1 and 1.0–5.0 μg mL−1, respectively. The absorbance was measured at 734 nm using
a Shimadzu UV-1800 spectrophotometer (Kyoto, Japan). Duplicate measurements of three extracts
were performed.
The antioxidant activity was expressed as IC50 values (extract or trolox concentration providing
50% of ABTS+• inhibition) as well as in mg of trolox equivalents per g of dry weight (mg TE g−1 DW).
3.5. Anti-Inﬂammatory Activity
Test solutions of B. bifurcata dichloromethane extract (100 mg mL−1) were prepared in ethanol
and diluted in a culture medium (prepared as described below). Ethanol concentrations ranged from
0.007 to 0.1% (v/v), corresponding to extract concentrations between 6.25 and 100 μg mL−1.
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3.5.1. Cell Culture
Raw 264.7, a mouse leukaemic monocyte macrophage cell line from American Type Culture
Collection (ATCC TIB-71), kindly supplied by Dr. Otília Vieira (Centro de Neurociências e Biologia
Celular, Universidade de Coimbra, Coimbra, Portugal), was cultured in Dulbecco’s Modiﬁed
Eagle Medium supplemented with 10% non-inactivated fetal bovine serum, 100 U mL−1 penicillin,
and 100 μg mL−1 streptomycin at 37 ◦C in a humidiﬁed atmosphere of 95% air and 5% CO2.
During the experiments, cells were monitored by microscope observation in order to detect any
morphological changes.
3.5.2. Determination of Cell Viability
Assessment of metabolically active cells was performed using a resazurin (a nonﬂuorescent blue
dye) based assay [58]. Brieﬂy, cell duplicates were plated at a density of 0.1 × 106/well, in a 96 well
plate and allowed to stabilize overnight. Following this period, cells were either maintained in culture
medium (control) or pre-incubated with B. bifurcata extract diluted in culture medium for 1 h, and later
activated with 50 ng mL−1 of the Toll-like receptor 4 agonist lipopolysaccharide (LPS) for 24 h. After the
treatments, resazurin solution (50 μM in culture medium) was added to each well and incubated at
37 ◦C for 1 h, in a humidiﬁed atmosphere of 95% air and 5% CO2. Viable cells are able to reduce
resazurin into resoruﬁn (ﬂuorescent pink) and, hence, their number correlates with the magnitude
of dye reduction. Quantiﬁcation of resoruﬁn was performed on a Biotek Synergy HT plate reader
(Biotek, Winooski, VT, USA) at 570 nm, with a reference wavelength of 620 nm.
3.5.3. Measurement of Nitrite Production by Griess Reagent
The production of nitric oxide (NO) was measured by the accumulation of nitrite in the culture
supernatants of cells treated with or without B. bifurcata dichloromethane extract (6.25–100 μg mL−1)
in the presence or absence of LPS, using a colorimetric reaction with the Griess reagent [59].
Brieﬂy, 170 μL of culture supernatants were diluted with equal volumes of the Griess reagent
[0.1% (w/v)N-(1-naphthyl)-ethylenediamine dihydrochloride and 1% (w/v) sulphanilamide containing
5% (w/v) H3PO4] and maintained during 30 min, in the dark. The absorbance at 550 nm was measured
in a Biotek Synergy HT plate reader. Culture medium was used as blank and nitrite concentration was
determined from a regression analysis using serial dilutions of sodium nitrite as standard (0.5–50 μM).
• Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0 for Mac OS X (GraphPad
Software, San Diego, CA, USA). For each experiment, the results are expressed as mean ± SD
of, at least, three independent experiments. Evaluation of statistical signiﬁcance was performed
using one-way ANOVA with Dunnett’s multiple comparison test. Values of p < 0.05 were considered
statistically signiﬁcant.
3.6. Antibacterial Activity
3.6.1. Bacterial Strains
Bacterial stocks of Gram-positive, Staphylococcus aureus ATCC®6538, S. aureus ATCC®43300 and
S. epidermidis and Gram-negative Escherichia coli ATCC®25922 and Pseudomonas aeruginosa PAOI were
kept in Brucella Broth (Fluka Chemie, Madrid, Spain) with 20% (v/v) glycerol (Sigma, Madrid, Spain)
at −80 ◦C.
Pre-inoculum was prepared by stocks defrosting at room temperature, suspension in Mueller
Hinton Broth (MHB; Lioﬁlchem, Roseto degli Abruzzi, Italy) followed by a 6 h incubation at 37 ◦C,
220 rpm. Afterwards, bacteria were streaked onto Mueller Hinton Agar (MHA; Lioﬁlchem, Roseto
degli Abruzzi, Italy) and incubated overnight at 37 ◦C. Then, bacteria were harvested with sterile
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peptone water (Lioﬁlchem), washed twice by centrifugation at 2700 rpm and bacterial pellet suspended
in MHB.
3.6.2. Growth Kinetics
For each strain, growth curves were performed in three independent experiments in order to
determine the respective exponential phase. Colonies from MHA were harvested with sterile peptone
water and bacterial pre-inoculum was prepared as mentioned above. The initial optical density of each
bacterial strain was adjusted to 0.04 in the referred media (λ = 600 nm). T-ﬂasks (Starsted, Numbrecht,
Germany) containing media and bacterial inoculums were incubated with agitation (220 rpm) at 37 ◦C.
At different time points, samples were taken and the optical density was measured at λ = 600 nm.
The correlation between the obtained optical density values with the number of colony-forming
units per mL (CFU mL−1) was accessed. For CFU mL−1 determination, bacteria were harvested from
liquid media at different time points; serial dilutions were done in peptone water (10−2 until 10−7) and
10 μL of each dilution plated in MHA. Incubation was done as previously described and the number
of CFUs was determined after 24 h. Experiments were performed twice and in triplicate (n = 6 for
each experiment).
3.6.3. Minimal Inhibitory Concentration (MIC) Determination
MIC assays were performed in accordance to the Clinical and Laboratory Standards Institute
(CLSL) guidelines [60]. Brieﬂy, bacterial cells in exponential growth phase (about 2 h of incubation,
previously deﬁned in Section 3.6.2) were suspended in MHB (Fluka Chemie) and the B. bifurcata
dichloromethane extract was dissolved in dimethyl sulfoxide (DMSO; AppliChem, Darmstadt,
Germany) to a ﬁnal stock concentration of 50 mg mL−1. The antibacterial performance of the extract
was screened using the microbroth dilution method in a range of concentrations from 8 to 2048 μg mL−1
in 96 well-plates (Starsted, Numbrecht, Germany) [61]. The MIC was qualitatively determined after
24 h of incubation, at 37 ◦C, by addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, Calbiochem® supplied by Millipore, Madrid, Spain) with slight adaptations to the
protocol described by Ellof et al. [62]. The use of MTT, metabolized to a formazan chromophore by
the viable cells, was required for MIC determination due to the coloration of the extract that turned
the naked eye MIC visualization impracticable. The following controls were performed: (i) solvent
control: bacterial cultures with 4% (v/v) of DMSO, which represents the maximum amount of solvent
added to the cultures, to infer its effect on bacterial growth; (ii) pure cultures (only bacterial inoculum);
and (iii) culture media. Experiments were performed twice and in triplicate (n = 6 for each experiment).
3.6.4. Synergistic Assays
The synergistic potential of the extract was accessed by conjugation of the extract with antibiotics,
namely: rifampicin. gentamicin, ampicillin, and tetracycline (all supplied by Sigma, Madrid, Spain)
in a concentration range between 2 and 512 μg mL−1; against the same bacterial panel. B. bifurcata
extract was used at the respective MIC concentration, calculated as described above. Antibiotics MIC,
when used alone or in extract + antibiotic combination were determined as mentioned above.
Experiments were performed twice and in triplicate (n = 6 for each experiment).
4. Conclusions
The complete study of the lipophilic fraction of B. bifurcata from a Portuguese aquaculture
system was characterized in detail by GC-MS. B. bifurcata dichloromethane extract was
composed mainly of diterpenes (1892.78 ± 133.97 mg kg−1 DW), followed by fatty acids
(947.88 ± 21.94 mg kg−1 DW). Considerable amounts of sterols (406.45 ± 26.19 mg kg−1 DW) were also
found, with fucosterol accounting for 317.68 ± 26.11 mg kg−1 DW. The sterols, long-chain aliphatic
alcohols, and monoglycerides proﬁle of B. bifurcata is reported for the ﬁrst time. Additionally, two
diterpenes, phytol and neophytadiene, are also reported for the ﬁrst time as constituents of
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B. bifurcata. This extract showed relevant antioxidant activities against both DPPH and ABTS
radicals. Additionally, antibacterial activity was shown to be strain-dependent, with activity being
veriﬁed against both Gram-positive (S. aureus) and Gram-negative (E. coli) strains. B. bifurcata extract
was shown to increase antibiotic antimicrobial activity, with this effect being microbial strain- and
antibiotic-dependent. This study provides the basis for further exploitation of this alga’s biomolecules
for current antimicrobial chemotherapeutics, showing the practical utility of marine natural products
to sensitize pathogenic bacteria, increasing their susceptibility. In addition, the studied extract showed
promising anti-inﬂammatory activity, which is reported for the ﬁrst time. It is important to point
out that all biological activities were expressed using low extract concentrations, on the order of μg
mL−1. This study is, therefore, an important contribution for the valorization of B. bifurcata macroalga
from aquaculture systems, with promising applications in the functional food, nutraceutical, cosmetic,
and biomedical ﬁelds, obviously considering the development of eco-friendly methodologies to extract
this lipophilic fraction.
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Abstract: The lipids from gonads and polyhydroxynaphthoquinone pigments from body walls of
sea urchins are intensively studied. However, little is known about the body wall (BW) lipids.
Ethanol extract (55 ◦C) contained about equal amounts of saturated (SaFA) and monounsaturated
fatty acids (MUFA) representing 60% of total fatty acids, with myristic, palmitic and eicosenoic acids
as major SaFAs and MUFAs, respectively. Non-methylene-interrupted dienes (13%) were composed of
eicosadienoic and docosadienoic acids. Long-chain polyunsaturated fatty acids (LC-PUFA) included
two main components, n6 arachidonic and n3 eicosapentaenoic acids, even with equal concentrations
(15 μg/mg) and a balanced n6/n3 PUFA ratio (0.86). The UPLC-ELSD analysis showed that a great
majority of the lipids (80%) in the ethanolic extract were phosphatidylcholine (60 μg/mg) and
phosphatidylethanolamine (40 μg/mg), while the proportion of neutral lipids remained lower
than 20%. In addition, alkoxyglycerol derivatives—chimyl, selachyl, and batyl alcohols—were
quantiﬁed. We have assumed that the mechanism of action of body wall lipids in the present study is
via the inhibition of MAPK p38, COX-1, and COX-2. Our ﬁndings open the prospective to utilize this
lipid fraction as a source for the development of drugs with anti-inﬂammatory activity.
Keywords: sea urchin; body wall lipids; inhibition of p38 MAPK; COX; GC-MS; UPLC-ELSD
1. Introduction
Sea urchins have wide distribution and they play an important role in ecosystem of both
shallow and deeper waters of the ocean. A number of species of sea urchin are intensively utilized
in food, pharmaceutical, and cosmetic industries. In 2015, the total world production of edible
sea urchin was 71,229 tons [1]. Green sea urchin, Strongylocentrotus droebachiensis, is an edible
species of the phylum Echinodermata, which is a typical inhabitant of the polar region of Russia,
including the Barents Sea. The gonads are delicacies in many parts of the world and considered as
highly valued seafood. Several studies have indicated that the gonads of S. droebachiensis are rich in
important bioactive compounds like polyunsaturated fatty acids (PUFA), phospholipids, tocopherols,
sterols [2–4], carotenoids [2,5], and amino acids [6,7]. Extract of gonad tissue has also revealed effective
anti-inﬂammatory and antidiabetic properties [4].
After removal of gonads, the residual shells and spines (body wall, BW) of sea urchins which
account for more than 40% of total body weight are discarded as waste. Previous studies have also
shown that sea urchin BW contain polyhydroxynaphthoquinones. These pigments have evoked
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renewed interest as a promising source for the development of drugs. A number of bioactivities have
been found, for example antiallergic [8], antidiabetic [9], antihypertensive [10], anti-inﬂammatory [11],
antioxidant [12–14], cardioprotective [15], and hypocholesterolemic [16] effects.
Total concentration of pigments in sea urchin body wall is quite low (1.2–1.6 mg/g) [17], however,
a puriﬁcation method has been recently reported in order to improve the yield of shell pigments [18].
The inner layer of the body wall, on the contrary, is covered with a biomembrane, consisting of lipids.
However, their proﬁle has not been described yet. Marine lipids are unique sources of essential fatty
acids, phospholipids, sterols, and alkoxyglycerols, and they have a broad pharmacological activity.
The aim of this study was to analyze the ethanolic extract of lipids underlying the body wall (BW)
of green sea urchin by using gas chromatography-mass spectrometry (GC-MS) and ultra-performance
liquid chromatography (UPLC-ELSD). In addition, the anti-inﬂammatory potential of BW lipids was
investigated in vitro.
2. Results
2.1. Fatty Acid Composition of Body Wall (BW) Lipids
The ethanolic (95%) extract, which was prepared at 55 ◦C for 3 h, contained about equal amounts of
saturated (SaFA) and monounsaturated fatty acids (MUFA) representing 60% of total fatty acids. Myristic,
palmitic, and eicosenoic acids were the main SaFAs and MUFAs, respectively (Table 1 and Figure 1).
The principalMUFA is unusual and this isomer is suggested to be 20:1n15. Among non-methylene-interrupted
dienes (NMID, 13%), eicosadienoic (20:2) and docosadienoic (22:2) acids were characteristic. They are typical
constituents of sea urchin among which 20:2Δ5,11 often appears as the most abundant isomer. In addition,
n12 and n5 isomers of 18:1, 20:3n9 and cyclopropaneoctanoic and -decanoic acid 2-octyl methyl esters
accounted 10 μg/mg.
The composition of long-chain polyunsaturated fatty acids (LC-PUFA) was characterized by
two major components, n6 arachidonic (20:4n6; AA) and n3 eicosapentaenoic acids (20:5n3; EPA),
with equal concentrations (15 μg/mg) and a balanced n6/n3 PUFA ratio (0.86). These LC-PUFAs
possess important properties, since they act as the precursors of eicosanoids.
A very low amount of docosahexaenoic acid (22:6n3, DHA) was typical for BW lipid extract
(Table 1), as well as the high proportion of free (22%) vs. esteriﬁed fatty acids. Quantitatively, free AA
covered 1/3 of total AA and free EPA 1/4 of total EPA, respectively, reﬂecting decomposition of bound
fatty acids during extraction procedure. The relatively high proportion of LC-PUFAs, n6 AA, and n3
EPA (20%), would suggest that the extract is rich in phospholipids.
Table 1. The concentrations (μg/mg; mean ± SD, n = 3) and relative amounts (%) of bound and free
fatty acids in ethanolic extract of BW lipids of sea urchin determined by GC-MS.
Fatty Acids Bound Fatty Acids as FAME % FFA %
C10:0–C13:0 0.4 ± 0.1 0.3 - -
C14:0 15.1 ± 0.7 9.6 3.7 ± 0.1 8.4
C15:0 1.5 ± 0.1 0.9 0.5 ± 0.1 1.1
C16:0 21.9 ± 1.2 13.9 5.0 ± 0.2 11.4
C18:0 4.0 ± 0.2 2.5 2.1 ± 0.1 4.8
C19:0 1.0 ± 0.1 0.6 - -
C20:0 0.6 ± 0.1 0.4 - -
Σ SaFAΣ 44.5 ± 2.1 28.2 11.3 ± 0.3 25.7
C14:1n5 1.1 ± 0.1 0.7 - -
C16:1n9 0.9 ± 0.1 0.6 - -
C16:1n7 7.8 ± 0.6 4.9 1.9 ± 0.1 4.3
C16:1n5 4.5 ± 0.2 2.8 - -
C18:1n9 3.0 ± 0.2 1.9 1.4 ± 0.1 3.2
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Table 1. Cont.
Fatty Acids Bound Fatty Acids as FAME % FFA %
C18:1n7 4.2 ± 0.2 2.7 2.9 ± 0.1 6.6
C20:1n15 16.7 ± 0.8 10.6 - -
C20:1n9 5.2 ± 0.3 3.3 8.2 ± 0.4 18.6
C20:1n7 1.3 ± 0.1 0.8 - -
C22:1n9 4.3 ± 0.2 2.7 - -
ΣMUFA 49.0 ± 1.3 31.0 14.4 ± 0.4 32.7
20:2Δ5,11 12.2 ±1.2 7.7 - -
20:2Δ5,13 3.0 ± 0.5 1.9 - -
22:2Δ7,13 0.9 ± 0.2 0.6 - -
22:2Δ7,15 4.7 ± 0.4 3.0 - -
Σ NMID 20.9 ± 1.9 13.2 - -
C18:2n6 1.5 ± 0.1 0.9 5.2 ± 0.2 11.8
C20:2n6 1.9 ± 0.1 1.2 - -
C20:3n6 0.9 ± 0.1 0.6 - -
C20:4n6 15.8 ± 0.6 10.0 7.3 ± 0.1 16.6
Σ n6 PUFA 20.1 ± 1.0 12.7 12.5 ± 0.8 28.4
C18:3n3 1.2 ± 0.1 0.8 - -
C18:4n3 2.3 ± 0.1 1.5 - -
C20:3n3 2.3 ± 0.2 1.5 - -
C20:4n3 0.6 ± 0.1 0.4 - -
C20:5n3 15.2 ± 0.7 9.6 5.8 ± 1.0 13.2
C22:5n3 0.2 ± 0.1 0.1 - -
C22:6n3 1.7 ± 0.1 1.1 - -
Σ n3 PUFA 23.5 ± 1.1 14.9 5.8 ± 1.0 13.2
Σ Fatty acids 158.0 ± 5.3 100.0 44.0 ± 1.8 100.0
n6/n3 PUFA 0.86 2.16
FAME, fatty acid methyl ester; FFA, free fatty acid; SaFA, saturated fatty acid; MUFA, mono-unsaturated fatty acid;
NMID, non-methylene-interrupted diene; PUFA, polyunsaturated fatty acid.
Figure 1. GC-MS analysis of transesteriﬁed and trimethylsilylated (TMS) fatty acids from ethanolic
extract of BW lipids of sea urchin. Total ion (TIC) and extracted ion chromatogram (m/z 205) shows
TMS derivatives of alkylglycerols (AOG; (1) 16:0-AOG, (2) 18:1-AOG, and (3) 18:0-AOG) and sterols
(peaks 4–11, TIC): (4–5) unidentiﬁed sterols, (6) cholesterol, (7) desmosterol, (8) cholecalciferol as
shoulder, (9) campesterol, (10) stigmasterol, and (11) clionasterol. Heptadecanoic acid (as FAME and
TMS derivative) was used as internal standard (IS). Other peaks represent FAMEs and TMS ethers.
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2.2. Sterols and Alkoxyglycerols (AOG)
Sterol and AOG samples were analyzed by GC-MS as TMS-derivatives. BW lipid extract contained
mainly cholesterol (50 μg/mg) (Figure 1 and Table 2). Minor non-cholesterol sterols included
desmosterol, campesterol, stigmasterol, and clionasterol (gamma-sitosterol) which is a common
constituent in oyster, for example [19]. For GC-MS analyses from abundant AOG sources, puriﬁed
samples from unsaponiﬁable fraction have been used. Because of low concentration, extracted ion
chromatogram (m/z 205) of silylated AOG was taken to conﬁrm the peak location. This fragment is
formed after cleavage between carbons 1 and 2 of the glycerol moiety [20]. Quantiﬁed AOG derivatives
were chimyl (C16:0), selachyl (C18:1) and batyl alcohols (C18:0).
Table 2. Sterol and alkoxyglycerol (AOG) content (μg/mg; mean ± SD, n = 3) of ethanolic extract of
BW lipids of sea urchin. Sterols and AOGs were determined as TMS ethers by GC-MS.
Sterols and AOGs μg/mg
Cholesterol 50.3 ± 2.8
Non-cholesterol sterols * 10.6 ± 0.5
C16:0-AOG 1.0 ± 0.1
C18:1-AOG 0.4 ± 0.1
C18:0-AOG 0.3 ± 0.1
Σ Alkoxyglycerols 1.7 ± 0.2
* Non-cholesterol sterols include desmosterol, campesterol, stigmasterol, clionasterol, and two unidentiﬁed sterols
(Figure 1).
2.3. Lipid Classes
The UPLC-ELSD analyses from the ethanol extract of BW lipids, shown in Figure 2 and Table 3,
demonstrate high abundance of phospholipids (PL, 80%), especially those of phosphatidylcholine
(PC, 60 μg/mg) and phosphatidylethanolamine (PE, 40 μg/mg). The proportion of neutral lipids
remained less than 20%. It is clear that ethanol extracts polar PLs better than neutral lipids (NL) like
triacylglycerols and cholesteryl esters. The fatty acid proﬁle with relatively high content of PUFAs
indicates that the fatty acids have mostly originated from PLs. Lysophosphatidylcholine (LPC) eluted
late as a broad peak and covered about 8% of total lipids.
Figure 2. UPLC-ELSD chromatogram of BW lipids of ethanol (95%) extract of sea urchin. UPLC, ultra-
performance liquid chromatography; ELSD, evaporative light scattering detector; WE, wax ester,
SE, steryl ester; TG, triacylglycerol; Chol, cholesterol; ip, impurity; Cer, ceramide; CL, cardiolipin;
PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; PC, phosphatidylcholine;
SPH, sphingomyelin; LPC, lysophosphatidylcholine.
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Table 3. Concentration of major lipid classes (μg/mg, mean ± SD; n = 3) and their relative amounts (%)
in ethanolic extract of BW lipids of sea urchin. Analyses were carried out by UPLC-ELSD.
Lipid Classes μg/mg %
WE + SE 14.6 ± 0.7 8.4
TG 15.9 ± 1.0 9.1
Σ Neutral lipids 30.5 ± 1.6 17.5
PE 38.6 ± 1.1 22.2
PI + PS 27.8 ± 0.1 16.0
PC 63.3 ± 1.7 36.4
LPC 13.5 ± 0.5 7.8
Σ Phospholipids 143.2 ± 0.7 82.5
Σ Total lipids 173.7 ± 2.3 100.0
WE, wax ester; SE, steryl ester; TG, triacylglycerol; PE, phosphatidylethanolamine; PS, phosphatidylserine;
PI, phosphatidylinositol; PC, phosphatidylcholine; LPC, lysophosphatidylcholine.
2.4. Bioactivity of Body Wall (BW) Lipids
Inﬂammation is a part of the body’s normal response to infection and injury, extreme or
inappropriate inﬂammation, on the contrary, is linked to the pathobiology of several diseases [21].
The anti-inﬂammatory effect of S. droebachiensis lipids of the extract was assessed in the human
mononuclear U937 cells stimulated with lipopolysaccharide (LPS). The stimulation of U937 resulted
in direct activation of MAPK p38. The results (Table 4) revealed that BW lipids dose-dependently
inhibited MAPK p38. The most effective dose of the lipid extract was 0.033 μg/mL. In addition,
BW lipids were clearly more potent than a speciﬁc MAPK p38 inhibitor SB203580 (1.88 μg/mL) at
the doses of 0.0037–0.1 μg/mL. The COX-1 and COX-2 isoenzymes were inhibited by BW lipids
dose-dependently with IC50 = 15.7 μg/mL and 21 μg/mL, respectively.
Table 4. Effect of body wall (BW) lipids on the phosphorylation of MAPK p38 in the human mononuclear
U937 cells Mean ± SEM, (n = 6).
Sample, Concentration Percentage of MAPK p38 (%)
Intact cells (no stimulation with LPS) 23.0 ± 1.2
Control cells stimulated with LPS (1 μg/mL) 100
SB203580 (1.88 μg/mL) + LPS 30.0 ± 1.7
BWL (10 μg/mL) + LPS 59.0 ± 1.3
BWL (5 μg/mL) + LPS 53.0 ± 1.9
BWL (1 μg/mL) + LPS 49.0 ± 0.9
BWL (0.5 μg/mL) + LPS 38.0 ± 1.6
BWL (0.1 μg/mL) + LPS 17.0 ± 1.5
BWL (0.033 μg/mL) + LPS 12.0 ± 0.5
BWL (0.011 μg/mL) + LPS 21.0 ± 1.7
BWL (0.0037μg/mL) + LPS 27.0 ± 0.7
BWL (0.0012 μg/mL) + LPS 38.0 ± 1.6
BWL (0.0004 μg/mL) + LPS 52.0 ± 1.2
3. Discussion
The fatty acid composition of the ethanol extract of body wall (BW) lipids of sea urchin
(Table 1 and Figure 1) was consistent with literature including non-methylene interrupted dienes
(NMID) and unusual cyclopropane derivatives [2,22,23]. The principal PUFAs were n6 arachidonic
(AA) and n3 eicosapentaenoic acids (EPA). The proportion docosahexanoic acid (22:6n3, DHA) in BW
lipids, on the contrary, was very low as has been reported also by others [2,22]. In our previous study,
gonads of sea urchin contained about 50 μg/mg of EPA and DHA [4]. Analysis of lipid classes showed
two major phospholipids—i.e., phosphatidylcholine and phosphatidylethanolamine. This data is in
general agreement with the phospholipids proﬁle of gonads of S. droebachiensis [7].
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Fats in human diet are responsible for severe health problems because of long-term intake of
unbalanced proportions of SaFA, MUFA, n6, and n3 PUFA. The n6 and n3 PUFA intake favors too much
n6 PUFA. This presupposes an adequate intake of PUFA precursors (n6 linoleic and n3 alpha-linolenic
acids) to form long-chain LC-PUFAs (n6-AA and n3-EPA), which, in turn, act as eicosanoid precursors
which determine the balance and effects of eicosanoids in the body [24]. Arachidonic acid is converted
to thromboxane-type eicosanoids via cyclo-oxygenase enzyme, while EPA is converted to prostacycline,
antagonizing the conversion of AA to eicosanoids. This would enhance anti-aggregatory and
anti-inﬂammatory conditions [25].
From a biological point of view, the biomembrane covering the inner layer of the body wall
plays an important protective role for survival of the sea urchin. Damage of the body wall will
follow with inﬂammation. Mitogen-activated protein kinases (MAPKs) are among the most important
molecules in the signaling pathways among which MAPK p38 signaling plays an essential role
in regulating cellular processes, especially inﬂammation [26]. In our study, we observed 88% of
MAPK p38 inhibition by body wall (BW) lipids at a very low dose of 0.033 μg/mL (Table 4).
The inhibition of MAPK p38 might be attributed to the different active compounds of BW lipids.
Ait-Said et al. [27] established that EPA, unlike DHA, failed to inhibit nuclear factor-κB (NF-κB)
activation, and suppressed MAPK p38 phosphorylation in IL-1β stimulated human pulmonary
microvascular endothelial cells. The anti-inﬂammatory properties of EPA in LPS-stimulated BV2
microglia cells were mediated by downregulation of NF-κB and MAPKs such as ERK, p38, JNK,
and Akt activation [28].
Cyclooxygenase-2 (COX-2) isoenzyme could be induced by a wide range of proinﬂammatory
agents. Prostaglandin-dependent ampliﬁcation of COX-2 is hypothesized to be an important part of
sustained proliferative and chronic inﬂammatory conditions [29]. EPA as well as DHA effectively
inhibited COX-2 expression in LPS-stimulated HUVEC endothelial cells [30]. Recently, we have
reported that lipid rich fraction from gonads of S. droebachiensis inhibited COX-2 with IC50 = 49 μg/mL,
but was not effective against COX-1 isoform [4]. It is important to note that, in our current study,
body wall lipids were more effective and inhibited COX-2 in lower dose and inhibited COX-1 with
IC50 = 15.7 μg/mL.
Low amounts of ether-bonded alkoxyglycerols were also found in ethanolic extract of BW lipids
(Figure 2 and Table 3). The total amount of AOG was less than 0.2% which would correspond about
the level in human milk and plasma lipids, for example [31]. By using the present UPLC-ELSD
method, however, it was not possible to detect glycerophospholipid-based alkyl- and alkenylacyl
lipids, since their analysis ﬁrst requires the separation of phospholipid subclasses. These lipids, such
as glycerophosphatidylethanolamine and -choline, are known to have important activities.
Biological activity of alkoxyglycerols has been known already more than half a century. Some of
the activities, such as anti-inﬂammatory effects and protection against radiation damage, are still
under study together with the more recent interest in the possible cell-signaling properties of
phospholipid-based ether-bonded compounds. These lipids have shown multiple pharmacological
activities such as anti-cancer [32], wound healing [33], and immunostimulatory effects [34]. It has
been demonstrated that AOG differentially modulate LPS-mediated MAPK and NF-κB signaling in
adipocytes and that they do not activate signaling in the absence of LPS. Saturated alkyl chain increased
LPS-mediated activation of the MAPK signaling, which could cause the expression of inﬂammatory
genes. Conversely, unsaturated alkyl chain decreased LPS-mediated activation of the MAPK and
NF-κB signaling [35].
Taking into account all these aspects, we can hypothesize that the lipids containing n3 PUFA,
especially EPA, could contribute anti-inﬂammatory activity. Besides the content of neutral lipid
alkoxyglycerols, it is necessary to conﬁrm the occurrence of alkyl- and alkenylacyl lipids and fatty acid
compositions of individual phospholipid classes in BW lipid extracts.
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4. Material and Methods
4.1. Sample Preparation and Extraction of Lipids
Green sea urchins, Strongylocentrotus droebachiensis, were harvested in the Barents Sea in 2016
by divers. After removal of gonads, coelomic ﬂuid, and internal organs, the shells with spines were
washed in cold tap water, dried at 4 ◦C for two days and stored in a dark place. The shells with spines
(20 g) were ground and macerated with 160 mL of 95% ethanol for 3 h with constant stirring at 55 ◦C.
The extract was ﬁltered and evaporated into dryness by rotary evaporator (IKA RV 10; IKA®-Werke
GmbH & Co. KG, Staufen, Germany). The yield of the body wall lipids was 1.2%.
4.2. Chemical Analyses
4.2.1. Analysis of Fatty Acids, Sterols and Alkoxyglycerols by GC-MS
Analyses of bound and free (FFA) fatty acids were carried out by using the method described
previously [4]. Shortly, the lipid extract, spiked with internal standards (IS) TG(17:0/17:0/17:0) and
FFA 17:0, were transesteriﬁed with 0.5 N sodium methoxide at 45 ◦C for 5 min. After acidiﬁcation,
fatty acid methyl esters (FAMEs) as well as FFAs were extracted with petroleum ether. The method
enabled the esteriﬁcation of bound fatty acids from neutral lipids and also from phospholipids [36].
The mixtures of FAMEs and FFAs were used as reference substances.
The analyses were performed on an Agilent 7890A GC mounted with Gerstel MPS injection
system and an Agilent 5975C mass selective detector. The column was an Agilent FFAP silica capillary
column (25 m × 0.2 mm × 0.3 μm) and helium was used as the carrier gas. The oven temperature
raised from 70 ◦C to 235 ◦C, with a total run time of 30 min. The temperatures of the injector and MS
source were 220 and 230 ◦C, respectively, and the data were collected in EI mode (70 eV) at a mass
range of m/z 40–600.
After analyzing the composition of FAMEs by GC-MS, the same samples were derivatized to
determine the contents of FFAs, cholesterol, and minor sterols. Analyses of alkoxyglycerols (AOG) were
done according to a previous method [31]. Samples were evaporated, re-dissolved in dichloromethane,
and silylated with MSTFA [N-Methyl-N-(trimethylsilyl)-triﬂuoroacetamide] (Pierce, Rockford, IL, USA)
at 80 ◦C for 20min. TMS-derivatives were analyzed on an Rtx-5-ms column (15m× 0.25mm× 0.25 μm)
(Restek, Bellefonte, PA, USA). The split ratio was 20:1 and the oven temperature was programmed to go
from 70 (1 min) to 270 ◦C at a rate of 10 ◦C/min, the total run time was 30 min. The data was collected
by MSD ChemStation software (Agilent Technologies, Inc., Santa Clara, CA, USA). Identiﬁcation of
the compounds was based on retention times of reference substances, library comparisons (The Wiley®
Registry of Mass Spectral Data, John Wiley and Sons, Inc., New York, NY, USA; NIST 08 spectral library,
National Institute of Standards and Technology, Gaithersburg, MD, USA) and on literature data.
4.2.2. Analysis of Lipid Classes by UPLC-ELSD
The same lipid extract as above (without derivatization) was analyzed on a Waters AcquityTM
H-class UPLC (ultra-performance liquid chromatograph) equipped with an evaporative light scattering
detector (ELSD) by modifying previous conditions [37]. Separation of the lipid classes was carried
out on a Waters Spherisorb silica column (3 μm, 100 × 2.1 mm I.D.). The gradient solvent system
consisted of (A) iso-octane-tetrahydrofurane (99:1), (B) 2-propanol-dichloromethane (3:2) and (C)
2-propanol-water (1:1) with an analysis time of 20 min. The temperature of the drift tube was 40 ◦C
and air ﬂow 50 psi. The multigradient system started from 100% A, the proportion of A decreased
to 32%, that of B increased to 52% and simultaneously that of C (containing water) increased to
16%. Stable retention times were obtained by keeping continuous cycle running. The ﬂow rate was
0.800 mL/min and the injection volume 2 μL. The temperature of the sample manager was 10 ◦C.
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4.3. Biological Assays
4.3.1. Cell Lines and Cell Culture
The human mononuclear U937 cells were purchased from the Russian Collection of Cell Culture
(Institute of Cytology of Russian Academy of Science, Saint-Petersburg, Russia), and maintained
at 37 ◦C in a humidiﬁed 95% air and 5% CO2 in RPMI1640 supplemented with 2 mM glutamine,
10% heat-inactivated FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. BW lipids were
dissolved in dimethyl sulfoxide (DMSO) as a stock solution at a 10 mg/mL concentration, and the stock
solution was then diluted with the medium to the desired concentration prior to use. Cells derived from
the freeze-down batch were thawed, grown, and seeded (106 cells per well) onto 12-well tissue culture
plates and cultured in medium for 24 h. The cells were then stimulated with 1 μg/mL Escherichia coli
LPS (Sigma-Aldrich, St. Louis, MO, USA) at 37 ◦C for 1 h. After that the cells were treated with
SB203580 (Sigma-Aldrich, St. Louis, MO, USA) and various concentrations of BWL at 37 ◦C for 1 h.
4.3.2. Western Blotting
Cells were washed in cold (4 ◦C) phosphate-buffered saline (PBS; 0.5 mol/L sodium phosphate,
pH 7.5) and separated by centrifugation (Hermle Labortechnik, Germany) at 1500 rpm−1 for 5 min at
4 ◦C, harvested by gentle scraping, and used to prepare total protein or nuclear extracts. Cells were
treated with lysis buffer—1 mol/L Tris-HCl pH 7.5, 1.5 mol/L NaCl, 10% Triton X-100, 0.2 mol/L
Na3VO4, 1 mol/L NaF, 0.2 mol/L EDTA, phenylmethylsulphonyl ﬂuoride (PMSF), Abcam’s protease
inhibitor cocktail, and Abcam’s phosphatase inhibitor cocktail—for 20 min at 4 ◦C. The lysates were
then clariﬁed by centrifugation at 15,000 rpm−1 for 15 min at 4 ◦C and the supernatant was collected.
The protein concentrations of the extracts were determined using the [38] with an XMark
spectrophotometer (Bio-Rad, Hercules, CA, USA). For Western blot analysis, 40 μg of protein
were desaturated by boiling with Laemmli buffer (5 min at 100 ◦C) and subjected to 4–14%
SDS-polyacrylamide gels, and transferred to nitrocellulose membrane membranes (Bio-Rad) by
electroblotting. The membranes were blocked with 5% non-fat dry milk in PBS with Tween 20 buffer
(PBS-T) (Tris-HCl (pH 7.5), 1.5 mol NaCl, and 0.1% Tween 20) for 1 h at room temperature. Membranes
were then incubated overnight at 4 ◦C with the primary antibodies, probed with enzyme-linked
secondary antibodies, and visualized using a chemiluminescent detection with LumiGLO® reagent
(Cell Signaling Technology, Danvers, MA, USA) according to the manufacturer’s instructions.
After detection, the membranes were scanned (Epson Perfection V330 Photo, Seiko Epson Corporation,
Nagano, Japan) and processed with Scion Image software (Alpha 4.0.3.2, Scion, Fredrick, MD, USA).
The band intensities were used for calculations. Phospho-p38 MAPK antibody, rabbit, p38 MAPK XP
rabbit mAb, β-actin rabbit mAb, and anti-rabbit IgG, HRP-linked antibody were from Cell Signaling
Technology (Danvers, MA, USA).
4.3.3. Assessment of Cyclooxygenase Activity
Inhibition of human recombinant cyclooxygenase COX-1 and COX-2 (Cayman Chemical,
Ann Arbor, MI, USA) was assessed according to the manufacturer’s instructions. Indomethacin
(1 μg/mL) from Sigma (St. Louis, MO, USA) was used as reference. The BWL was dissolved in DMSO
prior to analysis.
4.4. Statistical Analysis
Data were analyzed using Statistica version 10.0. All biological assay data are presented as
mean ± SEM or mean ± SD. Differences among groups were evaluated by one way analysis
of variance (ANOVA) and post-hoc Tukey’s test. In all comparisons, p < 0.05 was accepted as
statistically signiﬁcant.
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5. Conclusions
To the best of our knowledge, this is the first time when the profile of body wall lipids is reported.
It can be assumed that themechanism of action of bodywall lipids in the present study is via the inhibition
of MAPK p38, COX-1, and COX-2. Our findings open the potential to utilize this lipid fraction as a source
for the development of drugs with anti-inflammatory activity. Further- more, the anti-inflammatory
properties of the lipid extract may be useful for ameliorating neuro- degenerative diseases, as well as
suppressing LPS-induced shock.
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Abstract: Fish oil is used in the production of feed for cultured ﬁsh owing to its high polyunsaturated
fatty acid content (PUFA). The over-exploitation of ﬁsheries and events like “El Niño” are reducing
the ﬁsh oil supply. Some marine microorganisms are considered potentially as alternative fatty acid
sources. This study assesses a strain of Rhodotorula sp. (strain CNYC4007; 27% docosahexaenoic
acid (DHA) of total fatty acids), as feed for ﬁsh larvae. The total length and ribonucleic acid
(RNA)/deoxyribonucleic acid (DNA) ratio of Danio rerio larvae was determined at ﬁrst feeding
at six and 12 days old (post-yolk absorption larvae). Larvae fed with microencapsulated Rhodotorula
sp. CNYC4007 had a signiﬁcantly higher RNA/DNA ratio than control group (C1). At six days
post-yolk absorption group, the RNA/DNA ratio of larvae fed with Rhodotorula sp. bioencapsulated
in Brachionus sp. was signiﬁcantly higher than control group fed with a commercial diet high in DHA
(C2-DHA). Finally, at 12 days post-yolk absorption, the RNA/DNA ratio was signiﬁcantly higher in
larvae fed with Rhodotorula sp. CNYC4007 and C2-DHA (both bioencapsulated in Artemia sp. nauplii)
than in control group (C1). These results suggest that Rhodotorula sp. CNYC4007 can be an alternative
source of DHA for feeding ﬁsh at larval stage, providing a sustainable source of fatty acids.
Keywords: Rhodotorula; DHA; EPA; Danio rerio; larvae nutrition; RNA/DNA ratio
1. Introduction
Marine resources for ﬁshmeal and ﬁsh oil have been exploited beyond maximum sustainable
yields [1], and the rate of exploitation is increasing by 8.8% per year [2]. One of the ﬁsh oil uses is
the production of feed for aquaculture [3], an area that has expanded signiﬁcantly, resulting in the
rising demand for ﬁsh oil, which has consequently increased the price of this product [4]. Fish oil is
used because of its high nutritional value and essential polyunsaturated fatty acid content (PUFA),
among which are docosahexaenoic acid (C22:6, DHA), eicosapentaenoic acid (C20:5, EPA) and
docosapentaenoic acid (C22:5, DPA), [5]. Freshwater ﬁsh generally have sufﬁcient elongase and
desaturase activities to produce these fatty acids from the 18C precursor. On the contrary, marine ﬁsh
have a very limited capacity to synthesize these fatty acids [6], hence a strict requirement for long-chain
PUFA, eicosapentaenoic, docosahexaenoic and arachidonic acids (essential fatty acid; EFA). Therefore,
when these fatty acids are not synthesized in ﬁsh they should be incorporated into the diets of the
larval-to-adult stages of the species that are of commercial interest [7,8]. Their presence is important
for normal growth, reproduction, metabolic functions, feeding efﬁciency and immunocompetence [9].
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Speciﬁcally, DHA has a high biological value during larval development and is selectively incorporated
in neural tissue, contributing to pigmentation and visual acuity [10]. Lipids are maternally supplied
and sustain both embryonic and yolk sac larvae development, but when the yolk absorption is
completed and ﬁrst feeding is started an exogenous source of PUFA is required [3]. Then, at the time
of ﬁrst feeding the larvae should receive a diet that covers all the nutritional requirements, so for
aquaculture species the research focus has been to improve the nutritional content of artiﬁcial diets for
larvae [7,11], as diets lacking in nutritional content result in low survival rates [12].
Fatty acids have also been encapsulated in rotifers (Brachionus sp.) and Artemia sp. nauplii [13,14],
these organisms allow for the passing of essential nutrients to the larvae [15,16]. Morphological and
histological parameters, as well as molecular ratios like the ribonucleic acid (RNA)/deoxyribonucleic
acid (DNA) ratio, have been used to determine if effectively delivered nutrients improve the nutritional
condition of the target species [17]. Theoretically, RNA levels in cells vary in relation to protein
synthesis [18], while DNA concentrations remain constant even during starvation [19]. Therefore,
the RNA/DNA ratio is a potential indicator of cellular protein synthesis and growth [17].
The declining supply of traditional sources of essential fatty acids and their high cost has led to the
search for alternative sources [20], among which are vegetable seed oils [21] that contain alpha-linolenic
acid (ALA, 18:3 ω-3), a precursor of DHA and EPA that is assimilated, but not necessarily transformed,
into fatty acids [22]. However, it has not been fully possible to enhance these oils for their use in
aquaculture as anti-nutritional components have been found in them that affect lipid homeostasis and
energy metabolism [23], along with weakening immune response [24]. Another alternative to ﬁsh
oil is single-cell oils (SCO) from one-cell organisms like bacteria, algae, fungoid protists and marine
fungi, which have great potential because of their high essential long-chain unsaturated fatty acid
content [25,26]. Marine fungi has also been described as producers of carotenoids, omega-3 fatty acids,
including DHA and EPA [27], and omega-6 acids like arachidonic acid (20:04 ω6, AA) [28].
Given their characteristics, strains of marine microorganisms constitute as alternative sources that
can partially or totally replace ﬁsh oil for the nutrition of ﬁsh [25,29,30]. For example, Schizochytrium sp.,
a strain that produces a high level of DHA (28% of its dry weight), has been highly studied because it
has been proven with juvenile Salmo salar that the complete replacement of ﬁsh oil with this strain does
not negatively affect growth, immune response, and digestibility of nutrients [25]. Its use with other
marine species under intensive cultivation like Sparus aurata [31] has also been tested and with positive
results. Schizochytrium sp. has therefore been proposed as a sustainable source of fatty acids [25].
A strain of Rhodotorula sp. (CNYC4007) from the Humboldt Current System off Central Chile was
isolated and grown in a bioreactor. The strain, which has high levels of DHA, EPA and carotenoids [27],
could be considered as a suitable source of omega-3 for the aquaculture demand. In reference to the
above the aim of this study was to evaluate the use of strain CNYC4007 for feeding Danio rerio larvae.
The zebraﬁsh (D. rerio) has been widely studied in various ﬁelds of biology [32], and in recent years
has been proposed as a possible model in studies of nutrition and growth in ﬁsh [33], especially as
a model in aquaculture research [34]. However, despite potential limitations due to species-speciﬁc
differences in fatty acid metabolism, zebraﬁsh is a useful tool in the initial screening of new supplies
for larval nutrition with lower cost and rearing times than the use of aquaculture species [35]. To date,
research has been provided on the anti-nutritional aspects of some alternative ingredients [36] and
individualized the requirements for mineral and trace element requirements that have been established
for adequate larval development and growth in zebraﬁsh that could beneﬁt other ﬁsh species [16].
Therefore, we used zebraﬁsh larvae as a model in the ﬁrst step to determine the potential use of
Rhodotorula sp. (CNYC4007) in larval nutrition according to the usual feeding protocols implemented
in larval rearing.
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2. Results
2.1. RNA/DNA Ratio as a Proxy for the Nutritional Condition of Danio rerio
The total DNA content per individual did not present a signiﬁcant difference among live larvae up
to the 5th day ﬁve of the experiment, when the larvae were 10 days old (Kruskal-Wallis test, p = 0.0565).
As well, no signiﬁcant differences were observed for the same parameter among the treatments
during the days of the assay (Figure 1). However, there was 100% mortality rate by 6th day of the
larvae in starvation (11 days old), while there was 100% survival rate among the larvae that were fed.
The quantity of RNA in larval tissue (Figure 1) progressively increased over the course of the treatment
with the standard feed, presenting signiﬁcant differences throughout the assay (one-way analysis of
variance (ANOVA), F-statistic = 31.09, p-value = 4.18 × 10−5). In contrast, RNA content in the tissue of
the larvae under the starvation treatment decreased over the course of the assay. Comparing RNA
content when the larvae were 10 days old (Figure 1), a signiﬁcant difference between larvae fed with the
standard feed (C1) and those in starvation (one-way analysis of variance (ANOVA), F-statistic = 11.6,
p-value = 0.00362) was found. The average of the RNA/DNA ratio of the treatment with the standard
feed (Figure 2) when larvae were 10 days old (5th day of the treatment) was 0.81 ± 0.12, and the
starvation treatment had a lower average (0.71 ± 0.06). This ratio presents signiﬁcant differences
between the treatments (two-way ANOVA, F-statistic = 5.873, p-value = 0.0210).
Figure 1. Average nucleic acid content (ng) versus larvae age of Danio rerio fed with standard feed
compared to treatment with larvae in starvation. Each point represents the average of four larvae
per treatment. * p < 0.05.
 
Figure 2. Ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) ratio versus test of larvae of Danio rerio
fed with standard feed compared to that of larvae in starvation. The daily average is based on four
larvae per treatment. * p < 0.05.
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2.2. Assay with Six-Day-Old Larvae (First-Feeding Larvae, One Day Post-Yolk Absorption)
There were signiﬁcant differences among the three treatments (one-way ANOVA,
F-statistic = 1809, p-value = 2 × 10−16) by the ﬁnal day of the assay (Figure 3). A signiﬁcantly greater
average larval length (7.7 ± 0.3 mm) was obtained with the control feed (control group) than with
the microencapsulated Rhodotorula sp. CNYC4007 and with the ﬂour lyophilized of Rhodotorula sp.
CNYC4007 (7.0 ± 0.2 mm and 7.1 ± 0.2 mm, respectively; Tukey test; p-value = 0.000125 for both
treatments). There were no signiﬁcant differences in the total length between larvae fed on ﬂour and
those fed on microencapsulated Rhodotorula sp. CNYC4007 (Tukey test, p = 0.3641). With respect to the
molecular analysis, the three treatments did not present any signiﬁcant differences over the course of
the assay (Kruskal-Wallis p = 0.148), except for the ﬁnal day (Figure 4) when the RNA/DNA ratios
in the larvae in both the treatments with microencapsulated Rhodotorula sp. CNYC4007 and with
lyophilized ﬂour (which had the same ratios; 0.8 ± 0.14) were higher than that of the larvae in the
control group (0.53 ± 0.09).
 
Figure 3. Total length versus larvae age of Danio rerio at ﬁrst feeding larvae. The daily average is based
on six larvae per treatment. * p < 0.05.
 
Figure 4. RNA/DNA ratio versus larvae age of Danio rerio at ﬁrst feeding larvae. The daily average
daily is based on six larvae per treatment. * p < 0.05.
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2.3. Feeding Six-Day-Old Larvae (Post-Yolk Absorption) with Encapsulation in Brachionus sp.
There were no signiﬁcant differences in the total length between the larvae (Table 1) fed with
rotifers without enrichment (control treatment), rotifers enriched with C2-DHA (positive control) and
rotifers enriched with Rhodotorula sp. CNYC4007 (one-way ANOVA, F-statistic = 0.89, p-value = 0.41),
nor were signiﬁcant differences observed in the lengths of larvae from the different treatments on the
ﬁnal day of the assay (one-way ANOVA, F-statistic = 0.34, p-value = 0.72). Similarly, there were no
signiﬁcant differences in the RNA/DNA ratios of the larvae from the three treatments (Kruskal-Wallis
p = 0.148), except for 7th day of the assay when larvae are 12 days old (Table 2), the RNA/DNA
ratios of larvae fed with Brachionus sp. (control treatments) and Brachionus sp. enriched with C2-DHA
(positive control) were signiﬁcantly lower than those of larvae fed with Rhodotorula sp. CNYC4007
(Tukey test, p = 0.0017 and p = 0.0087, respectively). There were no signiﬁcant differences (Tukey test,
p = 0.6803) between the treatments with Brachionus sp. (control treatment) and Brachionus sp. enriched
with C2-DHA (Table 2).
Table 1. Total larval length (average ± SD) for assay with six-day-old larvae of Danio rerio after
post-yolk absorption. Larvae were fed with bioencapsulated Brachionus sp. rotifers and Artemia sp.
nauplii. The daily average is based on six larvae per treatment. C1: without enrichment; C2-DHA:
feed rich in docosahexaenoic acid (DHA) treatment; CNYC4007: Rhodotorula sp. CNYC4007 treatment.
Larvae Age
(Days)
Total Length Larvae (mm)
Brachionus sp. Artemia sp. nauplii
C1 C2-DHA CNYC4007 C1 C2-DHA CNYC4007
6 5.0 ± 0.2 5.0 ± 0.2 5.0 ± 0.2 n/a n/a n/a
8 5.2 ± 0.3 5.5 ± 0.4 5.1 ± 0.2 n/a n/a n/a
10 5.6 ± 0.1 5.6 ± 0.3 5.6 ± 0.3 n/a n/a n/a
12 5.6 ± 0.1 5.7 ± 0.2 5.8 ± 0.2 5.6 ± 0.3 5.6 ± 0.3 5.6 ± 0.3
14 n/a n/a n/a 5.6 ± 0.3 5.7 ± 0.3 5.8 ± 0.4
16 n/a n/a n/a 5.6 ± 0.2 6.0 ± 0.3 6.0 ± 0.4
18 n/a n/a n/a 6.6 ± 0.1 6.9 ± 0.3 7.0 ± 0.3
20 n/a n/a n/a 9.5 ± 0.4 10.2 ± 0.3 10.1 ± 0.7
22 n/a n/a n/a 9.9 ± 0.8 10.6 ± 0.3 10.6 ± 0.5
Table 2. RNA/DNA ratio for assay with six-day-old larvae of Danio rerio after post-yolk absorption.
Larvae were fed with bioencapsulated Brachionus sp. rotifers and Artemia sp. nauplii. The daily average
is based on six larvae per treatment. C1: without enrichment; C2-DHA: feed rich in DHA treatment;
CNYC4007: Rhodotorula sp. CNYC4007 treatment.
Larvae Age
(Days)
RNA/DNA Ratio
Brachionus sp. Artemia sp. nauplii
C1 C2-DHA CNYC4007 C1 C2-DHA CNYC4007
6 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 n/a n/a n/a
8 1.3 ± 0.2 1.1 ± 0.3 1.4 ± 0.3 n/a n/a n/a
10 1.2 ± 0.2 1.5 ± 0.1 1.5 ± 0.3 n/a n/a n/a
12 1.0 ± 0.2 1.1 ± 0.1 1.4 ± 0.2 * 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2
14 n/a n/a n/a 1.1 ± 0.1 0.9 ± 0.2 1.1 ± 0.3
16 n/a n/a n/a 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.3
18 n/a n/a n/a 1.0 ± 0.2 1.1 ± 0.1 1.2 ± 0.2
20 n/a n/a n/a 0.8 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
22 n/a n/a n/a 0.8 ± 0.1 * 1.1 ± 0.1 1.0 ± 0.1
* = p-value < 0.05; n/a = not available.
2.4. Experiments with 12-Day-Old Larvae
There were no signiﬁcant differences in the total length of these larvae (Table 1) used in the
treatment with the enriched Artemia sp. nauplii (one-way ANOVA, F-statistic = 0.713, p-value = 0.493),
either throughout or on the ﬁnal day of the assay (one-way ANOVA, F-statistic = 0.869, p-value = 0.43).
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However, by the ﬁnal day there were signiﬁcant differences in the RNA/DNA ratio (Table 2) between
the control group and the group treatment with nauplii enriched with C2-DHA and with the strain
CNYC4007 (Tukey test, p-value = 0.0003 and p-value = 0.005, respectively). Finally, there were no
signiﬁcant differences on the ﬁnal day of assay between the treatment with Artemia sp. nauplii enriched
with C2-DHA and that with nauplii enriched with CNYC4007 (Tukey test, p-value = 0.39).
2.5. DHA and EPA Enrichment of Artemia sp. nauplii
There was a signiﬁcant high DHA concentration (Figure 5) in nauplii enriched with the strain
CNYC4007 (Rhodotorula sp.) compared to those without enrichment or enriched with C2-DHA
(one-way ANOVA, p-value = 0.0036). There were no signiﬁcant differences in DHA concentrations
(p-value > 0.05) between nauplii without enrichment (control treatment) and those fed with C2-DHA.
The same was observed with EPA concentrations, which were signiﬁcantly high for nauplii fed with
the strain CNYC4007 (Rhodotorula sp.) compared to those of nauplii without enrichment or enriched
with C2-DHA (one-way ANOVA, p-value = 0.00017). There were no signiﬁcant differences in EPA
concentrations (p-value > 0.05) between Artemia sp. nauplii without enrichment (control treatment)
and those fed with C2-DHA.
 
Figure 5. Average DHA and eicosapentaenoic acid (EPA) concentrations (± S.D.) in Artemia sp. nauplii
without enrichment (C1), fed feed rich in DHA (C2-DHA) and fed with the strain Rhodotorula sp.
CNYC4007. * p-value < 0.05.
3. Discussion
The use of strains of marine microorganisms in commercial ﬁsh feed and other applications,
such as a source of food for human consumption, requires in vivo validation. The ﬁrst step is to rule
out toxic effects and then verify the nutritional contribution to the species under study. The condition
index of Fulton [37] is generally used for organisms that are sufﬁciently large to be easily weighed and
measured. However, with ﬁsh larvae the determination of difference in a very small body mass tends to
lack precision. The present work studied the effect of the strain CNYC4007 of the marine basidiomycete
Rhodotorula sp. [27] in the RNA/DNA ratio, which was used as a proxy for the nutritional state of
Danio rerio larvae. The larvae were fed in their different stages of development and the strain was
administered in three forms (ﬂour, microencapsulated, and bioencapsulated).
The results show the efﬁcacy of the RNA/DNA method to evaluate the nutritional condition of
larvae in the experiments carried out, given that it effectively distinguished between the conditions of
the larvae that were fed and those in starvation (Figures 1 and 2). This method is relevant and has been
used above all with animals at the size scale of zooplankton [22,38] and ﬁsh larvae [17,39,40]. This ratio
is considered a metabolic index and has been used as a measurement of individual growth rate and
nutritional state [18,41]. The increase in RNA concentrations in larvae fed with standard feed (Figure 1)
suggests there was protein synthesis and with this a progressive increase in larval size throughout
the assay, as has been observed with other species like Sardina pilchardus, Engraulis encrasicolus,
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Atherina presbyter and Paralichthys orbignyanus in different development stages [42]. This pattern
concurs with that described by Chung and Segnini [43], who found that RNA levels were higher in
rainbow trout larvae that were fed, as opposed to those in starvation. In the present work, average DNA
levels per individual were observed to be constant during technical standardization assays (Figure 1).
It has been described that DNA levels do not vary under stress, whether caused by starvation or
environmental conditions [44]. Coincident with our results, Ben Khemis et al. [17] proposed that
RNA/DNA is a useful molecular tool to evaluate larval condition in aquaculture.
In all of the assays the RNA/DNA ratio in the larval stages of Danio rerio ranged between 0.7 and 2.
These values were similar to those obtained in Oncorhynchus mykiss (1.5–2.5) [45]. It was observed that
the ratio was sensitive to changes in the diet composition; this concurs with what has been described in
rainbow trout, where the RNA/DNA ratio of larvae varied in response to distinct protein compositions
included in their diet (40–50%) [45]. There were no differences among the feeding treatments when
only considering larval length, although there were differences in nutritional state.
The ﬁrst feeding assay with Danio rerio larvae indicates that the strain Rhodotorula sp. CNYC4007
can be used effectively for this purpose. Larvae fed with ﬂour and microcapsules had similar lengths
(Figure 3) and were in a similar nutritional condition (Figure 4), indicating that the two forms
of administrating feed can be considered as appropriate. The microencapsulated feed contained
stabilizers (maltodextrine and capsule) that protected the fatty acids against moisture, light and
other environmental factors [46], which because of storage or contact with water can deteriorate the
feed [47]. Furthermore, the preparation of microcapsules only required 4% of the microorganisms
biomass required for the ﬂour lyophilized with Rhodotorula sp. CNYC4007 and its physical properties
allowed the feed to remain longer on the surface of the water, which facilitates feeding the larvae,
in contrast to the ﬂour, which decants rapidly. Thus, the microencapsulation method to administer
Rhodotorula sp. (CNYC4007) is recommended for ﬁrst-feeding the larvae because it is more stable,
offers better protection of fatty acids and is more bioavailable than the lyophilized ﬂour method
(100% of ﬂour), the latter thus requiring a large quantity of microorganisms to achieve the same effect.
As the larvae grow their mouth size and nutritional requirements increase, because of which the
quantity and nutritional composition of the feed must be modiﬁed [48]. Because of this, in aquaculture,
especially with marine species, live prey such as rotifers and Artemia sp. nauplii are used. However,
these have low levels of polyunsaturated fatty acids. Rotifers have 4.19% arachidonic acid and 2.29%
docosapentaenoic acid of total fatty acids, with the absence of DHA [16], and Artemia sp. nauplii
have low levels of EPA with the absence of DHA [47]. Consequently, it is necessary to enrich these
organisms for use as larval feed [13]. With larvae at six days post-yolk absorption (six days old),
Rhodotorula sp. CNYC4007 was bioencapsulated in rotifers. The results indicate that the strain is not
toxic for Brachionus sp., Artemia sp. nauplii or zebraﬁsh larvae (0% mortality in the assay). In the case
of larvae, its presence in the digestive tract was conﬁrmed and larvae presented a better molecular
condition than larvae fed on rotifers without enrichment. This concurs with the results obtained with
bioencapsulation in rotifers of Schizochytrium mangrovei, a marine fungoid used to enrich live prey [14].
By comparing the fatty acid content of rotifers with and without enrichment, the authors observed
that the rotifers absorbed signiﬁcant levels of the DHA present in the lyophilized of S. mangrovei [14].
Barclay and Zeller [49] also found the DHA content in rotifers fed with Schizochytrium sp. was
signiﬁcantly higher than that of control rotifers fed with beer yeast. Schizochytrium sp. is one of
the ingredients included in the formulation of feed, termed in this study as C2-DHA, which was
considered as a positive control in experiments in the present work. Both Schizochytrium mangrovei [14]
and the strain Rhodotorula sp. CNYC4007, used in this experiment, have high percentages of DHA
(31.53% and 27%, respectively, of total fatty acids).
The incorporation of the bioencapsulated strain CNYC4007 in feed resulted in signiﬁcantly
higher concentrations of polyunsaturated fatty acids in Artemia sp. nauplii than in nauplii fed
with bioencapsulated C2-DHA (Figure 5). Consequently, Rhodotorula sp. CNYC407, as well as
Schizochytrium sp. [50], represent alternative species for enriching nauplii, even though the percentages
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of DHA and EPA as part of the total of fatty acids differ between the two species (27% and 43% of
DHA; 7.2% and 2.8% of EPA for Rhodotorula sp. and Schizochytrium sp., respectively). With larvae at
12 days post-yolk absorption, the RNA/DNA ratio of larvae in the control treatment was lower than
that of larvae in the treatment with Artemia sp. nauplii enriched with feed rich in DHA (C2-DHA) and
with the strain Rhodotorula sp. CNYC4007. The bioencapsulation of highly unsaturated fatty acids of
the omega-3 series in Artemia sp. nauplii has been shown to improve growth and survival of marine
ﬁsh larvae [51], which concurs with what was observed with the enrichment of Artemia sp. with the
strain studied in this work.
Essential fatty acid requirements vary qualitatively and quantitatively with environmental origin
and during the ontogeny of ﬁsh, with early developmental stages and broodstock being critical
periods [3]. Speciﬁcally, as there is evidence that n-3 HUFA (highly unsaturated fatty acids) and
DHA may be more important and, possibly, essential in the larvae of some species of freshwater ﬁsh
compared with adults. In marine species, larvae are characterized by having a greater requirement
for n-3 HUFA than juvenile and pre-adult ﬁsh, although there are relatively few species where the
requirements at larval and juvenile stages can be directly compared. Notwithstanding the foregoing,
scarce data exists in relation to EFA requirements (expressed as % dry diet), in larvae and early juvenile
ﬁsh, with values that ranged between 1 to 5% [3], described the fatty acid requirements (n-3/n-6) in
zebraﬁsh larvae using larval growth as a proxy, and concluded that a diet with a low n-3/n-6 ratio
maximizes growth. This ﬁnding is coincident with the requirement of typical warm water species,
namely, a higher demand for n-6 PUFA, for example, tilapia.
While this study is based mainly on the use of the RNA/DNA ratio as a proxy for nutritional
condition, there are other methods to validate results that could be used in future studies, such as
the expression of genes related to growth, which can provide new tools for analyzing growth in
ﬁsh [52]. The levels of gene expression related to myogenesis and ATP concentrations in rainbow trout
are drastically reduced in response to starvation [50]. The analysis of microarrays also shows that
starvation in rainbow trout also decreases the levels of gene expression related to lipid metabolism
and immune response [53].
All the results obtained indicate that the marine basidiomycete strain Rhodotorula sp. CNYC4007
represents a potential feed and/or supplement for ﬁrst feeding of zebraﬁsh. Additionally, it can
be incorporated in species like rotifers and Artemia sp. nauplii to be bioencapsulated to potentially
improve the nutritional state of larvae. All trials carried out in our study considered a comparison
between Rhodotorula sp. and commercial sources of fatty acid (formulated diets or emulsions) at
different larval stages. In each case, zebraﬁsh larvae fed with Rhodotorula sp. showed at least
equal growth and nutritional condition than the larval treatment with the commercial alternative.
These results are similar in magnitude to those reported in species with differences in fatty acid
metabolism such as Salmo salar parr and Sparus aurata larvae, where ﬁsh oil replacement with alternative
sources of DHA (Schistochytrium sp. and Crypthecodinium cohnii) was suggested [25,31]. These results
are relevant, as in other species, nutritional studies on zebraﬁsh have determined positive or negative
inﬂuences of some food compounds [34] and correspond to the ﬁrst step in the screening process for
novel ingredients or additives with a potential use in aquaculture [35].
Previous studies on Rhodotorula yeast have proposed it as a source of carotenoids [54],
bioactive substances [55] and lipids, but just for aliphatic18-carbon atom fatty acid chains [56].
The Rhodotorula sp. strain CNYC4007 is the only Rhodotorula species that has been reported as a DHA
and EPA producer and to the best of our knowledge this is the ﬁrst work in which a Rhodotorula yeast
has been used as feed. Finally, this study seeks to contribute in the search for a sustainable source of
PUFAs for feeding ﬁsh [57] to avoid the use of ﬁsh oil from over-exploited marine resources.
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4. Materials and Methods
4.1. Obtaining and Producing the Strain Rhodotorula sp. CNYC4007
The strain used in this study has a 97% identity for the gene 18S ribosomal RNA (rRNA) of
Rhodotorula sp. [27]. It was extracted from Caleta Maule, Biobío Region, Chile, and is stored in the
National Collection of Yeast Cultures in the UK with the code CNYC4007. Two preparations were
obtained from the strain and used in the experiments: lyophilized ﬂour and microencapsulated,
which were prepared with atomization drying using two stabilizers (maltodextrin and capsule),
following the protocols established by Pino et al. [58]. Formulation and proximate composition of
the strain Rhodotorula sp. and commercial diets C1 (Mikrovit Hi-Protein, Silesia, Poland) y C2-DHA
(Algamac, Poland) used in experiments are detailed in Table 3.
Table 3. Proximate composition of the diets used as a control (C1), positive control (C2-DHA) and the
strain Rhodotorula sp. CNYC4007.
Components (%) C1 C2-DHA CNYC4007 Microencapsulated CNYC4007 Meal
Protein 49 17.6 n/a n/a
Carbohydrate n/a 15.9 92.5 36.0
Fat 8.5 56.2 0.3 7.6
Nitrogen compounds n/a n/a 1.4 6.1
Fiber 3 n/a 1.2 1.7
Moisture 6 2.1 3.7 83.1
Ash n/a 8.2 0.5 7.6
Calories (kcal) n/a 640 378.2 169.8
n/a = not available.
4.2. Obtaining and Maintaining Danio rerio Larvae
A breeding stock of D. rerio wild type strain was maintained at 27 ± 1 ◦C with a 12:12 h light:dark
photoperiod and constant ﬁltration. Males and females of the same age were kept together in a
glass aquarium with a density not exceeding four to ﬁve ﬁsh/L. The ﬁsh were fed twice daily with
Artemia sp. nauplii (Utah strain; Aquafauna Bio-Marine Inc., Hawthorne, CA, USA) and TetraMin
tropical ﬂakes. To obtain the larvae needed for the experiments, spawning was induced at three-day
intervals by placing plastic receptacles in the culture systems. The fertilized eggs were removed from
the receptacles and washed twice, ﬁrst with a mixture of 1× reconstituted saline solution (E3 medium:
NaCl2 19 mM; KCl 9 mM; CaCl2 16 mM; MgSO4 17 mM; Merck & Co., Inc., Kenilworth, NJ, USA) and
methylene blue 0.01% (w/v) and then with 1× E3 medium. The healthy embryos were incubated in a
temperature controlled camera (27 ◦C) until hatching occurred.
In preliminary observations on early development of zebra ﬁsh larvae we assessed the exact
moment when the larvae had the adequate mouth size to begin the feeding with rotifers and Artemia sp.
nauplii. At six days post-fertilization the larvae had completed yolk absorption and were used in
ﬁrst-feeding experiments (larvae at six days post-yolk absorption) or continued maturing until reaching
the phase required for the subsequent experiments, when the larvae were 12 days old (larvae at 12 days
post-yolk absorption). Plastic wells (700 mL) were used as rearing chambers, and installed in the
aquariums. To ensure optimal water quality, the wells were equipped with mesh walls to allow for
water circulation. The remains of feed and fecal matter were regularly removed from the bottom
of the wells. Wells of different sizes were used for the feeding experiments according to larval size.
The wells were placed in a 50-L tank at 26 ◦C, with constant oxygenation and a light/darkness ratio
14:10. The water was partially changed every two days to maintain optimal quality (total ammonia
nitrogen (TAN) = 0.2 mg L−1; conductivity = 201.9 μS cm−1, pH = 7.5, dissolved oxygen = 7.32 mg L−1).
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4.3. Validation of the RNA/DNA Method for Danio rerio Larvae
An assay was conducted with ﬁrst-feeding larvae (one day post-yolk absorption), when the
larvae were 6 days old, to validate the RNA/DNA method to compare larvae fed with a standard
commercial feed (C1; Mikrovit Hi-Protein Table 3) and larvae in starvation. Three larvae from each
treatment (group) were randomly selected every day to determine RNA and DNA concentrations.
The experiment lasted six days, when larvae were 11 days old, given that by this day there was 100%
mortality of the larvae in starvation, because of which the statistical analysis was applied only up to
the tenth day.
4.4. Estimating Larval Growth
Individual larvae were removed from the wells for analysis in all of the experiments.
Cold anesthesia was used for observation and measurement. Larvae were placed individually in a
petri dish over a gel pack bar frozen at −20 ◦C. Observations and measurements were made under a
stereoscopic magnifying glass equipped with a digital camera (Canon EOS REBEL T3, Canon U.S.A.,
Inc., Huntington, NY, USA). Photographs of the larvae were analyzed using Image Pro-Plus 6.0
software, Media Cybernetics, Inc., Rockville, MD, USA. Magniﬁcations of 10× or 12× was used to
determine the total length depending on the size of the larvae. The distance from the mouth to the
posterior point of the notochord was measured for pre-ﬂexion larvae, while the distance from the
mouth to the hypural plate (standard length) was used for more developed larvae. After measurement,
the larvae were immediately placed in Eppendorf tubes and stored at −80 ◦C.
4.5. Experiments with First-Feeding Age Larvae
4.5.1. Feeding with Rhodotorula sp. CNYC4007 Lyophilized in Flour and in Microcapsules
Thirty ﬁrst-feeding age larvae (one day post-yolk absorption), when the larvae were six days
old, they were placed in 700-mL wells. The experiment involved three treatments: (1) larvae fed
with standard commercial feed (control group; C1); (2) larvae fed with ﬂour lyophilized of the
strain Rhodotorula sp. CNYC4007; and (3) larvae fed with ﬂour microencapsulated of Rhodotorula sp.
CNYC4007 (Table 1). A preliminary experiment established a biomass of 30 mg (for 30 larvae) as an
adequate daily ration of commercial feed and the lyophilized ﬂour and 150 mg for microencapsulate.
The experiment lasted nine days during which unconsumed feed was removed daily. Every second day
three larvae per replicate were removed, measured (detail point 4) and stored at −80 ◦C individually
for subsequent molecular analysis (detail point 7).
4.5.2. Larval Feeding with Bioencapsulation in Brachionus sp.
Rotifers used in this experimentwere enriched following the protocol of Estudillo del Castillo et al. [16].
The assay involved three treatments with respective replicates: (1) larvae fed with non-enriched rotifers
(control group; C1); (2) larvae fed with rotifers enriched with a commercial feed high in DHA (C2-DHA);
and (3) larvae fed with rotifers enriched with flour lyophilized of Rhodotorula sp. CNYC4007. Each replicate
involved 20 larvae in a 300-mL well with 0.2-mm mesh walls that allowed for the flow of water while
preventing rotifers from escaping. On a daily basis, 1.000 enriched rotifers and 1.000 without enrichment
were applied according to the treatment, following the individual ration. Six randomly selected larvae
(three per replicate) were removed from each treatment, then observed, measured (see point 4) and stored
individually at−80 ◦C for subsequent molecular analysis (see point 7).
4.6. Experiments with Larvae at 12 Days Post-Yolk Absorption
To carry out this experiment Artemia sp. (Utah strain; Aquafauna Bio-Marine Inc.) nauplii were
enriched with Rhodotorula sp. CNYC4007 in the form of lyophilized ﬂour. The time and conditions
of the enrichment were deﬁned by modifying the protocols from Silva [48]. Six hundred Artemia sp.
152
Bo
ok
s
M
DP
I
Mar. Drugs 2017, 15, 369
nauplii (8 h post-hatching) were placed in 15-mL tubes containing 5 mL of seawater. The tubes were
incubated with continuous light and strong aeration at 26 ◦C. Three mg of C2-DHA or 3 mg of ﬂour
lyophilized with CNYC4007 were added, respectively, to the two tubes. The tubes containing nauplii
with and without enrichment were kept under the same conditions. The enrichment time was 16 h,
after which the nauplii were sieved (88 μm), washed and re-suspended in 2 mL of distilled water to
proceed with feeding the larvae.
The experimental design involved three treatments: (1) Larvae fed with Artemia sp. nauplii
without enrichment (control group; C1); (2) Larvae fed with Artemia sp. nauplii enriched with C2-DHA
(positive control group); and (3) Larvae fed with Artemia sp. nauplii enriched with ﬂour lyophilized
with Rhodotorula sp. CNYC4007. Thirty larvae were placed in 700-mL containers (3 replicates
per treatment). The experiment lasted nine days. Every second day three larvae per replicate were
removed, observed, measured and then stored individually at −80 ◦C for subsequent molecular
analysis. In all the trials (ﬂour, rotifers and Artemia sp. nauplii) at the moment of photographing
each larvae the presence of food in the gut was visually veriﬁed and then stored for posterior
molecular analysis.
4.7. Obtaining the RNA/DNA Ratio Used as a Proxy for the Condition of Danio rerio Larvae
The protocol from Clemmensen [59], with modiﬁcations, was used to extract larval nucleic acid.
The larvae were treated with Tris-EDTA (Ethylenediaminetetraacetic acid) buffer (Tris-HCl 0.05 M;
NaCl 0.1 M; EDTA 0.01 M at pH 8.0) and SDS (sodium dodecyl sulfate) at 20% p/v, after which
proteinase K (20 mg/mL) was added and homogenized with a glass swab until a uniform solution
was observed. The solution was then centrifuged for one minute and placed in a thermo-regulated
bath (50 ◦C) for 10 min, after which the samples were transferred to −20 ◦C for 20 min. The procedure
of heating and cooling the samples was repeated three times, following which the samples were
centrifuged. Chloroform, phenol and isoamyl alcohol (24:25:1) was added and homogenized in an
extraction chamber. After centrifugation for 15 min, the supernatant was transferred to a sterile
Eppendorf tube.
Nucleic acids were determined separately using the Quantiﬂuor ONE dsDNA System
(Promega Co., Fitchburg, WI, USA) for DNA and the Quantiﬂuor RNA System (Promega Co.,
Fitchburg, WI, USA) for RNA. The samples were prepared according the suppliers protocols.
Fluorescence was measured in a multi-detection microplate reader (BioTek, Winooski, VT, USA,
model FL×800) under a blue optical channel with excitation of 492 nm and an emission of 540 nm.
4.8. Analysis of Fatty Acid Content in Artemia sp. nauplii
Polyunsaturated fatty acids were extracted from Artemia sp. nauplii by saponiﬁcation reaction
and quantiﬁed by HPLC following the methodology described by Li et al. [60]. To do this, 100 mg
of Artemia sp. nauplii without enrichment, enriched with C2-DHA and ﬂour lyophilized from the
strain of Rhodotorula sp. CNYC4007 was used, each in triplicate. One mL of NaOH at 0.5 M in 96% of
ethanol was added to the samples and homogenized with an Ultra Turrax for one minute. Samples
were centrifuged at 7000 rpm for 5 min to eliminate solid residues after cell rupture. One mL of HCl at
0.6 N and 3 mL of ethyl acetate (LiChrosolv®, Rochester, NY, USA) was added to the supernatant and
agitated with vortex for one minute and incubated for 30 min at room temperature. The treated samples
were dried by a current of nitrogen (N2(g)) to eliminate the organic solvent, lyophilized to eliminate the
remains of water and stored at −20 ◦C until subsequent chromatographic analysis. Polyunsaturated
fatty acids were quantiﬁed with a HPLC VWR™ HITACHI (VWR International Ltd., Lutterworth, UK)
with an organizer (model L-2000), an ultraviolet (UV) detector (model L-2400), gradient editing pump
(model L-2100/2130) and a 15-cm-by-4.6-mm LC-18 column (Supelco®, Sigma-Aldrich, Inc., Darmstadt,
Germany). The mobile phase consisted of a ﬂow of 1 mL per min−1 of gradient A (25% acetonitrile),
to 50% of gradient B (100% acetonitrile), with a ﬂow of 2 mL per min−1 for the ﬁrst 15 min and then
1 mL per min−1 for another 15 min. DHA and EPA were identiﬁed through the construction of their
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respective calibration curves using HPLC grade standards (Sigma-Aldrich®, Darmstadt, Germany)
with an injection volume of 10 μL [27].
4.9. Statistical Analysis
The Statistica 10 program was used to analyze the data obtained. In the ﬁrst step the homogeneity
of variance (Bartlett, London, UK) and normality of data (Kolmogorov-Smirnov test) was analyzed.
A two-way ANOVA and multiple Tukey comparison test was applied for total larval length, DNA and
RNA concentrations and the RNA/DNA ratio. The treatments were compared on the ﬁnal day of the
assay. The Kruskal-Wallis test was applied to data that did not present homogeneity of variance or
normality. Mean was considered signiﬁcant when probability was less than 0.05 (p < 0.05).
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